

16.2.4 Demographic Data

- Listing 16.2.4.1 Demographics and Baseline Characteristics Randomized Set
- Listing 16.2.4.2 Demographics and Baseline Characteristics Subjects Screen Failed
- Listing 16.2.4.3 Medical History Randomized Set
- Listing 16.2.4.4 Prior and Concomitant Medications Safety Set
- Listing 16.2.4.5 Concomitant Procedures Safety Set

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2011030	42	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	179.1	70.9	22.1
US2011042	37	Female	Yes	WHITE	NOT HISPANIC OR LATINO	167.6	80.5	28.66
US2011043	52	Female	No/POST-MENOPAUSAL	M (b) (6)	HISPANIC OR LATINO	157.5	58.6	23.62
US2011056	30	Male		WHITE	NOT HISPANIC OR LATINO	188	86.8	24.56
US2011057	50	Male		WHITE	NOT HISPANIC OR LATINO	170.2	82.7	28.55
US2011060	49	Female	Yes	WHITE	NOT HISPANIC OR LATINO	175.3	64.1	20.86
US2011064	34	Female	Yes	WHITE	NOT HISPANIC OR LATINO	157.5	56.8	22.9
US2011067	28	Female	No/SURGICALLY STERILE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	165.1	74.5	27.33
US2011068	44	Male		WHITE	NOT HISPANIC OR LATINO	167.6	62.7	22.32

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2011069	51	Female	No/SURGICALLY STERILE	WHITE	HISPANIC OR LATINO	162.6	68.2	25.8
US2011070	50	Female	No/SURGICALLY STERILE	WHITE	HISPANIC OR LATINO	157.5	69.5	28.02
US2011086	21	Male		BLACK OR AFRICAN AMERICAN	HISPANIC OR LATINO	167.6	62.3	22.18
US2011088	47	Male		WHITE	NOT HISPANIC OR LATINO	177.8	81.8	25.88
US2021061	38	Male		ASIAN	NOT HISPANIC OR LATINO	167.5	73.8	26.3
US2021062	44	Male		WHITE	NOT HISPANIC OR LATINO	191	103.7	28.43
US2021073	51	Female	Yes	WHITE	NOT HISPANIC OR LATINO	166	65.7	23.84
US2021078	40	Male		WHITE	NOT HISPANIC OR LATINO	179	86	26.84
US2021082	47	Male		WHITE	NOT HISPANIC OR LATINO	173	79.2	26.46
US2021089	40	Male		WHITE	NOT HISPANIC OR LATINO	188.4	98.9	27.86

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2021094	53	Male		WHITE	NOT HISPANIC OR LATINO	173.6	74.3	24.65
US2021096	25	Female	Yes	WHITE	NOT HISPANIC OR LATINO	164	65	24.17
US2021107	26	Female	Yes	ASIAN	NOT HISPANIC OR LATINO	165.2	72.4	26.53
US2021111	36	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	165.5	80.5	29.39
US2021135	43	Male		BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	177	83.6	26.68
US2021137	26	Male		WHITE	NOT HISPANIC OR LATINO	178	86.4	27.27
US2021138	52	Female	Yes	WHITE	NOT HISPANIC OR LATINO	169	52.9	18.52
US2021144	18	Female	Yes	WHITE	NOT HISPANIC OR LATINO	173	73.7	24.62
US2021155	46	Male		WHITE	NOT HISPANIC OR LATINO	177	90.6	28.92

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2021161	53	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	163.6	69.4	25.93
US2021162	37	Female	Yes	WHITE	NOT HISPANIC OR LATINO	162	60	22.86
US2021175	36	Female	Yes	WHITE	NOT HISPANIC OR LATINO	168.4	55.6	19.61
US2031001	42	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	170.1	75.2	25.99
US2031009	36	Male		WHITE	NOT HISPANIC OR LATINO	175.2	78.5	25.57
US2031014	36	Female	Yes	WHITE	NOT HISPANIC OR LATINO	165.1	49.7	18.23
US2031022	35	Male		WHITE	NOT HISPANIC OR LATINO	188	83.4	23.6
US2031023	37	Female	Yes	WHITE	NOT HISPANIC OR LATINO	180.3	87.9	27.04
US2031029	40	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	158.7	62.1	24.66

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2031038	30	Male		WHITE	NOT HISPANIC OR LATINO	172.7	62.1	20.82
US2031040	30	Male		WHITE	NOT HISPANIC OR LATINO	172.2	58.9	19.86
US2031041	28	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	171.4	53.7	18.28
US2031043	46	Male		WHITE	NOT HISPANIC OR LATINO	165.1	76.2	27.96
US2031045	41	Male		WHITE	NOT HISPANIC OR LATINO	177.8	78	24.67
US2031048	21	Male		WHITE	NOT HISPANIC OR LATINO	175.2	64.4	20.98
US2031049	37	Female	Yes	WHITE	HISPANIC OR LATINO	174.2	73	24.06
US2031058	48	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	167.6	83.4	29.69
US2031071	36	Female	Yes	WHITE	NOT HISPANIC OR LATINO	165.1	74.8	27.44
US2031074	52	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	167.6	80.6	28.69

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2031081	36	Female	Yes	WHITE	NOT HISPANIC OR LATINO	174	78.9	26.06
US2041005	22	Female	Yes	WHITE	NOT HISPANIC OR LATINO	163.2	66.8	25.08
US2041011	51	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	174.2	66.2	21.82
US2041014	38	Male		WHITE	NOT HISPANIC OR LATINO	181.6	93.4	28.32
US2041019	20	Male		WHITE	NOT HISPANIC OR LATINO	187.9	76	21.53
US2041020	45	Male		WHITE	NOT HISPANIC OR LATINO	171.5	82.3	27.98
US2041022	40	Female	Yes	WHITE	NOT HISPANIC OR LATINO	170.2	77.6	26.79
US2041025	47	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	156.8	63.7	25.91
US2041029	48	Male		WHITE	NOT HISPANIC OR LATINO	167.6	82.4	29.33

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2041034	45	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	163.2	69.9	26.24
US2041042	35	Female	Yes	WHITE	NOT HISPANIC OR LATINO	163.8	75.2	28.03
US2041043	47	Female	Yes	WHITE	NOT HISPANIC OR LATINO	170.2	83.5	28.82
US2041056	23	Male		WHITE	NOT HISPANIC OR LATINO	191.1	92.5	25.33
US2041059	38	Female	Yes	WHITE	NOT HISPANIC OR LATINO	180.3	89.1	27.41
US2041062	38	Female	Yes	WHITE	NOT HISPANIC OR LATINO	160.1	63.6	24.81
US2041078	33	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	165.1	72.8	26.71
US2041086	25	Female	Yes	WHITE	NOT HISPANIC OR LATINO	172.7	74.9	25.11
US2041089	31	Male		WHITE	NOT HISPANIC OR LATINO	189.5	88.3	24.59

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2041090	21	Male		WHITE	NOT HISPANIC OR LATINO	180.3	68.7	21.13
US2051022	22	Female	Yes	WHITE	NOT HISPANIC OR LATINO	168.5	63.1	22.22
US2051035	20	Female	Yes	WHITE	NOT HISPANIC OR LATINO	177.3	60.3	19.18
US2051036	49	Male		WHITE	NOT HISPANIC OR LATINO	166.8	82.9	29.8
US2051044	38	Male		WHITE	NOT HISPANIC OR LATINO	170	80.2	27.75
US2061003	35	Female	Yes	WHITE	NOT HISPANIC OR LATINO	163.5	62.3	23.31
US2061015	19	Female	Yes	WHITE	NOT HISPANIC OR LATINO	162.5	50.2	19.01
US2061018	50	Female	Yes	WHITE	NOT HISPANIC OR LATINO	166	68.1	24.71
US2061021	43	Male		WHITE	NOT HISPANIC OR LATINO	182	84	25.36

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2061022	44	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	168	69.4	24.59
US2061025	32	Male		WHITE	NOT HISPANIC OR LATINO	189	92.8	25.98
US2061032	50	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	170	77	26.64
US2071012	40	Female	No/SURGICALLY STERILE	WHITE	HISPANIC OR LATINO	162.5	68.6	25.98
US2071014	18	Male		WHITE	HISPANIC OR LATINO	174	84.5	27.91
US2071017	36	Female	No/SURGICALLY STERILE	WHITE	HISPANIC OR LATINO	162.4	61.6	23.36
US2071022	29	Male		WHITE	NOT HISPANIC OR LATINO	179.5	95.6	29.67
US2071042	43	Male		WHITE	HISPANIC OR LATINO	176.5	86.1	27.64
US2071044	32	Female	Yes	WHITE	NOT HISPANIC OR LATINO	154	42.8	18.05
US2071046	23	Female	Yes	WHITE	HISPANIC OR LATINO	154	63.2	26.65
US2071049	28	Female	Yes	WHITE	NOT HISPANIC OR LATINO	164	79.6	29.6

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2071050	45	Male		WHITE	NOT HISPANIC OR LATINO	189	103	28.83
US2071059	32	Female	Yes	WHITE	NOT HISPANIC OR LATINO	168	72.7	25.76
US2071062	29	Male		WHITE	HISPANIC OR LATINO	174.4	77.3	25.41
US2071064	26	Female	Yes	WHITE	NOT HISPANIC OR LATINO	172.5	78.6	26.41
US2071066	25	Male		WHITE	HISPANIC OR LATINO	177	92	29.37
US2071070	34	Female	No/SURGICALLY STERILE	WHITE	HISPANIC OR LATINO	160	63.4	24.77
US2071072	39	Female	Yes	WHITE	HISPANIC OR LATINO	158	59.7	23.91
US2081026	49	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	154.9	70.9	29.55
US2081033	43	Female	Yes	WHITE	NOT HISPANIC OR LATINO	172.7	72.7	24.38
US2081038	30	Male		WHITE	NOT HISPANIC OR LATINO	182.9	71.8	21.46
US2081042	49	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	163.8	60.3	22.47

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2081046	45	Male		WHITE	NOT HISPANIC OR LATINO	188	99.8	28.24
US2081049	47	Female	Yes	WHITE	NOT HISPANIC OR LATINO	172.7	74.5	24.98
US2081057	45	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	166.4	78.5	28.35
US2081058	20	Female	Yes	WHITE	NOT HISPANIC OR LATINO	168.9	85.5	29.97

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2011020	27	Female	Yes	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	161.3	67.7	26.02
US2011029	38	Female	Yes	WHITE	NOT HISPANIC OR LATINO	167.6	80.5	28.66
US2011048	42	Female	Yes	AMERICAN INDIAN OR ALASKA NATIVE	HISPANIC OR LATINO	160	70.5	27.54
US2011051	20	Female	Yes	WHITE	HISPANIC OR LATINO	152.4	49.1	21.14
US2011055	45	Female	Yes	WHITE	NOT HISPANIC OR LATINO	167.6	76.8	27.34
US2011061	39	Male		BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	174	77.7	25.66
US2011084	49	Male		WHITE	HISPANIC OR LATINO	170.2	79.5	27.44
US2011087	33	Male		WHITE	NOT HISPANIC OR LATINO	177.8	84.5	26.73
US2011090	29	Male		WHITE	NOT HISPANIC OR LATINO	176.5	82.3	26.42
US2011091	54	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	162.6	70.5	26.67

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2011092	40	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	160	55.9	21.84
US2011093	38	Female	Yes	WHITE	NOT HISPANIC OR LATINO	168.9	70.5	24.71
US2011095	26	Female	Yes	WHITE	NOT HISPANIC OR LATINO	170.2	71.4	24.65
US2011102	41	Male		WHITE	HISPANIC OR LATINO	177.8	76.8	24.29
US2021058	24	Female	Yes	WHITE	NOT HISPANIC OR LATINO	169	57	19.96
US2021064	54	Female	Yes	WHITE	NOT HISPANIC OR LATINO	162	75.8	28.88
US2021084	34	Male		WHITE	NOT HISPANIC OR LATINO	177	68.8	21.96
US2021090	54	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	166.5	70.7	25.5
US2021147	51	Male		WHITE	NOT HISPANIC OR LATINO	166.6	78.5	28.28
US2021166	28	Female	Yes	OTHER: (b) (6)	NOT HISPANIC OR LATINO	161	62.9	24.27

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2021167	23	Female	Yes	WHITE	NOT HISPANIC OR LATINO	165.5	74.6	27.24
US2021179	38	Female	Yes	WHITE	NOT HISPANIC OR LATINO	167.8	65.8	23.37
US2031002	42	Female	Yes	WHITE	NOT HISPANIC OR LATINO	165.1	58.5	21.46
US2031004	31	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	165.1	68	24.95
US2031011	52	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	165.2	81	29.68
US2031016	21	Male		WHITE	NOT HISPANIC OR LATINO	185.4	86.1	25.05
US2031030	49	Female	Yes	WHITE	NOT HISPANIC OR LATINO	170.2	78	26.93
US2031042	19	Female	Yes	WHITE	NOT HISPANIC OR LATINO	162.6	63	23.83
US2031051	48	Female	Yes	WHITE	NOT HISPANIC OR LATINO	167.6	55.8	19.86
US2031056	48	Male		WHITE	HISPANIC OR LATINO	180.3	70.2	21.59

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2031057	26	Male		WHITE	NOT HISPANIC OR LATINO	181.6	70.9	21.5
US2031063	35	Male		WHITE	NOT HISPANIC OR LATINO	185.4	91.6	26.65
US2031066	40	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	170.1	57.2	19.77
US2031072	54	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	162.6	64.4	24.36
US2031080	23	Female	Yes	WHITE	NOT HISPANIC OR LATINO	162.5	69.8	26.43
US2041002	38	Male		WHITE	NOT HISPANIC OR LATINO	190.3	95.8	26.45
US2041003	18	Female	Yes	WHITE	NOT HISPANIC OR LATINO	177.8	91.5	28.94
US2041006	33	Female	Yes	WHITE	NOT HISPANIC OR LATINO	172	81.3	27.48
US2041007	33	Female	Yes	WHITE	NOT HISPANIC OR LATINO	173.5	82.8	27.51
US2041012	32	Female	Yes	WHITE	HISPANIC OR LATINO	160	66.9	26.13

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2041013	38	Male		BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	170.9	87.6	29.99
US2041016	39	Male		WHITE	NOT HISPANIC OR LATINO	175.3	87.1	28.34
US2041023	53	Female	Yes	WHITE	NOT HISPANIC OR LATINO	170	79	27.34
US2041027	40	Female	Yes	WHITE	NOT HISPANIC OR LATINO	160	67	26.17
US2041030	43	Female	Yes	WHITE	NOT HISPANIC OR LATINO	190.5	76.2	21
US2041036	42	Female	Yes	WHITE	NOT HISPANIC OR LATINO	162.5	64.2	24.31
US2041047	33	Male		WHITE	NOT HISPANIC OR LATINO	191.8	97.5	26.5
US2041049	23	Female	Yes	WHITE	NOT HISPANIC OR LATINO	163	50	18.82
US2041051	25	Female	Yes	WHITE	NOT HISPANIC OR LATINO	170.2	77	26.58

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2041053	28	Male		WHITE	NOT HISPANIC OR LATINO	178.3	77.4	24.35
US2041055	20	Female	Yes	AMERICAN INDIAN OR ALASKA NATIVE	HISPANIC OR LATINO	165	79	29.02
US2041058	39	Male		WHITE	NOT HISPANIC OR LATINO	182.9	93.2	27.86
US2041064	43	Female	Yes	WHITE	NOT HISPANIC OR LATINO	166.4	67.2	24.27
US2041071	23	Female	Yes	WHITE	NOT HISPANIC OR LATINO	167.6	61.1	21.75
US2041075	35	Male		(b) (6)	NOT HISPANIC OR LATINO	189.2	100.8	28.16
US2041076	40	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	157.4	73.8	29.79
US2041077	37	Female	Yes	WHITE	NOT HISPANIC OR LATINO	165.1	58.9	21.61
US2041088	18	Male		WHITE	NOT HISPANIC OR LATINO	190.5	81.5	22.46

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2041091	21	Female	Yes	WHITE	NOT HISPANIC OR LATINO	177.8	60.9	19.26
US2041092	52	Female	Yes	WHITE	NOT HISPANIC OR LATINO	162.6	81.1	30.67
US2051008	48	Female	Yes	WHITE	NOT HISPANIC OR LATINO	167.9	64.9	23.02
US2051009	51	Male		WHITE	NOT HISPANIC OR LATINO	167.4	69.2	24.69
US2051010	42	Female	Yes	WHITE	NOT HISPANIC OR LATINO	166.8	76.6	27.53
US2051011	46	Male		WHITE	NOT HISPANIC OR LATINO	171.5	80.3	27.3
US2051018	25	Female	Yes	WHITE	NOT HISPANIC OR LATINO	175.2	65.7	21.4
US2051027	40	Female	Yes	WHITE	NOT HISPANIC OR LATINO	178.8	87	27.21
US2051031	35	Male		WHITE	NOT HISPANIC OR LATINO	178.4	92.3	29

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2051032	41	Female	Yes	WHITE	NOT HISPANIC OR LATINO	170	84	29.07
US2051033	40	Female	Yes	WHITE	NOT HISPANIC OR LATINO	170.9	71.8	24.58
US2051034	36	Male		WHITE	NOT HISPANIC OR LATINO	192	99	26.86
US2051038	28	Female	Yes	WHITE	NOT HISPANIC OR LATINO	161.6	55	21.06
US2051040	48	Male		WHITE	NOT HISPANIC OR LATINO	186	77.9	22.52
US2051042	35	Male		WHITE	NOT HISPANIC OR LATINO	175.5	85.8	27.86
US2051043	38	Female	Yes	WHITE	NOT HISPANIC OR LATINO	165.3	77.1	28.22
US2051048	31	Female	Yes	WHITE	NOT HISPANIC OR LATINO	160.1	60	23.41
US2051050	46	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	171	84.6	28.93

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2061001	38	Female	Yes	WHITE	NOT HISPANIC OR LATINO	179	59.4	18.54
US2061006	35	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	170	82.6	28.58
US2061009	43	Female	Yes	WHITE	NOT HISPANIC OR LATINO	167	80.6	28.9
US2061011	49	Female	Yes	WHITE	NOT HISPANIC OR LATINO	173	73.7	24.62
US2061013	41	Male		WHITE	NOT HISPANIC OR LATINO	177.5	89.2	28.31
US2061019	45	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	174	90.2	29.79
US2061026	43	Male		WHITE	NOT HISPANIC OR LATINO	184	92.4	27.29
US2071001	28	Female	Yes	WHITE	NOT HISPANIC OR LATINO	177	79.3	25.31
US2071003	42	Female	Yes	WHITE	NOT HISPANIC OR LATINO	169.1	61.7	21.58

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2071004	39	Male		WHITE	NOT HISPANIC OR LATINO	186	101	29.19
US2071029	18	Male		WHITE	HISPANIC OR LATINO	168	60.8	21.54
US2071030	37	Female	Yes	WHITE	NOT HISPANIC OR LATINO	173	84.2	28.13
US2071032	24	Male		WHITE	HISPANIC OR LATINO	181	89.6	27.35
US2071033	26	Male		WHITE	HISPANIC OR LATINO	170	78.5	27.16
US2071063	37	Male		WHITE	NOT HISPANIC OR LATINO	172	87.6	29.61
US2071067	34	Female	Yes	WHITE	NOT HISPANIC OR LATINO	157.5	71	28.62
US2071074	40	Female	No/SURGICALLY STERILE	WHITE	HISPANIC OR LATINO	160.9	74.8	28.89
US2071081	33	Female	Yes	WHITE	NOT HISPANIC OR LATINO	160	73.1	28.55
US2081036	48	Male		WHITE	NOT HISPANIC OR LATINO	182.9	77.5	23.17
US2081039	21	Female	Yes	WHITE	NOT HISPANIC OR LATINO	177.8	68.5	21.67

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2081041	41	Male		WHITE	NOT HISPANIC OR LATINO	173.2	80	26.67
US2081052	37	Male		WHITE	NOT HISPANIC OR LATINO	180.3	95.5	29.38
US2081054	31	Male		WHITE	NOT HISPANIC OR LATINO	188	94.5	26.74
US2081059	39	Female	Yes	WHITE	NOT HISPANIC OR LATINO	172.7	73	24.48

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2011018	27	Male		BLACK OR AFRICAN AMERICAN	HISPANIC OR LATINO	177.8	67.7	21.42
US2011019	50	Female	No/SURGICALLY STERILE	ASIAN	NOT HISPANIC OR LATINO	165.1	54.5	19.99
US2011039	45	Female	No/SURGICALLY STERILE	WHITE	HISPANIC OR LATINO	153.7	51.4	21.76
US2011041	28	Male		BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	177.8	71.4	22.59
US2011046	21	Female	Yes	WHITE	NOT HISPANIC OR LATINO	170.2	53.6	18.5
US2011050	49	Male		WHITE	NOT HISPANIC OR LATINO	167.6	75	26.7
US2011059	46	Male		WHITE	HISPANIC OR LATINO	175.3	77.7	25.28
US2011065	51	Male		WHITE	NOT HISPANIC OR LATINO	170.2	55.5	19.16
US2011080	49	Female	Yes	WHITE	NOT HISPANIC OR LATINO	167.6	74.5	26.52
US2011085	31	Female	Yes	WHITE	NOT HISPANIC OR LATINO	167.6	60	21.36

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2011089	32	Female	Yes	WHITE	NOT HISPANIC OR LATINO	162.6	59.5	22.5
US2011103	51	Male		WHITE	NOT HISPANIC OR LATINO	181.6	81.8	24.8
US2021059	38	Female	Yes	OTHER: (b) (6)	HISPANIC OR LATINO	163.9	64.1	23.86
US2021063	40	Female	Yes	WHITE	NOT HISPANIC OR LATINO	164.1	55.7	20.68
US2021067	38	Male		WHITE	NOT HISPANIC OR LATINO	190.5	96.6	26.62
US2021068	40	Male		WHITE	NOT HISPANIC OR LATINO	191	108.3	29.69
US2021074	28	Female	Yes	WHITE	NOT HISPANIC OR LATINO	168.5	65.9	23.21
US2021080	49	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	167.6	69.4	24.71
US2021093	35	Female	Yes	WHITE	NOT HISPANIC OR LATINO	168	61.2	21.68
US2021099	49	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	167.2	65.6	23.47

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2021101	35	Female	Yes	WHITE	NOT HISPANIC OR LATINO	162.8	62.3	23.51
US2021121	22	Female	Yes	WHITE	NOT HISPANIC OR LATINO	165.3	72.3	26.46
US2021145	43	Female	Yes	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	163.5	56.4	21.1
US2021151	30	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	161.2	69.4	26.71
US2021154	34	Female	Yes	WHITE	NOT HISPANIC OR LATINO	153	53.7	22.94
US2021164	34	Female	Yes	WHITE	NOT HISPANIC OR LATINO	164	66.6	24.76
US2021180	31	Male		WHITE	NOT HISPANIC OR LATINO	175	80.5	26.29
US2021182	26	Female	Yes	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	164.1	75.6	28.07
US2031012	44	Female	Yes	WHITE	NOT HISPANIC OR LATINO	160	73.5	28.71

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2031013	41	Female	Yes	WHITE	NOT HISPANIC OR LATINO	158.7	68	27
US2031019	52	Male		WHITE	NOT HISPANIC OR LATINO	172.7	81.2	27.23
US2031020	50	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	165.1	80.8	29.64
US2031021	41	Male		WHITE	NOT HISPANIC OR LATINO	185.3	92.5	26.94
US2031026	54	Female	Yes	WHITE	NOT HISPANIC OR LATINO	175.2	80.3	26.16
US2031027	46	Male		WHITE	NOT HISPANIC OR LATINO	185.4	95	27.64
US2031033	44	Male		WHITE	NOT HISPANIC OR LATINO	175.3	90	29.29
US2031035	48	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	167.5	59.4	21.17
US2031037	35	Male		WHITE	NOT HISPANIC OR LATINO	193	85.3	22.9

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2031047	43	Female	Yes	WHITE	NOT HISPANIC OR LATINO	165.1	60.8	22.31
US2031050	51	Female	Yes	WHITE	NOT HISPANIC OR LATINO	171.5	61.6	20.94
US2031060	50	Female	Yes	WHITE	NOT HISPANIC OR LATINO	172.7	74.4	24.95
US2031062	33	Female	Yes	WHITE	NOT HISPANIC OR LATINO	168.9	78.5	27.52
US2031073	34	Male		WHITE	NOT HISPANIC OR LATINO	187.9	88	24.92
US2031079	34	Female	Yes	WHITE	NOT HISPANIC OR LATINO	172.7	81.1	27.19
US2031084	50	Male		WHITE	NOT HISPANIC OR LATINO	177.8	65.7	20.78
US2041008	37	Male		WHITE	NOT HISPANIC OR LATINO	188	70	19.81
US2041010	44	Female	Yes	WHITE	NOT HISPANIC OR LATINO	157	69.5	28.2

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2041024	51	Male		WHITE	NOT HISPANIC OR LATINO	177.8	87.9	27.81
US2041026	50	Male		WHITE	NOT HISPANIC OR LATINO	196	110.7	28.82
US2041041	37	Male		WHITE	NOT HISPANIC OR LATINO	177.8	75.7	23.95
US2041046	23	Male		WHITE	NOT HISPANIC OR LATINO	188.6	106	29.8
US2041048	25	Female	Yes	WHITE	NOT HISPANIC OR LATINO	172	79.7	26.94
US2041060	19	Female	Yes	WHITE	NOT HISPANIC OR LATINO	163.5	62.9	23.53
US2041061	52	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	167.1	50.9	18.23
US2041073	44	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	167.6	74.2	26.42
US2041079	26	Female	Yes	WHITE	NOT HISPANIC OR LATINO	160.5	72.3	28.07

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2041080	26	Female	Yes	WHITE	NOT HISPANIC OR LATINO	172.7	60	20.12
US2041084	52	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	160.3	52.7	20.51
US2051001	31	Male		WHITE	NOT HISPANIC OR LATINO	180.5	86.4	26.52
US2051002	30	Female	Yes	WHITE	NOT HISPANIC OR LATINO	177.8	68.1	21.54
US2051003	27	Male		BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	176.7	61.3	19.63
US2051012	28	Male		WHITE	NOT HISPANIC OR LATINO	179	84.4	26.34
US2051013	22	Male		WHITE	NOT HISPANIC OR LATINO	176.6	70.1	22.48
US2051017	22	Male		WHITE	HISPANIC OR LATINO	170.1	74.2	25.64
US2051019	39	Female	Yes	WHITE	NOT HISPANIC OR LATINO	165.5	70.2	25.63
US2051020	54	Female	Yes	WHITE	NOT HISPANIC OR LATINO	167.4	67.6	24.12

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2051024	50	Female	Yes	WHITE	NOT HISPANIC OR LATINO	178.6	61.9	19.41
US2051025	45	Female	Yes	WHITE	HISPANIC OR LATINO	170	67.5	23.36
US2051026	49	Male		WHITE	NOT HISPANIC OR LATINO	174.2	81	26.69
US2051028	23	Male		ASIAN	NOT HISPANIC OR LATINO	165.4	69.2	25.3
US2051029	28	Male		WHITE	NOT HISPANIC OR LATINO	176.6	75.5	24.21
US2051030	43	Female	Yes	WHITE	NOT HISPANIC OR LATINO	169	69.9	24.47
US2051045	36	Male		WHITE	NOT HISPANIC OR LATINO	171	85	29.07
US2061008	31	Male		WHITE	NOT HISPANIC OR LATINO	182.5	91	27.32
US2061010	43	Male		WHITE	NOT HISPANIC OR LATINO	177	63	20.11
US2061020	54	Male		WHITE	NOT HISPANIC OR LATINO	182	99	29.89

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2061023	19	Female	Yes	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	176	81.9	26.44
US2061024	38	Male		WHITE	NOT HISPANIC OR LATINO	167.5	65.7	23.42
US2061027	44	Female	Yes	WHITE	NOT HISPANIC OR LATINO	182	92.8	28.02
US2071002	39	Female	Yes	WHITE	NOT HISPANIC OR LATINO	160	72.3	28.24
US2071016	40	Female	No/SURGICALLY STERILE	WHITE	HISPANIC OR LATINO	168.5	78.6	27.68
US2071026	32	Male		WHITE	NOT HISPANIC OR LATINO	182	83.3	25.15
US2071036	18	Male		WHITE	NOT HISPANIC OR LATINO	181.5	79.3	24.07
US2071038	27	Male		WHITE	NOT HISPANIC OR LATINO	189	89.6	25.08
US2071039	53	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	162	57.6	21.95
US2071040	33	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	161	63.7	24.57

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2071051	32	Female	No/SURGICALLY STERILE	WHITE	HISPANIC OR LATINO	156	66.4	27.28
US2071068	53	Male		WHITE	NOT HISPANIC OR LATINO	178	89.3	28.18
US2071069	18	Male		WHITE	NOT HISPANIC OR LATINO	181	70.9	21.64
US2071071	45	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	167.5	82.3	29.33
US2071073	26	Female	Yes	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	171	83.8	28.66
US2071077	29	Male		WHITE	NOT HISPANIC OR LATINO	180	84.7	26.14
US2081023	53	Male		WHITE	NOT HISPANIC OR LATINO	181.6	84.1	25.5
US2081025	38	Male		WHITE	NOT HISPANIC OR LATINO	166.4	69.1	24.96
US2081028	51	Male		WHITE	NOT HISPANIC OR LATINO	185.4	99.4	28.92
US2081045	43	Male		WHITE	NOT HISPANIC OR LATINO	170.2	79.5	27.44

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2081051	50	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	161.3	53.9	20.72
US2081062	36	Male		WHITE	NOT HISPANIC OR LATINO	191.8	92.3	25.09
US2081063	22	Male		WHITE	NOT HISPANIC OR LATINO	191.8	78.5	21.34
US2081064	48	Male		WHITE	NOT HISPANIC OR LATINO	179.1	75.2	23.44

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2011007	69	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	153.7	60	25.4
US2011011	66	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	160	67.7	26.45
US2011023	62	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	144.8	59.5	28.38
US2011109	76	Female	No/POST-MENOPAUSAL	ASIAN	NOT HISPANIC OR LATINO	151.1	51.5	22.56
US2011114	61	Male		WHITE	NOT HISPANIC OR LATINO	166.4	73.1	26.4
US2011116	69	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	165.1	67.3	24.69
US2011120	65	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	163.8	66.4	24.75
US2011124	60	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	157.5	51.6	20.8
US2011126	61	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	152.4	63.2	27.21

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2011130	64	Male		WHITE	NOT HISPANIC OR LATINO	188	97.5	27.59
US2011131	57	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	172.7	78.7	26.39
US2011142	64	Male		WHITE	NOT HISPANIC OR LATINO	185.4	98.4	28.63
US2011145	61	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	166.4	66.7	24.09
US2011152	66	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	157.5	54.8	22.09
US2011155	61	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	168.9	54	18.93
US2011156	73	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	154.9	51.5	21.46
US2011157	63	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	160	69.8	27.27
US2021015	70	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	168	79.9	28.31

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2021021	71	Male		WHITE	NOT HISPANIC OR LATINO	188	100.9	28.55
US2021022	67	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	163	58	21.83
US2021043	65	Male		WHITE	NOT HISPANIC OR LATINO	186	85	24.57
US2021130	80	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	160.5	70.5	27.37
US2021185	55	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	166.5	69.5	25.07
US2021189	75	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	177	78.6	25.09
US2021196	63	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	172	76.6	25.89
US2021198	63	Female	No/SURGICALLY STERILE	WHITE	HISPANIC OR LATINO	167.4	66.7	23.8
US2021206	64	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	172.4	81.9	27.56
US2021207	58	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	147.7	52.7	24.16

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2021219	62	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	157.7	63.5	25.53
US2021222	65	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	167.6	72.5	25.81
US2031085	71	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	162.5	68.4	25.9
US2031089	65	Male		WHITE	NOT HISPANIC OR LATINO	183	99.3	29.65
US2031092	75	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	167.6	75.7	26.95
US2031095	57	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	167.5	61.6	21.96
US2031098	62	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	158.8	73.5	29.15
US2031100	68	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	152.5	54.8	23.56
US2031102	57	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	171.4	71.6	24.37

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2031103	66	Male		WHITE	NOT HISPANIC OR LATINO	176.5	88.9	28.54
US2031110	69	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	165	69.3	25.45
US2031116	66	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	172.7	80.7	27.06
US2031124	59	Male		WHITE	NOT HISPANIC OR LATINO	185.9	96.6	27.95
US2031125	68	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	163.8	71.7	26.72
US2031129	61	Male		WHITE	NOT HISPANIC OR LATINO	177.8	81.6	25.81
US2031131	72	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	167.6	78.9	28.09
US2041102	61	Male		WHITE	NOT HISPANIC OR LATINO	181.6	88	26.68
US2041114	62	Male		WHITE	NOT HISPANIC OR LATINO	191	98.1	26.89

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2041115	70	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	167.4	65.7	23.45
US2041121	65	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	166.9	82.7	29.69
US2041132	56	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	156.2	64.1	26.27
US2041142	63	Male		WHITE	NOT HISPANIC OR LATINO	196.3	92	23.88
US2041146	59	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	169	55.9	19.57
US2041151	57	Male		WHITE	NOT HISPANIC OR LATINO	177.8	90.1	28.5
US2041152	66	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	168.9	65.4	22.93
US2041166	65	Male		WHITE	NOT HISPANIC OR LATINO	181.6	88.5	26.84
US2051055	59	Male		WHITE	NOT HISPANIC OR LATINO	169.5	67.4	23.46

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2051063	56	Male		WHITE	NOT HISPANIC OR LATINO	172.2	82.9	27.96
US2051072	69	Male		WHITE	NOT HISPANIC OR LATINO	175.2	79.1	25.77
US2051073	74	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	164	66.1	24.58
US2051086	77	Male		WHITE	NOT HISPANIC OR LATINO	193	88.1	23.65
US2051087	74	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	160.6	72	27.92
US2051089	56	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	167	65.7	23.56
US2051098	55	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	163	54	20.32
US2051112	60	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	160.7	75.2	29.12
US2061035	71	Male		WHITE	NOT HISPANIC OR LATINO	183	87	25.98

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2061043	59	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	160	59.8	23.36
US2061046	62	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	160	57.7	22.54
US2061051	58	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	172	60.3	20.38
US2061055	84	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	165	74.9	27.51
US2071005	56	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	156	65.2	26.79
US2071041	64	Male		WHITE	NOT HISPANIC OR LATINO	178	74.7	23.58
US2071084	64	Male		WHITE	NOT HISPANIC OR LATINO	178	89.6	28.28
US2071085	75	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	164	68	25.28
US2071086	68	Male		WHITE	NOT HISPANIC OR LATINO	175	87.3	28.51

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2071088	70	Male		WHITE	NOT HISPANIC OR LATINO	179	88.8	27.71
US2071092	61	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	157.5	75.3	30.36
US2071094	63	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	178	89.9	28.37
US2071098	65	Female	No/POST-MENOPAUSAL	WHITE	HISPANIC OR LATINO	155	69.3	28.84
US2071100	61	Male		WHITE	NOT HISPANIC OR LATINO	182.8	94.1	28.16
US2071102	56	Female	No/PARTNER STERILE	WHITE	NOT HISPANIC OR LATINO	162.5	65.7	24.88
US2071103	59	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	168	83.8	29.69
US2071105	65	Male		WHITE	NOT HISPANIC OR LATINO	192	80.1	21.73
US2081004	60	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	149.9	56.4	25.1
US2081005	55	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	158.8	60.5	23.99

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2081007	64	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	167.6	57.7	20.54
US2081015	55	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	165.1	60.5	22.2
US2081017	62	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	167.6	58.6	20.86
US2081029	55	Male		WHITE	NOT HISPANIC OR LATINO	172.7	89.5	30.01
US2081030	69	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	167.6	59.7	21.25
US2081065	64	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	165.1	75.5	27.7
US2081066	66	Male		WHITE	NOT HISPANIC OR LATINO	180.3	90.9	27.96
US2081073	63	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	163.8	56.9	21.21
US2081077	66	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	157.5	64.1	25.84

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2081080	69	Male		WHITE	NOT HISPANIC OR LATINO	182.9	85	25.41
US2081087	65	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	157.5	54.5	21.97
US2081097	76	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	162.6	58.6	22.16
US2081103	58	Male		WHITE	NOT HISPANIC OR LATINO	182.9	85.9	25.68
US2081104	59	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	166.4	65.5	23.66
US2081113	60	Male		WHITE	NOT HISPANIC OR LATINO	200.7	102.4	25.42
US2081119	64	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	171.4	75.5	25.7
US2081125	62	Male		WHITE	NOT HISPANIC OR LATINO	180.3	77.7	23.9

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2011012	58	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	174	65.9	21.77
US2011014	63	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	167.6	76.8	27.34
US2011032	58	Male		WHITE	NOT HISPANIC OR LATINO	170.2	61.8	21.33
US2011040	66	Female	No/POST-MENOPAUSAL	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	160	67.7	26.45
US2011117	79	Male		WHITE	HISPANIC OR LATINO	180.3	78.7	24.21
US2011123	64	Male		WHITE	NOT HISPANIC OR LATINO	177.8	85.5	27.05
US2011125	59	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	168.9	62	21.73
US2011127	63	Male		WHITE	NOT HISPANIC OR LATINO	182.9	75.9	22.69
US2011137	56	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	162.6	74.5	28.18
US2011138	62	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	157.5	70.5	28.42

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2011153	60	Female	No/POST-MENOPAUSAL	WHITE	HISPANIC OR LATINO	160	61.7	24.1
US2021004	72	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	165.1	64.7	23.74
US2021012	66	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	156	54.2	22.27
US2021018	71	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	171	73.2	25.03
US2021019	59	Male		WHITE	NOT HISPANIC OR LATINO	188.9	105.3	29.51
US2021020	72	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	158	66.9	26.8
US2021045	61	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	160.4	66.9	26
US2021047	65	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	160.5	61.5	23.87
US2021133	75	Male		WHITE	NOT HISPANIC OR LATINO	177.4	80.4	25.55
US2021190	60	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	166.4	69.5	25.1

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2021192	62	Male		ASIAN	NOT HISPANIC OR LATINO	177.3	90.1	28.66
US2021205	56	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	161	77.3	29.82
US2021216	57	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	157	71.7	29.09
US2021217	66	Female	No/SURGICALLY STERILE	WHITE	NOT REPORTED	165.6	79.2	28.88
US2021220	76	Male		BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	177.8	87.2	27.58
US2021226	68	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	167.2	68.8	24.61
US2031086	68	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	162.5	70.6	26.74
US2031096	73	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	169	78.5	27.49
US2031097	86	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	162.5	75.2	28.48
US2031104	55	Female	Yes	WHITE	NOT HISPANIC OR LATINO	167.6	83	29.55

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2031105	67	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	167.6	61.7	21.97
US2031106	56	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	155	59.4	24.72
US2031107	59	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	165.1	67.6	24.8
US2031108	67	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	177.8	80.2	25.37
US2031109	65	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	162.5	67.6	25.6
US2031114	66	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	167.6	53	18.87
US2031121	67	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	154.9	64.4	26.84
US2031128	74	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	167.6	75.2	26.77
US2041094	56	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	160.2	63.7	24.82

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2041100	57	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	165.1	71.9	26.38
US2041103	66	Male		WHITE	NOT HISPANIC OR LATINO	185.4	86.2	25.08
US2041104	68	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	162.6	53.8	20.35
US2041106	76	Male		WHITE	NOT HISPANIC OR LATINO	179	74.8	23.35
US2041109	66	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	154.2	67.8	28.51
US2041111	66	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	175.2	76.4	24.89
US2041113	58	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	175.5	73.3	23.8
US2041118	65	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	168	70.2	24.87
US2041119	68	Male		WHITE	NOT HISPANIC OR LATINO	177.8	82.8	26.19

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2041127	69	Male		WHITE	NOT HISPANIC OR LATINO	174.5	87.8	28.83
US2041130	62	Male		WHITE	NOT HISPANIC OR LATINO	180.1	95	29.29
US2041139	69	Male		WHITE	NOT HISPANIC OR LATINO	172	83.4	28.19
US2041145	59	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	168.9	70.9	24.85
US2041150	66	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	172.7	81.4	27.29
US2041155	64	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	156.2	62.7	25.7
US2051057	61	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	151	54.5	23.9
US2051059	57	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	163.5	74	27.68
US2051060	65	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	162.8	77.2	29.13

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2051066	65	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	167.1	72	25.79
US2051068	68	Male		WHITE	NOT HISPANIC OR LATINO	174	88.7	29.3
US2051071	71	Male		WHITE	NOT HISPANIC OR LATINO	178.2	86.7	27.3
US2051078	73	Male		WHITE	NOT HISPANIC OR LATINO	166.1	75.2	27.26
US2051081	69	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	163.5	47.9	17.92
US2051092	65	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	162.8	67.2	25.35
US2051093	66	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	160	73	28.52
US2051094	57	Male		WHITE	NOT HISPANIC OR LATINO	181.2	72.1	21.96
US2051095	58	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	165	81.4	29.9

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2051096	58	Female	No/POST-MENOPAUSAL	ASIAN	NOT HISPANIC OR LATINO	164	74	27.51
US2051099	73	Male		WHITE	NOT HISPANIC OR LATINO	179.5	86.8	26.94
US2051100	68	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	163.8	57.2	21.32
US2051103	58	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	167.5	63.6	22.67
US2051105	56	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	161.6	71	27.19
US2051107	58	Male		WHITE	NOT HISPANIC OR LATINO	191.6	98.3	26.78
US2051109	55	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	170.6	75.9	26.08
US2061037	56	Female	No/SURGICALLY STERILE	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	NOT HISPANIC OR LATINO	161	72.1	27.82
US2061053	64	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	155	70.5	29.34

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2061057	79	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	164	58.5	21.75
US2061064	68	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	160	66	25.78
US2061068	63	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	165	50.4	18.51
US2071007	58	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	175.5	71	23.05
US2071024	63	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	165	64.7	23.76
US2071025	59	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	165	58.7	21.56
US2071083	87	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	168	67.6	23.95
US2071090	63	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	169	65.3	22.86
US2071099	62	Male		WHITE	HISPANIC OR LATINO	171	84.7	28.97
US2071101	65	Female	No/POST-MENOPAUSAL	WHITE	HISPANIC OR LATINO	161.3	75	28.83

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2071104	66	Male		WHITE	NOT HISPANIC OR LATINO	185.4	87.8	25.54
US2071106	64	Male		WHITE	NOT HISPANIC OR LATINO	168	75.5	26.75
US2081003	64	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	170.2	75.5	26.06
US2081009	59	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	171.4	65.5	22.3
US2081020	61	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	171.4	62.7	21.34
US2081070	71	Male		WHITE	NOT HISPANIC OR LATINO	170.2	61.4	21.2
US2081071	65	Male		WHITE	NOT HISPANIC OR LATINO	182.9	99.5	29.74
US2081085	63	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	172.2	89.5	30.18
US2081090	63	Male		WHITE	NOT HISPANIC OR LATINO	180.3	88.6	27.25

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2081092	77	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	165.1	60	22.01
US2081100	59	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	175.3	90.9	29.58
US2081110	62	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	167.6	71.4	25.42
US2081112	55	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	165.1	60.9	22.34
US2081118	70	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	157.5	61.8	24.91
US2081123	65	Male		WHITE	NOT HISPANIC OR LATINO	182.9	83.2	24.87

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2011004	55	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	168.9	52.3	18.33
US2011009	62	Female	No/SURGICALLY STERILE	WHITE	HISPANIC OR LATINO	154.9	61.8	25.76
US2011028	60	Male		WHITE	NOT HISPANIC OR LATINO	167.6	75.5	26.88
US2011113	63	Female	No/SURGICALLY STERILE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	149.9	60	26.7
US2011118	60	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	158.8	57	22.6
US2011121	61	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	170.2	78.5	27.1
US2011122	59	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	162.6	71.6	27.08
US2011128	61	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	162.6	56.4	21.33
US2011139	66	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	166.4	73.7	26.62
US2011149	74	Female	No/SURGICALLY STERILE	WHITE	HISPANIC OR LATINO	159	63.3	25.04

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2011159	72	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	159.8	64.1	25.1
US2011162	62	Female	No/POST-MENOPAUSAL	WHITE	HISPANIC OR LATINO	157.5	60.5	24.39
US2021003	58	Male		WHITE	NOT HISPANIC OR LATINO	190.1	84.6	23.41
US2021007	68	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	155.5	59.7	24.69
US2021011	58	Male		WHITE	HISPANIC OR LATINO	180	93.4	28.83
US2021031	72	Male		WHITE	NOT HISPANIC OR LATINO	175.3	91.8	29.87
US2021114	67	Male		WHITE	NOT HISPANIC OR LATINO	183	88.7	26.49
US2021115	59	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	167	58.6	21.01
US2021186	60	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	160.5	59.3	23.02
US2021208	56	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	156	58.7	24.12

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2021211	78	Female	No/POST-MENOPAUSAL	WHITE	HISPANIC OR LATINO	160.5	56.6	21.97
US2021214	73	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	175	63.5	20.73
US2021215	58	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	165	71.6	26.3
US2021218	56	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	157.7	60.3	24.25
US2021230	68	Female	No/POST-MENOPAUSAL	WHITE	HISPANIC OR LATINO	164.5	75.4	27.86
US2021232	61	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	169	65.7	23
US2021234	70	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	164	60.4	22.46
US2031091	61	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	167.6	73	25.99
US2031093	57	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	156.2	58.2	23.85
US2031101	64	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	152.4	68	29.28

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2031111	87	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	156.2	64.8	26.56
US2031112	56	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	160	54.9	21.45
US2031122	56	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	172.7	86.2	28.9
US2041096	64	Male		WHITE	NOT HISPANIC OR LATINO	182.9	86.8	25.95
US2041107	64	Male		WHITE	NOT HISPANIC OR LATINO	188	77.2	21.84
US2041108	67	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	168.9	73	25.59
US2041112	61	Male		WHITE	NOT HISPANIC OR LATINO	184	81	23.92
US2041117	73	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	172.5	74.7	25.1
US2041120	67	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	169.9	72.8	25.22

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2041122	82	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	144.3	44	21.13
US2041123	60	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	166.8	63.6	22.86
US2041125	57	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	172.7	89.1	29.87
US2041126	62	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	164.9	74.9	27.54
US2041131	62	Male		WHITE	NOT HISPANIC OR LATINO	181.4	78.7	23.92
US2041136	56	Male		WHITE	NOT HISPANIC OR LATINO	180	93.4	28.83
US2041138	68	Male		WHITE	NOT HISPANIC OR LATINO	187	105.4	30.14
US2041144	65	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	171.5	83.4	28.36
US2041149	65	Female	No/POST-MENOPAUSAL	AMERICAN INDIAN OR ALASKA NATIVE	NOT HISPANIC OR LATINO	163	73.9	27.81

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2051054	63	Male		WHITE	NOT HISPANIC OR LATINO	177.5	85.3	27.07
US2051064	59	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	162.6	50.7	19.18
US2051069	64	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	175.4	64	20.8
US2051070	63	Male		WHITE	NOT HISPANIC OR LATINO	172.3	79.1	26.64
US2051074	59	Male		WHITE	NOT HISPANIC OR LATINO	175.2	76.7	24.99
US2051075	69	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	163	68.4	25.74
US2051077	66	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	173.2	70.8	23.6
US2051084	61	Female	No/SURGICALLY STERILE	WHITE	HISPANIC OR LATINO	164.1	77.3	28.71
US2051085	65	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	165	63.1	23.18
US2051088	58	Male		WHITE	NOT HISPANIC OR LATINO	170.5	79.2	27.24

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2051097	70	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	171.5	88	29.92
US2051101	62	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	171.2	83	28.32
US2051102	62	Male		WHITE	NOT HISPANIC OR LATINO	173.2	72.8	24.27
US2051104	59	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	166.4	80.6	29.11
US2051106	56	Male		WHITE	NOT HISPANIC OR LATINO	176.4	82.3	26.45
US2051108	65	Male		WHITE	NOT HISPANIC OR LATINO	195.5	80.1	20.96
US2051111	70	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	167	81.8	29.33
US2061036	56	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	159	74.6	29.51
US2061045	66	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	164	62	23.05

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2061063	56	Male		WHITE	NOT HISPANIC OR LATINO	192	91.1	24.71
US2071006	71	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	179	93.7	29.24
US2071013	73	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	179	88.3	27.56
US2071037	71	Male		WHITE	NOT HISPANIC OR LATINO	185	93.2	27.23
US2071043	69	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	162	58.6	22.33
US2071082	57	Male		WHITE	NOT HISPANIC OR LATINO	187	90.3	25.82
US2071087	81	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	145.5	47.4	22.39
US2071089	66	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	159	63	24.92
US2071091	58	Male		WHITE	NOT HISPANIC OR LATINO	191	100.9	27.66
US2071093	67	Female	No/POST-MENOPAUSAL	WHITE	HISPANIC OR LATINO	166	55.1	20

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2071095	71	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	159	51.9	20.53
US2071096	55	Male		WHITE	NOT HISPANIC OR LATINO	183	98.2	29.32
US2081001	57	Male		WHITE	NOT HISPANIC OR LATINO	182.9	90.9	27.17
US2081002	69	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	171.4	76.8	26.14
US2081014	67	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	165.1	62.7	23
US2081016	55	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	160	54.5	21.29
US2081019	76	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	165.1	60.5	22.2
US2081035	68	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	163.8	67.5	25.16
US2081069	70	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	157.5	60.5	24.39

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2081072	59	Male		WHITE	NOT HISPANIC OR LATINO	199.4	104.5	26.28
US2081075	56	Male		WHITE	NOT HISPANIC OR LATINO	179.1	81.6	25.44
US2081076	55	Female	Yes	WHITE	NOT HISPANIC OR LATINO	154.9	49.2	20.51
US2081081	56	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	170.2	82.7	28.55
US2081088	63	Male		WHITE	NOT HISPANIC OR LATINO	182.9	84.5	25.26
US2081091	59	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	170.2	79.1	27.31
US2081093	66	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	157.5	67.4	27.17
US2081099	55	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	165.1	59.1	21.68
US2081108	66	Female	No/POST-MENOPAUSAL	WHITE	NOT HISPANIC OR LATINO	166.4	72.4	26.15

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020401.sas 19NOV2020 01:26 Database Lock Date: 05NOV2020

Listing 16.2.4.1
Demographics and Baseline Characteristics
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Age (Years)	Gender	Child-bearing Potential	Race	Ethnicity	Height (cm)	Weight (kg)	BMI (kg/m ²)
US2081116	75	Male		WHITE	NOT HISPANIC OR LATINO	170.2	70.9	24.48
US2081117	66	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	160	52.3	20.43
US2081120	72	Male		WHITE	NOT HISPANIC OR LATINO	176.5	89.5	28.73
US2081121	63	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	166.4	70	25.28
US2081129	58	Female	No/SURGICALLY STERILE	WHITE	NOT HISPANIC OR LATINO	180.3	91.9	28.27

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2011001	61	Female	WHITE	NOT HISPANIC OR LATINO
US2011003	71	Female	WHITE	NOT HISPANIC OR LATINO
US2011005	56	Female	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2011006	57	Male	WHITE	NOT HISPANIC OR LATINO
US2011008	65	Female	WHITE	NOT HISPANIC OR LATINO
US2011015	73	Male	WHITE	NOT HISPANIC OR LATINO
US2011021	26	Female	ASIAN	NOT HISPANIC OR LATINO
US2011022	29	Male	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2011024	49	Female	WHITE	HISPANIC OR LATINO
US2011027	28	Female	WHITE	HISPANIC OR LATINO
US2011033	47	Female	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2011034	62	Female	WHITE	NOT HISPANIC OR LATINO
US2011035	74	Female	WHITE	NOT HISPANIC OR LATINO
US2011037	68	Female	WHITE	NOT HISPANIC OR LATINO
US2011045	69	Female	WHITE	NOT HISPANIC OR LATINO
US2011049	60	Female	WHITE	NOT HISPANIC OR LATINO
US2011052	64	Male	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2011053	26	Male	ASIAN	NOT HISPANIC OR LATINO
US2011054	51	Female	WHITE	NOT HISPANIC OR LATINO
US2011062	20	Male	WHITE	NOT HISPANIC OR LATINO
US2011063	63	Female	WHITE	NOT HISPANIC OR LATINO
US2011066	45	Male	WHITE	HISPANIC OR LATINO
US2011071	23	Female	WHITE	NOT HISPANIC OR LATINO
US2011072	28	Male	WHITE	NOT HISPANIC OR LATINO
US2011074	46	Female	WHITE	NOT HISPANIC OR LATINO
US2011075	46	Female	WHITE	NOT HISPANIC OR LATINO
US2011076	20	Male	WHITE	HISPANIC OR LATINO
US2011077	30	Male	WHITE	HISPANIC OR LATINO
US2011078	33	Female	WHITE	HISPANIC OR LATINO
US2011079	54	Female	WHITE	HISPANIC OR LATINO
US2011083	47	Female	WHITE	NOT HISPANIC OR LATINO
US2011094	41	Female	WHITE	NOT HISPANIC OR LATINO
US2011096	46	Male	WHITE	NOT HISPANIC OR LATINO
US2011097	43	Female	WHITE	HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2011098	46	Female	WHITE	HISPANIC OR LATINO
US2011099	29	Male	WHITE	NOT HISPANIC OR LATINO
US2011100	49	Male	WHITE	NOT HISPANIC OR LATINO
US2011101	41	Female	WHITE	HISPANIC OR LATINO
US2011104	25	Male	WHITE	NOT HISPANIC OR LATINO
US2011105	39	Female	WHITE	NOT HISPANIC OR LATINO
US2011106	38	Female	WHITE	NOT HISPANIC OR LATINO
US2011107	41	Female	WHITE	NOT HISPANIC OR LATINO
US2011108	32	Female	WHITE	NOT HISPANIC OR LATINO
US2011111	69	Female	WHITE	NOT HISPANIC OR LATINO
US2011112	65	Male	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2011115	66	Male	WHITE	NOT HISPANIC OR LATINO
US2011119	70	Male	WHITE	NOT HISPANIC OR LATINO
US2011132	56	Female	WHITE	HISPANIC OR LATINO
US2011133	57	Female	WHITE	HISPANIC OR LATINO
US2011134	66	Male	WHITE	NOT HISPANIC OR LATINO
US2011135	58	Male	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2011136	55	Male	WHITE	NOT HISPANIC OR LATINO
US2011140	61	Male	WHITE	NOT HISPANIC OR LATINO
US2011143	57	Male	WHITE	NOT HISPANIC OR LATINO
US2011144	58	Male	WHITE	NOT HISPANIC OR LATINO
US2011146	73	Female	WHITE	NOT HISPANIC OR LATINO
US2011147	68	Female	WHITE	NOT HISPANIC OR LATINO
US2011148	68	Male	WHITE	NOT HISPANIC OR LATINO
US2011150	70	Female	WHITE	NOT HISPANIC OR LATINO
US2011151	70	Male	WHITE	NOT HISPANIC OR LATINO
US2011154	67	Male	WHITE	NOT HISPANIC OR LATINO
US2011158	61	Male	WHITE	NOT HISPANIC OR LATINO
US2011160	74	Female	WHITE	NOT HISPANIC OR LATINO
US2011161	60	Female	WHITE	NOT HISPANIC OR LATINO
US2021001	57	Female	WHITE	NOT HISPANIC OR LATINO
US2021002	57	Male	WHITE	NOT HISPANIC OR LATINO
US2021005	76	Female	WHITE	NOT HISPANIC OR LATINO
US2021008	74	Male	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2021009	56	Male	WHITE	NOT HISPANIC OR LATINO
US2021013	76	Female	WHITE	NOT HISPANIC OR LATINO
US2021014	73	Male	WHITE	NOT HISPANIC OR LATINO
US2021017	60	Female	WHITE	NOT HISPANIC OR LATINO
US2021025	69	Male	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2021026	60	Female	WHITE	NOT HISPANIC OR LATINO
US2021027	55	Male	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2021028	62	Female	WHITE	NOT HISPANIC OR LATINO
US2021030	56	Female	WHITE	NOT HISPANIC OR LATINO
US2021032	65	Female	WHITE	NOT HISPANIC OR LATINO
US2021033	62	Male	WHITE	NOT HISPANIC OR LATINO
US2021034	59	Female	WHITE	NOT HISPANIC OR LATINO
US2021036	64	Male	WHITE	NOT HISPANIC OR LATINO
US2021037	81	Male	WHITE	NOT HISPANIC OR LATINO
US2021038	71	Male	WHITE	NOT HISPANIC OR LATINO
US2021041	61	Female	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2021048	69	Female	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2021049	65	Female	WHITE	NOT HISPANIC OR LATINO
US2021050	61	Female	WHITE	NOT HISPANIC OR LATINO
US2021051	23	Male	WHITE	NOT HISPANIC OR LATINO
US2021052	23	Female	WHITE	NOT HISPANIC OR LATINO
US2021053	21	Female	WHITE	HISPANIC OR LATINO
US2021054	60	Male	WHITE	NOT HISPANIC OR LATINO
US2021055	19	Male	WHITE	NOT HISPANIC OR LATINO
US2021056	47	Male	WHITE	NOT HISPANIC OR LATINO
US2021057	21	Female	WHITE	HISPANIC OR LATINO
US2021060	54	Female	WHITE	NOT HISPANIC OR LATINO
US2021065	39	Male	WHITE	NOT HISPANIC OR LATINO
US2021066	53	Female	WHITE	NOT HISPANIC OR LATINO
US2021069	33	Male	WHITE	HISPANIC OR LATINO
US2021071	48	Male	WHITE	NOT HISPANIC OR LATINO
US2021072	42	Female	WHITE	NOT HISPANIC OR LATINO
US2021075	25	Male	WHITE	NOT HISPANIC OR LATINO
US2021077	54	Female	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2021079	20	Male	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2021081	46	Female	WHITE	NOT HISPANIC OR LATINO
US2021083	29	Male	WHITE	NOT HISPANIC OR LATINO
US2021085	27	Female	WHITE	NOT HISPANIC OR LATINO
US2021086	28	Male	WHITE	NOT HISPANIC OR LATINO
US2021087	28	Female	WHITE	NOT HISPANIC OR LATINO
US2021088	64	Male	WHITE	NOT HISPANIC OR LATINO
US2021091	41	Female	WHITE	NOT HISPANIC OR LATINO
US2021092	57	Female	WHITE	NOT HISPANIC OR LATINO
US2021095	48	Male	WHITE	NOT HISPANIC OR LATINO
US2021097	47	Male	WHITE	NOT HISPANIC OR LATINO
US2021098	40	Female	WHITE	NOT HISPANIC OR LATINO
US2021100	19	Female	WHITE	NOT HISPANIC OR LATINO
US2021102	21	Male	WHITE	NOT HISPANIC OR LATINO
US2021103	36	Male	WHITE	NOT HISPANIC OR LATINO
US2021105	40	Male	WHITE	NOT HISPANIC OR LATINO
US2021108	57	Female	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2021109	59	Male	WHITE	NOT HISPANIC OR LATINO
US2021110	58	Female	WHITE	NOT HISPANIC OR LATINO
US2021112	72	Male	WHITE	NOT HISPANIC OR LATINO
US2021113	57	Female	WHITE	NOT HISPANIC OR LATINO
US2021116	70	Male	WHITE	NOT HISPANIC OR LATINO
US2021117	55	Male	WHITE	NOT HISPANIC OR LATINO
US2021118	38	Female	WHITE	NOT HISPANIC OR LATINO
US2021119	40	Male	WHITE	NOT HISPANIC OR LATINO
US2021120	26	Male	WHITE	NOT HISPANIC OR LATINO
US2021122	36	Male	WHITE	NOT HISPANIC OR LATINO
US2021123	70	Female	WHITE	NOT HISPANIC OR LATINO
US2021124	26	Male	WHITE	NOT HISPANIC OR LATINO
US2021125	41	Male	WHITE	NOT HISPANIC OR LATINO
US2021126	33	Female	WHITE	NOT HISPANIC OR LATINO
US2021127	53	Female	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2021128	36	Female	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2021129	37	Male	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2021131	31	Male	WHITE	NOT HISPANIC OR LATINO
US2021132	60	Male	WHITE	NOT HISPANIC OR LATINO
US2021134	44	Female	WHITE	NOT HISPANIC OR LATINO
US2021136	36	Female	WHITE	NOT HISPANIC OR LATINO
US2021139	53	Male	WHITE	NOT HISPANIC OR LATINO
US2021140	50	Female	WHITE	NOT HISPANIC OR LATINO
US2021141	31	Female	WHITE	NOT HISPANIC OR LATINO
US2021142	44	Female	WHITE	NOT HISPANIC OR LATINO
US2021143	23	Female	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2021146	30	Male	WHITE	NOT HISPANIC OR LATINO
US2021148	26	Male	WHITE	NOT HISPANIC OR LATINO
US2021149	37	Female	WHITE	NOT HISPANIC OR LATINO
US2021150	33	Male	WHITE	NOT HISPANIC OR LATINO
US2021152	19	Male	WHITE	NOT HISPANIC OR LATINO
US2021153	30	Male	WHITE	NOT HISPANIC OR LATINO
US2021156	28	Female	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2021157	28	Female	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2021158	41	Male	WHITE	NOT HISPANIC OR LATINO
US2021159	40	Male	WHITE	NOT HISPANIC OR LATINO
US2021160	25	Female	WHITE	NOT HISPANIC OR LATINO
US2021163	50	Male	WHITE	NOT HISPANIC OR LATINO
US2021165	35	Female	WHITE	NOT HISPANIC OR LATINO
US2021168	53	Male	WHITE	NOT HISPANIC OR LATINO
US2021169	52	Male	WHITE	NOT HISPANIC OR LATINO
US2021170	32	Female	WHITE	NOT HISPANIC OR LATINO
US2021171	40	Male	WHITE	NOT HISPANIC OR LATINO
US2021172	36	Female	WHITE	NOT HISPANIC OR LATINO
US2021173	19	Male	WHITE	NOT HISPANIC OR LATINO
US2021174	18	Female	WHITE	NOT HISPANIC OR LATINO
US2021176	41	Female	WHITE	NOT HISPANIC OR LATINO
US2021177	53	Female	WHITE	NOT HISPANIC OR LATINO
US2021178	24	Male	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2021181	18	Male	WHITE	NOT HISPANIC OR LATINO
US2021183	41	Male	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2021184	65	Female	WHITE	NOT HISPANIC OR LATINO
US2021187	55	Male	WHITE	NOT HISPANIC OR LATINO
US2021188	73	Female	WHITE	NOT HISPANIC OR LATINO
US2021191	56	Female	WHITE	NOT HISPANIC OR LATINO
US2021193	68	Male	WHITE	NOT HISPANIC OR LATINO
US2021194	70	Male	WHITE	NOT HISPANIC OR LATINO
US2021195	63	Female	WHITE	NOT REPORTED
US2021197	69	Female	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2021199	61	Female	WHITE	HISPANIC OR LATINO
US2021201	57	Male	BLACK OR AFRICAN AMERICAN	HISPANIC OR LATINO
US2021202	68	Male	WHITE	NOT HISPANIC OR LATINO
US2021203	64	Female	WHITE	NOT HISPANIC OR LATINO
US2021204	75	Male	WHITE	NOT HISPANIC OR LATINO
US2021209	62	Female	WHITE	NOT HISPANIC OR LATINO
US2021210	56	Male	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2021212	65	Female	WHITE	NOT HISPANIC OR LATINO
US2021213	64	Male	WHITE	NOT HISPANIC OR LATINO

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020402.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2021221	69	Male	WHITE	NOT HISPANIC OR LATINO
US2021223	62	Female	WHITE	NOT HISPANIC OR LATINO
US2021224	78	Female	WHITE	NOT HISPANIC OR LATINO
US2021225	67	Female	WHITE	NOT HISPANIC OR LATINO
US2021227	64	Female	WHITE	HISPANIC OR LATINO
US2021228	59	Female	WHITE	NOT HISPANIC OR LATINO
US2021229	64	Female	WHITE	NOT HISPANIC OR LATINO
US2021231	59	Male	WHITE	NOT HISPANIC OR LATINO
US2021233	57	Female	WHITE	NOT HISPANIC OR LATINO
US2021235	59	Male	WHITE	NOT HISPANIC OR LATINO
US2021236	81	Male	WHITE	NOT HISPANIC OR LATINO
US2021237	55	Male	WHITE	NOT HISPANIC OR LATINO
US2021238	56	Male	WHITE	NOT HISPANIC OR LATINO
US2021239	61	Female	WHITE	NOT HISPANIC OR LATINO
US2021240	57	Male	WHITE	NOT HISPANIC OR LATINO
US2021241	67	Female	WHITE	NOT HISPANIC OR LATINO
US2031003	42	Male	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2031005	52	Female	WHITE	NOT HISPANIC OR LATINO
US2031006	53	Female	WHITE	NOT HISPANIC OR LATINO
US2031007	37	Male	WHITE	NOT HISPANIC OR LATINO
US2031008	47	Female	WHITE	NOT HISPANIC OR LATINO
US2031010	45	Female	WHITE	HISPANIC OR LATINO
US2031015	36	Female	WHITE	NOT HISPANIC OR LATINO
US2031017	29	Female	WHITE	NOT HISPANIC OR LATINO
US2031018	44	Female	WHITE	HISPANIC OR LATINO
US2031024	34	Female	WHITE	NOT HISPANIC OR LATINO
US2031025	47	Female	WHITE	HISPANIC OR LATINO
US2031028	50	Male	WHITE	NOT HISPANIC OR LATINO
US2031031	24	Female	WHITE	NOT HISPANIC OR LATINO
US2031032	20	Female	WHITE	NOT HISPANIC OR LATINO
US2031034	33	Female	WHITE	NOT HISPANIC OR LATINO
US2031036	39	Female	WHITE	NOT HISPANIC OR LATINO
US2031039	43	Female	WHITE	NOT HISPANIC OR LATINO
US2031044	41	Female	WHITE	NOT HISPANIC OR LATINO

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020402.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2031046	29	Female	WHITE	HISPANIC OR LATINO
US2031052	29	Female	WHITE	NOT HISPANIC OR LATINO
US2031053	43	Male	WHITE	NOT HISPANIC OR LATINO
US2031054	51	Female	WHITE	NOT HISPANIC OR LATINO
US2031055	29	Female	WHITE	HISPANIC OR LATINO
US2031059	27	Female	WHITE	NOT HISPANIC OR LATINO
US2031061	42	Female	WHITE	NOT HISPANIC OR LATINO
US2031064	22	Female	WHITE	NOT HISPANIC OR LATINO
US2031065	19	Female	WHITE	NOT HISPANIC OR LATINO
US2031067	36	Female	WHITE	NOT HISPANIC OR LATINO
US2031068	47	Female	WHITE	NOT HISPANIC OR LATINO
US2031069	27	Female	WHITE	NOT HISPANIC OR LATINO
US2031070	39	Female	WHITE	NOT HISPANIC OR LATINO
US2031075	22	Male	WHITE	HISPANIC OR LATINO
US2031076	37	Female	WHITE	NOT HISPANIC OR LATINO
US2031077	44	Male	WHITE	NOT HISPANIC OR LATINO
US2031078	46	Female	WHITE	NOT HISPANIC OR LATINO

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020402.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2031082	27	Female	WHITE	NOT HISPANIC OR LATINO
US2031083	41	Male	WHITE	NOT HISPANIC OR LATINO
US2031087	58	Female	WHITE	NOT HISPANIC OR LATINO
US2031088	72	Female	WHITE	NOT HISPANIC OR LATINO
US2031090	46	Female	WHITE	NOT HISPANIC OR LATINO
US2031099	72	Male	WHITE	NOT HISPANIC OR LATINO
US2031113	59	Male	WHITE	NOT HISPANIC OR LATINO
US2031115	71	Male	WHITE	NOT HISPANIC OR LATINO
US2031117	74	Female	WHITE	NOT HISPANIC OR LATINO
US2031118	55	Female	WHITE	NOT HISPANIC OR LATINO
US2031119	61	Female	WHITE	NOT HISPANIC OR LATINO
US2031120	58	Male	WHITE	NOT HISPANIC OR LATINO
US2031123	59	Female	WHITE	NOT HISPANIC OR LATINO
US2031126	61	Female	WHITE	NOT HISPANIC OR LATINO
US2031127	69	Female	WHITE	NOT HISPANIC OR LATINO
US2031130	63	Female	WHITE	NOT HISPANIC OR LATINO
US2031132	57	Female	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2031133	60	Male	WHITE	NOT HISPANIC OR LATINO
US2031134	63	Male	WHITE	NOT HISPANIC OR LATINO
US2031135	56	Female	WHITE	NOT HISPANIC OR LATINO
US2031136	73	Female	WHITE	NOT HISPANIC OR LATINO
US2041001	33	Male	WHITE	NOT HISPANIC OR LATINO
US2041004	41	Female	WHITE	NOT HISPANIC OR LATINO
US2041009	26	Male	WHITE	NOT HISPANIC OR LATINO
US2041015	40	Male	WHITE	NOT HISPANIC OR LATINO
US2041017	31	Female	WHITE	NOT HISPANIC OR LATINO
US2041018	39	Male	WHITE	NOT HISPANIC OR LATINO
US2041021	48	Male	WHITE	NOT HISPANIC OR LATINO
US2041028	19	Male	WHITE	NOT HISPANIC OR LATINO
US2041031	51	Female	WHITE	NOT HISPANIC OR LATINO
US2041032	42	Male	WHITE	NOT HISPANIC OR LATINO
US2041033	38	Female	WHITE	NOT HISPANIC OR LATINO
US2041035	49	Male	WHITE	NOT HISPANIC OR LATINO
US2041037	54	Male	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2041038	47	Female	WHITE	NOT HISPANIC OR LATINO
US2041039	36	Female	WHITE	NOT HISPANIC OR LATINO
US2041040	43	Female	WHITE	NOT HISPANIC OR LATINO
US2041044	19	Male	WHITE	NOT HISPANIC OR LATINO
US2041045	42	Female	WHITE	NOT HISPANIC OR LATINO
US2041050	39	Female	WHITE	NOT HISPANIC OR LATINO
US2041052	22	Male	WHITE	NOT HISPANIC OR LATINO
US2041054	53	Female	WHITE	NOT HISPANIC OR LATINO
US2041057	23	Female	WHITE	NOT HISPANIC OR LATINO
US2041063	26	Female	WHITE	HISPANIC OR LATINO
US2041065	48	Female	WHITE	NOT HISPANIC OR LATINO
US2041066	21	Male	WHITE	NOT HISPANIC OR LATINO
US2041067	31	Female	WHITE	NOT HISPANIC OR LATINO
US2041068	48	Female	WHITE	NOT HISPANIC OR LATINO
US2041069	52	Female	WHITE	NOT HISPANIC OR LATINO
US2041070	42	Female	WHITE	NOT HISPANIC OR LATINO
US2041072	34	Male	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2041074	22	Male	WHITE	NOT HISPANIC OR LATINO
US2041081	34	Male	WHITE	NOT HISPANIC OR LATINO
US2041082	54	Male	WHITE	NOT HISPANIC OR LATINO
US2041083	52	Male	AMERICAN INDIAN OR ALASKA NATIVE	NOT HISPANIC OR LATINO
US2041085	38	Male	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2041087	49	Male	WHITE	NOT HISPANIC OR LATINO
US2041093	44	Male	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2041095	78	Male	WHITE	NOT HISPANIC OR LATINO
US2041097	46	Female	WHITE	NOT HISPANIC OR LATINO
US2041098	19	Female	WHITE	NOT HISPANIC OR LATINO
US2041099	70	Male	WHITE	NOT HISPANIC OR LATINO
US2041101	66	Male	WHITE	NOT HISPANIC OR LATINO
US2041105	66	Female	WHITE	NOT HISPANIC OR LATINO
US2041110	63	Male	WHITE	NOT HISPANIC OR LATINO
US2041116	60	Female	WHITE	NOT HISPANIC OR LATINO
US2041124	61	Female	WHITE	NOT HISPANIC OR LATINO
US2041128	58	Female	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2041129	64	Male	WHITE	NOT HISPANIC OR LATINO
US2041133	67	Male	WHITE	NOT HISPANIC OR LATINO
US2041134	69	Male	WHITE	NOT HISPANIC OR LATINO
US2041135	55	Female	WHITE	UNKNOWN
US2041137	72	Female	WHITE	NOT HISPANIC OR LATINO
US2041140	59	Female	WHITE	NOT HISPANIC OR LATINO
US2041141	55	Female	WHITE	NOT HISPANIC OR LATINO
US2041143	61	Female	WHITE	NOT HISPANIC OR LATINO
US2041147	58	Female	WHITE	NOT HISPANIC OR LATINO
US2041148	65	Female	WHITE	NOT HISPANIC OR LATINO
US2041153	62	Female	WHITE	NOT HISPANIC OR LATINO
US2041154	61	Male	WHITE	NOT HISPANIC OR LATINO
US2041156	59	Female	WHITE	NOT HISPANIC OR LATINO
US2041157	64	Male	WHITE	NOT HISPANIC OR LATINO
US2041158	72	Male	WHITE	NOT HISPANIC OR LATINO
US2041159	74	Female	WHITE	NOT HISPANIC OR LATINO
US2041160	60	Female	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2041161	61	Male	WHITE	NOT HISPANIC OR LATINO
US2041162	57	Male	WHITE	NOT HISPANIC OR LATINO
US2041163	72	Male	WHITE	NOT HISPANIC OR LATINO
US2041164	59	Female	WHITE	HISPANIC OR LATINO
US2041165	66	Male	WHITE	NOT HISPANIC OR LATINO
US2041167	59	Male	WHITE	NOT HISPANIC OR LATINO
US2041168	58	Female	WHITE	NOT HISPANIC OR LATINO
US2041169	68	Male	WHITE	NOT HISPANIC OR LATINO
US2041170	67	Female	WHITE	NOT HISPANIC OR LATINO
US2041171	57	Female	WHITE	HISPANIC OR LATINO
US2041172	57	Male	WHITE	NOT HISPANIC OR LATINO
US2051004	52	Male	WHITE	NOT HISPANIC OR LATINO
US2051005	39	Male	MULTIPLE: (b) (6)	NOT HISPANIC OR LATINO
US2051006	43	Female	WHITE	NOT HISPANIC OR LATINO
US2051007	35	Male	WHITE	NOT HISPANIC OR LATINO
US2051014	37	Female	WHITE	NOT HISPANIC OR LATINO
US2051015	53	Female	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2051016	31	Male	WHITE	NOT HISPANIC OR LATINO
US2051021	21	Female	WHITE	NOT HISPANIC OR LATINO
US2051023	53	Female	WHITE	HISPANIC OR LATINO
US2051037	39	Female	WHITE	NOT HISPANIC OR LATINO
US2051039	38	Female	WHITE	NOT HISPANIC OR LATINO
US2051041	46	Male	WHITE	NOT HISPANIC OR LATINO
US2051046	48	Female	WHITE	NOT HISPANIC OR LATINO
US2051047	30	Male	WHITE	NOT HISPANIC OR LATINO
US2051049	52	Male	WHITE	NOT HISPANIC OR LATINO
US2051051	37	Male	WHITE	NOT HISPANIC OR LATINO
US2051052	50	Female	WHITE	NOT HISPANIC OR LATINO
US2051053	35	Female	WHITE	NOT HISPANIC OR LATINO
US2051056	58	Female	WHITE	NOT HISPANIC OR LATINO
US2051058	70	Female	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2051061	83	Male	WHITE	NOT HISPANIC OR LATINO
US2051062	68	Female	WHITE	NOT HISPANIC OR LATINO
US2051065	60	Male	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2051067	68	Female	WHITE	NOT HISPANIC OR LATINO
US2051076	58	Female	WHITE	NOT HISPANIC OR LATINO
US2051079	57	Female	WHITE	NOT HISPANIC OR LATINO
US2051080	70	Female	WHITE	NOT HISPANIC OR LATINO
US2051082	72	Male	WHITE	NOT HISPANIC OR LATINO
US2051083	66	Male	WHITE	NOT HISPANIC OR LATINO
US2051090	69	Female	WHITE	NOT HISPANIC OR LATINO
US2051091	69	Female	WHITE	NOT HISPANIC OR LATINO
US2051110	57	Female	WHITE	NOT HISPANIC OR LATINO
US2061002	45	Male	WHITE	NOT HISPANIC OR LATINO
US2061004	21	Male	WHITE	NOT HISPANIC OR LATINO
US2061005	31	Female	WHITE	NOT HISPANIC OR LATINO
US2061007	28	Male	ASIAN	NOT HISPANIC OR LATINO
US2061012	47	Female	WHITE	NOT HISPANIC OR LATINO
US2061014	23	Female	WHITE	NOT HISPANIC OR LATINO
US2061016	38	Female	WHITE	NOT HISPANIC OR LATINO
US2061017	22	Female	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2061028	29	Male	WHITE	NOT HISPANIC OR LATINO
US2061029	46	Male	WHITE	NOT HISPANIC OR LATINO
US2061030	18	Female	WHITE	NOT HISPANIC OR LATINO
US2061031	42	Female	WHITE	NOT HISPANIC OR LATINO
US2061033	41	Male	WHITE	NOT HISPANIC OR LATINO
US2061034	38	Female	WHITE	NOT HISPANIC OR LATINO
US2061038	62	Male	WHITE	NOT HISPANIC OR LATINO
US2061039	77	Male	WHITE	NOT HISPANIC OR LATINO
US2061040	62	Male	WHITE	NOT HISPANIC OR LATINO
US2061041	63	Male	WHITE	NOT HISPANIC OR LATINO
US2061042	73	Female	WHITE	NOT HISPANIC OR LATINO
US2061044	69	Female	WHITE	NOT HISPANIC OR LATINO
US2061047	58	Female	WHITE	NOT HISPANIC OR LATINO
US2061048	60	Female	WHITE	NOT HISPANIC OR LATINO
US2061049	69	Female	WHITE	NOT HISPANIC OR LATINO
US2061050	65	Female	WHITE	NOT HISPANIC OR LATINO
US2061052	64	Male	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2061054	63	Male	WHITE	NOT HISPANIC OR LATINO
US2061056	68	Male	WHITE	NOT HISPANIC OR LATINO
US2061058	62	Male	WHITE	NOT HISPANIC OR LATINO
US2061059	73	Female	WHITE	NOT HISPANIC OR LATINO
US2061060	60	Female	WHITE	NOT HISPANIC OR LATINO
US2061061	69	Female	WHITE	NOT HISPANIC OR LATINO
US2061062	73	Female	WHITE	NOT HISPANIC OR LATINO
US2061065	66	Female	WHITE	NOT HISPANIC OR LATINO
US2061066	65	Female	WHITE	NOT HISPANIC OR LATINO
US2061067	72	Female	WHITE	NOT HISPANIC OR LATINO
US2061069	60	Male	WHITE	NOT HISPANIC OR LATINO
US2061070	62	Female	AMERICAN INDIAN OR ALASKA NATIVE	NOT HISPANIC OR LATINO
US2061071	69	Female	WHITE	NOT HISPANIC OR LATINO
US2061072	60	Male	WHITE	NOT HISPANIC OR LATINO
US2071008	62	Female	WHITE	NOT HISPANIC OR LATINO
US2071009	27	Female	WHITE	HISPANIC OR LATINO
US2071010	27	Male	WHITE	HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2071011	47	Male	WHITE	NOT HISPANIC OR LATINO
US2071015	26	Female	WHITE	HISPANIC OR LATINO
US2071018	24	Female	WHITE	NOT HISPANIC OR LATINO
US2071019	56	Female	WHITE	HISPANIC OR LATINO
US2071020	64	Male	WHITE	HISPANIC OR LATINO
US2071021	35	Female	WHITE	NOT HISPANIC OR LATINO
US2071023	33	Male	WHITE	NOT HISPANIC OR LATINO
US2071027	38	Female	WHITE	NOT HISPANIC OR LATINO
US2071028	19	Male	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2071034	67	Female	WHITE	HISPANIC OR LATINO
US2071035	18	Male	WHITE	NOT HISPANIC OR LATINO
US2071045	36	Female	WHITE	HISPANIC OR LATINO
US2071048	58	Male	WHITE	NOT HISPANIC OR LATINO
US2071053	47	Male	WHITE	NOT HISPANIC OR LATINO
US2071054	58	Male	WHITE	NOT HISPANIC OR LATINO
US2071055	60	Female	WHITE	NOT HISPANIC OR LATINO
US2071056	27	Female	WHITE	HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2071058	36	Female	WHITE	HISPANIC OR LATINO
US2071060	33	Female	WHITE	NOT HISPANIC OR LATINO
US2071061	50	Male	WHITE	NOT HISPANIC OR LATINO
US2071065	31	Female	WHITE	HISPANIC OR LATINO
US2071075	32	Female	WHITE	NOT HISPANIC OR LATINO
US2071076	35	Male	WHITE	HISPANIC OR LATINO
US2071078	29	Male	WHITE	HISPANIC OR LATINO
US2071079	38	Female	WHITE	NOT HISPANIC OR LATINO
US2071080	19	Female	WHITE	HISPANIC OR LATINO
US2071097	61	Female	WHITE	NOT HISPANIC OR LATINO
US2081006	68	Male	WHITE	NOT HISPANIC OR LATINO
US2081008	65	Female	WHITE	NOT HISPANIC OR LATINO
US2081010	59	Female	WHITE	NOT HISPANIC OR LATINO
US2081011	62	Female	WHITE	NOT HISPANIC OR LATINO
US2081012	57	Female	WHITE	NOT HISPANIC OR LATINO
US2081013	60	Female	WHITE	NOT HISPANIC OR LATINO
US2081018	68	Male	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2081021	65	Male	WHITE	NOT HISPANIC OR LATINO
US2081022	74	Male	WHITE	NOT HISPANIC OR LATINO
US2081024	51	Male	WHITE	NOT HISPANIC OR LATINO
US2081027	40	Male	WHITE	NOT HISPANIC OR LATINO
US2081031	73	Male	WHITE	NOT HISPANIC OR LATINO
US2081032	44	Male	WHITE	NOT HISPANIC OR LATINO
US2081034	53	Male	WHITE	NOT HISPANIC OR LATINO
US2081037	62	Female	WHITE	NOT HISPANIC OR LATINO
US2081040	50	Male	WHITE	NOT HISPANIC OR LATINO
US2081043	35	Female	WHITE	NOT HISPANIC OR LATINO
US2081044	49	Female	NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	NOT HISPANIC OR LATINO
US2081047	39	Female	WHITE	NOT HISPANIC OR LATINO
US2081048	40	Male	WHITE	NOT HISPANIC OR LATINO
US2081050	34	Male	WHITE	NOT HISPANIC OR LATINO
US2081053	49	Male	WHITE	NOT HISPANIC OR LATINO
US2081055	49	Female	WHITE	NOT HISPANIC OR LATINO
US2081056	36	Male	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2081060	52	Female	WHITE	NOT HISPANIC OR LATINO
US2081061	46	Female	WHITE	NOT HISPANIC OR LATINO
US2081067	80	Female	WHITE	NOT HISPANIC OR LATINO
US2081068	76	Female	WHITE	NOT HISPANIC OR LATINO
US2081074	83	Female	WHITE	NOT HISPANIC OR LATINO
US2081078	58	Male	WHITE	NOT HISPANIC OR LATINO
US2081079	59	Female	WHITE	NOT HISPANIC OR LATINO
US2081082	58	Female	WHITE	NOT HISPANIC OR LATINO
US2081083	66	Female	WHITE	NOT HISPANIC OR LATINO
US2081084	68	Male	WHITE	NOT HISPANIC OR LATINO
US2081086	79	Female	WHITE	NOT HISPANIC OR LATINO
US2081089	67	Male	WHITE	NOT HISPANIC OR LATINO
US2081094	67	Female	WHITE	NOT HISPANIC OR LATINO
US2081095	62	Male	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO
US2081096	64	Male	WHITE	NOT HISPANIC OR LATINO
US2081098	66	Female	WHITE	NOT HISPANIC OR LATINO
US2081101	62	Female	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.2
Demographics and Baseline Characteristics
Subjects Screen Failed

Subject ID	Age (years)	Gender	Race	Ethnicity
US2081102	66	Male	WHITE	NOT HISPANIC OR LATINO
US2081105	58	Female	WHITE	NOT HISPANIC OR LATINO
US2081106	69	Male	WHITE	NOT HISPANIC OR LATINO
US2081107	64	Male	WHITE	NOT HISPANIC OR LATINO
US2081109	67	Male	WHITE	NOT HISPANIC OR LATINO
US2081111	65	Male	WHITE	NOT HISPANIC OR LATINO
US2081114	75	Male	WHITE	NOT HISPANIC OR LATINO
US2081115	57	Female	WHITE	NOT HISPANIC OR LATINO
US2081122	63	Female	WHITE	NOT HISPANIC OR LATINO
US2081124	66	Female	WHITE	NOT HISPANIC OR LATINO
US2081126	66	Male	WHITE	NOT HISPANIC OR LATINO
US2081127	70	Female	WHITE	NOT HISPANIC OR LATINO
US2081128	60	Male	WHITE	NOT HISPANIC OR LATINO
US2081130	59	Male	WHITE	NOT HISPANIC OR LATINO

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011030	INSOMNIA	Psychiatric disorders	Insomnia	1995		Yes
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2000	2000	
	SEASONAL ALLERGIES, UNSPECIFIED	Immune system disorders	Seasonal allergy	2003		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2012		Yes
	PANIC ATTACKS	Psychiatric disorders	Panic attack	2012		Yes
	NECK PAIN	Musculoskeletal and connective tissue disorders	Neck pain	2018-03		Yes
US2011042	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2000		Yes
	GASTROESOPHAGEAL REFLUX	Gastrointestinal disorders	Gastrooesophageal reflux disease	2010		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2012		Yes
US2011043	BIRTH DEFECT - BORN WITH ONE KIDNEY, LEFT	Congenital, familial and genetic disorders	Renal aplasia	(b) (6)		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	(b) (6)	2000	Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011056	ALLERGIC TO PENICILLIN	Immune system disorders	Drug hypersensitivity	1995		Yes
	ALLERGIC TO ZOFRAN	Immune system disorders	Drug hypersensitivity	2008		Yes
US2011060	OVARIAN CYSTS, LT OVARY	Reproductive system and breast disorders	Ovarian cyst	2015		Yes
	TOOTH PAIN, LEFT LOWER SECOND MOLAR	Gastrointestinal disorders	Toothache	2020-04		Yes
US2011064	UNSPECIFIED SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2015		Yes
	POSTPARTUM DEPRESSION	Psychiatric disorders	Perinatal depression	2017-01-01 (-1248)		Yes
US2011067	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2017-07-25 (-1044)	2017-07-25 (-1044)	
	WISDOM TOOTH SHIFTING PAIN	Gastrointestinal disorders	Toothache	2020		Yes
US2011068	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2013		Yes
	HEARTBURN	Gastrointestinal disorders	Dyspepsia	2016		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011069	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1997	1997	
US2011070	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	1980	1980	
	APPENDICITIS	Infections and infestations	Appendicitis	1980	1980	
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1988	1988	
US2011086	ENLARGED TONSILS	Respiratory, thoracic and mediastinal disorders	Tonsillar hypertrophy	2020-05-29 (-4)		Yes
US2021061	SWOLLEN TONSILS	Respiratory, thoracic and mediastinal disorders	Tonsillar hypertrophy	1989-07-05 (-11290)	1989-07-12 (-11283)	
	TONSILLECTOMY	Surgical and medical procedures	Tonsillectomy	1989-07-05 (-11290)	1989-07-12 (-11283)	
	TESTICULAR TORSION	Reproductive system and breast disorders	Testicular torsion	1996-04-01 (-8828)	1996-04-01 (-8828)	
	ORCHIECTOMY	Surgical and medical procedures	Orchidectomy	1996-04-01 (-8828)	1996-04-08 (-8821)	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021073	INSOMNIA	Psychiatric disorders	Insomnia	2017-11-15 (-930)		Yes
US2021078	INTERMITTENT HEADACHES	Nervous system disorders	Headache	1986		Yes
	LEFT NEPHRECTOMY - DONATED TO MEMBER, NO COMPLICATIONS	Surgical and medical procedures	Nephrectomy	2005	2005	
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2010		Yes
	VASECTOMY	Surgical and medical procedures	Vasectomy	2018	2018	
	LEFT KNEE JOINT REPAIR 1	Surgical and medical procedures	Knee operation	2019-01	2019-01	
	LEFT KNEE JOINT REPAIR 2	Surgical and medical procedures	Knee operation	2019-03	2019-03	
US2021082	LEFT INGUINAL HERNIA	Gastrointestinal disorders	Inguinal hernia	2003	2003	
	LEFT INGUINAL HERNIA REPAIR	Surgical and medical procedures	Inguinal hernia repair	2003-05	2003-05	
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2006	2006	
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	2006	2006	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021082	RIGHT SHOULDER ARTHROSCOPY - SLAP TEAR	Investigations	Arthroscopy	2012-12-12 (-2730)	2012-12-12 (-2730)	
	BILATERAL OSTEOARTHRITIS HANDS	Musculoskeletal and connective tissue disorders	Osteoarthritis	2015-06-01 (-1829)		Yes
	DIVERTICULITIS	Infections and infestations	Diverticulitis	2018-04-23 (-772)	2018-04-23 (-772)	
	COLON RESECTION	Surgical and medical procedures	Colectomy	2018-04-23 (-772)	2018-04-28 (-767)	
	DOXYCYCLINE ALLERGY	Immune system disorders	Drug hypersensitivity	2018-07-01 (-703)		Yes
	RIGHT ARM HERNIATED CERVICAL DISCS C5-6 & C6-7	Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	2020		Yes
	RIGHT SHOULDER PAIN	Musculoskeletal and connective tissue disorders	Musculoskeletal pain	2020-05		Yes
US2021089	AMOXICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	2000		Yes
	IODINE ALLERGY	Immune system disorders	Iodine allergy	2000		Yes
	SHELLFISH ALLERGY	Immune system disorders	Food allergy	2000		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021089	ACID REFLUX	Gastrointestinal disorders	Gastrooesophageal reflux disease	2018-09	2018-09	
	GASTRECTOMY	Surgical and medical procedures	Gastrectomy	2018-09	2018-09	
US2021094	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1986		Yes
	VASECTOMY	Surgical and medical procedures	Vasectomy	1997	1997	
	HYPERLIPIDEMIA	Metabolism and nutrition disorders	Hyperlipidaemia	2012		Yes
	LEFT INGUINAL HERNIA	Gastrointestinal disorders	Inguinal hernia	2015	2015	
	RIGHT INGUINAL HERNIA REPAIR	Surgical and medical procedures	Inguinal hernia repair	2015	2015	
US2021096	DYSMENORRHEA	Reproductive system and breast disorders	Dysmenorrhoea	2008		Yes
	DEPRESSION	Psychiatric disorders	Depression	2010	2018	
	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	2019-01	2019-01	
	APPENDICITIS	Infections and infestations	Appendicitis	2019-01	2019-01	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021111	GENERALIZED ANXIETY DISORDER	Psychiatric disorders	Generalised anxiety disorder	2002		Yes
	INTERSTITIAL CYSTITIS	Renal and urinary disorders	Cystitis interstitial	2003		Yes
	ECZEMA - BILATERAL SHINS	Skin and subcutaneous tissue disorders	Eczema	2008		Yes
	BILATERAL PLANTAR FASCIITIS	Musculoskeletal and connective tissue disorders	Plantar fasciitis	2010		Yes
	LOWER BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	2010		Yes
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2017	2017	
US2021137	ATTENTION DEFICIT HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2019-09		Yes
US2021144	ANXIETY	Psychiatric disorders	Anxiety	2019		Yes
	ATTENTION DEFICIT HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2019		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021161	IDIOPATHIC EDEMA	General disorders and administration site conditions	Oedema	2000		Yes
	HYPOESTROGENISM	Endocrine disorders	Oestrogen deficiency	2010		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2010	2010	
	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	2010	2010	
	OSTEOPOROSIS	Musculoskeletal and connective tissue disorders	Osteoporosis	2020-05-02 (-37)		Yes
US2021162	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2012	2012	
	DEPRESSION	Psychiatric disorders	Depression	2016		Yes
	ALLERGY TO CIPRO - RASH	Immune system disorders	Drug hypersensitivity	2020		Yes
US2021175	BONY DEFORMITY OF NOSE	Musculoskeletal and connective tissue disorders	Nose deformity	1996	2020-05-18 (-21)	
	ANXIETY	Psychiatric disorders	Anxiety	2020-03		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021175	RHINOPLASTY, CLOSED	Surgical and medical procedures	Rhinoplasty	2020-05-18 (-21)	2020-05-18 (-21)	
	BRADYCARDIA	Cardiac disorders	Bradycardia	2020-06-04 (-4)		Yes
US2031001	LEFT ARM ELBOW FRACTURE	Injury, poisoning and procedural complications	Upper limb fracture	2014-01	2014-01	
	LEFT ARM ELBOW FRACTURE REPAIR	Surgical and medical procedures	Fracture treatment	2014-01	2014-01	
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2014-04-13 (-2238)	2014-04-13 (-2238)	
US2031009	ALLERGY TO PENICILLIN	Immune system disorders	Drug hypersensitivity	1989		Yes
	ALLERGY TO CODEINE	Immune system disorders	Drug hypersensitivity	2000		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2000		Yes
	DEVIATED SEPTUM LEFT NOSTRIL	Respiratory, thoracic and mediastinal disorders	Nasal septum deviation	2001		Yes
	WISDOM TEETH EXTRACTION	Surgical and medical procedures	Wisdom teeth removal	2006	2006	
	RIGHT HALLUX NAIL FUNGUS	Infections and infestations	Onychomycosis	2015		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031014	ALLERGY TO PENICILLIN	Immune system disorders	Drug hypersensitivity	2002		Yes
	DILATION AND CUREHAGE	Surgical and medical procedures	Uterine dilation and curettage	2010	2010	
	MISCARRAGE	Pregnancy, puerperium and perinatal conditions	Abortion spontaneous	2010	2010	
US2031023	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1990		Yes
	ALLERGY TO REGLAN	Immune system disorders	Drug hypersensitivity	2000		Yes
	WISDOM TEETH EXTRACTION	Surgical and medical procedures	Wisdom teeth removal	2000	2000	
	DUODENAL ULCER	Gastrointestinal disorders	Duodenal ulcer	2001		Yes
	HEREDITARY HYPERLIPIDEMIA	Congenital, familial and genetic disorders	Type IIa hyperlipidaemia	2001		Yes
	TONSILLIECTOMY	Surgical and medical procedures	Tonsillectomy	2002	2002	
	TONSILLITIS	Infections and infestations	Tonsillitis	2002	2002	
	ALLERGY TO LEVAQUIN	Immune system disorders	Drug hypersensitivity	2008		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031029	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1980		Yes
	HEARING IMPAIRMENT RIGHT EAR	Ear and labyrinth disorders	Hypoacusis	1981		Yes
	BACTERIAL MENINGITIS	Infections and infestations	Meningitis bacterial	1981	1981	
	TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2009	2009	
US2031040	LEFT PIRIFORMIS SYNDROME	Nervous system disorders	Piriformis syndrome	2010	2017	
	LEFT PIRIFORMIS SYNDROME SURGERY	Surgical and medical procedures	Muscle operation	2017-11-02 (-942)	2017-11-02 (-942)	
	GENERALIZED PAIN	General disorders and administration site conditions	Pain	2018		Yes
US2031041	GLUTEN INTOLERANCE	Metabolism and nutrition disorders	Gluten sensitivity	2014		Yes
	LEFT ARM CARPAL TUNNEL SYNDROME	Nervous system disorders	Carpal tunnel syndrome	2016	2019	
	RIGHT ARM CARPAL TUNNEL SYNDROME	Nervous system disorders	Carpal tunnel syndrome	2016	2019	
	CESAREAN SECTION	Surgical and medical procedures	Caesarean section	2016-02-21 (-1563)	2016-02-21 (-1563)	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031041	CESEAREAN SECTION	Surgical and medical procedures	Caesarean section	2017-06-17 (-1081)	2017-06-17 (-1081)	
	LEFT ARM CARPAL TUNNEL SYNDROME REPAIR	Surgical and medical procedures	Carpal tunnel decompression	2019	2019	
	RIGHT ARM CARPAL TUNNEL SYNDROME SURGERY	Surgical and medical procedures	Carpal tunnel decompression	2019	2019	
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2019-01-27 (-492)	2019-01-27 (-492)	
	CESEARAN SECTION	Surgical and medical procedures	Caesarean section	2019-01-27 (-492)	2019-01-27 (-492)	
US2031043	RIGHT TENNIS ELBOW	Injury, poisoning and procedural complications	Epicondylitis	2016	2016	
	RIGHT TENNIS ELBOW REPAIR	Injury, poisoning and procedural complications	Epicondylitis	2016	2016	
US2031045	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	2008	2008	
	APPENDICITIS	Infections and infestations	Appendicitis	2008	2008	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031048	ACNE ON FACE	Skin and subcutaneous tissue disorders	Acne	2019		Yes
US2031049	MENORRHAGOA	Reproductive system and breast disorders	Menorrhagia	1999	2019	
	ENDOMETRIAL ABLATION	Surgical and medical procedures	Endometrial ablation	2019	2019	
	ESSURE CONTRACEPTIVE PROCEDURE	Surgical and medical procedures	Contraception	2019	2019	
US2031058	ALLERGY TO PENICILLIN	Immune system disorders	Drug hypersensitivity	1998	1998	
	TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2000	2000	
US2031074	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2008	2008	
	UTERINE FIBROIDS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	2008	2008	
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2015		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041005	ACNE (FACE)	Skin and subcutaneous tissue disorders	Acne	2010		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2012		Yes
US2041011	DILATION AND CURETTAGE	Surgical and medical procedures	Uterine dilation and curettage	2006	2006	
	MISCARRIAGE	Pregnancy, puerperium and perinatal conditions	Abortion spontaneous	2006	2006	
	CONSTIPATION	Gastrointestinal disorders	Constipation	2014		Yes
	MENOPAUSE	Social circumstances	Menopause	2018-02		Yes
US2041014	BED WETTING	Psychiatric disorders	Enuresis	1987	1987	
	URETHRA EXPANSION	Renal and urinary disorders	Urethral dilatation	1987	1987	
	CAT ALLERGY	Immune system disorders	Allergy to animal	1992		Yes
	VASECTOMY	Surgical and medical procedures	Vasectomy	2013	2013	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041014	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2018		Yes
US2041019	DEPRESSION	Psychiatric disorders	Depression	2019-10	2020-02	
US2041020	HERPES SIMPLEX 1	Infections and infestations	Herpes simplex	2010		Yes
	HYPERLIPIDEMIA	Metabolism and nutrition disorders	Hyperlipidaemia	2010		Yes
	VASECTOMY	Surgical and medical procedures	Vasectomy	2011	2011	
US2041022	BILATERAL WRIST CARPAL TUNNEL RELEASE	Surgical and medical procedures	Carpal tunnel decompression	2011	2011	
	BILATERAL WRIST CARPAL TUNNEL SYNDROME	Nervous system disorders	Carpal tunnel syndrome	2011	2011	
	ACNE FACE	Skin and subcutaneous tissue disorders	Acne	2018		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2018		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041022	ANXIETY	Psychiatric disorders	Anxiety	2019		Yes
US2041025	CESAREAN SECTION	Surgical and medical procedures	Caesarean section	1991-04-07 (-10649)	1991-04-07 (-10649)	
	CESAREAN SECTION	Surgical and medical procedures	Caesarean section	1997-10-31 (-8250)	1997-10-31 (-8250)	
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	1998	1998	
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	1998	1998	
	CESAREAN SECTION	Surgical and medical procedures	Caesarean section	1999-02-12 (-7781)	1999-02-12 (-7781)	
	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	2000-07	2005-02	
	UTERINE ABLATION	Surgical and medical procedures	Endometrial ablation	2005-02	2005-02	
	HYPERLIPIDEMIA	Metabolism and nutrition disorders	Hyperlipidaemia	2015		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2015-02		Yes
	DEPRESSION	Psychiatric disorders	Depression	2020-04-30 (-33)		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041029	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1979		Yes
US2041034	HEADACHES	Nervous system disorders	Headache	1994		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1994		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2014		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2018		Yes
US2041042	OVARIAN CYSTS	Reproductive system and breast disorders	Ovarian cyst	2014	2015	
	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	2015	2015	
	BILATERAL SALPINGECTOMY	Surgical and medical procedures	Salpingectomy	2015	2015	
	LEFT PARTIAL OOPHORECTOMY	Surgical and medical procedures	Oophorectomy	2015	2015	
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2017	2017	
	CHOLELITHIASIS	Hepatobiliary disorders	Cholelithiasis	2017	2017	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041042	DEPRESSION	Psychiatric disorders	Depression	2018-09		Yes
US2041043	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1975		Yes
	DEPRESSION	Psychiatric disorders	Depression	2017		Yes
US2041056	LEFT LABRAL REPAIR	Surgical and medical procedures	Chondroplasty	2017-12	2017-12	
	LEFT LABRAL TEAR	Injury, poisoning and procedural complications	Cartilage injury	2017-12	2017-12	
	ATTENTION DEFICIT HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2019-03		Yes
US2041059	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2012	2012	
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	2012	2012	
US2041062	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1990		Yes
	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	1990	1990	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041062	APPENDICITIS	Infections and infestations	Appendicitis	1990	1990	
US2041078	APPENDICITIS	Infections and infestations	Appendicitis	2006	2006	
	APPENECTOMY	Surgical and medical procedures	Appendicectomy	2006	2006	
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2006	2006	
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	2006	2006	
	BREAST REDUCTION BILATERAL	Surgical and medical procedures	Mammoplasty	2009	2009	
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2016	2016	
US2041086	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2013		Yes
	INNOCENT MURMUR	Investigations	Cardiac murmur	2018		Yes
	ACNE (FACE)	Skin and subcutaneous tissue disorders	Acne	2019		Yes
US2041089	RIGHT SECOND FINGER PHALANX FRACTURE	Injury, poisoning and procedural complications	Hand fracture	2013	2013	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041089	RIGHT SECOND FINGER PHALANX OPEN REDUCTION INTERNAL FIXATION	Surgical and medical procedures	Open reduction of fracture	2013	2013	
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2014		Yes
US2051022	EHLERS DUNLOS	Congenital, familial and genetic disorders	Ehlers-Danlos syndrome	1997-	(b) (6)	Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2005		Yes
	ACNE (CHIN)	Skin and subcutaneous tissue disorders	Acne	2013		Yes
	IRRITABLE BOWEL SYNDROME	Gastrointestinal disorders	Irritable bowel syndrome	2015		Yes
	LACTOSE INTOLERANT	Metabolism and nutrition disorders	Lactose intolerance	2015		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2016		Yes
US2051035	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2010		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051035	LEFT OVARIAN CYST RUPTURED (BENIGN)	Reproductive system and breast disorders	Ovarian cyst ruptured	2018	2018	
	BRADYCARDIA	Cardiac disorders	Bradycardia	2020		Yes
US2051036	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2000		Yes
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2010	2010	
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	2010	2010	
	DIASTASIS RECTI	Musculoskeletal and connective tissue disorders	Diastasis recti abdominis	2020-05		Yes
	VENTRAL HERNIA	Gastrointestinal disorders	Abdominal hernia	2020-05		Yes
US2051044	VASECTOMY	Surgical and medical procedures	Vasectomy	2018	2018	
US2061003	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1990-03		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2005-06		Yes
	DEPRESSION	Psychiatric disorders	Depression	2005-06		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2061003	DEGENERATIVE DISC DISORDER	Musculoskeletal and connective tissue disorders	Intervertebral disc degeneration	2010-06		Yes
	OSTEOARTHRITIS BACK	Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	2010-08		Yes
	MICRODISCECTOMY	Surgical and medical procedures	Intervertebral disc operation	2010-11	2010-11	
US2061015	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2003-05		Yes
	MIGRAINES, RECURRENT	Nervous system disorders	Migraine	2010-03		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2016-01		Yes
	BIPOLAR DISORDER	Psychiatric disorders	Bipolar disorder	2016-01		Yes
	DEPRESSION	Psychiatric disorders	Depression	2016-01		Yes
US2061018	HOT FLASHES	Vascular disorders	Hot flush	2015-01		Yes
	CARPAL TUNNEL LEFT ARM	Nervous system disorders	Carpal tunnel syndrome	2015-01	2019-01	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2061018	LIPOMA THIGHS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Lipoma	2016-01	2020-01	
	LIPOMA BILATERAL ARMS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Lipoma	2016-06	2020-01	
	CARPAL TUNNEL SURGERY	Surgical and medical procedures	Carpal tunnel decompression	2019-01	2019-01	
	LIPOMA EXCISION BILATERAL ARMS AND THIGHS	Surgical and medical procedures	Lipoma excision	2020-01	2020-01	
US2061021	ALLERGY TO BUG BITES	Immune system disorders	Allergy to arthropod bite	1993-01		Yes
	ALLERGY TO POISON IVY	Immune system disorders	Allergy to plants	1993-01		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2000-01		Yes
	LEFT TOENAIL IRREGULAR GROWTH	Skin and subcutaneous tissue disorders	Ingrowing nail	2004-01	2020-01	
	LEFT FOOT VASECTOMY	Surgical and medical procedures	Vasectomy	2013	2013	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2061021	TOENAIL REMOVAL	Surgical and medical procedures	Nail operation	2020-01	2020-01	
US2061022	DEPRESSION	Psychiatric disorders	Depression	1991-01		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1993-01		Yes
	ENDOMETRIOSIS	Reproductive system and breast disorders	Endometriosis	1997-06	2011-06	
	ALLERGY TO SULFA	Immune system disorders	Drug hypersensitivity	2001-01		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2005		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2011-06		Yes
	BILATERAL OOPHORECTOMY	Surgical and medical procedures	Oophorectomy bilateral	2011-06	2011-06	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2011-06	2011-06	
	OSTEOARTHRITIS BILATERAL KNEES	Musculoskeletal and connective tissue disorders	Osteoarthritis	2017-01		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2020-03		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2061025	ALLERGY TO CECLOR	Immune system disorders	Drug hypersensitivity	1990		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1994		Yes
	MYOPIA	Eye disorders	Myopia	2001		Yes
	BRONCHITIS	Infections and infestations	Bronchitis	2018-07	2018-07	
	STREP THROAT	Infections and infestations	Pharyngitis streptococcal	2019-08	2019-08	
	VASECTOMY	Surgical and medical procedures	Vasectomy	2019-10	2019-10	
US2061032	KIDNEY STONES, RECURRENT	Renal and urinary disorders	Nephrolithiasis	2001-04		Yes
	MIGRAINES	Nervous system disorders	Migraine	2008-03		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2010-01		Yes
	ENDOMETRIOSIS	Reproductive system and breast disorders	Endometriosis	2011-11	2011-12	
	POST MENOPAUSAL	Social circumstances	Postmenopause	2011-12		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2011-12	2011-12	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2061032	IRRITABLE BOWEL SYNDROME	Gastrointestinal disorders	Irritable bowel syndrome	2015-10		Yes
US2071012	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1996		Yes
	ENDOMETRIOSIS	Reproductive system and breast disorders	Endometriosis	2012	2012	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2012	2012	
US2071014	RECURRING STREP THROAT	Infections and infestations	Pharyngitis		2007	
	RED DYE ALLERGY	Immune system disorders	Streptococcal Allergy to chemicals	2004		Yes
	ADENOIDECTOMY	Surgical and medical procedures	Adenoidectomy	2007	2007	
	TONSILECTOMY	Surgical and medical procedures	Tonsillectomy	2007	2007	
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2010		Yes
US2071017	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2014-05-14 (-2211)	2014-05-14 (-2211)	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071022	IRRITABLE BOWEL SYNDROME	Gastrointestinal disorders	Irritable bowel syndrome	2014		Yes
	MILD DEPRESSION	Psychiatric disorders	Depression	2014		Yes
	MILD ANXIETY	Psychiatric disorders	Anxiety	2014		Yes
US2071042	VASECTOMY	Surgical and medical procedures	Vasectomy	2006	2006	
US2071044	SULFA ALLERGY	Immune system disorders	Drug hypersensitivity	1990		Yes
	CODEINE ALLERGY	Immune system disorders	Drug hypersensitivity	2002		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2016		Yes
US2071046	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2000		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2009		Yes
	MIGRAINES	Nervous system disorders	Migraine	2018		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071050	HYPERLIPIDEMIA	Metabolism and nutrition disorders	Hyperlipidaemia	2000		Yes
	VASECTOMY	Surgical and medical procedures	Vasectomy	2004-08	2004-08	
US2071059	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2011		Yes
	BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	2015		Yes
	MILD DEPRESSION	Psychiatric disorders	Depression	2015		Yes
	BULGING DISC	Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	2015	2020-05-11 (-28)	
	ANTERIOR CERVICAL FUSION	Surgical and medical procedures	Spinal fusion surgery	2020-05-11 (-28)	2020-05-11 (-28)	
US2071062	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2018		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2019		Yes
	LEFT NIPPLE PIERCING WITH INFLAMATION AND SWELLING	Reproductive system and breast disorders	Nipple swelling	2020-05-20 (-15)		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071064	ALCOHOLISM	Psychiatric disorders	Alcoholism	2019-01-01 (-521)		Yes
	FACIAL ACNE	Skin and subcutaneous tissue disorders	Acne	2019-01-01 (-521)		Yes
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2019-10	2019-10	
	CHOLELITHIASIS	Hepatobiliary disorders	Cholelithiasis	2019-10	2019-10	
US2071070	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2015	2015	
	CHOLELITHIASIS	Hepatobiliary disorders	Cholelithiasis	2015	2015	
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2018		Yes
	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	2020	2020	
	APPENDICITIS	Infections and infestations	Appendicitis	2020	2020	
US2081026	TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2003-12-29 (-6002)	2003-12-29 (-6002)	
	MIGRAINE	Nervous system disorders	Migraine	2015		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081026	ANXIETY	Psychiatric disorders	Anxiety	2019		Yes
US2081033	MIGRAINES	Nervous system disorders	Migraine	2019		Yes
US2081042	MENOPAUSE	Social circumstances	Menopause	2018-08		Yes
	DYSLIPIDEMIA	Metabolism and nutrition disorders	Dyslipidaemia	2019-07-17 (-329)		Yes
US2081046	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2018		Yes
US2081049	MIGRAINES	Nervous system disorders	Migraine	2000		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2015		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2015		Yes
US2081057	ANXIETY	Psychiatric disorders	Anxiety	2010		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2010		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081057	PTSD	Psychiatric disorders	Post-traumatic stress disorder	2010		Yes
	CHRONIC LEFT SIDE PELVIC PAIN [DUE TO FIBROID]	Reproductive system and breast disorders	Pelvic pain	2015		Yes
	UTERINE FIBROID	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	2015		Yes
	HYSTERECTOMY [INDICATION: BIRTH CONTROL]	Surgical and medical procedures	Hysterectomy	2018-12	2018-12	
	DYSLIPIDEMIA	Metabolism and nutrition disorders	Dyslipidaemia	2019		Yes
US2081058	ACNE [GENERALIZED]	Skin and subcutaneous tissue disorders	Acne	2015		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2019		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011029	HEADACHES	Nervous system disorders	Headache	1993		Yes
	MIGRAINES	Nervous system disorders	Migraine	1993		Yes
	ALLERGY, ANIMAL DANDER	Immune system disorders	Allergy to animal	1995		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	1995		Yes
	SEASONAL ALLERGIES, MOLD	Immune system disorders	Seasonal allergy	1995		Yes
	MYALGIAS, GENERAL	Musculoskeletal and connective tissue disorders	Myalgia	2018		Yes
	BACK PAIN, LUMBAR	Musculoskeletal and connective tissue disorders	Back pain	2020-01		Yes
US2011051	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2005		Yes
	DYSMENORRHEA	Reproductive system and breast disorders	Dysmenorrhoea	2012		Yes
US2011055	SEASONAL ALLERGIES, UNSPECIFIED	Immune system disorders	Seasonal allergy	1996		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011087	UNSPECIFIED SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2007		Yes
	PEANUT ALLERGY	Immune system disorders	Food allergy	2012		Yes
US2011090	ANXIETY	Psychiatric disorders	Anxiety	2020-04-01 (-64)		Yes
	DEPRESSION : MODERATE	Psychiatric disorders	Depression	2020-04-01 (-64)		Yes
US2011091	HEADACHES	Nervous system disorders	Headache	1984		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1984		Yes
	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2010		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2019-01		Yes
US2011092	ALLERGIC TO CIPRO	Immune system disorders	Drug hypersensitivity	1986		Yes
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2000		Yes
	ALLERGIC TO IV IRON	Immune system disorders	Drug hypersensitivity	2019-05		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011092	ANEMIA	Blood and lymphatic system disorders	Anaemia	2019-05		Yes
	ENDOMETRIAL ABLATION	Surgical and medical procedures	Endometrial ablation	2019-10	2019-10	
	HEAVY BLEEDING, POST LABOR	Pregnancy, puerperium and perinatal conditions	Postpartum haemorrhage	2019-10	2019-10	
US2011093	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2013		Yes
	HEARTBURN	Gastrointestinal disorders	Dyspepsia	2016		Yes
US2011095	ADHD	Psychiatric disorders	Attention deficit hyperactivity disorder	2013		Yes
	HERPES SIMPLEX	Infections and infestations	Herpes simplex	2015		Yes
	ALLERGY TO SHELLFISH	Immune system disorders	Food allergy	2018-12		Yes
	HPV	Infections and infestations	Papilloma viral infection	2019-11	2019-11	
	LEEP PROCEDURE	Surgical and medical procedures	Loop electrosurgical excision procedure	2019-11	2019-11	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011095	ALLERGY TO BEE STINGS	Immune system disorders	Allergy to arthropod sting	2019-12		Yes
	ALLERGY TO GLUTEN	Metabolism and nutrition disorders	Gluten sensitivity	2019-12		Yes
US2011102	SEASONAL ALLERGIES, UNSPECIFIED	Immune system disorders	Seasonal allergy	2009		Yes
US2021058	ALLERGY HYDROCODONE	Immune system disorders	Drug hypersensitivity	2015		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2015		Yes
	DEPRESSION	Psychiatric disorders	Depression	2015		Yes
	ALLERGIC METOCLOPRAMIDE	Immune system disorders	Drug hypersensitivity	2016		Yes
	CHRONIC BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	2016		Yes
	CHRONIC NECK PAIN	Musculoskeletal and connective tissue disorders	Neck pain	2016		Yes
	UNSPECIFIED MOOD DISORDER	Psychiatric disorders	Affective disorder	2016		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021058	MIGRAINE	Nervous system disorders	Migraine	2017		Yes
US2021064	ANXIETY	Psychiatric disorders	Anxiety	2018		Yes
	LEFT WRIST PAIN	Musculoskeletal and connective tissue disorders	Arthralgia	2020-05		Yes
US2021084	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1995		Yes
	LIPOMA BILATERAL UPPER EXTREMITIES	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Lipoma	2005		Yes
	DEPRESSION	Psychiatric disorders	Depression	2015	2017	
US2021090	POST MENOPAUSAL	Social circumstances	Postmenopause	2015		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2016-07-01 (-1432)		Yes
	ATTENTION DEFICIT DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2016-07-01 (-1432)		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021090	RIGHT CARPAL TUNNEL SYNDROME	Nervous system disorders	Carpal tunnel syndrome	2019		Yes
	TENSION HEADACHE	Nervous system disorders	Tension headache	2020-03-14 (-80)		Yes
US2021147	SHELLFISH ALLERGY - HIVES	Immune system disorders	Food allergy	1991		Yes
	BEE ALLERGY - SHORTNESS OF BREATH, SWELLING	Immune system disorders	Allergy to arthropod sting	2014		Yes
US2021166	CEPHALEXIN ALLERGY	Immune system disorders	Drug hypersensitivity	2002		Yes
	FIBROMYALGIA	Musculoskeletal and connective tissue disorders	Fibromyalgia	2011		Yes
	BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	2017		Yes
	CODEINE ALLERGY	Immune system disorders	Drug hypersensitivity	2019		Yes
US2021179	MIGRAINES	Nervous system disorders	Migraine	1996		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2012		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021179	ATTENTION DEFICIT HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2020-01		Yes
US2031004	CEASEARIAN SECTION	Surgical and medical procedures	Caesarean section	2010-05-21 (-3661)	2010-05-21 (-3661)	
	CEASARIAN SECTION	Surgical and medical procedures	Caesarean section	2012-10-08 (-2790)	2012-10-08 (-2790)	
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2016-02-12 (-1568)	2016-02-12 (-1568)	
	CESEARIAN SECTION	Surgical and medical procedures	Caesarean section	2016-02-12 (-1568)	2016-02-12 (-1568)	
US2031011	POSTMENOPAUSAL	Social circumstances	Postmenopause	2019-04		Yes
	HOT FLASHES	Vascular disorders	Hot flush	2019-12		Yes
US2031030	LEFT ANTERIOR CRUCIATE LIGAMENT INJURY	Injury, poisoning and procedural complications	Ligament injury	1987	1987	
	LEFT ANTERIOR CRUCIATE LIGAMENT REPAIR	Surgical and medical procedures	Ligament operation	1987	1987	
US2031042	ALLERGY TO NICKLE	Immune system disorders	Allergy to metals	2010		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031042	MIGRAINES	Nervous system disorders	Migraine	2016		Yes
	RIGHT SHOULDER PAIN	Musculoskeletal and connective tissue disorders	Musculoskeletal pain	2016	2016	
	RIGHT SHOULDER SCOPE	Investigations	Arthroscopy	2016	2016	
	WISDOM TEETH IMPACKETD	Gastrointestinal disorders	Tooth impacted	2019	2019-09	
	WISDOME TEETH EXTRACTION	Surgical and medical procedures	Wisdom teeth removal	2019-09	2019-09	
US2031051	ALLERGY TO TERAZOL	Immune system disorders	Drug hypersensitivity	1994		Yes
	ALLERGY TO INDOCIN	Immune system disorders	Drug hypersensitivity	1995		Yes
US2031056	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1972-05		Yes
US2031057	TESTICULAR HERNIA	Gastrointestinal disorders	Inguinal hernia	2014	2014	
	TESTICULAR HERNIA REPAIR	Surgical and medical procedures	Inguinal hernia repair	2014	2014	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031063	HYPERLIPIDEMIA	Metabolism and nutrition disorders	Hyperlipidaemia	2016		Yes
	VASECTOMY	Surgical and medical procedures	Vasectomy	2017	2017	
US2031066	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2000		Yes
	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	2013-01	2013-01	
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2013-06	2013-06	
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	2013-06	2013-06	
	TOTAL HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2013-07	2013-07	
	DEPRESSION	Psychiatric disorders	Depression	2015		Yes
US2031072	ENDOMETRIOSIS	Reproductive system and breast disorders	Endometriosis	1980	1985	
	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	1980	1985	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031072	ENDOMETRIAL ABLATION	Surgical and medical procedures	Endometrial ablation	1985	1985	
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2009	2009	
US2031080	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1998		Yes
US2041002	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2005		Yes
	RIGHT HERNIA	Gastrointestinal disorders	Inguinal hernia	2011	2011	
	RIGHT INGUINAL HERNIA REPAIR	Surgical and medical procedures	Inguinal hernia repair	2011	2011	
US2041003	ATTENTION DEFICIT HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2010		Yes
US2041006	ACL RECONSTRUCTION	Surgical and medical procedures	Ligament operation	2007-07	2007-07	
	RIGHT KNEE ACL TEAR RIGHT KNEE	Injury, poisoning and procedural complications	Ligament rupture	2007-07	2007-07	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041007	CHRONIC OTITIS MEDIA	Infections and infestations	Otitis media chronic	1987	1987	
	TYMPANOSTOMY TUBE INSERTION BILATERAL	Surgical and medical procedures	Ear tube insertion	1987	1987	
	TYMPANOSTOMY TUBE REMOVAL	Surgical and medical procedures	Ear tube removal	1988	1988	
	BILATERAL BREAST FIBROADENOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Fibroadenoma of breast	2006		Yes
	CYSTECTOMY OF FIBROADENOMA	Surgical and medical procedures	Benign breast lump removal	2006	2006	
	CESAREAN SECTION	Surgical and medical procedures	Caesarean section	2007-10-16 (-4612)	2007-10-16 (-4612)	
	CYSTECTOMY OF BREAST FIBROADENOMA	Surgical and medical procedures	Benign breast lump removal	2008	2008	
	CYSTECTOMY OF BREAST FIBROADENOMA	Surgical and medical procedures	Benign breast lump removal	2010	2010	
	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	2013	2013	
	APPENDICITIS	Infections and infestations	Appendicitis	2013	2013	
	POLY CYSTIC OVARY SYNDROME	Reproductive system and breast disorders	Polycystic ovaries	2014		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041007	CYSTECTOMY OF BREAST FRIBROADENOMA	Surgical and medical procedures	Benign breast lump removal	2014	2014	
US2041012	EPISTAXIS	Respiratory, thoracic and mediastinal disorders	Epistaxis	1995	2000	
	BLURRED VISION	Eye disorders	Vision blurred	1995	2020-01	
	BILATERAL EYES					
	CHRONIC TONSILITIS	Infections and infestations	Chronic tonsillitis	1998	2000	
	NOSE CAUTERIZATION	Surgical and medical procedures	Cautery to nose	2000	2000	
	TONSILLECTOMY	Surgical and medical procedures	Tonsillectomy	2000	2000	
	APENDICITIS	Infections and infestations	Appendicitis	2010	2010	
	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	2010	2010	
	LASIK SURGERY	Surgical and medical procedures	Keratomeiosis	2020-01	2020-01	
	BILATERAL EYES					
US2041013	PERICHONDRIAL HEMATOMA	Vascular disorders	Haematoma	2000		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041013	RIGHT FOREARM EXTENSOR TENDON LACERATION/TEAR	Injury, poisoning and procedural complications	Tendon rupture	2010-06	2010-06	
	RIGHT FOREARM EXTENSOR TENDON REPAIR	Surgical and medical procedures	Tenoplasty	2010-06	2010-06	
US2041016	TIDE LAUNDRY DETERGENT ALLERGY	Skin and subcutaneous tissue disorders	Dermatitis contact	2019		Yes
US2041023	TONSILITIS	Infections and infestations	Tonsillitis	1978	1978	
	TONSILLECTOMY	Surgical and medical procedures	Tonsillectomy	1978	1978	
	POLY CYSTIC OVARY SYNDROME	Reproductive system and breast disorders	Polycystic ovaries	1992		Yes
	LAPAROSCOPIC OVARIAN CYSECTOMY	Surgical and medical procedures	Ovarian cystectomy	1995	1995	
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	1998	1998	
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	1998	1998	
	CHRONIC HEADACHES	Nervous system disorders	Headache	2005		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041023	HERNIATED DISC	Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	2016-01	2016-02	
	DISECTOMY	Surgical and medical procedures	Intervertebral disc operation	2016-02	2016-02	
	ANXIETY	Psychiatric disorders	Anxiety	2020-02		Yes
	DEPRESSION	Psychiatric disorders	Depression	2020-02		Yes
US2041027	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	2004	2006	
	ENDOMETRIAL ABLATION	Surgical and medical procedures	Endometrial ablation	2006	2006	
	ACNE FACE	Skin and subcutaneous tissue disorders	Acne	2016		Yes
	ACROMIOCLAVICULAR ARTHRITIS RIGHT SHOULDER	Musculoskeletal and connective tissue disorders	Arthritis	2019-01	2019-08	
	RIGHT SHOULDER ARTHROSCOPY	Investigations	Arthroscopy	2019-08	2019-08	
	RIGHT ACL REPAIR (KNEE)	Surgical and medical procedures	Ligament operation	1994	1994	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041030	RIGHT ACL TEAR (KNEE)	Injury, poisoning and procedural complications	Ligament rupture	1994	1994	
	APPENDECTOMY	Surgical and medical procedures	Appendectomy	2001-05	2001-05	
	APPENDICITIS	Infections and infestations	Appendicitis	2001-05	2001-05	
	LEFT WRIST FRACTURE	Injury, poisoning and procedural complications	Wrist fracture	2002	2002	
	LEFT SCAPHOID WRIST REPAIR	Surgical and medical procedures	Wrist surgery	2002-06	2002-06	
US2041036	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1990		Yes
US2041047	ABDOMINAL HERNIA	Gastrointestinal disorders	Abdominal hernia	1990	1990	
	ABDOMINAL HERNIA REPAIR	Surgical and medical procedures	Abdominal hernia repair	1990	1990	
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2000		Yes
	ARTHROSCOPY RIGHT KNEE	Investigations	Arthroscopy	2008	2008	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041047	RIGHT MENISCUS TEAR	Injury, poisoning and procedural complications	Meniscus injury	2008	2008	
	NAVICULAR FRACTURE (LEFT)	Injury, poisoning and procedural complications	Foot fracture	2012	2012	
	NAVICULAR PERCUTANEOUS PINNING (LEFT)	Surgical and medical procedures	Foot operation	2012	2012	
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2015		Yes
	LOW BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	2019-06		Yes
	VASECTOMY	Surgical and medical procedures	Vasectomy	2019-11	2019-11	
	ALOPECIA	Skin and subcutaneous tissue disorders	Alopecia	2020-04-15 (-48)		Yes
US2041049	ANXIETY	Psychiatric disorders	Anxiety	2017		Yes
	DEPRESSION	Psychiatric disorders	Depression	2017		Yes
	IRRITABLE BOWEL SYNDROME	Gastrointestinal disorders	Irritable bowel syndrome	2020-01		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041051	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2003		Yes
US2041053	SULFA ALLERGY	Immune system disorders	Drug hypersensitivity	1993		Yes
US2041055	PREMENSTRUAL DYSPHORIC DISORDER	Reproductive system and breast disorders	Premenstrual dysphoric disorder	2017		Yes
US2041058	SHOULDER PAIN LEFT	Musculoskeletal and connective tissue disorders	Musculoskeletal pain	2012	2017-08	
	SHOULDER ARTHROSCOPY LEFT	Investigations	Arthroscopy	2017-08	2017-08	
US2041064	MENISCUS TEAR LEFT	Injury, poisoning and procedural complications	Meniscus injury	2006	2007	
	MENISCUS REPAIR LEFT	Surgical and medical procedures	Meniscus operation	2007	2007	
US2041071	HERPES TYPE 1	Infections and infestations	Herpes simplex	2018		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041075	ATTENTION DEFICIT HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2015		Yes
	DEPRESSION	Psychiatric disorders	Depression	2020-01		Yes
US2041076	ENDOMETRIOSIS	Reproductive system and breast disorders	Endometriosis	1996	2012	
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2010		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2012	2012	
US2041077	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2010		Yes
	POLYCYSTIC OVARY SYNDROME	Reproductive system and breast disorders	Polycystic ovaries	2010		Yes
	MIGRAINES	Nervous system disorders	Migraine	2018		Yes
	AMMENORRHEA	Reproductive system and breast disorders	Amenorrhoea	2019		Yes
	DEPRESSION	Psychiatric disorders	Depression	2019-12		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041088	AMOXICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	2015		Yes
	BACTRIM ALLERGY	Immune system disorders	Drug hypersensitivity	2016		Yes
	ACNE (FACE)	Skin and subcutaneous tissue disorders	Acne	2019		Yes
	IRON DEFICIENCY	Metabolism and nutrition disorders	Iron deficiency	2019		Yes
	LEFT SHOULDER LABRUM REPAIR	Surgical and medical procedures	Shoulder operation	2019-07	2019-07	
	LEFT SHOULDER LABRUM TEAR	Musculoskeletal and connective tissue disorders	Chondropathy	2019-07	2019-07	
US2041091	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	2010	2010	
	APPENDICITIS	Infections and infestations	Appendicitis	2010	2010	
	RIGHT HIP LABRAL REPAIR	Surgical and medical procedures	Hip surgery	2015	2015	
	RIGHT HIP LABRAL TEAR	Injury, poisoning and procedural complications	Cartilage injury	2015	2015	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041091	LACTOSE INTOLERANT	Metabolism and nutrition disorders	Lactose intolerance	2018		Yes
US2041092	LACERATED SPLEEN	Injury, poisoning and procedural complications	Splenic rupture	1984	1984	
	SPLENECTOMY	Surgical and medical procedures	Splenectomy	1984	1984	
	ANXIETY	Psychiatric disorders	Anxiety	2020-02		Yes
US2051008	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1990		Yes
	RESTLESS LEG SYNDROME	Nervous system disorders	Restless legs syndrome	2005		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2018		Yes
	HEADACHE	Nervous system disorders	Headache	2020-05-15 (-14)	2020-05-15 (-14)	
US2051009	HEADACHES OCCASSIONAL	Nervous system disorders	Headache	1990		Yes
	VASECTOMY	Surgical and medical procedures	Vasectomy	2004	2004	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051009	GENERAL MUSCLE PAIN	Musculoskeletal and connective tissue disorders	Myalgia	2008		Yes
	MYOPIA	Eye disorders	Myopia	2010		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2010		Yes
	RIGHT INGUINAL HERNIA	Gastrointestinal disorders	Inguinal hernia	2011	2011	
	RIGHT INGUINAL HERNIA REPAIR	Surgical and medical procedures	Inguinal hernia repair	2011	2011	
	OCCASIONAL NIGHT SWEATS	Skin and subcutaneous tissue disorders	Night sweats	2015		Yes
	ATTENTION DEFICIT DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2019-04-01 (-428)		Yes
US2051010	RIGHT ANKLE INJURY	Injury, poisoning and procedural complications	Joint injury	2001	2001	
	RIGHT ANKLE REPAIR	Surgical and medical procedures	Ankle operation	2001	2001	
	LEFT ANTERIOR CRUCIATE LIGAMENT REPAIR	Surgical and medical procedures	Ligament operation	2007	2007	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051010	LEFT ANTERIOR CRUCIATE LIGAMENT TEAR	Injury, poisoning and procedural complications	Ligament rupture	2007	2007	
	LEFT ACL TEAR	Injury, poisoning and procedural complications	Ligament rupture	2010	2011	
	LEFT ACL REPAIR	Surgical and medical procedures	Ligament operation	2011	2011	
	LEFT MENISCUS TEAR	Injury, poisoning and procedural complications	Meniscus injury	2011	2012	
	LEFT MENISCUS REPAIR	Surgical and medical procedures	Meniscus operation	2012	2012	
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2015		Yes
	LEFT ACL RECONSTRUCTION	Surgical and medical procedures	Ligament operation	2018	2018	
	HEADACHE	Nervous system disorders	Headache	2020-05-25 (-8)	2020-05-25 (-8)	
US2051011	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1974-(b) (6)		Yes
	HYPEROPIA	Eye disorders	Hypermetropia	1989		Yes
	LUMBAR BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	1997		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051011	RADICULOPATHY	Nervous system disorders	Radiculopathy	1997		Yes
	BILATERAL FEET (SENSORY)					
	DEGENERATIVE DISC DISEASE	Musculoskeletal and connective tissue disorders	Intervertebral disc degeneration	2005		Yes
	CERVICAL FUSION C4-C5	Surgical and medical procedures	Spinal fusion surgery	2005	2005	
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2015		Yes
	RAYNAUD'S SYNDROME	Vascular disorders	Raynaud's phenomenon	2018		Yes
	ATTENTION DEFICIT HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2019		Yes
	DETACHED RETINA, SPONTANEOUS LEFT	Eye disorders	Retinal detachment	2019	2019	
	VITRECTOMY SCLERAL BUCKLE TO REPAIR DETACHED RETINA LEFT	Surgical and medical procedures	Scleral buckling surgery	2019	2019	
US2051018	CEFZIL ALLERGY	Immune system disorders	Drug hypersensitivity	1998		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1998		Yes
	SULFA ALLERGY	Immune system disorders	Drug hypersensitivity	1998		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051018	ANXIETY	Psychiatric disorders	Anxiety	2008		Yes
	SCOLIOSIS	Musculoskeletal and connective tissue disorders	Scoliosis	2010-01-01 (-3811)		Yes
	SPINAL FUSION (UNKNOWN SPINE LEVEL)	Surgical and medical procedures	Spinal fusion surgery	2010-01-01 (-3811)	2010-01-01 (-3811)	
	DEPRESSION	Psychiatric disorders	Depression	2017		Yes
US2051027	RHINOPLASTY	Surgical and medical procedures	Rhinoplasty	2000	2000	
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2015-01-01 (-1985)		Yes
US2051031	METAL ALLERGY	Immune system disorders	Allergy to metals	(b) (6)		Yes
	MYOPIA	Eye disorders	Myopia	1997		Yes
	OCCASIONAL HEADACHES	Nervous system disorders	Headache	2020-05-18 (-15)		Yes
US2051032	MYOPIA	Eye disorders	Myopia	1989		Yes
	ARTHROSCOPIC SURGERY RIGHT KNEE	Investigations	Arthroscopy	1995	1995	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051032	TORN CARTILAGE RIGHT KNEE	Injury, poisoning and procedural complications	Cartilage injury	1995	1995	
	RIGHT KNEE ANTERIOR CRUCIATE LIGAMENT REPAIR	Surgical and medical procedures	Ligament operation	1996	1996	
	ANTERIOR CRUCIATE LIGAMENT REPAIR OF RIGHT KNEE	Surgical and medical procedures	Ligament operation	2010	2010	
	CESAREAN SECTION	Surgical and medical procedures	Caesarean section	2016	2016	
	DEPRESSION	Psychiatric disorders	Depression	2019		Yes
US2051033	ANXIETY	Psychiatric disorders	Anxiety	2000		Yes
	DEPRESSION	Psychiatric disorders	Depression	2000		Yes
US2051038	MYOPIA	Eye disorders	Myopia	2009		Yes
	HYPERHYDROSIS	Skin and subcutaneous tissue disorders	Hyperhidrosis	2017		Yes
US2051040	MYOPIA	Eye disorders	Myopia	1979		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051040	GLUTEN SENSITIVITY	Metabolism and nutrition disorders	Gluten sensitivity	2014		Yes
	SLIGHT HEART MURMUR	Investigations	Cardiac murmur	2014		Yes
	BRADYCARDIA	Cardiac disorders	Bradycardia	2020		Yes
	SPRAINED ANKLE LEFT	Injury, poisoning and procedural complications	Ligament sprain	2020-06-01 (-4)		Yes
US2051042	MYOPIA	Eye disorders	Myopia	1993		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2016		Yes
	ECZEMA (ELBOWS)	Skin and subcutaneous tissue disorders	Eczema	2019		Yes
	TOOTHACHES	Gastrointestinal disorders	Toothache	2020		Yes
	HEADACHE	Nervous system disorders	Headache	2020-05-15 (-18)	2020-05-15 (-18)	
US2051043	ACL REPAIR BILATERAL	Surgical and medical procedures	Ligament operation	1995	1995	
	VAGINAL YEAST INFECTION	Infections and infestations	Vulvovaginal mycotic infection	2000	2000	
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2009	2009	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051043	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	2009	2009	
	BREAST REDUCTION	Surgical and medical procedures	Mammoplasty	2017	2017	
	OSTEOARTHRITIS BILATERAL KNEES	Musculoskeletal and connective tissue disorders	Osteoarthritis	2019	2019	
	ALLERGY PENICILLIN	Immune system disorders	Drug hypersensitivity	2020-05-29 (-5)		Yes
US2051048	MIGRAINES, OCCASIONAL	Nervous system disorders	Migraine	2000		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2010		Yes
US2051050	CEFTIN ALLERGY	Immune system disorders	Drug hypersensitivity	1992		Yes
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	1993	1993	
	CHOLESCYSTECTOMY	Surgical and medical procedures	Cholecystectomy	1993	1993	
	MANGO RIND ALLERGY	Immune system disorders	Food allergy	1998		Yes
	HYPEROPIA	Eye disorders	Hypermetropia	2011		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2014	2017	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051050	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2015	2015	
	UTERINE PROLAPSE	Reproductive system and breast disorders	Uterine prolapse	2015	2015	
	ACL REPAIR LEFT	Surgical and medical procedures	Ligament operation	2016	2016	
US2061006	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2002-01		Yes
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2007-07-06 (-4716)	2007-07-06 (-4716)	
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2017-04		Yes
	DYSMENORRHEA	Reproductive system and breast disorders	Dysmenorrhoea	2019-12		Yes
US2061009	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2019-08		Yes
US2061011	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1988		Yes
US2061013	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2017-06		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2061013	VASECTOMY	Surgical and medical procedures	Vasectomy	2020-05-02 (-34)	2020-05-02 (-34)	
US2061019	BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	1998		Yes
	OBESITY	Metabolism and nutrition disorders	Obesity	2000		Yes
	HEADACHE, RECURRENT	Nervous system disorders	Headache	2000-01		Yes
	ALLERGY TO AZYTHROMYCIN	Immune system disorders	Drug hypersensitivity	2015		Yes
	ALLERGY TO DARVOCET	Immune system disorders	Drug hypersensitivity	2015		Yes
	ALLERGY TO HYDROCODONE	Immune system disorders	Drug hypersensitivity	2015		Yes
	ALLERGY TO OXYCODONE	Immune system disorders	Drug hypersensitivity	2015		Yes
	ALLERGY TO TORODOL	Immune system disorders	Drug hypersensitivity	2015		Yes
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2015		Yes
	PRESBYOPIA	Eye disorders	Presbyopia	2017		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2061019	UTERINE FIBROIDS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	2017	2017-06-14 (-1085)	
	PARTIAL HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2017-06-14 (-1085)	2017-06-14 (-1085)	
	ANXIETY	Psychiatric disorders	Anxiety	2019-09		Yes
	DEPRESSION	Psychiatric disorders	Depression	2019-09		Yes
US2061026	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1980-04		Yes
	SEIZURES	Nervous system disorders	Seizure	1997		Yes
	ROSACEA, FACE	Skin and subcutaneous tissue disorders	Rosacea	1997-06		Yes
	CLOSED REDUCTION OF DISLOCATED LEFT SHOULDER	Surgical and medical procedures	Joint dislocation reduction	2019-12	2019-12	
	DISLOCATED LEFT SHOULDER	Injury, poisoning and procedural complications	Joint dislocation	2019-12	2019-12	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071003	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1997		Yes
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2008	2008	
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	2008	2008	
	ANXIETY	Psychiatric disorders	Anxiety	2010		Yes
	CHRONIC CONSTIPATION	Gastrointestinal disorders	Constipation	2010		Yes
	HEARTBURN	Gastrointestinal disorders	Dyspepsia	2010		Yes
	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2010		Yes
	LUMBAR PAIN	Musculoskeletal and connective tissue disorders	Back pain	2014		Yes
	2 + LIGAMENTAL LAXITY BILATERAL KNEE	Musculoskeletal and connective tissue disorders	Ligament laxity	2015		Yes
	EDEMA BILATERAL LEGS	General disorders and administration site conditions	Oedema peripheral	2015		Yes
	ATTENTION DEFICIT HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2017		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071004	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	1999-02	1999-02	
	ECZEMA BILATERAL HANDS	Skin and subcutaneous tissue disorders	Eczema	2000-03		Yes
	VASECTOMY	Surgical and medical procedures	Vasectomy	2010	2010	
	GENERALIZED ANXIETY DISORDER	Psychiatric disorders	Generalised anxiety disorder	2016		Yes
	ATTENTION DEFICIT DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2018-06-01 (-734)		Yes
	LACERATION LEFT FINGER	Injury, poisoning and procedural complications	Skin laceration	2020-05-23 (-12)		Yes
US2071030	FLARE UP OF TINEA PEDIS ON LEFT BIG TOE	Infections and infestations	Tinea pedis	2000		Yes
US2071067	ANXIETY	Psychiatric disorders	Anxiety	2020-05		Yes
US2071074	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2006		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081036	MIGRAINES	Nervous system disorders	Migraine	1990		Yes
	ALLERGIC RHINITIS	Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	2020-02		Yes
US2081039	ATTENTION DEFICIT DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2017		Yes
US2081052	DEPRESSION	Psychiatric disorders	Depression	2015		Yes
	ATOPIC ECZEMA (SCALP)	Skin and subcutaneous tissue disorders	Dermatitis atopic	2018		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2019		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011019	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2014	2014	
US2011039	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2004	2004	
	SEASONAL ALLERGIES, UNSPECIFIED	Immune system disorders	Seasonal allergy	2010		Yes
US2011046	ANISOCORIA LEFT > RIGHT	Eye disorders	Pupils unequal	2009		Yes
	GENERAL ANXIETY	Psychiatric disorders	Anxiety	2015		Yes
	ALLERGIC RHINITIS	Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	2017-09		Yes
US2011065	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1990		Yes
	SINUS HEADACHES	Nervous system disorders	Sinus headache	1990		Yes
	TENSION HEADACHES	Nervous system disorders	Tension headache	1990		Yes
	CONGENITAL HEART MURMUR	Investigations	Cardiac murmur	1995		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011080	DYSMENORRHEA	Reproductive system and breast disorders	Dysmenorrhoea	1983		Yes
	ALLERGIC RHINITIS	Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	1989		Yes
	HOT FLASHES	Vascular disorders	Hot flush	2010		Yes
	ACID REFLUX	Gastrointestinal disorders	Gastroesophageal reflux disease	2019-04-01 (-429)		Yes
US2011085	PILONIDAL CYST, BENIGN	Infections and infestations	Pilonidal cyst	2002		Yes
	UNSPECIFIED SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2017		Yes
US2011089	HEADACHES : OCCASIONAL	Nervous system disorders	Headache	2006		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2019		Yes
US2021063	ALLERGY TO SULFA	Immune system disorders	Drug hypersensitivity	1988		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2009		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021063	RIGHT BUNION	Musculoskeletal and connective tissue disorders	Foot deformity	2012	2012	
	RIGHT BUNION REMOVAL	Surgical and medical procedures	Bunion operation	2012	2012	
US2021067	VASECTOMY	Surgical and medical procedures	Vasectomy	2019-10	2019-10	
US2021068	VASECTOMY	Surgical and medical procedures	Vasectomy	2019-07-14 (-324)		Yes
	ACQUIRED HYPOGONADISM	Endocrine disorders	Hypogonadism	2020-02-10 (-113)		Yes
US2021074	ALLERGY TO BENADRYL	Immune system disorders	Drug hypersensitivity	2009		Yes
	FACE ACNE	Skin and subcutaneous tissue disorders	Acne	2019		Yes
US2021080	SULFA ALLERGY	Immune system disorders	Drug hypersensitivity	1980		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1990		Yes
	HERPES SIMPLEX 2	Infections and infestations	Herpes simplex	2014		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021080	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	2017	2017	
	APPENDICITIS	Infections and infestations	Appendicitis	2017	2017	
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2017	2017	
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	2017	2017	
	ENDOMETRIOSIS	Reproductive system and breast disorders	Endometriosis	2017	2017	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2017	2017	
US2021099	TONSILLECTOMY	Surgical and medical procedures	Tonsillectomy	1976	1976	
	HERPES LABIALIS	Infections and infestations	Oral herpes	1996		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2018		Yes
US2021145	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2013		Yes
	SEVERE MENSTRUAL CRAMPS	Reproductive system and breast disorders	Dysmenorrhoea	2019		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021151	ALLERGY TO SULFA	Immune system disorders	Drug hypersensitivity	1995		Yes
	ATTENTION DEFICIT DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2004		Yes
	POLYCYSTIC OVARY SYNDROME	Reproductive system and breast disorders	Polycystic ovaries	2015	2015	
	TOTAL HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2015	2015	
	ANXIETY	Psychiatric disorders	Anxiety	2018		Yes
US2021154	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1992		Yes
	BAND-AID ADHESIVE ALLERGY	Skin and subcutaneous tissue disorders	Dermatitis contact	2000		Yes
	ATTENTION DEFICIT HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2009		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2010		Yes
US2021164	TONSILLECTOMY	Surgical and medical procedures	Tonsillectomy	1990	1990	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021164	AROUND MOUTH ACNE	Skin and subcutaneous tissue disorders	Acne	2000		Yes
	TONSILLECTOMY 2	Surgical and medical procedures	Tonsillectomy	2008	2008	
	CAESAREAN SECTION 1	Surgical and medical procedures	Caesarean section	2014-11-04 (-2043)	2014-11-06 (-2041)	
	CAESAREAN SECTION 2	Surgical and medical procedures	Caesarean section	2016-08-30 (-1378)	2016-09-02 (-1375)	
US2021182	RIGHT BROKEN WRIST	Injury, poisoning and procedural complications	Wrist fracture	2017-01	2017-01	
	RIGHT DISTAL RADIUS FRACTURE SURGERY	Surgical and medical procedures	Fracture treatment	2017-01	2017-01	
US2031012	TONSILLECTOMY	Surgical and medical procedures	Tonsillectomy	1983	1983	
	TONSILLITIS	Infections and infestations	Tonsillitis	1983	1983	
US2031013	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2010		Yes
US2031019	APPENDECITIS	Infections and infestations	Appendicitis	1985	1985	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031019	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	1985	1985	
	VASECTOMY	Surgical and medical procedures	Vasectomy	1999	1999	
US2031020	CODEINE ALLERGY	Immune system disorders	Drug hypersensitivity	1989		Yes
	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1989		Yes
	RIGHT SIDE INGUINAL HERNIA	Gastrointestinal disorders	Inguinal hernia	1990	1990	
	TONSILLECTOMY	Surgical and medical procedures	Tonsillectomy	1994	1994	
	TONSILLITIS	Infections and infestations	Tonsillitis	1994	1994	
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2002	2002	
	FLAGYL ALLERGY	Immune system disorders	Drug hypersensitivity	2005		Yes
	MENORRAGIA	Reproductive system and breast disorders	Menorrhagia	2008	2010	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2010-07	2010-07	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031026	DEPRESSION	Psychiatric disorders	Depression	2017		Yes
US2031033	ELEVATED BLOOD PRESSURE WITHOUT DIAGNOSIS OF HYPERTENSION	Investigations	Blood pressure increased	2000		Yes
	VASECTOMY	Surgical and medical procedures	Vasectomy	2006	2006	
US2031035	ALLERGY TO IV CONTRAST DYE	Immune system disorders	Contrast media allergy	1995		Yes
	POLYCYSTIC OVARIAN SYNDROME	Reproductive system and breast disorders	Polycystic ovaries	1995		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1998		Yes
	OVARIAN LASERING	Surgical and medical procedures	Ovarian operation	2000	2000	
	TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2007	2007	
US2031047	ALLERGY TO PENICILLIN	Immune system disorders	Drug hypersensitivity	1996		Yes
	BILATERAL CARPAL TUNNEL	Nervous system disorders	Carpal tunnel syndrome	1999	1999	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031047	BILATERAL CARPAL TUNNEL RELEASE	Surgical and medical procedures	Carpal tunnel decompression	1999	1999	
US2031060	SULFA ALLERGY	Immune system disorders	Drug hypersensitivity	1988		Yes
US2031062	ANXIETY	Psychiatric disorders	Anxiety	2018		Yes
US2031073	IBUPROFEN ALLERGY	Immune system disorders	Drug hypersensitivity	2010		Yes
US2031079	CHRONIC BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	2010-02		Yes
	DEPRESSION	Psychiatric disorders	Depression	2015		Yes
US2031084	INGUINAL HERNIA LEFT	Gastrointestinal disorders	Inguinal hernia	2014	2014	
	INGUINAL HERNIA REPAIR LEFT	Surgical and medical procedures	Inguinal hernia repair	2014	2014	
US2041008	VASECTOMY	Surgical and medical procedures	Vasectomy	2016	2016	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041008	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2018		Yes
US2041010	TONSILLECTOMY	Surgical and medical procedures	Tonsillectomy	1991	1991	
	ANXIETY	Psychiatric disorders	Anxiety	2002-10		Yes
	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	2007	2008	
	ENDOMETRIAL ABLATION	Surgical and medical procedures	Endometrial ablation	2008	2008	
	ATTENTION DEFICIT DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2015		Yes
	DIVERTICULOSIS	Gastrointestinal disorders	Diverticulum	2017-11		Yes
US2041024	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2015		Yes
	BASAL CELL CARCINOMA FACE	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	2019-09	2019-11	
	BASAL CELL REMOVAL FACE	Surgical and medical procedures	Skin neoplasm excision	2019-11	2019-11	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041026	TENDON LACERATION	Injury, poisoning and procedural complications	Tendon injury	1988	1988	
	TENDON REPAIR SURGERY	Surgical and medical procedures	Tenoplasty	1988	1988	
US2041041	ANXIETY	Psychiatric disorders	Anxiety	2005		Yes
	RIGHT BENIGN BREAST CYST	Reproductive system and breast disorders	Breast cyst	2008	2008	
	RIGHT BENIGN BREAST CYST REMOVAL	Surgical and medical procedures	Breast cyst excision	2008	2008	
US2041046	ARIPIRAZOLE ALLERGY	Immune system disorders	Drug hypersensitivity	2005		Yes
	BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	2015		Yes
	DEPRESSION	Psychiatric disorders	Depression	2015		Yes
US2041048	TONSILECTOMY	Surgical and medical procedures	Tonsillectomy	2003	2003	
	TONSILLITIS	Infections and infestations	Tonsillitis	2003	2003	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041048	ANXIETY	Psychiatric disorders	Anxiety	2015		Yes
	DEPRESSION	Psychiatric disorders	Depression	2015		Yes
US2041061	RIGHT KNEE ARTHROSCOPY	Investigations	Arthroscopy	2010	2010	
	RIGHT MENISCUS TEAR	Injury, poisoning and procedural complications	Meniscus injury	2010	2010	
	RIGHT BUNIONECTOMY	Surgical and medical procedures	Bunion operation	2015	2015	
	RIGHT LARGE TOE BUNION	Musculoskeletal and connective tissue disorders	Foot deformity	2015	2015	
	GENERAL OSTEOARTHRITIS	Musculoskeletal and connective tissue disorders	Osteoarthritis	2018		Yes
	LEVOFLOXACIN ALLERGY	Immune system disorders	Drug hypersensitivity	2018-10		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2018-12		Yes
	LEFT HIP REPLACEMENT	Surgical and medical procedures	Hip arthroplasty	2019-11	2019-11	
	RIGHT HIP REPLACEMENT	Surgical and medical procedures	Hip arthroplasty	2019-12	2019-12-02 (-183)	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041073	RESTLESS LEG SYNDROME	Nervous system disorders	Restless legs syndrome	2003		Yes
	CHRONIC LOW BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	2005		Yes
	PREMENSTRUAL DYSPHORIC DISORDER	Reproductive system and breast disorders	Premenstrual dysphoric disorder	2010		Yes
	DILAUDID ALLERGY	Immune system disorders	Drug hypersensitivity	2014		Yes
	BUSPIRONE ALLERGY	Immune system disorders	Drug hypersensitivity	2016		Yes
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2018	2018	
US2041079	TONSILITIS	Infections and infestations	Tonsillitis	2009	2010	
	TONSILLECTOMY	Surgical and medical procedures	Tonsillectomy	2010	2010	
	INSOMNIA	Psychiatric disorders	Insomnia	2012		Yes
US2041080	DEVIATED SEPTUM	Respiratory, thoracic and mediastinal disorders	Nasal septum deviation	1994-	(b) (6)) 2016-11	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041080	SEPTOPLASTY	Surgical and medical procedures	Nasal septal operation	2016-11	2016-11	
US2041084	FAMILIAL HYPERCHOLESTEROLEMIA	Congenital, familial and genetic disorders	Type IIa hyperlipidaemia	1990		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1990		Yes
	SULFA ALLERGY	Immune system disorders	Drug hypersensitivity	1990		Yes
	AMOXICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1997		Yes
	ACNE (FACE)	Skin and subcutaneous tissue disorders	Acne	1998		Yes
	ENDOMETRIAL HYPERPLASIA	Reproductive system and breast disorders	Endometrial hyperplasia	1998	2000	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2000	2000	
	FIBROMYALGIA	Musculoskeletal and connective tissue disorders	Fibromyalgia	2016		Yes
US2051001	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1998		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051001	MYOPIA	Eye disorders	Myopia	2004		Yes
US2051002	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2010		Yes
	BILATERAL ASTIGMATISM	Eye disorders	Astigmatism	2012		Yes
	IRON DEFICIENCY ANEMIA	Blood and lymphatic system disorders	Iron deficiency anaemia	2012		Yes
	PRESBYOPIA	Eye disorders	Presbyopia	2012		Yes
	AMENORRHEA	Reproductive system and breast disorders	Amenorrhoea	2014	2018	
	OCCASIONAL DIARRHEA	Gastrointestinal disorders	Diarrhoea	2018		Yes
	LEFT ULNA FRACTURE	Injury, poisoning and procedural complications	Ulna fracture	2018	2018	
	SURGERY TO REPAIR LEFT ULNA FRACTURE	Surgical and medical procedures	Fracture treatment	2018	2018	
	HYDROCODONE ALLERGY	Immune system disorders	Drug hypersensitivity	2019		Yes
	CONSTIPATION	Gastrointestinal disorders	Constipation	2020-05-27 (-6)	2020-06-01 (-1)	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051003	BENIGN CYST JAW	Musculoskeletal and connective tissue disorders	Jaw cyst	2009	2012	
	BENIGN CYST JAW REMOVAL 2 TIMES	Surgical and medical procedures	Bone cyst excision	2009	2012	
	INSOMNIA	Psychiatric disorders	Insomnia	2019		Yes
	HEADACHE	Nervous system disorders	Headache	2020-05-23 (-6)	2020-05-23 (-6)	
US2051012	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2016		Yes
	HYPEROPIA	Eye disorders	Hypermetropia	2016-01	2016-01	
	LASER EYE SURGERY BILATERAL	Surgical and medical procedures	Eye laser surgery	2016-01	2016-01	
US2051013	ANXIETY	Psychiatric disorders	Anxiety	2013		Yes
	DEPRESSION	Psychiatric disorders	Depression	2013		Yes
	CAT ALLERGY	Immune system disorders	Allergy to animal	2014		Yes
US2051017	ONYCHOMYCOSIS (TOENAILS)	Infections and infestations	Onychomycosis	2019		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051019	CONSTIPATION	Gastrointestinal disorders	Constipation	2010		Yes
	MIGRAINE	Nervous system disorders	Migraine	2010		Yes
	BRADYCARDIA	Cardiac disorders	Bradycardia	2015		Yes
	MENIERES DISEASE	Ear and labyrinth disorders	Meniere's disease	2016		Yes
	PROLACTINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prolactin-producing pituitary tumour	2017		Yes
	MISCARRIAGE X 3	Pregnancy, puerperium and perinatal conditions	Abortion spontaneous	2017	2019	
	INFERTILITY	Reproductive system and breast disorders	Infertility	2018		Yes
	IN VITRO FERTILIZATION	Surgical and medical procedures	In vitro fertilisation	2019-05	2019-05	
	BILATERAL ANKLE PAIN	Musculoskeletal and connective tissue disorders	Arthralgia	2019-07		Yes
	BILATERAL KNEE PAIN	Musculoskeletal and connective tissue disorders	Arthralgia	2019-07		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051020	FAR SIGHTED	Eye disorders	Hypermetropia	2015		Yes
US2051024	HERPES SIMPLEX VIRUS (COLD SORES)	Infections and infestations	Oral herpes	1985		Yes
	MIGRAINES	Nervous system disorders	Migraine	1987		Yes
	FLAGYL ALLERGY	Immune system disorders	Drug hypersensitivity	1995		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	1996		Yes
	CAESAREAN SECTION	Surgical and medical procedures	Caesarean section	1998	1998	
	CAESAREAN SECTION	Surgical and medical procedures	Caesarean section	2000	2000	
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2009	2009	
	CHOLELITHIASIS	Hepatobiliary disorders	Cholelithiasis	2009	2009	
US2051025	IRRITABLE BOWEL SYNDROME	Gastrointestinal disorders	Irritable bowel syndrome	2012		Yes
US2051026	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2017		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051028	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2019		Yes
	RIGHT HAND INJURY	Injury, poisoning and procedural complications	Limb injury	2020-05-22 (-13)	2020-05-22 (-13)	
US2051029	MYOPIA (WEARS CONTACTS)	Eye disorders	Myopia	2006		Yes
US2051030	DAIRY SENSITIVITY	Metabolism and nutrition disorders	Dairy intolerance	1977-(b) (6)		Yes
	TONSILLECTOMY	Surgical and medical procedures	Tonsillectomy	1985	1985	
	ASTIGMATISM	Eye disorders	Astigmatism	1987		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2001		Yes
	SINUSITIS (DUE TO SEASONAL ALLERGIES)	Respiratory, thoracic and mediastinal disorders	Allergic sinusitis	2001		Yes
	OCCASIONAL BRONCHITIS	Infections and infestations	Bronchitis	2001	2020-03	
	CHRONIC VAGINAL YEAST INFECTION	Infections and infestations	Vulvovaginal mycotic infection	2010	2014	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051030	BACK TORSO MOLE BENIGN	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Melanocytic naevus	2017	2017	
	RIGHT BREAST BIOPSY BENIGN	Investigations	Biopsy breast normal	2017	2017	
	RIGHT BREAST LUMP BENIGN	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign breast neoplasm	2017	2017	
US2051045	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1996		Yes
	OCCASIONAL HEADACHE	Nervous system disorders	Headache	2015		Yes
	OCCASIONAL IRRITABLE BOWEL SYNDROME	Gastrointestinal disorders	Irritable bowel syndrome	2018		Yes
US2061008	ALLERGY TO PENICILLIN	Immune system disorders	Drug hypersensitivity	1989-(b) (6)		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2010-(b) (6)		Yes
	DEPRESSION	Psychiatric disorders	Depression	2010		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2010		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2061008	HERNIATED DISC NECK	Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	2013		Yes
	ANGIOKERATOMA - SCROTUM	Skin and subcutaneous tissue disorders	Angiokeratoma	2018-06		Yes
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2020-02		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2020-02		Yes
	BAKERS CYSTS LEFT KNEE	Musculoskeletal and connective tissue disorders	Synovial cyst	2020-05-09 (-25)		Yes
US2061020	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2000		Yes
	MYOPIA	Eye disorders	Myopia	2000		Yes
US2061023	MIGRAINES	Nervous system disorders	Migraine	2013-01		Yes
US2061024	SCIATICA, BILATERAL	Nervous system disorders	Sciatica	2010-01-01 (-3806)		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2010-06		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2061027	GLYCOL ALLERGY	Immune system disorders	Drug hypersensitivity	2000		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2000		Yes
	TENNIS ELBOW RIGHT	Injury, poisoning and procedural complications	Epicondylitis	2019-05		Yes
US2071016	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2007	2007	
	HEARTBURN	Gastrointestinal disorders	Dyspepsia	2019		Yes
US2071026	AMOXICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1987-11		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1994		Yes
US2071038	OMNICEF ALLERGY	Immune system disorders	Drug hypersensitivity	1998		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2003		Yes
US2071039	CODINE ALLERGY	Immune system disorders	Drug hypersensitivity	1997		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071039	INSOMNIA	Psychiatric disorders	Insomnia	2005		Yes
	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2018		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2018	2018	
	PROLAPSED UTERUS	Reproductive system and breast disorders	Uterine prolapse	2018	2018	
US2071040	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2010		Yes
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2010-05-11 (-3681)	2010-05-11 (-3681)	
US2071051	INGUINAL HERNIA (LEFT SIDE)	Gastrointestinal disorders	Inguinal hernia	2004	2004	
	VAGINAL SEPTUM REMOVAL	Surgical and medical procedures	Vaginal operation	2011	2011	
	ECZEMA LEFT ELBOW	Skin and subcutaneous tissue disorders	Eczema	2014		Yes
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	2014-02-06 (-2311)	2014-02-06 (-2311)	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071051	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	2016		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2019		Yes
	ATTENTION DEFICIT HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2020-04		Yes
US2071071	ENDOMETRIOSIS	Reproductive system and breast disorders	Endometriosis	2005	2005	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2005	2005	
US2081025	ANXIETY	Psychiatric disorders	Anxiety	2000		Yes
	ATTENTION DEFICIT HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2013		Yes
	OBSTRUCTIVE SLEEP APNEA	Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	2017	2017-07-11 (-1058)	
	EPISCLERITIS[ACUTE, LEFT EYE]	Eye disorders	Episcleritis	2018		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081028	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2018		Yes
	DYSLIPIDEMIA	Metabolism and nutrition disorders	Dyslipidaemia	2019		Yes
US2081045	ROSACEA (FACE)	Skin and subcutaneous tissue disorders	Rosacea	2002		Yes
US2081051	ANXIETY	Psychiatric disorders	Anxiety	1994		Yes
	PTSD	Psychiatric disorders	Post-traumatic stress disorder	1994		Yes
	NECK PAIN	Musculoskeletal and connective tissue disorders	Neck pain	2010		Yes
	MENOPAUSE	Social circumstances	Menopause	2017		Yes
	DYSLIPIDEMIA	Metabolism and nutrition disorders	Dyslipidaemia	2018		Yes
US2081064	GOUT [HEELS]	Metabolism and nutrition disorders	Gout	2017		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011007	GENERAL MYALGIAS	Musculoskeletal and connective tissue disorders	Myalgia	2000		Yes
	HEADACHES	Nervous system disorders	Headache	2000		Yes
	BENIGN GROWTH ON UTERUS, UNKNOWN ORIGIN	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign uterine neoplasm	2000	2000	
	HYSTERECTOMY, FULL	Surgical and medical procedures	Hysterectomy	2000	2000	
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2017		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2017		Yes
US2011011	POST-MENOPAUSAL	Social circumstances	Postmenopause	2006		Yes
US2011023	HEAVY MENSTRUAL BLEEDING	Reproductive system and breast disorders	Menorrhagia	1996	1996	
	HYSTERECTOMY, PARTIAL	Surgical and medical procedures	Hysterectomy	1996	1996	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011023	POST-MENOPAUSAL	Social circumstances	Postmenopause	1997		Yes
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2005		Yes
	BENIGN FLOW HEART MURMUR	Investigations	Cardiac murmur	2008		Yes
	HEADACHES	Nervous system disorders	Headache	2010		Yes
	MIGRAINES	Nervous system disorders	Migraine	2010		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2010		Yes
	HEARTBURN	Gastrointestinal disorders	Dyspepsia	2019-12		Yes
	IRRITABLE BOWEL SYNDROME	Gastrointestinal disorders	Irritable bowel syndrome	2019-12		Yes
	NAUSEA	Gastrointestinal disorders	Nausea	2020-02		Yes
US2011109	POSTMENOPAUSAL	Social circumstances	Postmenopause	1988		Yes
	BENIGN DORSUM CYST, RIGHT HAND	General disorders and administration site conditions	Cyst	1990		Yes
	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2010		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011109	OSTEOPOROSIS	Musculoskeletal and connective tissue disorders	Osteoporosis	2017		Yes
US2011114	MIGRAINES	Nervous system disorders	Migraine	1998		Yes
	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2001		Yes
US2011116	UTERINE FIBROIDS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	2000	2000-02-08 (-7445)	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2000-02-08 (-7445)	2000-02-08 (-7445)	
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2001		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2007		Yes
	HEADACHES	Nervous system disorders	Headache	2010		Yes
	HEARTBURN	Gastrointestinal disorders	Dyspepsia	2010		Yes
	OSTEOARTHRITIS, BILATERAL HANDS	Musculoskeletal and connective tissue disorders	Osteoarthritis	2010		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011120	HEADACHES,	Nervous system disorders	Headache	2000		Yes
	ALLERGY-RELATED	Immune system disorders	Seasonal allergy	2000		Yes
	SEASONAL ALLERGIES, UNSPECIFIED	Vascular disorders	Hot flush	2006		Yes
	HOT FLASHES	Social circumstances	Postmenopause	2006		Yes
	POST-MENOPAUSAL	Reproductive system and breast disorders	Endometriosis	2007	2007	
	ENDOMETRIOSIS	Surgical and medical procedures	Uterine operation	2007	2007	
	FIBROID/ENDOMETRIOSIS SURGERY	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	2007	2007	
	UTERINE FIBROIDS	Musculoskeletal and connective tissue disorders	Osteopenia	2018		Yes
US2011124	OSTEOPENIA	Immune system disorders	Seasonal allergy	1980		Yes
	SEASONAL ALLERGIES, UNSPECIFIED	Psychiatric disorders	Insomnia	2010		Yes
	DIFFICULTY SLEEPING, DUE TO HOT FLASHES	Vascular disorders	Hot flush	2010		Yes
	HOT FLASHES					

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011124	MIGRAINES	Nervous system disorders	Migraine	2010		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2011		Yes
US2011126	GLAUCOMA, BILATERAL ANXIETY	Eye disorders	Glaucoma	2004		Yes
		Psychiatric disorders	Anxiety	2005		Yes
	OSTEOPENIA, LT KNEE	Musculoskeletal and connective tissue disorders	Osteopenia	2007		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2009		Yes
US2011130	SUN-DAMAGED SKIN, FACE AND BODY	Skin and subcutaneous tissue disorders	Photodermatosis	2018		Yes
US2011131	POSTMENOPAUSAL	Social circumstances	Postmenopause	2008		Yes
	RATTLE, LEFT EAR	Ear and labyrinth disorders	Tinnitus	2008		Yes
	HOT FLASHES	Vascular disorders	Hot flush	2015		Yes
	SEASONAL ALLERGIES, UNSPECIFIED	Immune system disorders	Seasonal allergy	2019-05-01 (-422)		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011142	BASAL CELL CARCINOMA REMOVAL, NOSE	Surgical and medical procedures	Skin neoplasm excision	2000-05	2000-05	
	BASAL CELL CARCINOMA, NOSE	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	2000-05	2000-05	
	ADHD	Psychiatric disorders	Attention deficit hyperactivity disorder	2010-05		Yes
	HYERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2018-05		Yes
US2011145	MIGRAINES	Nervous system disorders	Migraine	1974		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2010		Yes
US2011152	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2010	2010	
	UTERINE FIBROIDS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	2010	2010	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011155	KYPHOSIS THORACIC SPINE	Musculoskeletal and connective tissue disorders	Kyphosis	1962		Yes
	SPINE SURGERY, KYPHOSIS THORACIC SPINE	Surgical and medical procedures	Spinal operation	1965-06	1965-06	
	HERPES SIMPLEX	Infections and infestations	Herpes simplex	1978		Yes
	MIGRAINES	Nervous system disorders	Migraine	1984		Yes
	OSTEOPENIA	Musculoskeletal and connective tissue disorders	Osteopenia	2001		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2010		Yes
	DIVERTICULITIS	Infections and infestations	Diverticulitis	2011		Yes
	IRRITABLE BOWEL SYNDROME	Gastrointestinal disorders	Irritable bowel syndrome	2011		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2011		Yes
	BASAL CELL SKIN CANCER UPPER LIP	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	2019-06	2019-06	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011155	RIGHT KNEE INJURY, UNSPECIFIED	Injury, poisoning and procedural complications	Joint injury	2019-09	2019-10-01 (-273)	
	RIGHT KNEE REPLACEMENT	Surgical and medical procedures	Knee arthroplasty	2019-10-01 (-273)	2019-10-01 (-273)	
	HERNIA- UMBILICAL	Gastrointestinal disorders	Umbilical hernia	2020-01	2020-01	
	UMBILICAL HERNIA REPAIR	Surgical and medical procedures	Umbilical hernia repair	2020-01	2020-01	
US2011156	HERPES SIMPLEX I	Infections and infestations	Herpes simplex	1975		Yes
	SEASONAL ALLERGIES, UNSPECIFIED	Immune system disorders	Seasonal allergy	2000		Yes
	HEAVY MENSTRUAL BLEEDING	Reproductive system and breast disorders	Menorrhagia	2000	2000	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2000	2000	
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2005		Yes
	TENSION HEADACHES	Nervous system disorders	Tension headache	2010		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011156	MUSCLE TENSION, GENERAL	Musculoskeletal and connective tissue disorders	Muscle tightness	2017		Yes
	OSTEOPOROSIS	Musculoskeletal and connective tissue disorders	Osteoporosis	2017		Yes
	GERD	Gastrointestinal disorders	Gastrooesophageal reflux disease	2018		Yes
US2011157	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1989	1989	
	DEPRESSION, MILD	Psychiatric disorders	Depression	2005		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2010		Yes
	BASAL CELL CARCINOMA ON NOSE REMOVAL	Surgical and medical procedures	Skin neoplasm excision	2014	2014	
	BASAL CELL CARCINOMA, NOSE	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	2014	2014	
	GENERAL MYALGIAS	Musculoskeletal and connective tissue disorders	Myalgia	2019		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021015	POSTMENOPAUSAL	Social circumstances	Postmenopause	2010		Yes
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2014		Yes
	OVERACTIVE BLADDER	Renal and urinary disorders	Hypertonic bladder	2015		Yes
	DEPRESSION	Psychiatric disorders	Depression	2019		Yes
US2021021	VASECTOMY	Surgical and medical procedures	Vasectomy	1986	1986	
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2008		Yes
	BASAL CELL CARCINOMA - FACE	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	2018	2018	
US2021022	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1960		Yes
	SULFA ALLERGY	Immune system disorders	Drug hypersensitivity	1960		Yes
	APPENDICITIS	Infections and infestations	Appendicitis	1980	1980	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021022	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	1980-04	1980-04	
	ENDOMETRIOSIS	Reproductive system and breast disorders	Endometriosis	1995	1995-11	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1995-11	1995-11	
	POST MENOPAUSAL	Social circumstances	Postmenopause	1995-11-15 (-8965)		Yes
US2021043	VASECTOMY	Surgical and medical procedures	Vasectomy	1982	1982	
	HYPERLIPIDEMIA	Metabolism and nutrition disorders	Hyperlipidaemia	2014		Yes
US2021130	BILATERAL HARD OF HEARING	Ear and labyrinth disorders	Hypoacusis	1980		Yes
	HYPERLIPIDEMIA	Metabolism and nutrition disorders	Hyperlipidaemia	2002		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2002		Yes
	OSTEOPENIA	Musculoskeletal and connective tissue disorders	Osteopenia	2015		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021130	LEFT UPPER ARM ABRASION	Injury, poisoning and procedural complications	Skin abrasion	2020-06-04 (-22)	2020-06-26 (1)	
US2021185	DEPRESSION	Psychiatric disorders	Depression	2000		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2018		Yes
	RIGHT ANKLE FRACTURE	Injury, poisoning and procedural complications	Ankle fracture	2018-11	2018-12	
	OPEN REDUCTION INTERNAL FIXATION RIGHT ANKLE	Surgical and medical procedures	Open reduction of fracture	2018-12	2018-12	
	RIGHT SHOULDER PAIN	Musculoskeletal and connective tissue disorders	Musculoskeletal pain	2020-05-25 (-32)		Yes
US2021189	POSTMENOPAUSAL	Social circumstances	Postmenopause	1995		Yes
	CHRONIC LOW BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	2011		Yes
	OSTEOPOROSIS	Musculoskeletal and connective tissue disorders	Osteoporosis	2020-01		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021196	POST MENOPAUSAL	Social circumstances	Postmenopause	2008		Yes
US2021198	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1972		Yes
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1975	1975	
	PRE-CANCEROUS CHANGES ON PAP SMEAR	Investigations	Precancerous cells present	1981	1983	
	PARTIAL HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1983	1983	
	MIGRAINES	Nervous system disorders	Migraine	2010		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2012		Yes
US2021206	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1960		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2010		Yes
	OBSTRUCTIVE SLEEP APNEA	Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	2013		Yes
	BILATERAL GLAUCOMA	Eye disorders	Glaucoma	2016		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021206	HYPERCHOLESTEROEDMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2016		Yes
US2021207	GASTROESOPHAGEAL REFLEX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2015		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2015		Yes
US2021219	MIGRAINES	Nervous system disorders	Migraine	2007		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2015		Yes
	DRY EYES	Eye disorders	Dry eye	2017		Yes
US2021222	HEMORRHOIDS EXTERNAL	Gastrointestinal disorders	Haemorrhoids	1993		Yes
	HEMORRHOIDS INTERNAL	Gastrointestinal disorders	Haemorrhoids	1993		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2000		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2010		Yes
	HYPERLIPIDEMIA	Metabolism and nutrition disorders	Hyperlipidaemia	2014		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031085	ALLERGY TO PENICILLIAN	Immune system disorders	Drug hypersensitivity	1966		Yes
	HYPOESTROGENISM	Endocrine disorders	Oestrogen deficiency	1998		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	1998		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1998	1998	
	UTERINE FIBROIDS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	1998	1998	
US2031089	BENIGN PROSTATIC HYPERPLASIA	Reproductive system and breast disorders	Benign prostatic hyperplasia	2015		Yes
	CHRONIC BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	2015		Yes
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2015		Yes
	HYPERLIPIDEMIA	Metabolism and nutrition disorders	Hyperlipidaemia	2015		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031089	UPPER GASTROINTESTINAL TRACT ENDOSCOPY	Investigations	Endoscopy upper gastrointestinal tract	2015	2015	
US2031092	POST MENOPAUSAL	Social circumstances	Postmenopause	1989		Yes
	BLINDNESS RIGHT EYE	Eye disorders	Blindness unilateral	1992		Yes
	DETACHED RETNA	Eye disorders	Retinal detachment	1992		Yes
	RIGHT EYE HOTFLASHES	Vascular disorders	Hot flush	2005		Yes
	BILATERAL CATARACTS	Eye disorders	Cataract	2006	2006	
	BILATERAL CATERACT REMOVED	Surgical and medical procedures	Cataract operation	2006	2006	
	LEFT SHOULDER INJURY	Injury, poisoning and procedural complications	Limb injury	2008	2008	
	LEFT SHOULDER REPAIR ROTATOR CUFF	Surgical and medical procedures	Rotator cuff repair	2008	2008	
	BENIGN THYROID MASS REMOVED	Surgical and medical procedures	Thyroid nodule removal	2014	2014	
	OPEN-ANGLE GLAUCOMA LEFT EYE	Eye disorders	Open angle glaucoma	2019		Yes
US2031095	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1992	1992	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031095	SULFA ALLERGY	Immune system disorders	Drug hypersensitivity	2005		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2014		Yes
	RIGHT EAR TINNITUS	Ear and labyrinth disorders	Tinnitus	2017		Yes
US2031098	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	1975	1975	
	APPENDICITIS	Infections and infestations	Appendicitis	1975	1975	
	ALLERGY TO SULFA	Immune system disorders	Drug hypersensitivity	2000		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2010		Yes
	HYPERLIPIDEMIA	Metabolism and nutrition disorders	Hyperlipidaemia	2017		Yes
	BROKEN L ARM	Injury, poisoning and procedural complications	Upper limb fracture	2017	2017	
	OPEN REDUCTION INTERNAL FIXATION LEFT ARM	Surgical and medical procedures	Open reduction of fracture	2017	2017	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031100	POST MENOPAUSAL	Social circumstances	Postmenopause	1990		Yes
US2031102	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2014		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2014		Yes
US2031103	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2004	2004	
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	2004	2004	
	BASAL CELL CARCINOMA OF THE BACK	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	2020-05-25 (-35)	2020-06-03 (-26)	
	MOH'S PROCEDURE ON BACK	Surgical and medical procedures	Micrographic skin surgery	2020-06-03 (-26)	2020-06-03 (-26)	
US2031110	CODEINE SENSITIVITY	Immune system disorders	Drug hypersensitivity	1994		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	1996		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031116	POSTMENOPAUSAL	Social circumstances	Postmenopause	2000		Yes
US2031125	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	1999		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1999		Yes
	RESTLESS LEG SYNDROME	Nervous system disorders	Restless legs syndrome	2000		Yes
	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	2000	2002	
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2002		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2002	2002	
	ALLERGY TO OXYCODONE	Immune system disorders	Drug hypersensitivity	2012		Yes
	BILATERAL KNEE OSTEOARTHRITIS	Musculoskeletal and connective tissue disorders	Osteoarthritis	2012		Yes
	BILATERAL KNEE PARTIAL REPLACEMENT	Surgical and medical procedures	Knee arthroplasty	2012	2012	
	ACID REFLUX	Gastrointestinal disorders	Gastroesophageal reflux disease	2017		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031125	LEFT SHOULDER ROTATOR CUFF REPAIR	Surgical and medical procedures	Rotator cuff repair	2018	2018	
	LEFT SHOULDER ROTATOR CUFF TEAR	Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	2018	2018	
US2031129	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1978		Yes
	VASECTOMY	Surgical and medical procedures	Vasectomy	1991	1991	
	UMBILICAL HERNIA	Gastrointestinal disorders	Umbilical hernia	2017		Yes
US2031131	POSTMENOPAUSAL	Social circumstances	Postmenopause	1990		Yes
	RIGHT BUNION	Musculoskeletal and connective tissue disorders	Foot deformity	1992	2018	
	RIGHT BUNION SURGERY	Surgical and medical procedures	Bunion operation	2018	2018	
	LEFT BUNION PAIN	Musculoskeletal and connective tissue disorders	Foot deformity	2019-06	2019-07	
	LEFT BUNION SURGERY	Surgical and medical procedures	Bunion operation	2019-07	2019-07	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041114	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1960		Yes
	VASTECTOMY	Surgical and medical procedures	Vasectomy	2014	2017	
	VITAMIN D DEFICIENCY	Metabolism and nutrition disorders	Vitamin D deficiency	2018		Yes
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2018	2018	
	CHOLELITHIASIS	Hepatobiliary disorders	Cholelithiasis	2018	2018	
	UMBILICAL HERNIA	Gastrointestinal disorders	Umbilical hernia	2018	2018	
US2041115	UTERINE PROLAPSE	Reproductive system and breast disorders	Uterine prolapse	1980	1990	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1990	1990	
	POST MENOPAUSAL	Social circumstances	Postmenopause	2000		Yes
US2041121	CHRONIC SINUSITIS	Infections and infestations	Chronic sinusitis	2000		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2001	2001	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041121	UTERINE FIBROIDS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	2001	2001	
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2014	2014	
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	2014	2014	
US2041132	PREGNANCY	Pregnancy, puerperium and perinatal conditions	Pregnancy	1996-06	1997-03-14 (-8505)	
	CESAREAN SECTION	Surgical and medical procedures	Caesarean section	1997-03-14 (-8505)	1997-03-14 (-8505)	
	UTERINE PROLAPSE	Reproductive system and breast disorders	Uterine prolapse	2000	2003	
	POST MENOPAUSAL	Social circumstances	Postmenopause	2003		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2003	2003	
	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	2003	2003	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041142	VASECTOMY	Surgical and medical procedures	Vasectomy	1985	1985	
	LEFT-SHOULDER ARTHRITIS	Musculoskeletal and connective tissue disorders	Arthritis	2005	2012	
	LEFT-SUBMANDIBULAR GLAND INFECTION	Infections and infestations	Sialoadenitis	2010	2010	
	LEFT-SUBMANDIBULAR GLAND REMOVAL	Surgical and medical procedures	Salivary gland resection	2010	2010	
	LEFT-SHOULDER ARTHROSCOPY	Investigations	Arthroscopy	2012	2012	
	DEPRESSION	Psychiatric disorders	Depression	2015		Yes
	IODINE ALLEGY	Immune system disorders	Iodine allergy	2015		Yes
US2041146	HISTORY OF PULMONARY EMBOLISM	Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	2015	2015	
	ANXIETY	Psychiatric disorders	Anxiety	1998		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	1998		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041151	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1991		Yes
	GENERALIZED ACHES AND PAINS	General disorders and administration site conditions	Pain	2000		Yes
	INTERMITTENT INSOMNIA	Psychiatric disorders	Insomnia	2000		Yes
	GASTROESOPHAGEAL REFLUX DISORDER	Gastrointestinal disorders	Gastroesophageal reflux disease	2010		Yes
US2041152	POST MENOPAUSE	Social circumstances	Postmenopause	2013		Yes
US2041166	ANXIETY	Psychiatric disorders	Anxiety	2010		Yes
	DEPRESSION	Psychiatric disorders	Depression	2010		Yes
	VERTIGO	Ear and labyrinth disorders	Vertigo	2018		Yes
US2051055	HYPEROPIA	Eye disorders	Hypermetropia	1966		Yes
	LUMBAR BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	1979		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1980		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051055	VASECTOMY	Surgical and medical procedures	Vasectomy	2003	2003	
	PASSED KIDNEY STONE	Renal and urinary disorders	Nephrolithiasis	2004	2004	
	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	2008	2008	
	APPENDICITIS	Infections and infestations	Appendicitis	2008	2008	
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastroesophageal reflux disease	2014		Yes
US2051063	HYPOTHENAR EMINENCE ATROPHY BILATERAL HANDS	Musculoskeletal and connective tissue disorders	Muscle atrophy	2005		Yes
	CERVICAL SPINE TUMOR BENIGN	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of spinal cord	2005	2005	
	CERVICAL SPINE TUMOR BENIGN REMOVED	Surgical and medical procedures	Spinal operation	2005	2005	
US2051072	MYOPIA	Eye disorders	Myopia	1995		Yes
	LEFT EYE OPTIC NEUROPATHY	Eye disorders	Optic neuropathy	1998		Yes
	KIDNEY STONES	Renal and urinary disorders	Nephrolithiasis	1998	1998	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051072	LEFT EYE BLOOD CLOT (UNKNOWN TYPE)	Eye disorders	Eye haemorrhage	1998	1998	
	GENERALIZED BODY ACHES	General disorders and administration site conditions	Pain	2000		Yes
	RIGHT HEEL FRACTURE	Injury, poisoning and procedural complications	Foot fracture	2005	2005	
	RIGHT HEEL PAIN	Musculoskeletal and connective tissue disorders	Pain in extremity	2005	2005	
	RIGHT HEEL REPAIR	Surgical and medical procedures	Foot operation	2005	2005	
	PATRIAL HEARING LOSS BILATERAL EARS	Ear and labyrinth disorders	Deafness bilateral	2010		Yes
	EXTRACORPOREAL SHOCK WAVE	Surgical and medical procedures	Extracorporeal shock wave therapy	2010	2010	
	KIDNEY STONES	Renal and urinary disorders	Nephrolithiasis	2010	2010	
	OSTEOARTHRITIS LEFT ANKLE	Musculoskeletal and connective tissue disorders	Osteoarthritis	2016		Yes
	HERNIA (UNKNOWN TYPE)	General disorders and administration site conditions	Hernia	2016	2016	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051072	HERNIA REPAIR (UNKNOWN TYPE)	Surgical and medical procedures	Hernia repair	2016	2016	
	LEFT HEEL REPAIR	Surgical and medical procedures	Foot operation	2016	2016	
	LEFT HEEL FRACTURE	Injury, poisoning and procedural complications	Foot fracture	2016	2016-11	
	HEADACHES	Nervous system disorders	Headache	2020		Yes
	BRADYCARDIA	Cardiac disorders	Bradycardia	2020-06		Yes
US2051073	DILATION AND CURETTAGE DUE TO PAINFUL PERIODS	Surgical and medical procedures	Uterine dilation and curettage	1978	1978	
	HYPEROPIA	Eye disorders	Hypermetropia	1992		Yes
	POST-MENOPAUSAL	Social circumstances	Postmenopause	1996		Yes
	RESTLESS LEG SYNDROME	Nervous system disorders	Restless legs syndrome	1996		Yes
	OCCASIONAL ROSACEA FACE	Skin and subcutaneous tissue disorders	Rosacea	2010		Yes
	COLON POLYPECTOMY-BENIGN	Surgical and medical procedures	Large intestinal polypectomy	2011	2011	
	VERTIGO	Ear and labyrinth disorders	Vertigo	2019	2019	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051086	NERVE DEAFNESS RIGHT EAR	Ear and labyrinth disorders	Deafness unilateral	1942 (b) (6)		Yes
	NERVE DEAFNESS RIGHT EAR CONGENITAL	Ear and labyrinth disorders	Deafness unilateral	1942 (b) (6)		Yes
	ALLERGIC TO CATS	Immune system disorders	Allergy to animal	1948		Yes
	ALLERGIC TO RAGWEED	Immune system disorders	Seasonal allergy	1948		Yes
	HYPEROPIA	Eye disorders	Hypermetropia	2005		Yes
	BENIGN MOLE FOREHEAD	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Melanocytic naevus	2010	2010	
	BENIGN MOLE REMOVAL ON FOREHEAD	Surgical and medical procedures	Mole excision	2010	2010	
	ERECTILE DYSFUNCTION	Reproductive system and breast disorders	Erectile dysfunction	2012		Yes
	BILATERAL OSTEOARTHRITIS OF THE KNEES	Musculoskeletal and connective tissue disorders	Osteoarthritis	2013		Yes
	LEFT KNEE ARTHROSCOPY	Investigations	Arthroscopy	2013	2013	
	LEFT TORN MENISCUS	Injury, poisoning and procedural complications	Meniscus injury	2013	2013	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051086	ACTINIC KERATOSIS ON HEAD	Skin and subcutaneous tissue disorders	Actinic keratosis	2018-12-18 (-566)		Yes
US2051087	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1966		Yes
	SEASONAL ALLERGIC RHINITIS	Immune system disorders	Seasonal allergy	1971	1997	
	POST MENOPAUSAL	Social circumstances	Postmenopause	2000-01		Yes
	TENDONITIS RIGHT ELBOW	Musculoskeletal and connective tissue disorders	Tendonitis	2000-10-01 (-7218)	2005-01-01 (-5665)	
	BENIGN LEFT BREAST CYST REMOVED	Surgical and medical procedures	Breast cyst excision	2011	2011	
	BREAST CYST LEFT BENIGN	Reproductive system and breast disorders	Breast cyst	2011	2011	
US2051089	OVARIAN CYSTS RIGHT BENIGN	Reproductive system and breast disorders	Ovarian cyst	2011	2011	
	RIGHT OOPHORECTOMY	Surgical and medical procedures	Oophorectomy	2011	2011	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051089	RIGHT HIP CARTILAGE DEGENERATION	Musculoskeletal and connective tissue disorders	Osteoarthritis	2011	2011-08	
	RIGHT HIP REPLACEMENT	Surgical and medical procedures	Hip arthroplasty	2011-08	2011-08	
	POST MENOPAUSAL	Social circumstances	Postmenopause	2013		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2020		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2020-06-24 (-8)	2020-06-24 (-8)	
US2051098	HYPEROPIA	Eye disorders	Hypermetropia	1970		Yes
	MYOPIA	Eye disorders	Myopia	1970		Yes
	GENERAL BODY ACHES	General disorders and administration site conditions	Pain	1975		Yes
	CESAREAN	Surgical and medical procedures	Caesarean section	1991	1991	
	RAYNAUD'S	Vascular disorders	Raynaud's phenomenon	2005		Yes
	LASER EYE SURGERY - BILATERAL EYES (TRABECULECTOMY)	Surgical and medical procedures	Trabeculectomy	2010	2010	
	POST MENOPAUSAL	Social circumstances	Postmenopause	2015		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051098	HAY FEVER	Immune system disorders	Seasonal allergy	2020		Yes
US2051112	OOPHERECTOMY	Surgical and medical procedures	Oophorectomy	1982	1982	
	OVARIAN CYST LEFT BENIGN	Reproductive system and breast disorders	Ovarian cyst	1982	1982	
	MYOPIA	Eye disorders	Myopia	1990		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2010		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2016		Yes
US2061035	DEPRESSION	Psychiatric disorders	Depression	2019-01		Yes
US2061043	MYOPIA	Eye disorders	Myopia	1970		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2010		Yes
	POST-MENOPAUSAL	Social circumstances	Postmenopause	2018		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2018-01		Yes
US2061046	MYOPIA	Eye disorders	Myopia	1967		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2061046	POSTMENOPAUSAL	Social circumstances	Postmenopause	2001		Yes
	OSTEOARTHRITIS BILATERAL HANDS	Musculoskeletal and connective tissue disorders	Osteoarthritis	2018		Yes
US2061051	ALLERGY TO SULFA	Immune system disorders	Drug hypersensitivity	1984		Yes
	ANXIETY	Psychiatric disorders	Anxiety	1990		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1992	1992	
	UTERINE PROLAPSE	Reproductive system and breast disorders	Uterine prolapse	1992	1992	
	MIGRAINES	Nervous system disorders	Migraine	2015		Yes
US2061055	POST MENOPAUSAL	Social circumstances	Postmenopause	1975		Yes
	OSTEOARTHRITIS BILATERAL HANDS	Musculoskeletal and connective tissue disorders	Osteoarthritis	2010-01		Yes
US2071005	CHOLCYSTECTOMY	Surgical and medical procedures	Cholecystectomy	1987	1987	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071005	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	1987	1987	
	ENDOMETRIOSIS	Reproductive system and breast disorders	Endometriosis	1994	1995	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1995	1995	
	INSOMNIA	Psychiatric disorders	Insomnia	2000		Yes
	HYPERCHOLESTROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2018		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2018		Yes
	ATTENTION DEFICIT HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2019		Yes
US2071041	INGUINAL HERNIA	Gastrointestinal disorders	Inguinal hernia	2017	2020-09-30 (121)	
US2071084	ANXIETY	Psychiatric disorders	Anxiety	2001		Yes
US2071085	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1983	1983	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071085	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	1983	1983	
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2002		Yes
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2005		Yes
	COLECTOMY	Surgical and medical procedures	Colectomy	2005	2005	
	CHRONIC CONSTIPATION	Gastrointestinal disorders	Constipation	2009		Yes
	OSTEOPOROSIS	Musculoskeletal and connective tissue disorders	Osteoporosis	2012		Yes
	BILATERAL KNEE PAIN	Musculoskeletal and connective tissue disorders	Arthralgia	2015		Yes
	OVERACTIVE BLADDER	Renal and urinary disorders	Hypertonic bladder	2016		Yes
US2071086	GOUT IN THE RIGHT LARGE TOE	Metabolism and nutrition disorders	Gout	2018		Yes
US2071092	ALLERGY TO PENICILLIN	Immune system disorders	Drug hypersensitivity	1969		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071092	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1980-06-01 (-14635)	1980-06-01 (-14635)	
	ALLERGY TO BACTRIM	Immune system disorders	Drug hypersensitivity	1998		Yes
	OSTEOPOROSIS	Musculoskeletal and connective tissue disorders	Osteoporosis	2015		Yes
US2071094	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	1980		Yes
	BILATERAL OVARIAN CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Ovarian cancer	2003	2005	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2005	2005	
US2071098	HYPERLIPIDEMIA	Metabolism and nutrition disorders	Hyperlipidaemia	2010		Yes
	POST- MENOPAUSAL	Social circumstances	Menopause	2010		Yes
	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2015		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071102	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1974		Yes
	SULFA ALLERGY	Immune system disorders	Drug hypersensitivity	1974		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2000		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2010		Yes
	MILD DEPRESSION	Psychiatric disorders	Depression	2010		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2012		Yes
	BLADDER SUSPENSION	Surgical and medical procedures	Urinary bladder suspension	2013	2013	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2013	2013	
	PROLAPSED BLADDER	Renal and urinary disorders	Bladder prolapse	2013	2013	
	INSOMNIA	Psychiatric disorders	Insomnia	2018		Yes
	RESTLESS LEG SYNDROME	Nervous system disorders	Restless legs syndrome	2018		Yes
US2071103	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1964		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071103	POST MENOPAUSAL	Social circumstances	Postmenopause	2003		Yes
	RIGHT BREAST CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	2003	2004	
	MILD DEPRESSION	Psychiatric disorders	Depression	2004		Yes
	LUMPECTOMY	Surgical and medical procedures	Breast conserving surgery	2004	2004	
	INSOMNIA	Psychiatric disorders	Insomnia	2010		Yes
	BILATERAL EDEMA LEGS	General disorders and administration site conditions	Oedema peripheral	2017		Yes
	OSTEOARTHRITIS BILATERAL KNEES	Musculoskeletal and connective tissue disorders	Osteoarthritis	2020-01		Yes
US2071105	VASECTOMY	Surgical and medical procedures	Vasectomy	1983	1983	
	LUMBAR PAIN	Musculoskeletal and connective tissue disorders	Back pain	2013-10-23 (-2448)		Yes
	LOW TESTOSTERONE	Investigations	Blood testosterone decreased	2019		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071105	BILATERAL SHOULDER PAIN	Musculoskeletal and connective tissue disorders	Musculoskeletal pain	2020-06-29 (-7)		Yes
	NECK PAIN	Musculoskeletal and connective tissue disorders	Neck pain	2020-06-29 (-7)		Yes
US2081004	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2000		Yes
	MENOPAUSE	Social circumstances	Menopause	2010		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2015		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2017		Yes
	ADHD	Psychiatric disorders	Attention deficit hyperactivity disorder	2019		Yes
US2081005	MENOPAUSE	Social circumstances	Menopause	2006		Yes
US2081007	FIBROID REMOVAL	Surgical and medical procedures	Myomectomy	1988	1988	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081007	UTERINE FIBROIDS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	1988	1988	
	CESAREAN SECTION	Surgical and medical procedures	Caesarean section	1989	1989	
	CESAREAN SECTION	Surgical and medical procedures	Caesarean section	1991	1991	
	ALLERGIC RHINITIS	Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	2010		Yes
	PARTIAL HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2010	2010	
	INSOMNIA	Psychiatric disorders	Insomnia	2018		Yes
US2081015	MENOPAUSE	Social circumstances	Menopause	2013		Yes
	ATTENTION DEFICIT HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2018		Yes
US2081017	POST-MENOPAUSAL	Social circumstances	Postmenopause	2005		Yes
	BILATERAL DRY EYE	Eye disorders	Dry eye	2019		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081029	OSTEOARTHRITIS OF HANDS, R FOOT, AND HIPS	Musculoskeletal and connective tissue disorders	Osteoarthritis	2017		Yes
US2081030	ANEMIA	Blood and lymphatic system disorders	Anaemia	1994		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1995	1995	
	DYSLIPIDEMIA	Metabolism and nutrition disorders	Dyslipidaemia	2019		Yes
US2081065	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1992	1992	
	INSOMNIA	Psychiatric disorders	Insomnia	2000		Yes
	HIP PAIN (RIGHT)	Musculoskeletal and connective tissue disorders	Arthralgia	2015		Yes
	MAJOR DEPRESSIVE DISORDER	Psychiatric disorders	Major depression	2015		Yes
US2081073	HERPES LABIALIS	Infections and infestations	Oral herpes	1990		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081073	MIGRAINES	Nervous system disorders	Migraine	1990		Yes
	MENOPAUSE	Social circumstances	Menopause	2000-01-01 (-7482)		Yes
	VITAMIN D DEFICIENCY	Metabolism and nutrition disorders	Vitamin D deficiency	2012		Yes
	OSTEOPENIA	Musculoskeletal and connective tissue disorders	Osteopenia	2012-12-01 (-2764)		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2015		Yes
	ACID REFLUX	Gastrointestinal disorders	Gastrooesophageal reflux disease	2019		Yes
US2081077	HERPES LABIALIS	Infections and infestations	Oral herpes	1964		Yes
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1987-04-29 (-12116)	1987-04-29 (-12116)	
	DEPRESSION	Psychiatric disorders	Depression	2002		Yes
	MENOPAUSE	Social circumstances	Menopause	2006		Yes
	DYSLIPIDEMIA	Metabolism and nutrition disorders	Dyslipidaemia	2008		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081077	INSOMNIA	Psychiatric disorders	Insomnia	2017		Yes
	MEMORY IMPAIRMENT	Nervous system disorders	Memory impairment	2019		Yes
US2081080	ERECTILE DYSFUNCTION	Reproductive system and breast disorders	Erectile dysfunction	2010		Yes
	CHRONIC KNEE PAIN (LEFT)	Musculoskeletal and connective tissue disorders	Arthralgia	2014		Yes
	BENIGN PAROXYSMAL POSITIONAL VERTIGO	Ear and labyrinth disorders	Vertigo positional	2018		Yes
US2081087	MENOPAUSE	Social circumstances	Menopause	2006		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2006	2006	
US2081097	BENIGN POLYPS OF COLON	Gastrointestinal disorders	Large intestine polyp	2002	2007	
	MENOPAUSE	Social circumstances	Menopause	2004		Yes
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2010		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081097	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2015		Yes
	BASAL CELL CARCINOMA (RIGHT TIP OF NOSE)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	2016-09-07 (-1393)	2016-09-07 (-1393)	
	ACNE OF FACE	Skin and subcutaneous tissue disorders	Acne	2018		Yes
	DYSLIPIDEMIA	Metabolism and nutrition disorders	Dyslipidaemia	2019-11		Yes
US2081103	VASECTOMY	Surgical and medical procedures	Vasectomy	1999-09	1999-09	
	BENIGN PROSTATIC HYPERPLASIA	Reproductive system and breast disorders	Benign prostatic hyperplasia	2002-05		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2010-05		Yes
US2081104	ANXIETY	Psychiatric disorders	Anxiety	2000		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081104	DUCTAL CARCINOMA OF BREAST (RIGHT)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Invasive ductal breast carcinoma	2002	2002	
	DYSLIPIDEMIA	Metabolism and nutrition disorders	Dyslipidaemia	2002	2002	
	MASTECTOMY (RIGHT)	Surgical and medical procedures	Mastectomy	2002	2002	
	MENOPAUSE	Social circumstances	Menopause	2012		Yes
US2081113	NEUROGENIC BLADDER	Renal and urinary disorders	Neurogenic bladder	2007		Yes
	ERECTILE DYSFUNCTION	Reproductive system and breast disorders	Erectile dysfunction	2020		Yes
US2081119	ALLERGIC RHINITIS	Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	1970		Yes
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	1970-09-07 (-18200)		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081119	MENOPAUSE	Social circumstances	Menopause	2010		Yes
	OSTEOPENIA	Musculoskeletal and connective tissue disorders	Osteopenia	2012		Yes
	VITAMIN B12 DEFICIENCY	Metabolism and nutrition disorders	Vitamin B12 deficiency	2015		Yes
	VITAMIN D DEFICIENCY	Metabolism and nutrition disorders	Vitamin D deficiency	2015		Yes
US2081125	INSOMNIA	Psychiatric disorders	Insomnia	2016		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011012	ANXIETY	Psychiatric disorders	Anxiety	1995		Yes
	POST-MENOPAUSAL	Social circumstances	Postmenopause	2008		Yes
US2011014	MIGRAINES	Nervous system disorders	Migraine	1987		Yes
	ROSACEA, BILATERAL CHEEKS	Skin and subcutaneous tissue disorders	Rosacea	1994		Yes
	POST-MENOPAUSAL	Social circumstances	Postmenopause	2000		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2000	2000	
	UTERINE PROLOPSE	Reproductive system and breast disorders	Uterine prolapse	2000	2000	
	CHRONIC CONSTIPATION	Gastrointestinal disorders	Constipation	2009		Yes
	IRRITABLE BOWEL SYNDROME	Gastrointestinal disorders	Irritable bowel syndrome	2009		Yes
	HYPERTHYROIDISM	Endocrine disorders	Hyperthyroidism	2010		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2018		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011014	RIGHT HAND CARPAL TUNNEL	Nervous system disorders	Carpal tunnel syndrome	2018	2019-12-31 (-153)	
	RIGHT CARPAL TUNNEL SURGERY	Surgical and medical procedures	Carpal tunnel decompression	2019-12-31 (-153)	2019-12-31 (-153)	
US2011032	ALLERGIC TO CATS	Immune system disorders	Allergy to animal	1980		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2015		Yes
US2011040	POST-MENOPAUSAL	Social circumstances	Postmenopause	2008		Yes
	ALLERGIC RHINITIS : RAGWEED	Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	2017-01-01 (-1247)		Yes
	CATARACTS	Eye disorders	Cataract	2019-05	2019-05	
	OVERACTIVE BLADDER	Renal and urinary disorders	Hypertonic bladder	2020-03-26 (-67)		Yes
	SHINGLES, LEFT SUBSCAPULARIS	Infections and infestations	Herpes zoster	2020-04-30 (-32)	2020-05-06 (-26)	
	PRE DIABETES	Metabolism and nutrition disorders	Glucose tolerance impaired	2020-05-18 (-14)		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011117	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2015		Yes
	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2020-04-09 (-78)		Yes
US2011123	ALLERGY TO PENICILLIN	Immune system disorders	Drug hypersensitivity	1962		Yes
	ACCIDENT, UNSPECIFIED	Injury, poisoning and procedural complications	Accident	1986	1986	
	RIGHT EYE REMOVAL	Surgical and medical procedures	Eye excision	1986	1986	
	SEASONAL ALLERGIES, UNSPECIFIED	Immune system disorders	Seasonal allergy	1996		Yes
	ESOPHAGEAL TUMOR REMOVAL	Surgical and medical procedures	Oesophagectomy	2003	2003	
	ESOPHAGEAL TUMOR, CANCEROUS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Oesophageal carcinoma	2003	2003	
US2011125	SEASONAL ALLERGIES, CEDAR	Immune system disorders	Seasonal allergy	1980		Yes
	HERPES SIMPLEX	Infections and infestations	Herpes simplex	2000		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011125	POSTMENOPAUSAL	Social circumstances	Postmenopause	2014		Yes
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2018		Yes
US2011127	SEASONAL ALLERGIES, CEDAR	Immune system disorders	Seasonal allergy	1959		Yes
	SEASONAL ALLERGIES, OAK	Immune system disorders	Seasonal allergy	1959		Yes
	IRRITABLE BOWEL SYNDROME	Gastrointestinal disorders	Irritable bowel syndrome	1980		Yes
	HERNIA, INGUINAL, UNKNOWN LOCATION	Gastrointestinal disorders	Inguinal hernia	2008		Yes
	VASECTOMY	Surgical and medical procedures	Vasectomy	2009	2009	
US2011137	POSTMENOPAUSAL	Social circumstances	Postmenopause	2008		Yes
	OVERACTIVE BLADDER	Renal and urinary disorders	Hypertonic bladder	2017		Yes
US2011138	SEASONAL ALLERGIES, CEDAR	Immune system disorders	Seasonal allergy	1980		Yes
	SEASONAL ALLERGIES, ELM	Immune system disorders	Seasonal allergy	1980		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011138	SEASONAL ALLERGIES, GRASSES	Immune system disorders	Seasonal allergy	1980		Yes
	SEASONAL ALLERGIES, MOLD	Immune system disorders	Seasonal allergy	1980		Yes
	SEASONAL ALLERGIES, OAK	Immune system disorders	Seasonal allergy	1980		Yes
	SEASONAL ALLERGIES, RAGWEED	Immune system disorders	Seasonal allergy	1980		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2010		Yes
	ALLERGY TO SULFA	Immune system disorders	Drug hypersensitivity	2017		Yes
	TORN MENISCUS, LEFT KNEE	Injury, poisoning and procedural complications	Meniscus injury	2020-01-23 (-156)	2020-02-13 (-135)	
	ORTHOSCOPY, LT KNEE	Investigations	Arthroscopy	2020-02-13 (-135)	2020-02-13 (-135)	
US2011153	SEASONAL ALLERGIES, UNSPECIFIED	Immune system disorders	Seasonal allergy	2005		Yes
	RIGHT KNEE PAIN	Musculoskeletal and connective tissue disorders	Arthralgia	2012		Yes
	ALLERGY TO BEETS	Immune system disorders	Food allergy	2015		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2015		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021004	HERPES SIMPLEX TYPE 2	Infections and infestations	Herpes simplex	1990		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	1998		Yes
	BILATERAL INGUINAL HERNIA	Gastrointestinal disorders	Inguinal hernia	2005	2005	
	HERNIORRHAPHY, BILATERAL INGUINAL	Surgical and medical procedures	Inguinal hernia repair	2005	2005	
US2021012	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1960-01		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2005-12-05 (-5292)		Yes
	CHRONIC LEFT FOOT PAIN	Musculoskeletal and connective tissue disorders	Pain in extremity	2016-08		Yes
	MORPHINE ALLERGY	Immune system disorders	Drug hypersensitivity	2016-08		Yes
	LEFT ANKLE FRACTURE	Injury, poisoning and procedural complications	Ankle fracture	2016-08	2016-08	
	LEFT ANKLE SURGERY	Surgical and medical procedures	Ankle operation	2016-08	2016-08	
	LEFT ANKLE REMOVAL OF HARDWARE	Surgical and medical procedures	Medical device removal	2016-12	2016-12	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021012	NERVE CUT LEFT ANKLE	Injury, poisoning and procedural complications	Nerve injury	2019-01	2019-01	
	LEFT UPPER FIRST MOLAR INTERMITTENT PAIN	Gastrointestinal disorders	Toothache	2020-05-01 (-31)		Yes
US2021018	POST MENOPAUSAL	Social circumstances	Postmenopause	1995-12-05 (-8942)		Yes
	OSTEOPENIA	Musculoskeletal and connective tissue disorders	Osteopenia	2000		Yes
	OVERACTIVE BLADDER	Renal and urinary disorders	Hypertonic bladder	2010		Yes
	BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	2016		Yes
US2021019	PERIPHERAL SENSORY NEUROPATHY BILATERAL FEET AND ANKLES	Nervous system disorders	Peripheral sensory neuropathy	2005		Yes
	LASER ABLATION VARICOSE VEINS RIGHT LEG	Surgical and medical procedures	Endovenous ablation	2005	2005	
	VARICOSE VEINS RIGHT LEG	Vascular disorders	Varicose vein	2005	2005	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021020	SCOLIOSIS	Musculoskeletal and connective tissue disorders	Scoliosis	1968		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	1995		Yes
US2021045	POST MENOPAUSAL	Social circumstances	Postmenopause	2010		Yes
	LEFT KNEE PAIN	Musculoskeletal and connective tissue disorders	Arthralgia	2014	2014	
	LEFT TOTAL KNEE REPLACEMENT	Surgical and medical procedures	Knee arthroplasty	2014	2014	
	RIGHT KNEE PAIN	Musculoskeletal and connective tissue disorders	Arthralgia	2019	2019	
	RIGHT TOTAL KNEE REPLACEMENT	Surgical and medical procedures	Knee arthroplasty	2019	2019	
US2021047	LEFT KIDNEY IMPAIRED FUNCTION	Renal and urinary disorders	Renal impairment	1970	1970	
	LEFT NEPHRECTOMY	Surgical and medical procedures	Nephrectomy	1970	1970	
	POST MENOPAUSAL	Social circumstances	Postmenopause	2000-05-02 (-7335)		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021047	CARPAL TUNNEL SYNDROME, RIGHT	Nervous system disorders	Carpal tunnel syndrome	2009	2010-02	
	CARPAL TUNNEL SYNDROME, LEFT	Nervous system disorders	Carpal tunnel syndrome	2009	2010-10	
	RIGHT CARPAL TUNNEL SURGERY	Surgical and medical procedures	Carpal tunnel decompression	2010-02	2010-02	
	LEFT CARPAL TUNNEL SURGERY	Surgical and medical procedures	Carpal tunnel decompression	2010-10	2010-10	
US2021133	VASECTOMY	Surgical and medical procedures	Vasectomy	1978	1978	
	DEPRESSION	Psychiatric disorders	Depression	2012		Yes
	RIGHT SHOULDER PAIN	Musculoskeletal and connective tissue disorders	Musculoskeletal pain	2012		Yes
	DUPUYTREN'S CONTRACTURE, BILATERAL	Musculoskeletal and connective tissue disorders	Dupuytren's contracture	2015	2020-05-08 (-49)	
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2016		Yes
	HYPERLIPIDEMIA	Metabolism and nutrition disorders	Hyperlipidaemia	2016		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021133	BILATERAL RELEASE OF DUPUYTREN'S CONTRACTURE	Surgical and medical procedures	Dupuytren's contracture operation	2020-05-05 (-52)	2020-05-05 (-52)	
US2021190	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	2007	2007	
	PARTIAL HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2007	2007	
	POST MENOPAUSAL OBESITY	Social circumstances Metabolism and nutrition disorders	Postmenopause Obesity	2007 2012	2007	Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2014		Yes
	SHINGLES FACE	Infections and infestations	Herpes zoster	2014	2014	
US2021192	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	1972	1972	
	APPENDICITIS	Infections and infestations	Appendicitis	1972	1972	
	VASECTOMY	Surgical and medical procedures	Vasectomy	1985	1985	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021205	MORPHINE ALLERGY	Immune system disorders	Drug hypersensitivity	1982		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	1995		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1995	1995	
	MENOMETRORRHAGIA	Reproductive system and breast disorders	Menometrorrhagia	1995	1995	
	BILATERAL LENS REPLACEMENT	Surgical and medical procedures	Intraocular lens implant	2015	2015	
	BILATERAL RETINAL DETACHMENTS	Eye disorders	Retinal detachment	2015	2015	
	BILATERAL RETINAL SURGERY	Surgical and medical procedures	Retinal operation	2015	2015	
US2021216	POST MENOPAUSAL	Social circumstances	Postmenopause	2012		Yes
US2021217	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1984	1984	
	DRY EYES	Eye disorders	Dry eye	2005		Yes
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2007		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021217	POST MENOPAUSAL	Social circumstances	Postmenopause	2015		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2020		Yes
US2021220	SULFA ALLERGY	Immune system disorders	Drug hypersensitivity	1953		Yes
	INTERMITTENT HEADACHES	Nervous system disorders	Headache	1955		Yes
US2021226	MIGRAINE	Nervous system disorders	Migraine	1998		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	1998		Yes
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2010		Yes
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2015		Yes
	LEFT SHOULDER PAIN	Musculoskeletal and connective tissue disorders	Musculoskeletal pain	2015		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2018		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2018		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021226	CERVICAL SPONDYLOSIS	Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	2019		Yes
	FACIAL ROSACEA	Skin and subcutaneous tissue disorders	Rosacea	2020-01		Yes
US2031086	ALLERGY TO SULFA	Immune system disorders	Drug hypersensitivity	1963		Yes
	OSTEOPOROSIS	Musculoskeletal and connective tissue disorders	Osteoporosis	1999		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2005		Yes
	ELECTIVE TOTAL HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2005	2005	
US2031096	POSTMENOPAUSAL	Social circumstances	Postmenopause	1989		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1989	1989	
	UTERINE FIBROIDS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	1989	1989	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031096	LATEX ALLERGY	Immune system disorders	Rubber sensitivity	1990		Yes
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2016	2016	
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	2016	2016	
US2031097	SULFA ALLERGY	Immune system disorders	Drug hypersensitivity	1970		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	1988		Yes
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2015		Yes
	BILATERAL GLAUCOMA	Eye disorders	Glaucoma	2016		Yes
	CHRONIC RIGHT SHOULDER PAIN	Musculoskeletal and connective tissue disorders	Musculoskeletal pain	2018		Yes
	GENERALIZED OSTEOARTHRITIS	Musculoskeletal and connective tissue disorders	Osteoarthritis	2018		Yes
US2031104	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2000		Yes
	SULFA ALLERGIES	Immune system disorders	Drug hypersensitivity	2001		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031105	MENORRAGIA	Reproductive system and breast disorders	Menorrhagia	1990	1991	
	POSTMENOPAUSAL	Social circumstances	Postmenopause	1991		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1991	1991	
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	1999	1999	
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	1999	1999	
	RESTLESS LEG SYNDROME	Nervous system disorders	Restless legs syndrome	2005		Yes
US2031106	POST MENOPAUSAL	Social circumstances	Postmenopause	2016		Yes
	DEPRESSION	Psychiatric disorders	Depression	2019		Yes
US2031107	HOT FLASHED	Vascular disorders	Hot flush	2010		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2010		Yes
	DEPRESSION	Psychiatric disorders	Depression	2012		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2012		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031108	POST MENOPAUSAL	Social circumstances	Postmenopause	2000		Yes
	MORPHINE ALLERGY	Immune system disorders	Drug hypersensitivity	2018		Yes
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2019-06		Yes
US2031109	POST MENOPAUSAL	Social circumstances	Postmenopause	2005		Yes
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2015		Yes
US2031114	POSTMENOPAUSAL	Social circumstances	Postmenopause	2003		Yes
US2031121	ALLERGY TO PENICILLIN	Immune system disorders	Drug hypersensitivity	1960		Yes
	ALLERGY TO ASPRIN	Immune system disorders	Drug hypersensitivity	1970		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1985	1985	
	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	1985	1985	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031121	ALLERGY TO SULFA	Immune system disorders	Drug hypersensitivity	2000		Yes
	ALLERGY TO DAYPRO	Immune system disorders	Drug hypersensitivity	2005		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2015		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2018		Yes
US2031128	POSTMENOPAUSAL	Social circumstances	Postmenopause	1998		Yes
	OSTEOPENIA	Musculoskeletal and connective tissue disorders	Osteopenia	2014		Yes
	BILATERAL MACULAR DEGENERATION	Eye disorders	Macular degeneration	2018		Yes
	LEFT ULNAR SIDED WRIST PAIN	Musculoskeletal and connective tissue disorders	Arthralgia	2018-01	2020-01	
	LEFT ULNAR SHORTENING OSTEOTOMY	Surgical and medical procedures	Osteotomy	2020-01	2020-01	
US2041094	ADDENOIDITIS	Infections and infestations	Adenoiditis	2006	2010	
	CHRONIC SINUSITIS	Infections and infestations	Chronic sinusitis	2006	2010	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041094	TONSILLITIS	Infections and infestations	Tonsillitis	2006	2010	
	LATEX ALLERGY	Immune system disorders	Rubber sensitivity	2010		Yes
	LEVAQUINE ALLERGY	Immune system disorders	Drug hypersensitivity	2010		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2010		Yes
	ADDENOIDECTOMY	Surgical and medical procedures	Adenoidectomy	2010	2010	
	ENDOSCOPIC SINUS SURGERY	Surgical and medical procedures	Sinus operation	2010	2010	
	TONSILLECTOMY	Surgical and medical procedures	Tonsillectomy	2010	2010	
	POST MENOPAUSAL	Social circumstances	Postmenopause	2016		Yes
	BILATERAL CHRONIC DRY EYES	Eye disorders	Dry eye	2017		Yes
US2041100	POST MENOPAUSAL	Social circumstances	Postmenopause	2012		Yes
	POST MENOPAUSAL SYMPTOMS	Reproductive system and breast disorders	Menopausal symptoms	2016		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041100	OSTEOPOROSIS	Musculoskeletal and connective tissue disorders	Osteoporosis	2019		Yes
US2041103	VASECTOMY	Surgical and medical procedures	Vasectomy	1983	1983	
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	1998		Yes
	BILATERAL GLAUCOMA	Eye disorders	Glaucoma	2005		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2015		Yes
US2041104	CHIARI MALFORMATION	Congenital, familial and genetic disorders	Arnold-Chiari malformation	(b) (6) (b) (6)		Yes
	CEREBRAL BYPASS	Surgical and medical procedures	Brain operation	1962	1962	
	CEREBRAL SHUNT PLACEMENT	Surgical and medical procedures	CSF shunt operation	1992	1992	
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	1999	1999	
	CHOLELITHIASIS	Hepatobiliary disorders	Cholelithiasis	1999	1999	
	POST MENOPAUSAL	Social circumstances	Postmenopause	2000		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041106	BILATERAL GLAUCOMA	Eye disorders	Glaucoma	2010		Yes
	BILATERAL HEARING LOSS	Ear and labyrinth disorders	Deafness bilateral	2010		Yes
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2010		Yes
	BILATERAL FOOT GOUT	Metabolism and nutrition disorders	Gout	2015		Yes
US2041109	LEFT EAR DRUM PERFORATION	Ear and labyrinth disorders	Tympanic membrane perforation	1990	1990	
	LEFT EAR DRUM REPAIR	Surgical and medical procedures	Tympanoplasty	1990	1990	
	RIGHT EAR CANAL CHOLESTEATOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cholesteatoma	1990	1990	
	RIGHT EAR CANAL RECONSTRUCTION SURGERY	Surgical and medical procedures	Ear operation	1990	1990	
	POST MENOPAUSAL	Social circumstances	Postmenopause	1997		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2013		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041109	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2016		Yes
US2041111	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	1971	1971	
	APPENDICITIS	Infections and infestations	Appendicitis	1971	1971	
	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	2005	2011	
	FACTOR V LEIDEN	Congenital, familial and genetic disorders	Factor V Leiden mutation	2008		Yes
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2010		Yes
	BILATERAL NASAL TURINATE RECONSTRUCTION	Surgical and medical procedures	Turbinoplasty	2011	2011	
	BILATERAL TURBinate FRACTURE	Injury, poisoning and procedural complications	Facial bones fracture	2011	2011	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2011-09	2011-09	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041111	GENERAL JOINT PAIN	Musculoskeletal and connective tissue disorders	Arthralgia	2015		Yes
US2041113	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1980		Yes
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	1985	1985	
	CHOLELITHIASIS	Hepatobiliary disorders	Cholelithiasis	1985	1985	
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1999	1999	
	HEADACHES	Nervous system disorders	Headache	2000		Yes
US2041118	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1998	1998	
	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	1998	1998	
	SEASONAL ALLERIGIES	Immune system disorders	Seasonal allergy	2005		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2018		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041118	BENIGN THYROID NODULES	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	2020-05		Yes
US2041119	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1980	2010	
	HIATAL HERNIA	Gastrointestinal disorders	Hiatus hernia	1998	1998	
	NISSAN PROCEDURE	Surgical and medical procedures	Oesophagogastric fundoplasty	1998	1998	
	ANXIETY	Psychiatric disorders	Anxiety	2000		Yes
	LEFT HIP OSTEOARTHRITIS	Musculoskeletal and connective tissue disorders	Osteoarthritis	2000	2013	
	LEFT HIP REPLACEMENT	Surgical and medical procedures	Hip arthroplasty	2013	2013	
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2015		Yes
	CHRONIC LOWER BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	2017		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041119	ENLARGED PROSTATE	Reproductive system and breast disorders	Prostatomegaly	2019		Yes
	BASAL CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	2020-04-01 (-96)	2020-04-01 (-96)	
	BASAL CELL CARCINOMA REMOVAL	Surgical and medical procedures	Skin neoplasm excision	2020-04-01 (-96)	2020-04-01 (-96)	
US2041127	PROSTATIC HYPERPLASIA	Reproductive system and breast disorders	Benign prostatic hyperplasia	2015		Yes
	ERECTILE DYSFUNCTION	Reproductive system and breast disorders	Erectile dysfunction	2018		Yes
US2041130	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1970		Yes
	BILATERAL SCIATICA	Nervous system disorders	Sciatica	2014	2019	
	ANXIETY	Psychiatric disorders	Anxiety	2019		Yes
	RIGHT SCIATIC NERVE DAMAGE	Injury, poisoning and procedural complications	Sciatic nerve injury	2019		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041130	LAMINOTOMY L4-L5	Surgical and medical procedures	Spinal laminectomy	2019-03	2019-03	
US2041139	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1952		Yes
	MICROSCOPIC BLOOD IN URINE	Renal and urinary disorders	Haematuria	1978	1980	
	LEFT-SECOND FINGER DISLOCATION	Injury, poisoning and procedural complications	Joint dislocation	1980	1980	
	LEFT-SECOND FINGER DISLOCATION REPAIR	Surgical and medical procedures	Finger repair operation	1980	1980	
	URETHRAL WIDENING PROCEDURE	Surgical and medical procedures	Urethral dilation procedure	1980	1980	
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2000		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2020		Yes
US2041145	DUST MITE ALLERGY	Immune system disorders	Mite allergy	1965		Yes
	ANXIETY	Psychiatric disorders	Anxiety	1995		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041145	CYSTIC ACNE-FACE	Skin and subcutaneous tissue disorders	Acne cystic	2000		Yes
	HOT FLASHES	Vascular disorders	Hot flush	2009		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2017		Yes
US2041150	BILATERAL HIP OSTEOARTHRITIS	Musculoskeletal and connective tissue disorders	Osteoarthritis	2005	2019-04	
	POST MENOPAUSAL	Social circumstances	Postmenopause	2010		Yes
	LEFT TOTAL HIP REPLACEMENT	Surgical and medical procedures	Hip arthroplasty	2019-02	2019-02	
	RIGHT TOTAL HIP REPLACEMENT	Surgical and medical procedures	Hip arthroplasty	2019-04	2019-04	
US2041155	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	1980		Yes
	BACTRIM ALLERGY	Immune system disorders	Drug hypersensitivity	1990		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2000		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2010		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041155	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2015	2015	
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	2015	2015	
US2051057	PERIODIC ROSACEA - FACE	Skin and subcutaneous tissue disorders	Rosacea	2014		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2015		Yes
	GENERALIZED MUSCLE ACHES DUE TO OVERDOING EXERCISE	Musculoskeletal and connective tissue disorders	Myalgia	2018		Yes
	HYPEROPIA	Eye disorders	Hypermetropia	2018		Yes
US2051059	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1970		Yes
	MIGRAINES	Nervous system disorders	Migraine	1978		Yes
	ABDOMINAL APRON	Gastrointestinal disorders	Abdominal fat apron	1983	2000	
	OSTEOARTHRITIS RIGHT KNEE	Musculoskeletal and connective tissue disorders	Osteoarthritis	1993		Yes
	ABDOMINALPLASTY	Surgical and medical procedures	Abdominoplasty	2000	2000	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051059	FRACTURED LEFT RADIUS	Injury, poisoning and procedural complications	Radius fracture	2001	2001	
	LEFT RADIUS SURGICAL REPAIR	Surgical and medical procedures	Fracture treatment	2001	2001	
	LOWER BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	2003		Yes
	CAESAREAN SECTION - DELIVERIES X1	Surgical and medical procedures	Caesarean section	2004	2004	
	HEADACHES (NON-MIGRAINE)	Nervous system disorders	Headache	2005		Yes
	ADULT ACNE - FACE	Skin and subcutaneous tissue disorders	Acne	2008		Yes
	MYOPIA	Eye disorders	Myopia	2008		Yes
	HOT FLASHES	Vascular disorders	Hot flush	2012		Yes
	OSTEOARTHRITIS LEFT HIP	Musculoskeletal and connective tissue disorders	Osteoarthritis	2015		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2015-11		Yes
US2051060	MYOPIA	Eye disorders	Myopia	1963		Yes
	DEPRESSION	Psychiatric disorders	Depression	2002-01-01 (-6751)	2020-04	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051060	LEFT SHOULDER REPLACEMENT	Surgical and medical procedures	Shoulder arthroplasty	2008	2008	
	LEFT TORN ROTATOR CUFF	Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	2008	2008	
	POSTMENOPASAL	Social circumstances	Postmenopause	2010		Yes
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2010-01-01 (-3829)		Yes
	OBESE	Metabolism and nutrition disorders	Obesity	2020-06		Yes
US2051066	DRUSEN (MACULA) BILATERAL	Eye disorders	Retinal drusen	1964		Yes
	MELANOMA BACK OF LEFT CALF	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Malignant melanoma	1984	1984	
	MELANOMA EXCISION SURGERY BACK OF LEFT CALF	Surgical and medical procedures	Skin neoplasm excision	1984	1984	
	DYSMENORRHEA	Reproductive system and breast disorders	Dysmenorrhoea	2003	2003	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051066	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2003	2003	
	BILATERAL CATARACTS	Eye disorders	Cataract	2004	2004	
	CATARACT REMOVAL	Surgical and medical procedures	Cataract operation	2004	2004	
	BILATERAL					
US2051068	HAYFEVER SEASONAL	Immune system disorders	Seasonal allergy	1970		Yes
	MYOPIA	Eye disorders	Myopia	1990		Yes
	OSTEOARTHRITIS	Musculoskeletal and connective tissue disorders	Osteoarthritis	1994		Yes
	BILATERAL KNEE					
	CHRONIC NECK PAIN	Musculoskeletal and connective tissue disorders	Neck pain	2000		Yes
	GOUT RIGHT TOE	Metabolism and nutrition disorders	Gout	2000		Yes
	BILATERAL HANDS					
	PRESBYOPIA	Eye disorders	Presbyopia	2000		Yes
	BILATERAL EYE FLOATERS	Eye disorders	Vitreous floaters	2005		Yes
	DIVERTICULOSIS	Gastrointestinal disorders	Diverticulum	2006	2006	
	LEFT CARPAL TUNNEL SYNDROME	Nervous system disorders	Carpal tunnel syndrome	2012	2019	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051068	VERTIGO	Ear and labyrinth disorders	Vertigo	2018		Yes
	LEFT CARPAL TUNNEL SURGERY	Surgical and medical procedures	Carpal tunnel decompression	2019	2019	
US2051071	HYPEROPIA	Eye disorders	Hypermetropia	1961		Yes
	DUST ALLERGY	Immune system disorders	Dust allergy	1984		Yes
	LASIKS BILATERAL	Surgical and medical procedures	Keratomileusis	1990	1990	
	VISION CORRECTION - BOTH EYES	Surgical and medical procedures	Vision correction operation	1990	1990	
	HYPERTENSION	Vascular disorders	Hypertension	2015		Yes
	TENDONITIS LEFT FOOT	Musculoskeletal and connective tissue disorders	Tendonitis	2020-06-27 (-2)	2020-08-18 (51)	
US2051078	VASECTOMY	Surgical and medical procedures	Vasectomy	1980	1980	
	MYOPIA	Eye disorders	Myopia	1995		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2019		Yes
US2051081	MYOPIA	Eye disorders	Myopia	1971		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1987		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051081	ANXIETY	Psychiatric disorders	Anxiety	1992		Yes
	MIGRAINES	Nervous system disorders	Migraine	1992		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2002		Yes
	SEASONAL ECZEMA ON LEFT LOWER BACK	Skin and subcutaneous tissue disorders	Eczema	2010		Yes
	LASIK LEFT EYE	Surgical and medical procedures	Keratomileusis	2011	2011	
US2051092	HYPEROPIA	Eye disorders	Hypermetropia	1964		Yes
	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	1964	1964	
	APPENDICITIS	Infections and infestations	Appendicitis	1964	1964	
	SUPRAVENTRICULAR TACHYCARDIA	Cardiac disorders	Supraventricular tachycardia	2000		Yes
	INTERMITTENT POST MENOPAUSAL	Social circumstances	Postmenopause	2006		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2015		Yes
	SNEEZING SINUS CONGESTION					

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051093	TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1979	1979	
	HYPEROPIA	Eye disorders	Hypermetropia	1985		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	1998		Yes
	LEFT BREAST CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	1998	1998	
	LYMPHADENECTOMY (LEFT AXILLARY) DUE TO LEFT BREAST CANCER	Surgical and medical procedures	Axillary lymphadenectomy	1998	1998	
	MIGRAINES - OCCASIONAL	Nervous system disorders	Migraine	2000		Yes
	LATEX ALLERGY	Immune system disorders	Rubber sensitivity	2008		Yes
	RIGHT BROKEN WRIST	Injury, poisoning and procedural complications	Wrist fracture	2008	2008	
	LEFT BROKEN WRIST	Injury, poisoning and procedural complications	Wrist fracture	2009	2009	
	ACID REFLUX	Gastrointestinal disorders	Gastrooesophageal reflux disease	2010		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051093	GENERAL ACHES AND PAINES	General disorders and administration site conditions	Pain	2010		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2015		Yes
	DEPRESSION	Psychiatric disorders	Depression	2015		Yes
	SEVERED ARTERY RIGHT FOOT	Injury, poisoning and procedural complications	Limb injury	2015	2015	
US2051094	BILATERAL OSTEOARTHRITIS OF THE KNEE	Musculoskeletal and connective tissue disorders	Osteoarthritis	2013		Yes
	MYOPIA	Eye disorders	Myopia	2013		Yes
US2051095	LOW BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	1975		Yes
	FAINTING	Nervous system disorders	Syncope	1976	1985	
	ANEMIA WHEN YOUNGER	Blood and lymphatic system disorders	Anaemia	1977	2000	
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1992	1992	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051095	DIVERTICULOSIS	Gastrointestinal disorders	Diverticulum	2000	2000	
	PMS SYMPTOM	Reproductive system and breast disorders	Premenstrual syndrome	2002	2015	
	LASIK SURGERY	Surgical and medical procedures	Keratomileusis	2003	2003	
	BILATERAL MYOPIA	Eye disorders	Myopia	2003	2003	
	RASH DEODORANT INGREDIENT	Skin and subcutaneous tissue disorders	Drug eruption	2007-12		Yes
	HYPEROPIA	Eye disorders	Hypermetropia	2008		Yes
	APPENDECTOMY	Surgical and medical procedures	Appendectomy	2011	2011	
	INSOMNIA	Psychiatric disorders	Insomnia	2012		Yes
	RIGHT SHOULDER FROZEN	Musculoskeletal and connective tissue disorders	Periarthritis	2018	2018	
US2051096	SURGERY TO CORRECT FROZEN SHOULDER	Surgical and medical procedures	Shoulder operation	2018	2018	
	MYOPIA	Eye disorders	Myopia	1969		Yes
	SULFA MEDICATION ALLERGY	Immune system disorders	Drug hypersensitivity	1985		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051096	POST MENOPAUSAL	Social circumstances	Postmenopause	2010		Yes
	ACID REFLUX	Gastrointestinal disorders	Gastroesophageal reflux disease	2015	2015	
	GALL BLADDER REMOVAL	Surgical and medical procedures	Cholecystectomy	2015	2015	
	INCONTINENCE	Renal and urinary disorders	Incontinence	2018	2018	
US2051099	SULFA ALLERGY	Immune system disorders	Drug hypersensitivity	1948		Yes
	HEADACHES	Nervous system disorders	Headache	1967		Yes
	INTERMITTENT SITUATIONAL DEPRESSION	Psychiatric disorders	Adjustment disorder with depressed mood	1974		Yes
	VASECTOMY	Surgical and medical procedures	Vasectomy	1981	1981	
	MYOPIA	Eye disorders	Myopia	1996		Yes
	ERECTILE DYSFUNCTION	Reproductive system and breast disorders	Erectile dysfunction	1999		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2000		Yes
	PRESBYOPIA	Eye disorders	Presbyopia	2001		Yes
	OCULAR MIGRAINE	Nervous system disorders	Migraine with aura	2003		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051099	PULMONARY EMBOLISM LEFT LUNG	Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	2004	2004	
	DISCECTOMY L4-L5	Surgical and medical procedures	Intervertebral disc operation	2008-12	2008-12	
	HERNIATED DISC L4-L5	Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	2008-12	2008-12	
	BENIGN PROSTATIC HYPERPLASIA	Reproductive system and breast disorders	Benign prostatic hyperplasia	2013		Yes
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2016		Yes
	BILATERAL CATARACT EXCISION	Surgical and medical procedures	Cataract operation	2017-07	2017-07	
	BILATERAL CATARACTS OCCASIONAL INSOMNIA	Eye disorders Psychiatric disorders	Cataract Insomnia	2017-07 2020-06-01 (-35)	2017-07	Yes
US2051100	ALLERGIC TO ASPIRIN	Immune system disorders	Drug hypersensitivity	1957		Yes
	HERPES SIMPLEX	Infections and infestations	Herpes simplex	1960		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1984	1984	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051100	UTERINE FIBROIDS, BENIGN	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	1984	1984	
	MYOPIA	Eye disorders	Myopia	1991		Yes
	OSTEOPENIA	Musculoskeletal and connective tissue disorders	Osteopenia	2005		Yes
	RESTLESS LEG SYNDROME	Nervous system disorders	Restless legs syndrome	2019		Yes
	BASAL CELL- RIGHT CALF	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	2020-02	2020-02	
	EXCISION BASAL CELL SKIN CANCER- RIGHT CALF	Surgical and medical procedures	Skin neoplasm excision	2020-02	2020-02	
US2051103	FACTOR LEIDEN	Congenital, familial and genetic disorders	Factor V Leiden carrier	(b) (6)		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	(b) (6)	1980	Yes
	CHRONIC MIGRAINE	Nervous system disorders	Migraine	1986		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051103	GERD	Gastrointestinal disorders	Gastrooesophageal reflux disease	1986		Yes
	HERNIATED DISC	Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	1991		Yes
	BUNION RIGHT FOOT	Musculoskeletal and connective tissue disorders	Foot deformity	1996	1996	
	BUNIONECTOMY RIGHT FOOT	Surgical and medical procedures	Bunion operation	1996	1996	
	FRACTURE RIGHT PINKY TOE	Injury, poisoning and procedural complications	Foot fracture	1996	1996	
	NEUTROPENIA	Blood and lymphatic system disorders	Neutropenia	2001		Yes
	VASOSPASTIC RANAUDS PHENOMENON	Vascular disorders	Raynaud's phenomenon	2011		Yes
	OSTEOARTHRITIS BILATERAL HANDS	Musculoskeletal and connective tissue disorders	Osteoarthritis	2012		Yes
	OSTEOARTHRITIS RIGHT HAND	Musculoskeletal and connective tissue disorders	Osteoarthritis	2012		Yes
	PRESBYOPIA	Eye disorders	Presbyopia	2012		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051103	COLON POLYPS BENIGN	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Large intestine benign neoplasm	2013		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2016		Yes
	NERVE IMPINGMENT BILATERAL SHOULDERS	Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	2016-04		Yes
	SHOULDER PAIN BILATERAL	Musculoskeletal and connective tissue disorders	Musculoskeletal pain	2016-04		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2017		Yes
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2020-06		Yes
	BUG BITE ON NECK	Injury, poisoning and procedural complications	Arthropod bite	2020-06-29 (-3)		Yes
US2051105	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1965		Yes
	MYOPIA	Eye disorders	Myopia	1972		Yes
	GALL BLADDER REMOVAL	Surgical and medical procedures	Cholecystectomy	1982	1982	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051105	BILATERAL TUBALIGATION	Surgical and medical procedures	Female sterilisation	1999-06	1999-06	
	GENERALIZED ACHES AND PAINS	General disorders and administration site conditions	Pain	2000-01-01 (-7488)		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2016-08		Yes
	POLYPS W/COLONOSCOPY BENIGN INSOMNIA	Gastrointestinal disorders Psychiatric disorders	Large intestine polyp Insomnia	2017 2017-01-01 (-1278)	2017	Yes
US2051107	GENERAL ACHES AND PAINS	General disorders and administration site conditions	Pain	2000		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2000		Yes
	OSTEOARTHRITIS LEFT KNEE	Musculoskeletal and connective tissue disorders	Osteoarthritis	2000	2019-09-25 (-281)	
	OSTEOARTHRITIS RIGHT KNEE	Musculoskeletal and connective tissue disorders	Osteoarthritis	2000	2019-11-25 (-220)	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051107	ARTHROSCOPIC CARTILAGE DEBRIDEMENT LEFT KNEE	Surgical and medical procedures	Joint debridement	2004	2004	
	TORN CARTILAGE LEFT KNEE	Injury, poisoning and procedural complications	Cartilage injury	2004	2004	
	ARTHROSCOPIC CARTILAGE DEBRIDEMENT RIGHT KNEE	Surgical and medical procedures	Joint debridement	2007	2007	
	TORN CARTILAGE RIGHT KNEE	Injury, poisoning and procedural complications	Cartilage injury	2007	2007	
	ACID REFLUX	Gastrointestinal disorders	Gastrooesophageal reflux disease	2010		Yes
	MUSCLE SPASMS BECK INTERMITTENT	Musculoskeletal and connective tissue disorders	Muscle spasms	2012		Yes
	KARATOCONJUNCTIVITIS SICCA BILATERAL	Eye disorders	Dry eye	2015		Yes
	PRESBYOBIA	Eye disorders	Presbyopia	2015		Yes
	REPAIR TORN ROTATOR CUFF RIGHT	Surgical and medical procedures	Rotator cuff repair	2015-10	2015-10	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051107	TORN ROTATOR CUFF RIGHT	Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	2015-10	2015-10	
	REPAIR TORN ROTATOR CUFF LEFT	Surgical and medical procedures	Rotator cuff repair	2018-08	2018-08	
	TORN ROTATOR CUFF LEFT	Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	2018-08	2018-08	
	TOTAL KNEE REPLACEMENT LEFT	Surgical and medical procedures	Knee arthroplasty	2019-09-25 (-281)	2019-09-25 (-281)	
	TOTAL KNEE REPLACEMENT RIGHT	Surgical and medical procedures	Knee arthroplasty	2019-11-25 (-220)	2019-11-25 (-220)	
	IRRITABLE BOWEL DIARRHEA	Gastrointestinal disorders	Irritable bowel syndrome	2020		Yes
US2051109	BRONCHITIS	Infections and infestations	Bronchitis	1971	1971	
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1975		Yes
	PNEUMONIA	Infections and infestations	Pneumonia	1983-12	1983-12	
	GENITAL HERPES	Infections and infestations	Genital herpes	1998-01-01 (-8222)		Yes
	FISTULA IN ANO (UNKNOWN CAUSE)	Gastrointestinal disorders	Anal fistula	2002	2002-01	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051109	FISTULA IN ANO SURGERY	Surgical and medical procedures	Anal fistula repair	2002-01-01 (-6761)	2002-01-01 (-6761)	
	ALLERGIC TO ADHESIVES	Skin and subcutaneous tissue disorders	Dermatitis contact	2003-03		Yes
	FISTULA IN ANO (UNKNOWN CAUSE)	Gastrointestinal disorders	Anal fistula	2004-01	2004-01	
	FISTULA IN ANO SURGERY	Surgical and medical procedures	Anal fistula repair	2004-01-01 (-6031)	2004-01-01 (-6031)	
	TUBALIGATION	Surgical and medical procedures	Female sterilisation	2004-12	2004-12	
	FISTULA IN ANO (UNKNOWN CAUSE)	Gastrointestinal disorders	Anal fistula	2006-01	2006-01	
	FISTULA IN ANO SURGERY	Surgical and medical procedures	Anal fistula repair	2006-01-01 (-5300)	2006-01-01 (-5300)	
	FISTULA IN ANO (UNKNOWN CAUSE)	Gastrointestinal disorders	Anal fistula	2007-01	2007-01	
	BILATERAL SCIATICA	Nervous system disorders	Sciatica	2007-01-01 (-4935)		Yes
	FISTULA IN ANO SURGERY	Surgical and medical procedures	Anal fistula repair	2007-01-01 (-4935)	2007-01-01 (-4935)	
	ALLERGIC TO MORPHINE	Immune system disorders	Drug hypersensitivity	2007-06		Yes
	DEGENERATIVE DISC DISEASE	Musculoskeletal and connective tissue disorders	Intervertebral disc degeneration	2009-01-01 (-4204)		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051109	POST TRAUMATIC STRESS DISORDER	Psychiatric disorders	Post-traumatic stress disorder	2013		Yes
	POLYPS WITH COLONOSCOPY BENIGN	Gastrointestinal disorders	Large intestine polyp	2018	2018	
	BRONCHITIS	Infections and infestations	Bronchitis	2019	2019	
US2061037	ALLERGY TO CODIENE	Immune system disorders	Drug hypersensitivity	1980		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1980		Yes
	MYOPIA	Eye disorders	Myopia	1984		Yes
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1993	1993	
	POST MENOPAUSAL	Social circumstances	Postmenopause	2008		Yes
	ALLERGY TO SULFA	Immune system disorders	Drug hypersensitivity	2010		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2017-06		Yes
US2061053	ANXIETY	Psychiatric disorders	Anxiety	2000-01		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2000-01		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2061053	POST MENOPAUSAL	Social circumstances	Postmenopause	2007-01		Yes
	LOWER BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	2010-01		Yes
	DEPRESSION	Psychiatric disorders	Depression	2020-01		Yes
US2061057	ANXIETY	Psychiatric disorders	Anxiety	1981-01-01 (-14426)		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	1981-01-01 (-14426)		Yes
	MYOPIA	Eye disorders	Myopia	1985-01-01 (-12965)		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	1985-01-01 (-12965)		Yes
	OVERACTIVE BLADDER	Renal and urinary disorders	Hypertonic bladder	2008-01-01 (-4565)		Yes
	URINARY INCONTINENCE	Renal and urinary disorders	Urinary incontinence	2008-01-01 (-4565)		Yes
	OSTEOARTHRITIS, RIGHT KNEE	Musculoskeletal and connective tissue disorders	Osteoarthritis	2013-01-01 (-2738)		Yes
	OSTEOPOROSIS	Musculoskeletal and connective tissue disorders	Osteoporosis	2013-01-01 (-2738)		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2061057	ACTINIC KERATOSIS, GENERALIZED	Skin and subcutaneous tissue disorders	Actinic keratosis	2013-10-22 (-2444)		Yes
	HYPERLIPIDEMIA	Metabolism and nutrition disorders	Hyperlipidaemia	2013-10-22 (-2444)		Yes
	OSTEOPENIA	Musculoskeletal and connective tissue disorders	Osteopenia	2013-10-22 (-2444)		Yes
	CERVICALGIA	Musculoskeletal and connective tissue disorders	Neck pain	2018-07-10 (-722)		Yes
	DEGENERATIVE DISC DISEASE	Musculoskeletal and connective tissue disorders	Intervertebral disc degeneration	2018-07-10 (-722)		Yes
	BRADYCARDIA	Cardiac disorders	Bradycardia	2018-08-29 (-672)		Yes
	CYSTOCELE	Reproductive system and breast disorders	Cystocele	2019-03-19 (-470)		Yes
	UTERINE POLYPS -BENIGN	Reproductive system and breast disorders	Uterine polyp	2019-03-19 (-470)		Yes
	FRACTURED LEFT PATELLA	Injury, poisoning and procedural complications	Patella fracture	2019-07-01 (-366)	2019-09-01 (-304)	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2061057	FRACTURED RIGHT HIP	Injury, poisoning and procedural complications	Hip fracture	2020-03-09 (-114)	2020-03-27 (-96)	
	TOTAL RIGHT HIP REPLACEMENT	Surgical and medical procedures	Hip arthroplasty	2020-03-27 (-96)	2020-03-27 (-96)	
US2061064	PRESBYOPIA	Eye disorders	Presbyopia	1980		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1980		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1997	1997	
	UTERINE FIBROIDS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	1997	1997	
	OSTEOARTHRITIS, GENERALIZED	Musculoskeletal and connective tissue disorders	Osteoarthritis	2009		Yes
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2017		Yes
	OSTEOPENIA	Musculoskeletal and connective tissue disorders	Osteopenia	2020-01-01 (-181)		Yes
	DEPRESSION	Psychiatric disorders	Depression	2020-02-01 (-150)		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2061068	MIGRAINES, RECURRENT	Nervous system disorders	Migraine	2007-01		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2008-01		Yes
	HOT FLASHES	Vascular disorders	Hot flush	2010-01		Yes
US2071007	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1982		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2000	2000	
	UTERINE FIBROIDS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	2000	2000	
	DAIRY ALLERGY	Metabolism and nutrition disorders	Dairy intolerance	2010		Yes
US2071024	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2010		Yes
	POST MENOPASUAL	Social circumstances	Postmenopause	2010		Yes
US2071025	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1989		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071025	POST MENOPAUSAL	Social circumstances	Postmenopause	2013		Yes
	VITAMIN D DEFICIENCY	Metabolism and nutrition disorders	Vitamin D deficiency	2019-08		Yes
US2071083	POST MENOPAUSAL	Social circumstances	Postmenopause	1980		Yes
	BILATERAL OSTEOARTHRITIS HANDS	Musculoskeletal and connective tissue disorders	Osteoarthritis	2015		Yes
	HYPERCHOLESTOLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2015		Yes
	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2019-05-13 (-410)		Yes
US2071090	MIGRAINES	Nervous system disorders	Migraine	1994		Yes
	ALLERGY TO SULFA DRUGS	Immune system disorders	Drug hypersensitivity	1999		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2005		Yes
	POST-MENOPAUSAL	Social circumstances	Postmenopause	2007		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071099	OSTEOARTHRITIS BILATERAL KNEES	Musculoskeletal and connective tissue disorders	Osteoarthritis	2010		Yes
	ELEVATED LIVER FUNCTION	Investigations	Liver function test increased	2020-06-24 (-13)		Yes
US2071101	POST MENOPAUSAL	Social circumstances	Postmenopause	2010		Yes
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2010-10-15 (-3545)		Yes
	MILD DEPRESSION	Psychiatric disorders	Depression	2015		Yes
US2071104	MASS ON PROSTATE MALIGNANT	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Prostate cancer	2004-01-01 (-6031)	2004-01-01 (-6031)	
	PROSTATECTOMY	Surgical and medical procedures	Prostatectomy	2004-01-01 (-6031)	2004-01-01 (-6031)	
	HYPERCHOLESTROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2016		Yes
US2071106	HYPERCHOLESTROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	1995		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071106	VASECTOMY	Surgical and medical procedures	Vasectomy	2000	2000	
US2081003	MIGRAINES	Nervous system disorders	Migraine	1970		Yes
	HEARING AIDS	Social circumstances	Hearing aid user	1980		Yes
	DEGENERATIVE DISC DISEASE	Musculoskeletal and connective tissue disorders	Intervertebral disc degeneration	2000		Yes
	OSTEOPOROSIS	Musculoskeletal and connective tissue disorders	Osteoporosis	2010		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2013	2013	
	FOOD ALLERGIES (GARLIC)	Immune system disorders	Food allergy	2014		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2015		Yes
	THYROID NODULES (BENIGN)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign neoplasm of thyroid gland	2015		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081009	ALLERGIC RHINITIS	Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	1960-07		Yes
	MENOPAUSE	Social circumstances	Menopause	2010		Yes
US2081020	TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1994-05-19 (-9511)	1994-05-19 (-9511)	
	POST-MENOPAUSAL	Social circumstances	Postmenopause	2008		Yes
	DYSLIPIDEMIA	Metabolism and nutrition disorders	Dyslipidaemia	2015		Yes
US2081070	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2000		Yes
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2015		Yes
	ANEMIA	Blood and lymphatic system disorders	Anaemia	2018		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081071	ALLERGIC RHINITIS	Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	2006		Yes
	VITAMIN D DEFICIENCY	Metabolism and nutrition disorders	Vitamin D deficiency	2018		Yes
	OBSTRUCTIVE SLEEP APNEA	Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	2019		Yes
US2081085	MIGRAINE	Nervous system disorders	Migraine	1974		Yes
	PERIPHERAL POLYNEUROPATHY	Nervous system disorders	Polyneuropathy	2008		Yes
	MENOPAUSE	Social circumstances	Menopause	2009		Yes
	DEGENERATIVE DISC DISEASE	Musculoskeletal and connective tissue disorders	Intervertebral disc degeneration	2010		Yes
	DEGENERATIVE JOINT DISEASE	Musculoskeletal and connective tissue disorders	Osteoarthritis	2010		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081085	OSTEOARTHRITIS OF LUMBAR SPINE	Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	2010		Yes
	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2017		Yes
	OSTEOPENIA	Musculoskeletal and connective tissue disorders	Osteopenia	2017-03-28 (-1193)		Yes
	VERTIGO	Ear and labyrinth disorders	Vertigo	2018-04		Yes
	HYPERCHOLESTEREMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2018-11-07 (-604)		Yes
	LIVER MASS (BENIGN)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Benign hepatic neoplasm	2019		Yes
US2081092	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1980	1980	
	OSTEOARTHRITIS [LEFT HIP AND LEFT KNEE]	Musculoskeletal and connective tissue disorders	Osteoarthritis	2010		Yes
	LICHEN PLANUS (SCALP)	Skin and subcutaneous tissue disorders	Lichen planus	2019		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081100	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2000		Yes
	MENOPAUSE	Social circumstances	Menopause	2013		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2016	2020	
	DEPRESSION R/T DYSTHYMIC DISORDER	Psychiatric disorders	Depression	2018		Yes
	DYSTHYMIC DISORDER	Psychiatric disorders	Persistent depressive disorder	2018		Yes
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2018		Yes
US2081110	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1985		Yes
	MENOPAUSE	Social circumstances	Menopause	2007		Yes
	GLAUCOMA (BILATERAL)	Eye disorders	Glaucoma	2010		Yes
US2081112	MIGRAINES	Nervous system disorders	Migraine	2015		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2016	2016	
	INSOMNIA	Psychiatric disorders	Insomnia	2018		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081118	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1992	1992	
	INSOMNIA	Psychiatric disorders	Insomnia	2018		Yes
US2081123	OSTEOARTHRITIS (LOWER BACK)	Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	2000		Yes
	SPINAL STENOSIS	Musculoskeletal and connective tissue disorders	Spinal stenosis	2000		Yes
	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2003		Yes
	DEPRESSION	Psychiatric disorders	Depression	2008		Yes
	ERECTILE DYSFUNCTION	Reproductive system and breast disorders	Erectile dysfunction	2018		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011004	POST-MENOPAUSAL	Social circumstances	Postmenopause	2012		Yes
	MILD RASH LEFT UPPER ARM, UNKNOWN TYPE	Skin and subcutaneous tissue disorders	Rash	2020-05-26 (-6)		Yes
US2011009	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1970		Yes
	ENDOMETRIOSIS	Reproductive system and breast disorders	Endometriosis	1986	1986	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1986	1986	
	SEASONAL ALLERGIES, MOLD	Immune system disorders	Seasonal allergy	2000		Yes
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2005	2005	
	GALLSTONES	Hepatobiliary disorders	Cholelithiasis	2005	2005	
	HEARTBURN	Gastrointestinal disorders	Dyspepsia	2015		Yes
	MENOPAUSE	Social circumstances	Menopause	2015		Yes
	MILD OSTEOARTHRITIS, NECK	Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	2019-11		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011028	SKIN CANCER, SQUAMOUS, RT FOREARM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma of skin	2012	2012	
US2011113	ENDOMETRIOSIS	Reproductive system and breast disorders	Endometriosis	1999	1999	
	HYSTERECTOMY, PARTIAL	Surgical and medical procedures	Hysterectomy	1999	1999	
	SEASONAL ALLERGIES, UNSPECIFIED	Immune system disorders	Seasonal allergy	2010		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2017		Yes
US2011118	POSTMENOPAUSAL	Social circumstances	Postmenopause	2009		Yes
US2011121	MIGRAINES	Nervous system disorders	Migraine	1986		Yes
	ALLERGY TO CAT HAIR	Immune system disorders	Allergy to animal	1989		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2014		Yes
	SEASONAL ALLERGIES, UNSPECIFIED	Immune system disorders	Seasonal allergy	2016		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011122	POSTMENOPAUSAL	Social circumstances	Postmenopause	2011		Yes
US2011128	MIGRAINES	Nervous system disorders	Migraine	1977		Yes
	HEMORRAGE, INTRAUTERINE	Reproductive system and breast disorders	Uterine haemorrhage	2005	2005	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2005	2005	
US2011139	ALLERGIC RHINITIS, ANIMAL DANDER	Immune system disorders	Allergy to animal	1963		Yes
	ALLERGY TO BENOPEROXIDE	Immune system disorders	Drug hypersensitivity	1966		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1999	1999	
	UTERINE FIBROIDS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	1999	1999	
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2000		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011139	OSTEOPENIA	Musculoskeletal and connective tissue disorders	Osteopenia	2010		Yes
	SQUAMOUS CELL CARCINOMA, UPPER LIP	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Lip squamous cell carcinoma	2019-07	2019-07	
US2011149	HYSTERECTOMY, PARTIAL	Surgical and medical procedures	Hysterectomy	1970	1970	
	UTERINE FIBROIDS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	1970	1970	
	POSTMENOPAUSAL	Social circumstances	Postmenopause	1971		Yes
US2011159	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1967		Yes
	HYPERCHOLESTEREMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	1985		Yes
	HEAVY BLEEDING, INTRAUTERINE	Reproductive system and breast disorders	Uterine haemorrhage	1985	1985	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2011159	PARTIAL HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1985	1985	
	POST MENOPAUSAL	Social circumstances	Postmenopause	1989		Yes
	DEPRESSION- MILD	Psychiatric disorders	Depression	1996		Yes
	ATTENTION DEFICIT/HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2001		Yes
	OSTEOARTHRITIS-BILATERAL HANDS	Musculoskeletal and connective tissue disorders	Osteoarthritis	2005		Yes
US2011162	SEASONAL ALLERGIES, MOLD	Immune system disorders	Seasonal allergy	1995		Yes
	ALLERGY TO ROSEMARY	Immune system disorders	Allergy to plants	2015		Yes
	HOT FLASHES	Vascular disorders	Hot flush	2018		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2019		Yes
US2021003	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1990		Yes
	NECK PAIN	Musculoskeletal and connective tissue disorders	Neck pain	2013		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021003	BILATERAL LOWER PERIPHERAL EDEMA	General disorders and administration site conditions	Oedema peripheral	2016		Yes
	LOW TESTOSTERONE	Investigations	Blood testosterone decreased	2016		Yes
	BONE SPURS RIGHT SHOULDER	Musculoskeletal and connective tissue disorders	Exostosis	2018	2018	
	RIGHT SHOULDER SURGERY	Surgical and medical procedures	Shoulder operation	2018	2018	
	RIGHT SHOULDER TORN LABRUM	Injury, poisoning and procedural complications	Cartilage injury	2018	2018	
	ERECTILE DYSFUNCTION	Reproductive system and breast disorders	Erectile dysfunction	2019		Yes
US2021007	TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1982	1982	
	MENOPAUSE	Social circumstances	Menopause	2001-11-30 (-6758)		Yes
	FIBROID	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	2001-11-30 (-6758)	2001-11-30 (-6758)	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021007	TOTAL HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2001-11-30 (-6758)	2001-11-30 (-6758)	
	OSTEOARTHRITIS GENERALIZED	Musculoskeletal and connective tissue disorders	Osteoarthritis	2019		Yes
	ARTHROPLASTY LEFT HIP	Surgical and medical procedures	Hip arthroplasty	2019-03-27 (-432)	2019-03-27 (-432)	
	OSTEOARTHRITIS	Musculoskeletal and connective tissue disorders	Osteoarthritis	2019-03-27 (-432)	2019-03-27 (-432)	
US2021031	FISH ALLERGY	Immune system disorders	Food allergy	1966		Yes
	SEAFOOD ALLERGY	Immune system disorders	Food allergy	1966		Yes
	HYPERLIPDEMIA	Metabolism and nutrition disorders	Hyperlipidaemia	1976		Yes
	ANXIETY	Psychiatric disorders	Anxiety	1985		Yes
	DEPRESSION	Psychiatric disorders	Depression	1985		Yes
	LOW TESTOSTERONE	Investigations	Blood testosterone decreased	2015		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021114	LEFT POST-AURICULAR BASAL CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	2011	2011	
	LEFT HAND NUMBNESS	Nervous system disorders	Hypoaesthesia	2018		Yes
	HYPERLIPIDEMIA	Metabolism and nutrition disorders	Hyperlipidaemia	2020-02		Yes
US2021115	ALLERGY TO SULFA	Immune system disorders	Drug hypersensitivity	1985		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2005		Yes
	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	2007	2007	
	POST MENOPAUSAL	Social circumstances	Postmenopause	2015		Yes
US2021186	POST MENOPAUSAL	Social circumstances	Postmenopause	2005		Yes
	VAGINAL DRYNESS	Reproductive system and breast disorders	Vulvovaginal dryness	2010		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021208	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2014		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2016		Yes
	SPINAL FUSION	Surgical and medical procedures	Spinal fusion surgery	2017-09	2017-09	
	SPONDYLOSIS OF THE LUMBOSACRAL SPINE	Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	2017-09	2017-09	
US2021211	ALLERGY CODEINE	Immune system disorders	Drug hypersensitivity	1975		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	1995		Yes
	GASTROESOPHEGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2004		Yes
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2004		Yes
	OSTEOARTHRITIS BILATERAL KNEES	Musculoskeletal and connective tissue disorders	Osteoarthritis	2010		Yes
	DRY EYES	Eye disorders	Dry eye	2012		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021214	POST MENOPAUSAL	Social circumstances	Postmenopause	1991		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1991	1991	
	UTERINE FIBROIDS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	1991	1991	
	GENITAL HERPES SIMPLEX I	Infections and infestations	Genital herpes simplex	2010		Yes
	AZITHROMYCIN ALLERGY	Immune system disorders	Drug hypersensitivity	2015		Yes
	RIGHT HIP BURSITIS	Musculoskeletal and connective tissue disorders	Bursitis	2016		Yes
US2021215	POST MENOPAUSAL	Social circumstances	Postmenopause	2016		Yes
	LEFT TRIGGER THUMB	Musculoskeletal and connective tissue disorders	Trigger finger	2017	2017	
	LEFT TRIGGER THUMB RELEASE	Surgical and medical procedures	Tendon sheath incision	2017	2017	
	BIKE FALL	Injury, poisoning and procedural complications	Fall	2020-06-25 (-4)	2020-07-16 (18)	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021218	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1991		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2018		Yes
US2021230	POST MENOPAUSAL	Social circumstances	Postmenopause	2003		Yes
	ELEVATED BLOOD PRESSURE WITHOUT HISTORY OF HYPERTENSION	Investigations	Blood pressure increased	2018		Yes
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2018		Yes
	HIATAL HERNIA	Gastrointestinal disorders	Hiatus hernia	2018		Yes
US2021232	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1975		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2011		Yes
US2021234	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2002		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2002		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2021234	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2015		Yes
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2016		Yes
	RIGHT KNEE PAIN	Musculoskeletal and connective tissue disorders	Arthralgia	2017-06	2017-06	
	RIGHT KNEE REPLACEMENT STENOSIS NECK	Surgical and medical procedures Musculoskeletal and connective tissue disorders	Knee arthroplasty Cervical spinal stenosis	2017-06 2019-09-15 (-296)	2017-06	Yes
US2031091	MIGRAINES	Nervous system disorders	Migraine	1973		Yes
	PREGNANCY	Pregnancy, puerperium and perinatal conditions	Pregnancy	1981	1981-09-16 (-14163)	
	CESAREAN SECTION	Surgical and medical procedures	Caesarean section	1981-09-16 (-14163)	1981-09-16 (-14163)	
	PREGNANCY	Pregnancy, puerperium and perinatal conditions	Pregnancy	1983	1983-12-16 (-13342)	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031091	CESAREAN SECTION	Surgical and medical procedures Pregnancy, puerperium and perinatal conditions	Caesarean section	1983-12-16 (-13342)	1983-12-16 (-13342)	
	PREGNANCY		Pregnancy	1988	1988-05-23 (-11722)	
	CESAREAN SECTION	Surgical and medical procedures Immune system disorders Reproductive system and breast disorders	Caesarean section	1988-05-23 (-11722)	1988-05-23 (-11722)	
	ALLERGY TO AMOXICILLIN		Drug hypersensitivity	2005		Yes
	ENDOMETRIOSIS		Endometriosis	2007	2007	
US2031093	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2007	2007	
	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1987		Yes
	SULFA ALLERGY	Immune system disorders	Drug hypersensitivity	2010		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2015		Yes
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2019-10		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031101	ALLERGY TO AMOXICILLIN	Immune system disorders	Drug hypersensitivity	1970		Yes
	HOT FLASHES	Vascular disorders	Hot flush	1999		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2000		Yes
	ACID REFLUX	Gastrointestinal disorders	Gastrooesophageal reflux disease	2017		Yes
US2031111	NOVACAINE ALLERGY	Immune system disorders	Drug hypersensitivity	1951		Yes
	SULFA ALLERGY	Immune system disorders	Drug hypersensitivity	1958		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	1983		Yes
US2031112	POSTMENOPAUSAL	Social circumstances	Postmenopause	2016		Yes
US2031122	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	2008	2010	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2010	2010	
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2019		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2031122	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2019-10	2019-10	
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	2019-10	2019-10	
US2041107	TONSILECTOMY	Surgical and medical procedures	Tonsillectomy	1962	1962	
	TONSILLITIS	Infections and infestations	Tonsillitis	1962	1962	
	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	1970	1970	
	APPENDICITIS	Infections and infestations	Appendicitis	1970	1970	
	IRRITABLE BOWEL SYNDROME	Gastrointestinal disorders	Irritable bowel syndrome	1998		Yes
US2041108	TONSILLECTOMY	Surgical and medical procedures	Tonsillectomy	1960	1960	
	TONSILLITIS	Infections and infestations	Tonsillitis	1960	1960	
	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	1980	1980	
	APPENDICITIS	Infections and infestations	Appendicitis	1980	1980	
	POST MENOPAUSAL	Social circumstances	Postmenopause	2005		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041108	ABDOMINAL HERNIA	Gastrointestinal disorders	Abdominal hernia	2005	2005	
	ABDOMINAL HERNIA REPAIR	Surgical and medical procedures	Abdominal hernia repair	2005	2005	
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2010		Yes
	OVER ACTIVE BLADDER	Renal and urinary disorders	Hypertonic bladder	2018		Yes
	DISTAL LEFT RADIUS FRACTURE	Injury, poisoning and procedural complications	Radius fracture	2019-02	2019-02	
	DISTAL LEFT RADIUS FRACTURE REPAIR	Surgical and medical procedures	Fracture treatment	2019-02	2019-02	
US2041112	RIGHT INDEX FINGER TENDON INJURY	Injury, poisoning and procedural complications	Tendon injury	1983	1983	
	RIGHT INDEX FINGER TENDON REPAIR	Surgical and medical procedures	Tenoplasty	1983	1983	
	DISCECTOMY L5-S1	Surgical and medical procedures	Intervertebral disc operation	1989	1989	
	HERNIATED DISC L5-S1	Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	1989	1989	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041112	LAMINECTOMY L5-S1	Surgical and medical procedures	Spinal laminectomy	1989	1989	
	URINARY RETENTION	Renal and urinary disorders	Urinary retention	2018		Yes
US2041117	UTERINE MYOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	1980	1988	
	POST MENOPAUSAL	Social circumstances	Postmenopause	1988		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1988	1988	
	OSTEOPOROSIS	Musculoskeletal and connective tissue disorders	Osteoporosis	1990		Yes
	RIGHT CALF BASAL CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	2018	2018	
	RIGHT CALF BASAL CELL CARCINOMA REMOVAL	Surgical and medical procedures	Skin neoplasm excision	2018	2018	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041120	UTERINE MYOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	2001	2002	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2002	2002	
	POST MENOPAUSAL	Social circumstances	Postmenopause	2005		Yes
	RIGHT SHOULDER ROTATOR CUFF REPAIR	Surgical and medical procedures	Rotator cuff repair	2017	2017	
	RIGHT SHOULDER ROTATOR CUFF TEAR	Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	2017	2017	
US2041122	INSOMNIA	Psychiatric disorders	Insomnia	1956		Yes
	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	1970	1990	
	POST MENOPAUSAL	Social circumstances	Postmenopause	1990		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1990	1990	
	BILATERAL BREAST AUGMENTATION	Surgical and medical procedures	Mammoplasty	1995	1995	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041122	BILATERAL MASTECTOMY	Surgical and medical procedures	Mastectomy	1995	1995	
	LEFT BREAST CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	1995	1995	
	OVER ACTIVE BLADDER	Renal and urinary disorders	Hypertonic bladder	2000		Yes
	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	2000		Yes
	RIGHT HIP OSTEOARTHRITIS	Musculoskeletal and connective tissue disorders	Osteoarthritis	2010		Yes
	RIGHT HIP REPLACEMENT	Surgical and medical procedures	Hip arthroplasty	2019	2019	
US2041123	RIGHT ULNA FRACTURE OPEN REDUCTION INTERNAL FIXATION	Surgical and medical procedures	Open reduction of fracture	1981	1981	
	RIGHT ULNAR FRACTURE	Injury, poisoning and procedural complications	Ulna fracture	1981	1981	
	ABDOMINOPLASTY	Surgical and medical procedures	Abdominoplasty	1997	1997	
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1997	1997	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041123	POST MENOPAUSAL	Social circumstances	Postmenopause	2010		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2019		Yes
US2041125	POST MENOPAUSAL	Social circumstances	Postmenopause	2007		Yes
	LEFT KNEE FRACTURE	Injury, poisoning and procedural complications	Lower limb fracture	2007-02-21 (-4877)	2007-02-21 (-4877)	
	LEFT KNEE FRACTURE OPEN REDUCTION INTERNAL FIXATION	Surgical and medical procedures	Open reduction of fracture	2007-02-21 (-4877)	2007-02-21 (-4877)	
	CHRONIC CONSTIPATION	Gastrointestinal disorders	Constipation	2008		Yes
	LEFT TOTAL KNEE REVISION WITH ARTHROSCOPY	Investigations	Arthroscopy	2011	2011	
US2041126	UTERINE FIBROIDS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	1980	1993	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1993	1993	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041126	HEADACHES	Nervous system disorders	Headache	2000		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2010		Yes
	RIGHT FOOT BUNYUON	Musculoskeletal and connective tissue disorders	Foot deformity	2010	2017-11	
	RIGHT BUNYUONECTOMY	Surgical and medical procedures	Bunion operation	2017-11	2017-11	
US2041138	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	1953	1953	
	APPENDICITIS	Infections and infestations	Appendicitis	1953	1953	
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1970		Yes
	RIGHT SIDE ABDOMINAL LIPOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Lipoma	2008	2009	
	RIGHT SIDE ABDOMINAL LIPOMA REMOVAL	Surgical and medical procedures	Lipoma excision	2009	2009	
	BRONCHITIS	Infections and infestations	Bronchitis	2014	2014	
	RIGHT EYE RETINAL ATTACHMENT	Surgical and medical procedures	Retinal operation	2014	2014	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2041138	RIGHT EYE SURGERY	Surgical and medical procedures	Eye operation	2014	2014	
US2041144	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2000		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2013		Yes
US2041149	POST MENOPAUSAL	Social circumstances	Postmenopause	1999		Yes
	DEPRESSION	Psychiatric disorders	Depression	2018		Yes
US2051054	VASECTOMY	Surgical and medical procedures	Vasectomy	1988	1998	
	HYPEROPIA	Eye disorders	Hypermetropia	1995		Yes
	CAT HAIR ALLERGY	Immune system disorders	Allergy to animal	1997		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1997		Yes
	GULLAIN BARRE SYNDROME	Nervous system disorders	Guillain-Barre syndrome	1998	1998	
US2051064	PRESBYLPIA	Eye disorders	Presbyopia	2001		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051064	POST MENOPAUSAL	Social circumstances	Postmenopause	2006		Yes
	ADULT ACNE FACE SCALP	Skin and subcutaneous tissue disorders	Acne	2013		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2020-03		Yes
US2051069	SCOLIOSIS (CONGENITAL)	Congenital, familial and genetic disorders	Congenital scoliosis	(b) (6)		Yes
	BULIMIA	Psychiatric disorders	Bulimia nervosa	1976	1998	
	DEPRESSION	Psychiatric disorders	Depression	1984	1997	
	ANEMIA	Blood and lymphatic system disorders	Anaemia	1990	2005	
	ABNORMALITY ON LEFT BREAST XRAY	Investigations	Mammogram abnormal	1994	1994	
	BENIGN LEFT BREAST BIOPSY	Investigations	Biopsy breast normal	1994	1994	
	POST MENOPAUSAL	Social circumstances	Postmenopause	2007		Yes
	HYPEROPIA	Eye disorders	Hypermetropia	2016		Yes
	ENLARGED AORTA	Vascular disorders	Aortic dilatation	2017		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051069	SENSITIVE GALL BLADDER	Hepatobiliary disorders	Gallbladder disorder	2018		Yes
	BRADYCARDIA	Cardiac disorders	Bradycardia	2020		Yes
US2051070	HEADACHES	Nervous system disorders	Headache	1980		Yes
	HEARTBURN	Gastrointestinal disorders	Dyspepsia	1980		Yes
	LEFT ROTATOR CUFF REPAPIR	Surgical and medical procedures	Rotator cuff repair	2012	2012	
	LEFT ROTATOR CUFF TEAR	Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	2012	2012	
	MIGRAINES	Nervous system disorders	Migraine	2012	2012	
	INSOMNIA	Psychiatric disorders	Insomnia	2015		Yes
	SEASONAL ALLERGIC RHINITIS	Immune system disorders	Seasonal allergy	2015		Yes
	OSTEOARTHRITIS RIGHT KNEE	Musculoskeletal and connective tissue disorders	Osteoarthritis	2017		Yes
	RIGHT KNEE PAPIN	Musculoskeletal and connective tissue disorders	Arthralgia	2017		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051070	DIVERTICULITIS	Infections and infestations	Diverticulitis	2019		Yes
	RIGHT ROTATOR CUFF TEAR	Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	2019-12		Yes
	RIGHT SHOULDER PAIN	Musculoskeletal and connective tissue disorders	Musculoskeletal pain	2019-12		Yes
US2051074	HEADACHES	Nervous system disorders	Headache	1981		Yes
	MYOPIA	Eye disorders	Myopia	2000		Yes
	VASECTOMY	Surgical and medical procedures	Vasectomy	2002	2002	
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2010		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2017		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2018		Yes
	ROTATOR CUFF TEAR LEFT	Musculoskeletal and connective tissue disorders	Rotator cuff syndrome	2019	2019	
	ROTATOR CUFF TEAR REPAIR LEFT	Surgical and medical procedures	Rotator cuff repair	2019	2019	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051075	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1980	1980	
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1990		Yes
	HYPEROPIA	Eye disorders	Hypermetropia	1995		Yes
	OSTEOARTHRITIS BONE ON BONE BILATERAL KNEES	Musculoskeletal and connective tissue disorders	Osteoarthritis	1995		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	1996		Yes
	GENERAL BODY ACHES AND PAINS	General disorders and administration site conditions	Pain	2000		Yes
	DEPRESSION	Psychiatric disorders	Depression	2005		Yes
	LATEX ALLERGY	Immune system disorders	Rubber sensitivity	2015		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2016		Yes
	BASAL CELL CARCINOMA RIGHT BICEP	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Basal cell carcinoma	2019	2019	
	BASAL CELL CARCINOMA RIGHT BICEP REMOVAL	Surgical and medical procedures	Skin neoplasm excision	2019	2019	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051075	HIGH CHOLESTEROLEMIA	Investigations	Blood cholesterol increased	2020		Yes
US2051077	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1975		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2002-01-01 (-6755)		Yes
	MYOPIA	Eye disorders	Myopia	2015		Yes
US2051084	LACTOSE INTOLERANCE	Metabolism and nutrition disorders	Lactose intolerance	1964		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1989		Yes
	TETRACYCLINE ALLERGY	Immune system disorders	Drug hypersensitivity	1989		Yes
	COCKROACH ALLERGY	Immune system disorders	Cockroach allergy	1990		Yes
	HYPEROPIA LEFT EYE	Eye disorders	Hypermetropia	2006		Yes
	MYOPIA RIGHT EYE	Eye disorders	Myopia	2006		Yes
	LASIK RIGHT EYE	Surgical and medical procedures	Keratomileusis	2006	2006	
	VISION CORRECTION RIGHT EYE	Surgical and medical procedures	Vision correction operation	2006	2006	
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastroesophageal reflux disease	2017		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051084	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2017	2017	
	UTERINE PROLAPSE	Reproductive system and breast disorders	Uterine prolapse	2017	2017	
	DRY EYE LEFT EYE	Eye disorders	Dry eye	2020		Yes
	PAIN IN LEFT EYE	Eye disorders	Eye pain	2020		Yes
US2051085	MYOPIA	Eye disorders	Myopia	1963		Yes
	LEFT ARTHROSCOPIC KNEE MENISCUS TEAR	Injury, poisoning and procedural complications	Meniscus injury	1980	1980	
	VERICROSE VEINS-BILATERAL	Vascular disorders	Varicose vein	1989		Yes
	LEFT EAR HEARING LOSS	Ear and labyrinth disorders	Deafness unilateral	1995		Yes
	REYNAUD'S SYNDROME	Vascular disorders	Raynaud's phenomenon	2001		Yes
	HYPEROPIA	Eye disorders	Hypermetropia	2004		Yes
	OSTEOARTHRITIS OF BILATERAL KNEES	Musculoskeletal and connective tissue disorders	Osteoarthritis	2004		Yes
	GALL BLADDER REMOVED	Surgical and medical procedures	Cholecystectomy	2004	2004	
	GALL STONES	Hepatobiliary disorders	Cholelithiasis	2004	2004	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051085	LEFT BREAST BIOPSY (ABNORMAL FINDING ON MAMMOGRAM RESULT NEGATIVE NO LUMP)	Investigations	Biopsy breast normal	2005	2005	
	DRY EYE BILATERAL	Eye disorders	Dry eye	2008		Yes
	POST-MENOPAUSAL	Social circumstances	Postmenopause	2008		Yes
	LEFT KNEE REPLACEMENT	Surgical and medical procedures	Knee arthroplasty	2014	2014	
US2051088	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	1990	1990	
	APPENDICITIS	Infections and infestations	Appendicitis	1990	1990	
	MYOPIA	Eye disorders	Myopia	2001		Yes
	NOCTURIA	Renal and urinary disorders	Nocturia	2015		Yes
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2019		Yes
US2051097	PRESBYOPIA	Eye disorders	Presbyopia	1994	2010	
	PAIN LEFT CALF	Musculoskeletal and connective tissue disorders	Pain in extremity	1997		Yes
	SCIATICA BACK PAIN LEFT	Nervous system disorders	Sciatica	1997		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051097	OSTEOARTHRITIS KNEES BILATERAL	Musculoskeletal and connective tissue disorders	Osteoarthritis	2000		Yes
	LEFT FOOT HAMMER TOE	Musculoskeletal and connective tissue disorders	Foot deformity	2003	2003	
	LEFT FOOT HAMMER TOE CORRECTION SURGERY	Surgical and medical procedures	Toe operation	2003	2003	
	POST-MENOPAUSAL	Social circumstances	Postmenopause	2004		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2005		Yes
	VARICOSE VEINS BILATERAL LEGS	Vascular disorders	Varicose vein	2010		Yes
	BILATERAL LENS REPLACEMENT	Surgical and medical procedures	Intraocular lens implant	2010	2010	
	WALKING PNEUMONIA	Infections and infestations	Atypical pneumonia	2012	2012	
	BILATERAL KNEE REPLACEMENT	Surgical and medical procedures	Knee arthroplasty	2013	2013	
	APPENDECTOMY	Surgical and medical procedures	Appendicectomy	2017	2017	
	RIGHT ANKLE SURGURY	Surgical and medical procedures	Ankle operation	2017	2017	
	RUPTURED APPENDIX	Infections and infestations	Appendicitis perforated	2017	2017	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051097	TORN RIGHT ANKLE TENDON	Injury, poisoning and procedural complications	Tendon rupture	2017	2017	
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2018		Yes
	ABNORMAL CURVATURE L2-L3	Musculoskeletal and connective tissue disorders	Spinal deformity	2019	2019	
	BACK SURGERY (INTERVAL POSTERIOR FUSION L2-L3)	Surgical and medical procedures	Spinal fusion surgery	2019	2019	
	OBESITY	Metabolism and nutrition disorders	Obesity	2020		Yes
US2051101	CESAREAN	Surgical and medical procedures	Caesarean section	1989	1989	
	CHOLECYSTECTOMY	Surgical and medical procedures	Cholecystectomy	2008-01-01 (-4570)	2008-01-01 (-4570)	
	GALLSTONES	Hepatobiliary disorders	Cholelithiasis	2008-01-01 (-4570)	2008-01-01 (-4570)	
	POST-MENOPAUSAL	Social circumstances	Postmenopause	2015		Yes
	HEADACHE	Nervous system disorders	Headache	2020		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051101	HYPERTENSION	Vascular disorders	Hypertension	2020		Yes
	READING GLASSES	Social circumstances	Corrective lens user	2020		Yes
US2051102	ASTIGMATISM	Eye disorders	Astigmatism	1969		Yes
	REPAIR - RIGHT MENISCUS TEAR	Surgical and medical procedures	Meniscus operation	1999	1999	
	RIGHT MENISCUS TEAR	Injury, poisoning and procedural complications	Meniscus injury	1999	1999	
	KNEE - LEFT TORN MENISCUS	Injury, poisoning and procedural complications	Meniscus injury	2003	2003	
	LEFT KNEE TORN MENISCUS - SURGERY TO REPAIR	Surgical and medical procedures	Meniscus operation	2003	2003	
	RIGHT MENISCUS TEAR	Injury, poisoning and procedural complications	Meniscus injury	2005	2005	
	OSTEOARTHRITIS KNEE - BILATERAL	Musculoskeletal and connective tissue disorders	Osteoarthritis	2008		Yes
	LEFT HIP BROKEN	Injury, poisoning and procedural complications	Hip fracture	2009-11	2009-11	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051102	SURGERY TO REPAIR (ROD AND PIN INSERTION) - LEFT HIP BROKEN	Surgical and medical procedures	Hip surgery	2009-11	2009-11	
	LACTOSE INTOLERANT	Metabolism and nutrition disorders	Lactose intolerance	2010		Yes
	TOE NAIL FUNGUS BILATERAL FEET	Infections and infestations	Onychomycosis	2019-06-01 (-401)		Yes
US2051104	SEASONAL ALLERGIC RHINITIS	Immune system disorders	Seasonal allergy	1963		Yes
	URINARY TRACT INFECTION	Infections and infestations	Urinary tract infection	1975	2015	
	INSOMNIA	Psychiatric disorders	Insomnia	2006		Yes
	OSTEOARTHRITIS LEFT HAND	Musculoskeletal and connective tissue disorders	Osteoarthritis	2010		Yes
	OSTEOARTHRITIS RIGHT KNEE	Musculoskeletal and connective tissue disorders	Osteoarthritis	2010		Yes
	POST-MENOPAUSAL	Social circumstances	Postmenopause	2011		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051104	OBESITY	Metabolism and nutrition disorders	Obesity	2012		Yes
	PRESBYOPIA	Eye disorders	Presbyopia	2012	2019-03	
	LEFT FOOT PAIN	Musculoskeletal and connective tissue disorders	Pain in extremity	2013		Yes
	OSTEOARTHRITIS RIGHT HIP	Musculoskeletal and connective tissue disorders	Osteoarthritis	2013		Yes
	GOUT LEFT FOOT	Metabolism and nutrition disorders	Gout	2014		Yes
	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2014		Yes
	DIVERTICULITIS	Infections and infestations	Diverticulitis	2015		Yes
	ALLERGIC TO DOXYCYCLINE	Immune system disorders	Drug hypersensitivity	2017		Yes
	SITUATIONAL DEPRESSION	Psychiatric disorders	Adjustment disorder with depressed mood	2018		Yes
	LEFT BUNIONECTOMY	Surgical and medical procedures	Bunion operation	2018-12	2018-12	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051104	LEFT FOOT BUNION	Musculoskeletal and connective tissue disorders	Foot deformity	2018-12	2018-12	
	RIGHT TOTAL KNEE REPLACEMENT	Surgical and medical procedures	Knee arthroplasty	2018-12	2018-12	
	LASIKS- BILATERAL EYES	Surgical and medical procedures	Keratomileusis	2019-03	2019-03	
US2051108	DISCECTOMY	Surgical and medical procedures	Intervertebral disc operation	1991	1991	
	HERNIATED DISC L5	Musculoskeletal and connective tissue disorders	Intervertebral disc protrusion	1991	1991	
	PRESBYOPIA	Eye disorders	Presbyopia	2015		Yes
	BACK STIFFNESS	Musculoskeletal and connective tissue disorders	Musculoskeletal stiffness	2018		Yes
	SCOLIOSIS	Musculoskeletal and connective tissue disorders	Scoliosis	2018		Yes
	RIGHT INGUINAL HERNIA	Gastrointestinal disorders	Inguinal hernia	2020-02	2020-02	
	RIGHT INGUINAL HERNIORRAPHY	Surgical and medical procedures	Inguinal hernia repair	2020-02	2020-02	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2051111	TONSILLECTOMY	Surgical and medical procedures	Tonsillectomy	1955	1955	
	TONSILLITIS	Infections and infestations	Tonsillitis	1955	1955	
	MENORRHAGIA	Reproductive system and breast disorders	Menorrhagia	1967	1968	
	ANXIETY	Psychiatric disorders	Anxiety	1990		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	1991		Yes
	BILATERAL BROKEN WRIST	Injury, poisoning and procedural complications	Wrist fracture	2004	2004	
	DOG BITE RIGHT HAND	Injury, poisoning and procedural complications	Animal bite	2020		Yes
	URINARY URGENCY	Renal and urinary disorders	Micturition urgency	2020		Yes
US2061036	BACK PAIN	Musculoskeletal and connective tissue disorders	Back pain	1988-01		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1993-01		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2061036	ANXIETY	Psychiatric disorders	Anxiety	2000-01		Yes
	DEPRESSION	Psychiatric disorders	Depression	2000-01		Yes
	POSTMENOPAUSAL	Social circumstances	Postmenopause	2014-01		Yes
	TOENAIL INFECTION RIGHT GREAT TOE	Infections and infestations	Nail infection	2020-06-07 (-19)		Yes
US2061045	ALLERGY TO LODINE	Immune system disorders	Iodine allergy	1995		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2010-01-01 (-3832)		Yes
	OSTEOPENIA	Musculoskeletal and connective tissue disorders	Osteopenia	2015		Yes
	PAINFUL INTERCOURSE	Reproductive system and breast disorders	Dyspareunia	2017		Yes
US2061063	OSTEOARTHRITIS BILATERAL KNEES	Musculoskeletal and connective tissue disorders	Osteoarthritis	1995-06		Yes
	LEFT KNEE REPLACEMENT	Surgical and medical procedures	Knee arthroplasty	2018-02	2018-02	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071006	POST MENOPAUSAL	Social circumstances	Postmenopause	2000		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2000		Yes
US2071013	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1956		Yes
	UTERINE FIBROID TUMORS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	1996	1996-09-11 (-8665)	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1996-09-11 (-8665)	1996-09-11 (-8665)	
	BILATERAL GLAUCOMA	Eye disorders	Glaucoma	2014		Yes
US2071037	CHOLECCYSTECTOMY	Surgical and medical procedures	Cholecystectomy	1995	1995	
	CHOLECYSTITIS	Hepatobiliary disorders	Cholecystitis	1995	1995	
	ATTENTION DEFICIT DISPRDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2013		Yes
	BENIGN PROTSTATE HYPERPLASIA	Reproductive system and breast disorders	Benign prostatic hyperplasia	2016		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071037	INSOMNIA	Psychiatric disorders	Insomnia	2016		Yes
	MILD DEPRESSION	Psychiatric disorders	Depression	2016		Yes
US2071043	CODEINE ALLERGY	Immune system disorders	Drug hypersensitivity	1960		Yes
	PENICILLIN ALLERGY	Immune system disorders	Drug hypersensitivity	1960		Yes
	FIBROID TUMOR REMOVAL	Surgical and medical procedures	Myomectomy	1983	1983	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1983	1983	
	UTERINE FIBROIDS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	1983	1983	
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1990		Yes
	MIGRAINES	Nervous system disorders	Migraine	1995		Yes
	NECK PAIN	Musculoskeletal and connective tissue disorders	Neck pain	2005		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071082	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1973		Yes
	TRANSIENT ISCHEMIC ATTACK	Nervous system disorders	Transient ischaemic attack	1996	1996	
	VASECTOMY	Surgical and medical procedures	Vasectomy	1998		Yes
	OSTEOARTHRITIS IN LEFT KNEE AND LEFT SHOULDER	Musculoskeletal and connective tissue disorders	Osteoarthritis	2000		Yes
	BENIGN PROSTATIC HYPERPLASIA	Reproductive system and breast disorders	Benign prostatic hyperplasia	2010		Yes
	IRON DEFICIENT	Metabolism and nutrition disorders	Iron deficiency	2010		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2015		Yes
	ATTENTION DEFICIT HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2018		Yes
US2071087	POST MENOPAUSAL	Social circumstances	Postmenopause	1990		Yes
	VICODIN ALLERGY	Immune system disorders	Drug hypersensitivity	1998		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071087	HYPERCHOLESTEROLEMIA	Metabolism and nutrition disorders	Hypercholesterolaemia	2013		Yes
	RIGHT ANKLE PAIN	Musculoskeletal and connective tissue disorders	Arthralgia	2016-02		Yes
	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2018		Yes
	PERIPHERAL NEUROPATHY BILATERAL LEGS	Nervous system disorders	Neuropathy peripheral	2018		Yes
	OSTEOPOROSIS	Musculoskeletal and connective tissue disorders	Osteoporosis	2019		Yes
US2071089	UTERINE FIBROIDS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Uterine leiomyoma	1985	1986	
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1986	1986	
	SKIN MELANOMA NECK	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Malignant melanoma	2008	2008	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2071089	HIGH CHOLESTEROL	Investigations	Blood cholesterol increased	2010		Yes
US2071091	VASECTOMY	Surgical and medical procedures	Vasectomy	1998	1998	
US2071093	CODINE ALLERGY	Immune system disorders	Drug hypersensitivity	1986		Yes
	POST MENOPAUSAL	Social circumstances	Postmenopause	2005		Yes
	GLAUCOMA LEFT EYE	Eye disorders	Glaucoma	2017		Yes
	OSTEOPOROSIS	Musculoskeletal and connective tissue disorders	Osteoporosis	2019		Yes
US2071095	POST MENOPAUSAL	Social circumstances	Postmenopause	2005		Yes
	BILATERAL CATARACTS	Eye disorders	Cataract	2020-05-27 (-33)		Yes
US2071096	ALLERGY TO DAIRY	Metabolism and nutrition disorders	Dairy intolerance	1984		Yes
US2081002	MENOPAUSE	Social circumstances	Menopause	2005		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081002	DYSLIPIDEMIA	Metabolism and nutrition disorders	Dyslipidaemia	2008		Yes
US2081014	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2000		Yes
	MENOPAUSE	Social circumstances	Menopause	2003		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2010		Yes
	DYSLIPIDEMIA	Metabolism and nutrition disorders	Dyslipidaemia	2014		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2017		Yes
	MAJOR DEPRESSION	Psychiatric disorders	Major depression	2017		Yes
US2081016	MENIERE'S DISEASE	Ear and labyrinth disorders	Meniere's disease	2015		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2017		Yes
	MENOPAUSE	Social circumstances	Menopause	2018		Yes
	DOUBLE OOPHRECTOMY	Surgical and medical procedures	Oophorectomy bilateral	2018	2018	

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081019	MENOPAUSE	Social circumstances	Menopause	1989		Yes
	DEPRESSION	Psychiatric disorders	Depression	1998		Yes
	CONSTIPATION	Gastrointestinal disorders	Constipation	2011		Yes
US2081035	MENOPAUSE	Social circumstances	Menopause	2003		Yes
	ATTENTION-DEFICIT HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2010		Yes
US2081069	MENOPAUSE	Social circumstances	Menopause	2000		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2011		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2015		Yes
	URINARY FREQUENCY	Renal and urinary disorders	Pollakiuria	2018		Yes
	HERPES LABIALIS [FEVER BLISTERS OF MOUTH]	Infections and infestations	Oral herpes	2020-02-04 (-143)		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081072	BORDERLINE HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2017-10-26 (-974)		Yes
	DEPRESSION	Psychiatric disorders	Depression	2019-05-24 (-399)		Yes
US2081075	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	1990		Yes
US2081076	ANXIETY	Psychiatric disorders	Anxiety	2005		Yes
	DEPRESSION	Psychiatric disorders	Depression	2010		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2010		Yes
US2081081	MENOPAUSE	Social circumstances	Menopause	1989		Yes
	HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	1989	1989	
	BOWEL OBSTRUCTION (4 INCIDENTS)	Gastrointestinal disorders	Intestinal obstruction	1989	2009	
	IBS	Gastrointestinal disorders	Irritable bowel syndrome	1991		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2006		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081081	DEPRESSION	Psychiatric disorders	Depression	2006		Yes
	MIGRAINE	Nervous system disorders	Migraine	2006		Yes
	BRAIN TUMOR (BENIGN)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Brain neoplasm benign	2008	2008	
	GASTROPARESIS	Gastrointestinal disorders	Impaired gastric emptying	2010		Yes
US2081088	HYPERLIPIDEMIA	Metabolism and nutrition disorders	Hyperlipidaemia	2015		Yes
	GASTROESOPHAGEAL REFLUX DISEASE	Gastrointestinal disorders	Gastrooesophageal reflux disease	2019		Yes
US2081091	MIGRAINES	Nervous system disorders	Migraine	2000		Yes
	ATTENTION DEFICIT HYPERACTIVITY DISORDER	Psychiatric disorders	Attention deficit hyperactivity disorder	2009		Yes
	DEPRESSION	Psychiatric disorders	Depression	2009		Yes
	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2009		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081091	MENOPAUSE	Social circumstances	Menopause	2009-05		Yes
	STAGE III COLORECTAL CANCER (IN REMISSION)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Colorectal cancer stage III	2009-05	2009-12	
	COLOSTOMY BAG	Surgical and medical procedures	Colostomy	2009-12		Yes
	SEASONAL ALLERGIES	Immune system disorders	Seasonal allergy	2010		Yes
	MIXED HYPERLIPIDEMIA	Congenital, familial and genetic disorders	Type V hyperlipidaemia	2017		Yes
US2081093	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2008		Yes
	MENOPAUSE	Social circumstances	Menopause	2010		Yes
	OSTEOARTHRITIS [RIGHT KNEE]	Musculoskeletal and connective tissue disorders	Osteoarthritis	2017		Yes
	OBSTRUCTIVE SLEEP APNEA	Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	2018-02		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081099	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2008		Yes
	MENOPAUSE	Social circumstances	Menopause	2019-07		Yes
US2081108	GILBERT'S DISEASE	Congenital, familial and genetic disorders	Gilbert's syndrome	1954	(b) (6)	Yes
	MENOPAUSE	Social circumstances	Menopause	2010	(b) (6)	Yes
	OSTEOPENIA [LUMBAR SPINE AND TOTAL HIP]	Musculoskeletal and connective tissue disorders	Osteopenia	2010		Yes
	VITAMIN D DEFICIENCY R/T OSTEOPENIA	Metabolism and nutrition disorders	Vitamin D deficiency	2010		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2015		Yes
US2081116	SCOLIOSIS (BIRTH) (MILD)	Congenital, familial and genetic disorders	Congenital scoliosis		(b) (6)	Yes
	OTOSCLEROSIS (MILD)	Ear and labyrinth disorders	Otosclerosis	1965	(b) (6)	Yes
	BILATERAL NEPHROLITHIASIS	Renal and urinary disorders	Nephrolithiasis	2010		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081116	HEPATIC LOBULATED HYPODENSE LESION (BENIGN)	Hepatobiliary disorders	Hepatic lesion	2017		Yes
	ERECTILE DYSFUNCTION	Reproductive system and breast disorders	Erectile dysfunction	2018		Yes
US2081117	GENITAL HERPES	Infections and infestations	Genital herpes	1978		Yes
	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1991	1991	
	ALLERGIC RHINITIS	Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	2005		Yes
US2081120	ERECTILE DYSFUNCTION	Reproductive system and breast disorders	Erectile dysfunction	2017		Yes
US2081121	BILATERAL TUBAL LIGATION	Surgical and medical procedures	Female sterilisation	1982	1982	
	SPINAL STENOSIS	Musculoskeletal and connective tissue disorders	Spinal stenosis	2013		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.3
Medical History
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Condition	System Organ Class	Preferred Term	Start Date (Day)	Stop Date (Day)	Ongoing
US2081121	MENOPAUSE	Social circumstances	Menopause	2015		Yes
	OSTEOARTHRITIS (BACK)	Musculoskeletal and connective tissue disorders	Spinal osteoarthritis	2019		Yes
US2081129	ENDOMETRIOSIS	Reproductive system and breast disorders	Endometriosis	1982	2000	
	ALLERGIC RHINITIS	Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	2000		Yes
	ANXIETY	Psychiatric disorders	Anxiety	2000		Yes
	DEPRESSION	Psychiatric disorders	Depression	2000		Yes
	PARTIAL HYSTERECTOMY	Surgical and medical procedures	Hysterectomy	2000	2000	
	HYPOTHYROIDISM	Endocrine disorders	Hypothyroidism	2008		Yes
	INSOMNIA	Psychiatric disorders	Insomnia	2008		Yes

Day is defined as study day from first injection date.
MedDRA version 23.0

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020403.sas 19NOV2020 01:27 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011030	PANIC ATTACKS	DULOXETINE/ DULOXETINE	P/C/A	2016-09/ Ongoing	20 (mg) / QD/ ORAL	No
	NECK PAIN	MOTRIN/ IBUPROFEN	P/C/A	2018/ Ongoing	400 (mg) / QD/ ORAL	No
	NECK PAIN	TYLENOL W/ CODEINE/ CODEINE PHOSPHATE; PARACETAMOL	P/C/A	2018/ Ongoing	(mg) / PRN/ ORAL	No
	ANXIETY	BUSPIRONE/ BUSPIRONE	P/C/A	2019-12/ Ongoing	20 (mg) / QD/ ORAL	No
	INSOMNIA	MELATONIN/ MELATONIN	P/C/A	2020-01/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011030	HEADACHE	MOTRIN/ IBUPROFEN	P	2020-06-01 (-1) / 2020-06-01 (-1)	400 (mg) / ONCE / ORAL	No
	HEADACHE	TYLENOL WITH CODEINE / CODEINE PHOSPHATE; PARACETAMOL	P	2020-06-01 (-1) / 2020-06-01 (-1)	(mg) / ONCE / ORAL	No
US2011042	SEASONAL ALLERGIES	CLARITIN / LORATADINE	P/C/A	2009 / Ongoing	10 (mg) / PRN / ORAL	No
	BIRTH CONTROL	LO LOESTRIN (NORETHINDRONE ACETATE, ETHINYL ESTRADIOL) / ETHINYLESTRADIOL; NORETHIS TERONE ACETATE	P/C/A	2010 / Ongoing	(OTHER: MG / UG) / QD / ORAL	No
	GERD	PEPCID / FAMOTIDINE	P/C/A	2010 / Ongoing	20 (mg) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011042	ANXIETY	PROZAC/ FLUOXETINE HYDROCHLORIDE	P/C/A	2013/ Ongoing	40 (mg) / QD/ ORAL	No
US2011043	HEADACHE	ALEVE/ NAPROXEN SODIUM	C/A	2020-06-07 (7) / Ongoing	220 (mg) / PRN/ ORAL	Yes
US2011060	OVARIAN CYST	VIENVA/ ETHINYLESTRADIOL; LEVONORG ESTREL	P/C/A	2020-02-01 (-122) / Ongoing	1 (TABLET) / QD/ ORAL	No
	TOOTH PAIN, LEFT LOWER SECOND MOLAR	CLINDAMYCIN/ CLINDAMYCIN	C/A	2020-07-23 (52) / 2020-07-30 (59)	150 (mg) / QID/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011064	CONTRACEPTION	LILETTA/ LEVONORGESTREL	P/C/A	2017/ Ongoing	1 (OTHER: DEVICE) / OTHER: Q5YR/ OTHER: INTRAUTERINE	No
	POSTPARTUM DEPRESSION	SERTRALINE/ SERTRALINE	P/C/A	2017-01-01 (-1248) / Ongoing	150 (mg) / QD/ ORAL	No
	POISON OAK LEFT ARM	CALAMINE LOTION/ CALAMINE	C	2020-07-24 (53) / 2020-07-29 (58)	1 (OTHER: APPLICATION) / PRN/ TOPICAL	No
US2011067	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-06-09 (7) / 2020-06-09 (7)	500 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011068	SEASONAL ALLERGIES	FLONASE/ FLUTICASONE PROPIONATE	P/C/A	2013/ Ongoing	2 (PUFF) / PRN/ NASAL	No
	SEASONAL ALLERGIES	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2013/ Ongoing	10 (mg) / PRN/ ORAL	No
	HEARTBURN	OMEPRazole/ OMEPRazole	P/C/A	2016/ Ongoing	10 (mg) / PRN/ ORAL	No
US2011088	STYE, LEFT EYE	ASPIRIN/ ACETYLSALICYLIC ACID	C	2020-07-18 (45) / 2020-07-25 (52)	243 (mg) / PRN/ ORAL	No
US2021062	HAMSTRING LEFT LEG PAIN	IBUPROFEN/ IBUPROFEN	C	2020-06-09 (6) / 2020-06-09 (6)	600 (mg) / ONCE/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021062	SINUS CONGESTION	CLARITIN-D LORATADINE PSEUDOEPHEDRINE SULFATE/ LORATADINE;PSEUDOEPHEDRIN E SULFATE	C	2020-06-25 (22) / 2020-06-25 (22)	(mg) / ONCE/ ORAL	No
US2021073	BIRTH CONTROL	MICROGESTIN/ ETHINYLESTRADIOL;NORETHIS TERONE ACETATE	P/C/A	1999-08-15 (-7597) / Ongoing	(OTHER: MG/MCG) / QD/ ORAL	No
	INSOMNIA	KLONOPIN/ CLONAZEPAM	P/C/A	2017-11-15 (-930) / Ongoing	0.5 (mg) / PRN/ ORAL	No
	HEADACHE	ALEVE/ NAPROXEN SODIUM	C	2020-06-07 (6) / 2020-06-07 (6)	220 (mg) / ONCE/ ORAL	Yes
	LESION ON GUMS BENIGN	AMOXICILLIN/ AMOXICILLIN	C	2020-07-20 (49) / 2020-07-27 (56)	500 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021078	SEASONAL ALLERGIES	FLUTICASONE/ FLUTICASONE	P/C/A	2020-03-27 (-68) / Ongoing	50 (ug) / PRN/ NASAL	No
	INTERMITTENT HEADACHES	ACETAMINOPHEN/ PARACETAMOL	C/A	2020-07-15 (43) / Ongoing	500 (mg) / PRN/ ORAL	No
	INTERMITTENT HEADACHES	ACETAMINOPHEN/ASPIRIN/CAFFE INE/ ACETYLSALICYLIC ACID;CAFFEINE;PARACETAMOL	C/A	2020-07-15 (43) / Ongoing	(mg) / PRN/ ORAL	No
	INTERMITTENT HEADACHES	ACETAMINOPHEN/DIPHENHYDRAMINE/ DIPHENHYDRAMINE HYDROCHLORIDE;PARACETAMOL	C/A	2020-07-15 (43) / Ongoing	(mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021082	BILATERAL OSTEOARTHRITIS HANDS	CELEBREX/ CELECOXIB	P/C/A	2015-06-01 (-1829) / Ongoing	200 (mg) / PRN / ORAL	No
	RIGHT SHOULDER PAIN	TRIAMCINOLONE AND 1% LIDOCAINE / LIDOCAINE; TRIAMCINOLONE	P/C/A	2020-05-01 (-33) / Ongoing	50 (mg) / PRN / INTRAMUSCULAR	No
US2021094	HYPERLIPIDEMIA	SIMVASTATIN / SIMVASTATIN	P/C/A	2012 / Ongoing	40 (mg) / QD / ORAL	No
	SINUS PRESSURE/HEADACHE	ADVIL COLD AND SINUS / IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE	C	2020-06-29 (25) / 2020-06-30 (26)	1 (TABLET) / QD / ORAL	No
US2021096	DYSMENORRHEA	IBUPROFEN / IBUPROFEN	P/C/A	2008 / Ongoing	400 (mg) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021096	HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-07-04 (32) / 2020-07-04 (32)	400 (mg) / ONCE / ORAL	Yes
US2021107	BIRTH CONTROL	TRI-SPRINTEC/ ETHINYLESTRADIOL;NORGESTI MATE	P/C/A	2010/ Ongoing	(mg) / QD / ORAL	No
US2021111	ECZEMA - BILATERAL SHINS	DESOXIMETASONE/ DESOXIMETASONE	P/C/A	2008/ Ongoing	1 (OTHER: APPLICATION) / PRN / TOPICAL	No
	LOWER BACK PAIN	ALEVE/ NAPROXEN SODIUM	P/C/A	2010/ Ongoing	200 (mg) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021111	PLANTAR FASCIITIS BILATERAL	NAPROXEN/ NAPROXEN	P/C/A	2010-06-10 (-3651) / Ongoing	220 (mg) / PRN / ORAL	No
	ECZEMA - BILATERAL SHINS	EUCRISA/ CRISABOROLE	P/C/A	2017 / Ongoing	1 (OTHER: APPLICATION) / QD / TOPICAL	No
	GENERALIZED ANXIETY	CLONAZEPAM/ CLONAZEPAM	P/C/A	2018-06-09 (-730) / Ongoing	0.5 (mg) / PRN / ORAL	No
	COUGH	MUCINEX D / GUAIFENESIN; PSEUDOEPHEDRI NE HYDROCHLORIDE	C	2020-07-12 (35) / 2020-07-12 (35)	(mg) / BID / ORAL	No
	HEADACHE	NAPROXEN / NAPROXEN	C	2020-07-12 (35) / 2020-07-12 (35)	220 (mg) / BID / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021137	ATTENTION DEFICIT HYPERACTIVITY DISORDER	ADDERALL/ AMFETAMINE ASPARTATE; AMFETAMINE SULFATE; DEXAMFETAMINE SACCHARATE; DEXAMFETAMINE SULFATE	P/C/A	2019-09/ Ongoing	20 (mg) / QD/ ORAL	No
US2021144	BIRTH CONTROL PILL	AMETHYST LEVONORGESTREL AND ETHINYL ESTRADIOL/ ETHINYLESTRADIOL; LEVONORG ESTREL	P/C/A	2018/ Ongoing	(mg) / QD/ ORAL	No
	ANXIETY	LEXAPRO/ ESCITALOPRAM OXALATE	P/C/A	2019/ Ongoing	20 (mg) / QD/ ORAL	No
	ANXIETY	TRAZODONE/ TRAZODONE	P/C/A	2019/ Ongoing	50 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021144	ATTENTION DEFICIT HYPERACTIVITY DISORDER	VYVANSE/ LISDEXAMFETAMINE MESILATE	P/C/A	2019/ Ongoing	40 (mg) / QD/ ORAL	No
	HEADACHES	IBUPROFEN/ IBUPROFEN	C	2020-06-07 (3) / 2020-06-07 (3)	200 (mg) / ONCE/ ORAL	Yes
US2021161	HYPOESTROGENISM	ESTRADIOL/ ESTRADIOL	P/C/A	2012/ Ongoing	0.025 (mg) / QD/ TRANSDERMAL	No
	IDIOPATHIC EDEMA	TRIAMTERENE/ TRIAMTERENE	P/C/A	2014/ Ongoing	50 (mg) / PRN/ ORAL	No
	OSTEOPOROSIS	ALENDRONATE/ ALENDRONATE SODIUM	P/C/A	2020-05-02 (-37) / Ongoing	70 (mg) / EVERY WEEK/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021162	DEPRESSION	CELEXA/ CITALOPRAM HYDROBROMIDE	P/C/A	2016/ Ongoing	10 (mg) / QD/ ORAL	No
US2021175	BIRTH CONTROL	LEVONORGESTREL INTRAUTERINE/ LEVONORGESTREL	P/C/A	2015-11/ Ongoing	13.5 (mg) / OTHER: EVERY 5 YEARS/ VAGINAL	No
	ANXIETY	ESCITALOPRAM/ ESCITALOPRAM	P/C/A	2020-03/ Ongoing	10 (mg) / QD/ ORAL	No
	HEADACHE	ACETAMINOPHEN/ASPIRIN/CAFFE INE/ ACETYLSALICYLIC ACID;CAFFEINE;PARACETAMOL	C	2020-08-02 (56) / 2020-08-02 (56)	(mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031023	CONTRACEPTION	LOLOESTRIN FE/ ETHINYLESTRADIOL; FERROUS FUMARATE; NORETHISTERONE ACETATE	P/C/A	2005/ Ongoing	1 (TABLET) / QD/ ORAL	No
	SEASONAL ALLERGIES	FLONASE/ FLUTICASONE PROPIONATE	P/C/A	2015-06/ Ongoing	50 (ug) / QD/ NASAL	No
	SEASONAL ALLERGIES	ZYRTEC D 24 HOURS- CETIRIZINE-PSEUDOEPHEDRINE/ CETIRIZINE HYDROCHLORIDE; PSEUDOEPHED RINE HYDROCHLORIDE	P/C/A	2020-02/ Ongoing	(mg) / QD/ ORAL	No
	DUODENAL ULCER	LANSOPRAZOLE/ LANSOPRAZOLE	P/C	2020-05-18 (-11) / 2020-06-01 (4)	15 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031029	SEASONAL ALLERGIES	FLONASE/ FLUTICASONE PROPIONATE	P/C/A	2016/ Ongoing	0.05 (mg) / PRN/ NASAL	No
	SEASONAL ALLERGIES	SINGULAR/ MONTELUKAST SODIUM	P/C/A	2018/ Ongoing	10 (mg) / PRN/ ORAL	No
	OVER ACTIVE BLADDER	MIRABENGRAN/ MIRABEGRON	C/A	2020-06-17 (16) / Ongoing	50 (mg) / QD/ ORAL	No
	UPPER RESPIRATORY INFECTION	LORATADINE/ LORATADINE	C/A	2020-08-03 (63) / 2020-08-10 (70)	10 (mg) / PRN/ ORAL	No
	UPPER RESPIRATORY INFECTION	PSEUDOEPHEDRINE/ PSEUDOEPHEDRINE	C/A	2020-08-03 (63) / 2020-08-10 (70)	30 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031029	UPPER RESPIRATORY INFECTION	SALICYLATES- ASPRIN/ ACETYLSALICYLIC ACID	C/A	2020-08-03 (63) / 2020-08-10 (70)	650 (mg) / PRN/ ORAL	No
US2031040	GENERALIZED PAIN	TRAMODOL/ TRAMADOL	P/C/A	2018/ Ongoing	50 (mg) / PRN/ ORAL	No
US2031041	UPPER RESPIRATORY INFECTION	AZITHROMYCIN/ AZITHROMYCIN	C	2020-07-05 (34) / 2020-07-11 (40)	500 (mg) / QD/ ORAL	No
US2031048	ACNE ON FACE	KEFLEX/ CEFALEXIN	P/C/A	2019/ Ongoing	500 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031074	SINUS INFECTION/ BILATERAL OTOTOS MEDIA	AUGMENTIN AMOXICILLIN CLAVULANATE/ AMOXICILLIN;CLAVULANATE POTASSIUM	C	2020-06-11 (10) / 2020-06-19 (18)	(mg) / BID / ORAL	No
US2041005	ACNE (FACE)	MINOCYCLINE/ MINOCYCLINE	P/C/A	2010 / Ongoing	50 (mg) / QD / ORAL	No
	MEDICAL HISTORY - ANXIETY	ESCITALOPHRAM/ ESCITALOPRAM	P/C/A	2012 / Ongoing	10 (mg) / QD / ORAL	No
	NAUSEA SOLICITED SYMPTOM	TYLENOL/ PARACETAMOL	C	2020-06-26 (29) / 2020-06-26 (29)	325 (mg) / BID / ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041011	OTHER - NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2005/ Ongoing	1 (TABLET) / QD/ ORAL	No
	MEDICAL HISTORY - CONSTIPATION	MIRALAX/ MACROGOL 3350	P/C/A	2014/ Ongoing	1 (OTHER: PACKET) / PRN/ ORAL	No
US2041014	OTHER - NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2000/ Ongoing	1 (TABLET) / PRN/ ORAL	No
	MEDICAL HISTORY - HYPERCHOLESTEREMIA	ROSUVASTATIN/ ROSUVASTATIN	P/C/A	2018/ Ongoing	20 (mg) / QD/ ORAL	No
US2041020	OTHER - NUTRITIONAL SUPPLEMENT HYPERLIPIDEMIA	FISH OIL/ FISH OIL	P/C/A	2010/ Ongoing	2000 (mg) / BID/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041020	MEDICAL HISTORY - HYPERLIPIDEMIA	PRAVASTATIN/ PRAVASTATIN	P/C/A	2010/ Ongoing	40 (mg) / QD/ ORAL	No
	MEDICAL HISTORY - HERPES SIMPLEX 1	VALACYCLOVIR/ VALACICLOVIR	P/C/A	2010/ Ongoing	500 (mg) / QD/ ORAL	No
US2041022	ACNE-FACE	SPIRONOLACTONE/ SPIRONOLACTONE	P/C/A	2018/ Ongoing	50 (mg) / QD/ ORAL	No
	MEDICAL HISTORY - INSOMNIA	TRAZADONE/ TRAZODONE	P/C/A	2018/ Ongoing	50 (mg) / PRN/ ORAL	No
	ANXIETY	BUPROPION/ BUPROPION	P/C/A	2019/ Ongoing	300 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041025	MEDICAL HISTORY - HYPERLIPIDEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	2015/ Ongoing	10 (mg) / QD/ ORAL	No
	OTHER - NUTRITIONAL SUPPLEMENT	VITAMIN D/ VITAMIN D NOS	P/C/A	2015/ Ongoing	5000 (IU) / QD/ ORAL	No
	OTHER - NUTRITIONAL SUPPLEMENT	CALCIUM/ CALCIUM	P/C/A	2019/ Ongoing	500 (mg) / QD/ ORAL	No
	MEDICAL HISTORY- DEPRESSION	SERTRALINE/ SERTRALINE	P/C/A	2020-05-04 (-29) / Ongoing	50 (mg) / QD/ ORAL	No
US2041034	HEADACHES	IBUPROFEN/ IBUPROFEN	P/C/A	1995/ Ongoing	200 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041034	SEASONAL ALLERGIES	MUCINEX D/ GUAIFENESIN;PSEUDOEPHEDRI NE HYDROCHLORIDE	P/C/A	2005/ Ongoing	(mg) / PRN/ ORAL	No
	ANXIETY	CITALOPRAM/ CITALOPRAM	P/C/A	2015/ Ongoing	20 (mg) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2020-04-30 (-32) / Ongoing	1 (TABLET) / QD/ ORAL	No
US2041042	DEPRESSION	BUPROPION/ BUPROPION	P/C/A	2018-09/ Ongoing	150 (mg) / QD/ ORAL	No
US2041043	DEPRESSION	WELLBUTRIN/ BUPROPION HYDROCHLORIDE	P/C/A	2017/ Ongoing	300 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041043	OTHER- CONTRACEPTIVE	NEXPLANON/ ETONOGESTREL	P/C/A	2019-09/ Ongoing	1 (OTHER: PLACEMENT) / No OTHER: Q 3 YEARS/ OTHER: SUBDERMAL	
US2041056	ATTENTION DEFICIT HYPERACTIVITY DISORDER	AMPHETAMINE DEXTROAMPHETAMINE/ AMFETAMINE; DEXAMFETAMINE	P/C/A	2020-01/ Ongoing	30 (mg) / QD/ ORAL	No
US2041059	CONTRACEPTIVE	ISIBLOOM/ DESOGESTREL; ETHINYLESTRAD IOL	P/C/A	2018/ Ongoing	(mg) / QD/ ORAL	No
US2041062	SEASONAL ALLERGIES	SUDAFED (PSEUDOEPHEDRINE) / PSEUDOEPHEDRINE HYDROCHLORIDE	P/C/A	2000/ Ongoing	10 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041086	ACNE FACE	SPIRONOLACTONE/ SPIRONOLACTONE	P/C/A	2019/ Ongoing	10 (mg) / QD/ ORAL	No
US2041089	SEASONAL ALLERGIES	LORATADINE-D/ LORATADINE;PSEUDOEPHEDRIN E HYDROCHLORIDE	P/C/A	2014/ Ongoing	(mg) / PRN/ ORAL	No
US2051022	SEASONAL ALLERGIES	CLARITIN/ LORATADINE	P/C/A	2015/ Ongoing	10 (mg) / QD/ ORAL	No
	CONTRACEPTION	MICROGESTIN FE/ ETHINYLESTRADIOL; FERROUS FUMARATE; NORETHISTERONE ACETATE	P/C/A	2015/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051022	ACNE (CHIN)	SPIRONOLACTONE/ SPIRONOLACTONE	P/C/A	2017/ Ongoing	100 (mg) / QD/ ORAL	No
	ANXIETY	BUSPIRONE/ BUSPIRONE	P/C/A	2018/ Ongoing	5 (mg) / QD/ ORAL	No
	HEALTH MAINTENANCE	FIBER SUPPLEMENT/ FIBRE, DIETARY	P/C/A	2020-01/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEALTH MAINTENANCE	GLUCOSAMINE/ GLUCOSAMINE	P/C/A	2020-01/ Ongoing	3000 (mg) / QD/ ORAL	No
	HEADACHE, PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-07 (35) / 2020-07-09 (37)	600 (mg) / OTHER: EVERY 6-8 HOURS/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051022	ODYNOPHAGIA	IBUPROFEN/ IBUPROFEN	C	2020-07-29 (57) / 2020-08-04 (63)	600 (mg) / OTHER: EVERY 6 HOURS / ORAL	No
	ODYNOPHAGIA	SUDAFED/ PSEUDOEPHEDRINE HYDROCHLORIDE	C	2020-07-29 (57) / 2020-08-04 (63)	60 (mg) / OTHER: EVERY 6 HOURS / ORAL	No
US2051035	SEASONAL ALLERGIES	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2010-01-01 (-3807) / Ongoing	10 (mg) / PRN / ORAL	No
	BIRTH CONTRL	KYLEENA/ LEVONORGESTREL	P/C/A	2018 / Ongoing	(OTHER: IUD) / OTHER: EVERY 5 YEARS / VAGINAL	No
US2051036	GASTROESOPHAGEAL REFLUX DISEASE	OMEPRAZOLE/ OMEPRAZOLE	P/C/A	2000-01-01 (-7458) / Ongoing	20 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051036	HIV PRE PROPHYLAXIS	DESCOVY/ EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE	P/C/A	2020-02-01 (-122) / Ongoing	1 (TABLET) / QD/ ORAL	No
	SUPPLEMENT	MULTIVITAMIN ANTIOXIDANT GUMMY/ VITAMINS NOS	P/C/A	2020-05-29 (-4) / Ongoing	1 (OTHER: GUMMY) / BID/ ORAL	No
US2051044	DIETARY SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2006-01-01 (-5269) / Ongoing	1 (TABLET) / QD/ ORAL	No
US2061003	DEGENERATIVE DISC DISEASE	CELEBREX/ CELECOXIB	P/C/A	2017-01/ Ongoing	100 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061003	SEASONAL ALLERGIES	ZYRTEC-D/ CETIRIZINE HYDROCHLORIDE; PSEUDOEPHED RINE HYDROCHLORIDE	P/C/A	2018-04/ Ongoing	10 (mg) / QD/ ORAL	No
	ANXIETY	TRINTELLIX/ VORTIOXETINE HYDROBROMIDE	P/C/A	2020-04-21 (-44) / Ongoing	10 (mg) / QD/ ORAL	No
US2061015	DEPRESSION	DESYREL (TRAZADONE) / TRAZODONE HYDROCHLORIDE	P/C/A	2017-01/ Ongoing	75 (mg) / QD/ ORAL	No
	BIPOLAR DISORDER	LAMICTAL XR (LAMOTRIGINE) / LAMOTRIGINE	P/C/A	2017-01/ Ongoing	200 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061015	BIRTH CONTROL	LO LOESTRINE FE (NORETHINDRONE ACETLETH) / ETHINYLESTRADIOL; FERROUS FUMARATE; NORETHISTERONE ACETATE	P/C/A	2017-01/ Ongoing	1 (TABLET) / QD/ ORAL	No
	DEPRESSION	LEXAPRO (ESCITALOPRAM) / ESCITALOPRAM OXALATE	P/C/A	2018-01/ Ongoing	5 (mg) / QD/ ORAL	No
	MIGRAINES, RECURRENT	IMITREX/ SUMATRIPTAN	P/C/A	2020-04-15 (-49) / Ongoing	50 (mg) / PRN/ ORAL	No
US2061018	HOT FLASHES	TYLENOL/ PARACETAMOL	P/C/A	2015-01/ Ongoing	500 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061018	NUTRITIONAL SUPPLEMENT	VITAMIN D3/ COLECALCIFEROL	P/C/A	2017-01/ Ongoing	5000 (IU) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	MAGNESIUM CITRATE/ MAGNESIUM CITRATE	P/C/A	2018-01/ Ongoing	250 (mg) / QD/ ORAL	No
	HOT FLASHES	VENLAFAXINE/ VENLAFAXINE	P/C/A	2018-01/ Ongoing	37.5 (mg) / BID/ ORAL	No
	NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2019-12/ Ongoing	1 (TABLET) / BID/ ORAL	No
US2061021	INSOMNIA	CLONAZEPAM/ CLONAZEPAM	P/C/A	2020-03/ Ongoing	0.5 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061022	SEASONAL ALLERGIES	BENADRYL/ DIPHENHYDRAMINE HYDROCHLORIDE	P/C/A	1993-01/ Ongoing	25 (mg) / BID/ ORAL	No
	DEPRESSION	EFFEXOR XR/ VENLAFAXINE HYDROCHLORIDE	P/C/A	2001-01/ 2020-08-13 (72)	75 (mg) / QD/ ORAL	No
	SEASONAL ALLERGIES	FLONASE/ FLUTICASONE PROPIONATE	P/C/A	2018-03/ Ongoing	2 (OTHER: SPRAY) / PRN/ NASAL	No
	NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2019-07/ Ongoing	1 (TABLET) / QD/ ORAL	No
	ANXIETY	LORAZEPAM/ LORAZEPAM	P/C/A	2020-03/ Ongoing	1 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061022	INSOMNIA	TYLENOL PM/ DIPHENHYDRAMINE HYDROCHLORIDE; PARACETAMOL	C/A	2020-07-01 (29) / Ongoing	2 (TABLET) / QD / ORAL	No
US2061032	MIGRAINE	AIMOVIG/ ERENUMAB	P/C/A	2018-10 / Ongoing	70 (mg) / QM / SUBCUTANEOUS	No
US2071012	HYSTERECTOMY-HORMONE REPLACEMENT	ESTRADIOL / ESTRADIOL	P/C/A	2020-03 / Ongoing	0.1 (mg) / QD / TRANSDERMAL	No
US2071022	DEPRESSION	TRINTELLIX / VORTIOXETINE HYDROBROMIDE	P/C/A	2020-01 / 2020-08-01 (60)	10 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071044	CONTRACEPTION	LO LOESTRINE FE- ETHINYL ESTRADIOL, NORETHINDRONE ACETATE, IRON/ ETHINYLESTRADIOL; FERROUS FUMARATE; NORETHISTERONE ACETATE	P/C/A	2017-05/ Ongoing	10 (IU) / QD/ ORAL	No
US2071046	CONTRACEPTION	IMPLANON/ ETONOGESTREL	P/C/A	2018/ Ongoing	68 (mg) / QD/ TRANSDERMAL	No
	MIGRAINES	EXCEDRIN (ACETAMINOPHEN), CAFFEINE, ASPIRIN/ ACETYLSALICYLIC ACID; CAFFEINE; PARACETAMOL	P/C/A	2019/ Ongoing	(mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071049	CONTRACEPTION	ISIBLOOM- DESOGESTREL, ETHINYL ESTRAROL/ DESOGESTREL;ETHINYLESTRAD IOL	P/C/A	2020-02/ Ongoing	(mg) / QD/ ORAL	No
US2071050	HYPERLIPIDEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	2000/ Ongoing	80 (mg) / QD/ ORAL	No
US2071064	BIRTH CONTROL	MIRENA/ LEVONORGESTREL	P/C/A	2018-08/ Ongoing	52 (mg) / QD/ OTHER: INTRAUTERINE	No
	WEIGHT LOSS SUPPLEMENT	PHENTERMINE/ PHENTERMINE	C/A	2020-07-01 (27) / Ongoing	15 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071072	CONTRACEPTION	ORTHO TRI-CYCLEN/ ETHINYLESTRADIOL;NORGESTI MATE	P/C/A	2019-04/ Ongoing	1 (TABLET) / QD/ ORAL	No
US2081026	MIGRAINE	EXCEDRIN [ACETAMINOPHEN 250 MG, ASPIRIN 250 MG, AND CAFFEINE 65 MG] / ACETYLSALICYLIC ACID;CAFFEINE;PARACETAMOL	P/C/A	2015/ Ongoing	500 (mg) / PRN/ ORAL	No
	ANXIETY	ESCITALOPRAM/ ESCITALOPRAM	P/C/A	2019/ Ongoing	20 (mg) / QD/ ORAL	No
	PAIN AT INJECTION SITE DAY 2	IBUPROFEN/ IBUPROFEN	C	2020-06-05 (2) / 2020-06-05 (2)	500 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081026	PAIN AT INJECTION SITE	ALEVE (GENERIC) / NAPROXEN SODIUM	C	2020-07-08 (35) / 2020-07-08 (35)	500 (mg) / BID / ORAL	Yes
US2081033	MIGRAINES	IMITREX / SUMATRIPTAN	P/C/A	2019-09-16 (-260) / Ongoing	100 (mg) / PRN / ORAL	No
	SWIMMER'S EAR (LEFT EAR)	NEOMYCIN-POLYMYXIN HC EAR SOLUTION (1%) / HYDROCORTISONE; NEOMYCIN; P OLYMYXIN B	C	2020-07-13 (42) / 2020-07-18 (47)	1 (OTHER: DROP) / QID / OTHER: OTIC ROUTE	No
US2081038	PAIN RELATED TO CUT ON ARM (LEFT FOREARM)	IBUPROFEN / IBUPROFEN	C	2020-06-08 (1) / 2020-06-09 (2)	400 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081042	SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2010/ Ongoing	1 (TABLET) / QD/ ORAL	No
	MENOPAUSE	ESTRADIOL PELLET/ ESTRADIOL	P/C/A	2018/ Ongoing	(OTHER: DOSAGE CHANGES EVERY 3 MONTHS) / OTHER: EVERY 3 MONTHS/ SUBCUTANEOUS	No
	MENOPAUSE	PROGESTERONE/ PROGESTERONE	P/C/A	2018/ Ongoing	250 (mg) / QD/ ORAL	No
	MENOPAUSE [GROWTH HORMONE RELEASING HORMONE]	SERMORELIN/ SERMORELIN	P/C/A	2020-06-02 (-8) / Ongoing	0.2 (ug) / OTHER: 5 TIMES PER WEEK/ SUBCUTANEOUS	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081046	SEASONAL ALLERGIES	CETIRIZINE HYDROCHLORIDE/ CETIRIZINE HYDROCHLORIDE	P/C/A	2020-03/ Ongoing	10 (mg) / QD/ ORAL	No
	SEASONAL ALLERGIES	FLUTICASONE PROPIONATE/ FLUTICASONE PROPIONATE	P/C/A	2020-03/ Ongoing	50 (ug) / QD/ NASAL	No
US2081049	BIRTH CONTROL	MIRENA [LEVONORGESTREL] / LEVONORGESTREL	P/C/A	2015/ 2020-09-02 (86)	52 (mg) / QD/ OTHER: INTRAUTERINE	No
	SEASONAL ALLERGIES	FLONASE / FLUTICASONE PROPIONATE	P/C/A	2015/ Ongoing	100 (ug) / QD/ NASAL	No
	MIGRAINES	MAXALT / RIZATRIPTAN BENZOATE	P/C/A	2015/ Ongoing	10 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081049	ANXIETY	XANAX/ ALPRAZOLAM	P/C/A	2015/ Ongoing	0.25 (mg) / PRN/ ORAL	No
	ANXIETY	LEXAPRO/ ESCITALOPRAM OXALATE	P/C/A	2019/ Ongoing	10 (mg) / QD/ ORAL	No
	GASTROENTERITIS	CIPROFLOXACIN/ CIPROFLOXACIN	C	2020-07-22 (44) / 2020-07-28 (50)	500 (mg) / BID/ ORAL	No
	GASTROENTERITIS	FLAGYL/ METRONIDAZOLE	C	2020-07-22 (44) / 2020-07-28 (50)	500 (mg) / BID/ ORAL	No
US2081057	ANXIETY	ALPRAZOLAM/ ALPRAZOLAM	P/C/A	2018/ Ongoing	0.5 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081057	ANTI-INFLAMMATORY [GENERAL JOINT PAIN]	NAPROXEN/ NAPROXEN	P/C/A	2018/ Ongoing	500 (mg) / PRN/ ORAL	No
	SUPPLEMENT	BIO CLEANSE [BIOFLAVONOID COMPLEX] / BIOFLAVONOIDS NOS	P/C/A	2019-10/ Ongoing	3 (TABLET) / QD/ ORAL	No
	SUPPLEMENT	PROBIO 5/ LACTOBACILLUS ACIDOPHILUS	P/C/A	2019-10/ Ongoing	2 (TABLET) / QD/ ORAL	No
	SUPPLEMENT	XFACTOR/ FACTOR X (STUART PROWER FACTOR)	P/C/A	2019-10/ Ongoing	2 (TABLET) / QD/ ORAL	No
	HEADACHE	ADVIL/ IBUPROFEN	C	2020-06-08 (4) / 2020-06-10 (6)	400 (mg) / BID/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081057	HEADACHE/MUSCLE STIFFNESS IN NECK	IBUPROFEN/ IBUPROFEN	C	2020-06-08 (4) / 2020-06-10 (6)	400 (mg) / BID/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection. WHODrug version: WHODrug-Global-B3 March 2020
[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011029	MYALGIAS	MELOXICAM/ MELOXICAM	P/C/A	2019/ Ongoing	15 (mg) / QD/ ORAL	No
	INSOMNIA	TRAZODONE/ TRAZODONE	P/C/A	2019/ Ongoing	50 (mg) / QD/ ORAL	No
	MYALGIAS	LYRICA/ PREGABALIN	P/C/A	2019-10-01 (-244) / Ongoing	75 (mg) / BID/ ORAL	No
US2011051	DYSMENORRHEA	PAMPRIN/ MEPYRAMINE MALEATE; PAMABROM; PARACETA MOL	P/C/A	2012/ Ongoing	1 (TABLET) / PRN/ ORAL	No
	DYSMENORRHEA	IBUPROFEN/ IBUPROFEN	P/C/A	2019-08/ Ongoing	500 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011051	CONTRACEPTION	DEPO-PROVERA/ MEDROXYPROGESTERONE ACETATE	P/C/A	2020-01/ Ongoing	400 (mg) / OTHER: Q6M/ INTRAMUSCULAR	No
	MACULOPAPULAR RASH, ALL OVER BODY	TRIAMCINOLONE 1%/ TRIAMCINOLONE	C	2020-06-24 (23) / 2020-07-02 (31)	1 (OTHER: APPLICATION) / BID/ TOPICAL	No
	MACULOPAPULAR RASH, ALL OVER BODY	LEVOCETIRIZINE/ LEVOCETIRIZINE	C	2020-06-24 (23) / 2020-07-07 (36)	5 (mg) / QD/ ORAL	No
	MACULOPAPULAR RASH, ALL OVER BODY	HYDROXYZINE HCL/ HYDROXYZINE HYDROCHLORIDE	C	2020-06-24 (23) / 2020-07-15 (44)	10 (mg) / QD/ ORAL	No
	MUSCLE ACHES/JOINT ACHES (ALL OVER BODY)	IBUPROFEN/ IBUPROFEN	C	2020-07-07 (36) / 2020-07-07 (36)	400 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011055	BIRTH CONTROL	MIRENA/ LEVONORGESTREL	P/C/A	2018-02-01 (-852) / Ongoing	(OTHER: IUD) / OTHER: CONTINUOUS DOSAGE / VAGINAL	No
	NAUSEA	ZANTAC/ RANITIDINE HYDROCHLORIDE	C	2020-06-21 (20) / 2020-06-21 (20)	75 (mg) / QD / ORAL	No
	MUSCLE ACHES, ALL OVER BODY	ALEVE/ NAPROXEN SODIUM	C	2020-06-22 (21) / 2020-06-24 (23)	440 (mg) / QD / ORAL	No
US2011087	SEASONAL ALLERGIES	LORATADINE/ LORATADINE	P/C/A	2015 / Ongoing	10 (mg) / PRN / ORAL	No
	SEASONAL ALLERGIES	ADVIL/ IBUPROFEN	C	2020-07-02 (30) / 2020-07-02 (30)	200 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011087	SEASONAL ALLERGIES	ADVIL/ IBUPROFEN	C	2020-07-07 (35) / 2020-07-07 (35)	200 (mg) / QD/ ORAL	No
US2011090	PROPHYLAXIS FOR HIV	TRUVADA/ EMTRICITABINE; TENOFOVIR	P/C/A	2020-04-15 (-50) / Ongoing	200 (mg) / QD/ ORAL	No
	DEPRESSION	VENLAFAXINE/ VENLAFAXINE	P/C	2020-05-01 (-34) / 2020-06-11 (8)	50 (mg) / QD/ ORAL	No
	DEPRESSION	VENLAFAXINE/ VENLAFAXINE	C/A	2020-06-12 (9) / Ongoing	100 (mg) / QD/ ORAL	No
US2011091	HEADACHES	IBUPROFEN/ IBUPROFEN	P/C/A	1984 / Ongoing	600 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011091	SEASONAL ALLERGIES	LORATIDINE/ LORATADINE	P/C/A	1984/ Ongoing	10 (mg) / PRN/ ORAL	No
	HYPOTHYROIDISM	LEVOTHYROXINE/ LEVOTHYROXINE	P/C/A	2010/ Ongoing	112 (ug) / QD/ ORAL	No
US2011092	HIGH CHOLESTEROL	ATORVASTIN/ ATORVASTATIN CALCIUM	P/C/A	2000/ Ongoing	40 (mg) / QD/ ORAL	No
	CARDIAC PROPHYLAXIS	BABY ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2019/ Ongoing	81 (mg) / QD/ ORAL	No
	FEVER	ADVIL/ IBUPROFEN	C	2020-07-08 (34) / 2020-07-08 (34)	400 (mg) / TID/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011095	BIRTH CONTROL	KYLEENA/ LEVONORGESTREL	P/C/A	2018-09/ Ongoing	19.5 (mg) / OTHER: Q5Y/ OTHER: INTRAUTERINE	No
	PAIN IN LEFT HIP	ADVIL/ IBUPROFEN	C	2020-06-09 (5) / 2020-06-09 (5)	600 (mg) / ONCE/ ORAL	No
	HERPES PREVENTION	VALTREX/ VALACICLOVIR HYDROCHLORIDE	C/A	2020-07-01 (27) / Ongoing	500 (mg) / BID/ ORAL	No
US2011102	SEASONAL ALLERGIES	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2009/ Ongoing	10 (mg) / PRN/ ORAL	No
	MUSCLE ACHES (ALL OVER BODY, SOLICITED SYMPTOM)	IBUPROFEN/ IBUPROFEN	C	2020-07-07 (30) / 2020-07-07 (30)	400 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021058	ANXIETY	BUPROPION/ BUPROPION	P/C/A	2017/ Ongoing	150 (mg) / QD/ ORAL	No
	MOOD DISORDER	LAMOTRIGINE/ LAMOTRIGINE	P/C/A	2017/ Ongoing	200 (mg) / QD/ ORAL	No
	MIGRAINES	RIZATRIPTAN/ RIZATRIPTAN	P/C/A	2017/ Ongoing	10 (mg) / QD/ ORAL	No
	MIGRAINES	TOPAMAX/ TOPIRAMATE	P/C/A	2017/ Ongoing	25 (mg) / QD/ ORAL	No
	BIRTH CONTROL	LILETTA/ LEVONORGESTREL	P/C/A	2018-02/ Ongoing	1 (OTHER: DEVICE) / OTHER: EVERY 3-4 YEARS/ VAGINAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021058	PAIN AT INJECTION SITE	ADVIL/ IBUPROFEN	C	2020-06-05 (1) / 2020-06-08 (4)	200 (mg) / QD/ ORAL	Yes
	HEADACHE	ADVIL/ IBUPROFEN	C	2020-06-06 (2) / 2020-06-08 (4)	200 (mg) / PRN/ ORAL	Yes
	FEVER	MOTRIN/ IBUPROFEN	C	2020-07-07 (33) / 2020-07-07 (33)	800 (mg) / ONCE/ ORAL	Yes
US2021064	ANXIETY	ESCITALOPRAM/ ESCITALOPRAM	P/C/A	2018/ Ongoing	20 (mg) / QD/ ORAL	No
	LEFT WRIST PAIN	ALEVE/ NAPROXEN SODIUM	P/C/A	2020-05/ Ongoing	220 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021084	SEASONAL ALLERGIES	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2018/ Ongoing	10 (mg) / QD/ ORAL	No
	HEADACHES	TYLENOL/ PARACETAMOL	C	2020-07-08 (34) / 2020-07-08 (34)	500 (mg) / ONCE/ ORAL	Yes
US2021090	ANXIETY	LEXAPRO/ ESCITALOPRAM OXALATE	P/C/A	2016-07-01 (-1432) / Ongoing	40 (mg) / QD/ ORAL	No
	ATTENTION DEFICIT DISORDER	VYVANCE/ LISDEXAMFETAMINE MESILATE	P/C/A	2016-07-01 (-1432) / Ongoing	40 (mg) / QD/ ORAL	No
	HEADACHE	PROPRANOLOL/ PROPRANOLOL	P/C/A	2020-03-14 (-80) / Ongoing	80 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021090	HEADACHE	IBUPROFEN/ IBUPROFEN	C/A	2020-07-07 (36) / Ongoing	200 (mg) / PRN/ ORAL	Yes
US2021147	FEVER	TYLENOL/ PARACETAMOL	C	2020-07-08 (34) / 2020-07-08 (34)	500 (mg) / BID/ ORAL	Yes
US2021166	MUSCLE SPASM BACK	TIZANIDINE HCL/ TIZANIDINE HYDROCHLORIDE	C	2020-06-22 (18) / 2020-06-26 (22)	4 (mg) / QD/ ORAL	No
	MUSCLE SPASM BACK	TRAMADOL HCL/ TRAMADOL HYDROCHLORIDE	C	2020-06-22 (18) / 2020-06-26 (22)	50 (mg) / QD/ ORAL	No
	PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-10 (36) / 2020-07-10 (36)	200 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021166	TESNION HEADACHE	ACETAMINOPHEN/ASPIRIN/ ACETYLSALICYLIC ACID; PARACETAMOL	C/A	2020-07-31 (57) / Ongoing	(mg) / PRN/ ORAL	No
US2021167	FEVER	ACETOMINOPHEN/ PARACETAMOL	C	2020-07-08 (31) / 2020-07-08 (31)	500 (mg) / ONCE/ ORAL	Yes
US2021179	MIGRAINES	SUMATRIPTAN/ SUMATRIPTAN	P/C/A	2000/ Ongoing	100 (mg) / PRN/ ORAL	No
	ANXIETY	SERTRALINE/ SERTRALINE	P/C/A	2012/ Ongoing	25 (mg) / QD/ ORAL	No
	BIRTH CONTROL	NORETHINDRONE E. ESTRADIOL/ ETHINYLESTRADIOL; NORETHIS TERONE	P/C/A	2015/ Ongoing	(OTHER: MG/MCG) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021179	ATTENTION DEFICIT HYPERACTIVITY DISORDER	DEXTROAMP AMPHETAMIN/ AMFETAMINE;DEXAMFETAMINE	P/C/A	2020-01/ Ongoing	10 (mg) / BID/ ORAL	No
	INJECTION SITE PAIN	IBUPROFEN/ IBUPROFEN	C	2020-06-09 (2) / 2020-06-09 (2)	400 (mg) / QD/ ORAL	No
	PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-08 (31) / 2020-07-08 (31)	400 (mg) / QD/ ORAL	Yes
US2031002	CONTRACEPTION	NUVA RING/ ETHINYLESTRADIOL;ETONOGES TREL	P/C/A	2005/ Ongoing	1 (OTHER: RING) / QM/ VAGINAL	No
	NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2019/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031004	NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2000-05-01 (-7333) / Ongoing	1 (TABLET) / QD/ ORAL	No
	GENERALIZED ARTHALGIA BILATERAL AXILLARY TENDERNESS, LOW GRADE FEVER, GENERALIZED MYALGIA	TYLENOL/ PARACETAMOL	C	2020-05-30 (2) / 2020-05-31 (3)	1000 (mg) / PRN/ ORAL	Yes
	GENERALIZED ARTHALGIA BILATERAL AXILLARY TENDERNESS, LOW GRADE FEVER, GENERALIZED MYALGIA	TYLENOL/ PARACETAMOL	C	2020-06-29 (32) / 2020-07-02 (35)	1000 (mg) / PRN/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031004	URINARY TRACT INFECTION	AMOXICILLIN/ AMOXICILLIN	C	2020-07-13 (46) / 2020-07-22 (55)	500 (mg) / BID/ ORAL	No
US2031011	NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2010/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HOT FLASHES	ESTROVEN/ BORON; CALCIUM; CIMICIFUGA RACEMOSA EXTRACT; FOLIC ACID; GLYCINE MAX EXTRACT; MAGNOLIA OFFICINALIS; NICOTINIC ACID; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; SELENIUM; THIAMINE; TOCOPHE ROL; VITAMIN B12 NOS	P/C/A	2020-04/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031016	HEADACHE	TYLONOL/ PARACETAMOL	P/C	2020-06-03 (-1) / 2020-06-04 (1)	250 (mg) / PRN / ORAL	Yes
US2031042	CONTRACEPTION	TRI-SPRINTEC/ ETHINYLESTRADIOL;NORGESTI MATE	P/C/A	2015/ Ongoing	1 (TABLET) / QD / ORAL	No
	MIGRAINES	SUMATRIPTAN/ SUMATRIPTAN	P/C/A	2020-01/ Ongoing	25 (mg) / PRN / ORAL	No
	HEADACHE AND GENERALIZED MUSCLE ACHE	TYLENOL/ PARACETAMOL	C	2020-07-07 (34) / 2020-07-08 (35)	1000 (mg) / PRN / ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031051	CONTRACEPTION	MIRENA/ LEVONORGESTREL	P/C/A	2018/ Ongoing	52 (mg) / OTHER: REPLACED EVERY 5 YEARS/ VAGINAL	No
US2031056	SEASONAL ALLERGIES	LORATADINE/ LORATADINE	P/C/A	2018/ Ongoing	10 (mg) / PRN/ ORAL	No
	GENERALIZED JOINT PAIN	IBUPROFEN/ IBUPROFEN	C	2020-07-01 (31) / 2020-07-01 (31)	400 (mg) / ONCE/ ORAL	Yes
US2031063	HYPERLIPIDEMIA	PROVASTATIN/ PRAVASTATIN	P/C/A	2016/ Ongoing	80 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031066	GENERALIZED MYALGIA, GENERALIZED ARTHRALGIA	IBUPROFEN/ IBUPROFEN	C	2020-07-01 (30) / 2020-07-02 (31)	800 (mg) / PRN / ORAL	Yes
US2031072	HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-06-04 (2) / 2020-06-05 (3)	650 (mg) / PRN / ORAL	Yes
	HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-06-09 (7) / 2020-06-09 (7)	650 (mg) / PRN / ORAL	Yes
	RIGHT EYE IRRITATION SECONDARY TO FOREIGN OBJECT IN EYE	LOTEPREDNOL TOBRAMYCIN OPHTHALMIC .5%/.3% / LOTEPREDNOL; TOBRAMYCIN	C	2020-06-17 (15) / 2020-06-20 (18)	1 (OTHER: DROP) / QID / INTRAOCULAR	No
	FEVER; GENERALIZED MUSCLE ACHES	ACETAMINOPHEN / PARACETAMOL	C	2020-07-07 (35) / 2020-07-09 (37)	1000 (mg) / PRN / ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031072	FEVER AND GENERALIZED MUSCLE ACHES	IBUPROFEN/ IBUPROFEN	C	2020-07-07 (35) / 2020-07-09 (37)	400 (mg) / PRN / ORAL	Yes
US2031080	CONTRACEPTION	FALMINA/ ETHINYLESTRADIOL; LEVONORG ESTREL	P/C/A	2020-03-01 (-95) / Ongoing	1 (TABLET) / QD / ORAL	No
	INJECTION SITE PAIN	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-03 (30) / 2020-07-03 (30)	1000 (mg) / PRN / ORAL	Yes
US2041002	SEASONAL ALLERGIES	LORATADINE/ LORATADINE	P/C/A	2005 / Ongoing	10 (mg) / QD / ORAL	No
	SOLICITED SYMPTOM-HEADACHE	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-01 (30) / 2020-07-01 (30)	250 (mg) / PRN / ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041003	CONTRACEPTIVE	NEXPLANON/ ETONOGESTREL	P/C/A	2014/ Ongoing	1 (OTHER: PLACEMENT) / No OTHER: Q3YEARS/ OTHER: SUBDERMAL	No
	ATTENTION HYPERACTIVITY DISORDER	METHYLPHENIDATE/ METHYLPHENIDATE	P/C/A	2019-08/ Ongoing	20 (mg) / QD/ ORAL	No
US2041006	PROPHYLAXIS	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2012/ Ongoing	1 (TABLET) / QD/ ORAL	No
	PROPHYLAXIS	OMEGA 3 FATTY ACID/ OMEGA-3 FATTY ACIDS	P/C/A	2019-10/ Ongoing	1 (CAPSULE) / QD/ ORAL	No
US2041007	HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-06-03 (3) / 2020-06-03 (3)	200 (mg) / QD/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041012	OTHER - CONTRACEPTIVE	MIRENA/ LEVONORGESTREL	P/C/A	2019-01/ Ongoing	(OTHER: NA) / UNKNOWN/ OTHER: INTRAUTERINE	No
US2041023	CHRONIC HEADACHES	IBUPROFEN/ IBUPROFEN	P/C/A	2017/ Ongoing	1000 (mg) / PRN/ ORAL	No
	CONTRACEPTION	INTRAUTERINE DEVICE/ INTRAUTERINE CONTRACEPTIVE DEVICE	P/C/A	2018-08/ Ongoing	(OTHER: NA) / OTHER: EVERY 5 YEARS/ OTHER: INTRAUTERINE	No
	MEDICAL HISTORY - DEPRESSION/ANXIETY	VENLAFAXINE/ VENLAFAXINE	P/C/A	2020-04/ Ongoing	75 (mg) / QD/ ORAL	No
US2041027	MEDICAL HISTORY - ACNE	CLINDAMYCIN/ CLINDAMYCIN	P/C/A	2016/ Ongoing	300 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041027	MEDICAL HISTORY - ACNE	SPIRONOLACTONE/ SPIRONOLACTONE	P/C/A	2016/ Ongoing	75 (mg) / QD/ ORAL	No
	SOLICITED SYMPTOM- HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-06-03 (3) / 2020-06-03 (3)	200 (mg) / PRN/ ORAL	Yes
	SOLICITED SYMPTOMS- GENERALIZED PAIN/BODY ACHES	IBUPROFEN/ IBUPROFEN	C	2020-06-30 (30) / 2020-06-30 (30)	800 (mg) / QD/ ORAL	Yes
US2041030	OTHER- NUTRITIONAL SUPPLEMENT	FISH OIL/ FISH OIL	P/C/A	2020-01/ Ongoing	1000 (mg) / QD/ ORAL	No
US2041047	GASTROESOPHAGEAL RELUX DISEASE	FAMOTIDINE/ FAMOTIDINE	P/C/A	2018/ Ongoing	5 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041047	LOW BACK PAIN	TRAMODOL/ TRAMADOL	P/C/A	2019/ Ongoing	50 (mg) / PRN/ ORAL	No
	ALOPECIA	FINASTERIDE/ FINASTERIDE	P/C/A	2020-04-15 (-48) / Ongoing	1 (mg) / QD/ ORAL	No
	SEASONAL ALLERGIES	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	A	2020-08/ Ongoing	10 (mg) / PRN/ ORAL	No
US2041049	ANXIETY	PROZAC/ FLUOXETINE HYDROCHLORIDE	P/C	2018/ 2020-06-08 (5)	50 (mg) / QD/ ORAL	No
	DEPRESSION	GABAPENTIN/ GABAPENTIN	P/C	2019/ 2020-06-08 (5)	200 (mg) / BID/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041049	IRRITABLE BOWEL SYNDROME	DICYCLOMINE/ DICYCLOVERINE	C/A	2020-06-12 (9) / Ongoing	10 (mg) / QD/ ORAL	No
	SOLICITED SYMPTOM- HEADACHE	ACETAMINOPHEN/ASPIRIN/CAFFE INE/ ACETYLSALICYLIC ACID;CAFFEINE;PARACETAMOL	C	2020-07-15 (42) / 2020-07-15 (42)	(mg) / ONCE/ ORAL	Yes
	ANXIETY AND DEPRESSION	PROZAC/ FLUOXETINE HYDROCHLORIDE	C	2020-07-16 (43) / 2020-07-23 (50)	20 (mg) / QD/ ORAL	No
	ANXIETY AND DEPRESSION	PROZAC/ FLUOXETINE HYDROCHLORIDE	C/A	2020-07-23 (50) / Ongoing	40 (mg) / QD/ ORAL	No
US2041051	SEASONAL ALLERGIES	CETIRIZINE/ CETIRIZINE	P/C/A	2004/ Ongoing	10 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041051	CONTRACEPTIVE	WERA/ ETHINYLESTRADIOL;NORETHIS TERONE	P/C/A	2017/ Ongoing	(mg) / QD/ ORAL	No
US2041055	PREMENSTRUAL DYSPHORIC DISORDER	PAROXETINE/ PAROXETINE	P/C/A	2017/ Ongoing	40 (mg) / QD/ ORAL	No
	CONTRACEPTION	TRI-SPRINTEC/ ETHINYLESTRADIOL;NORGESTI MATE	P/C/A	2017/ Ongoing	(mg) / QD/ ORAL	No
US2041064	CONTRACEPTIVE	LILETTA/ LEVONORGESTREL	P/C/A	2018-02/ Ongoing	1 (OTHER: DEVICE) / OTHER: Q 5 YEARS/ OTHER: INTRAUTERINE	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041071	CONTRACEPTION	ORTHO-NOVUM/ MESTRANOL;NORETHISTERONE	P/C/A	2013/ Ongoing	(mg) / QD/ ORAL	No
	HERPES TYPE 1	VALACYCLOVIR/ VALACICLOVIR	P/C/A	2018/ Ongoing	500 (mg) / QD/ ORAL	No
US2041075	ADHD	ADDERALL/ AMFETAMINE ASPARTATE;AMFETAMINE SULFATE;DEXAMFETAMINE SACCHARATE;DEXAMFETAMINE SULFATE	P/C/A	2015/ Ongoing	30 (mg) / QD/ ORAL	No
	DEPRESSION	LEXAPRO/ ESCITALOPRAM OXALATE	P/C/A	2020-01/ Ongoing	20 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041076	NUTRITIONAL SUPPLEMENT	MCT OIL/ MEDIUM-CHAIN TRIGLYCERIDES	P/C/A	2019/ Ongoing	1 (OTHER: PACKET) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2019/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEADACHES	IBUPROFEN/ IBUPROFEN	C	2020-06-08 (7) / 2020-06-10 (9)	200 (mg) / PRN/ ORAL	Yes
	SOLICITED HEADACHES NOTED IN DIARY	TRAMADOL/ TRAMADOL	C	2020-07-07 (36) / 2020-07-07 (36)	50 (mg) / PRN/ ORAL	Yes
	SOLICITED HEADACHES NOTED IN DIARY	IBUPROFEN/ IBUPROFEN	C	2020-07-07 (36) / 2020-07-15 (44)	200 (mg) / PRN/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041077	GASTROESOPHAGEAL REFLUX DISEASE	DEXILANT/ DEXLANSOPRAZOLE	P/C/A	2010/ Ongoing	60 (mg) / QD/ ORAL	No
	POLYCYSTIC OVARY SYNDROME	METFORMIN/ METFORMIN	P/C/A	2010/ Ongoing	500 (mg) / QD/ ORAL	No
	CONTRACEPTIVE	MICRONOR/ NORETHISTERONE	P/C/A	2010/ Ongoing	0.35 (mg) / QD/ ORAL	No
	MIGRAINES	FIORICET/ BUTALBITAL;CAFFEINE;PARAC ETAMOL	P/C/A	2018/ Ongoing	(mg) / PRN/ ORAL	No
	DEPRESSION	CYMBALTA/ DULOXETINE HYDROCHLORIDE	P/C/A	2019-12/ Ongoing	60 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041088	IRON DEFICIENCY	IRON/ IRON	P/C/A	2019/ Ongoing	10.5 (mg) / QD/ ORAL	No
	ACNE (FACE)	MYORISAN/ ISOTRETINOIN	P/C/A	2019/ Ongoing	10 (mg) / QD/ ORAL	No
	SOLICITED SYMPTOMS-HEADACHE, FATIGUE, MUSCLE ACHES	IBUPROFEN/ IBUPROFEN	C	2020-07-11 (34) / 2020-07-11 (34)	600 (mg) / ONCE/ ORAL	Yes
US2041091	NUTRITIONAL SUPPLEMENT	VITAMIN D/ VITAMIN D NOS	P/C/A	2016/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041091	CONTRACEPTIVE	DESOGESTREL-ETHINYL ESTRADIOL/ DESOGESTREL;ETHINYLESTRAD IOL	P/C/A	2020-01/ Ongoing	(mg) / QD/ ORAL	No
US2041092	NUTRITIONAL SUPPLEMENT	VITAMIN B12/ VITAMIN B12 NOS	C/A	2020/ Ongoing	1 (TABLET) / PRN/ ORAL	No
	ANXIETY	ESCITALOPRAM/ ESCITALOPRAM	P/C/A	2020-02/ Ongoing	20 (mg) / QD/ ORAL	No
	HYPERTENSION	LISINOPRIL/ LISINOPRIL	C/A	2020-06-24 (17) / Ongoing	5 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051008	ANXIETY	FLUOXETINE/ FLUOXETINE	P/C/A	2018/ Ongoing	20 (mg) / QD/ ORAL	No
	HEALTH SUPPLEMENT	VITAMIN D3/ COLECALCIFEROL	P/C/A	2018/ Ongoing	5000 (IU) / QD/ ORAL	No
	HEADACHE	IBUPROFEN/ IBUPROFEN	P	2020-05-15 (-14) / 2020-05-15 (-14)	400 (mg) / ONCE/ ORAL	No
US2051009	HEADACHES	IBUPROFEN/ IBUPROFEN	P/C/A	1990-01-01 (-11110) / Ongoing	400 (mg) / PRN/ ORAL	No
	GENERAL MUSCLE PAIN	ALEVE/ NAPROXEN SODIUM	P/C/A	2008-01-01 (-4536) / Ongoing	440 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051009	SEASONAL ALLERGIES	CLARITIN/ LORATADINE	P/C/A	2010-01-01 (-3805) / Ongoing	10 (mg) / QD / ORAL	No
	ATTENTION DEFICIT DISORDER	ADDERALL/ AMFETAMINE ASPARTATE; AMFETAMINE SULFATE; DEXAMFETAMINE SACCHARATE; DEXAMFETAMINE SULFATE	P/C/A	2019-04-01 (-428) / Ongoing	30 (mg) / QD / ORAL	No
	ATTENTION DEFICIT DISORDER	ADDERALL/ AMFETAMINE ASPARTATE; AMFETAMINE SULFATE; DEXAMFETAMINE SACCHARATE; DEXAMFETAMINE SULFATE	P/C/A	2019-04-01 (-428) / Ongoing	10 (mg) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051009	DIETARY SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2020-01-01 (-153) / Ongoing	1 (TABLET) / QD/ ORAL	No
	ARM SORENESS PAIN AT INJECTION SITE LEFT ARM	IBUPROFEN/ IBUPROFEN	C	2020-06-06 (5) / 2020-06-06 (5)	200 (mg) / ONCE/ ORAL	Yes
	MUSCULOSKELETAL BACK PAIN	ALEVE/ NAPROXEN SODIUM	C	2020-07-05 (34) / 2020-07-05 (34)	440 (mg) / ONCE/ ORAL	No
US2051010	HEADACHE	TYLENOL/ PARACETAMOL	P	2020-05-25 (-8) / 2020-05-25 (-8)	650 (mg) / ONCE/ ORAL	No
	URINARY TRACT INFECTION	MACROBID/ NITROFURANTOIN	C	2020-06-14 (13) / 2020-06-19 (18)	100 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051010	URINARY TRACT INFECTION	CEPHALEXIN/ CEFALEXIN	C	2020-06-24 (23) / 2020-06-30 (29)	500 (mg) / QD/ ORAL	No
	CHILLS AND FEVER (ADVERSE REACTIONS)	TYLENOL/ PARACETAMOL	C	2020-07-01 (30) / 2020-07-01 (30)	1000 (mg) / PRN/ ORAL	Yes
	URINARY TRACT INFECTION	AMOXICILLIN/ AMOXICILLIN	C	2020-07-09 (38) / 2020-07-16 (45)	500 (mg) / BID/ ORAL	No
	URINARY TRACT INFECTION	AMOXICILLIN/ AMOXICILLIN	C/A	2020-07-17 (46) / 2020-08-23 (83)	500 (mg) / QD/ ORAL	No
US2051011	LUMBAR BACK PAIN	NAPROXEN/ NAPROXEN	P/C/A	1997-01-01 (-8554) / Ongoing	220 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051011	SEASONAL ALLERGIES	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2015-01-01 (-1980) / Ongoing	10 (mg) / QD / ORAL	No
	RAYNAUD'S SYNDROM	AMLODIPINE / AMLODIPINE	P/C/A	2018-01-01 (-884) / Ongoing	5 (mg) / PRN / ORAL	No
	ATTENTION DEFICIT HYPERACTIVITY DISORDER	ADDERALL XR / AMFETAMINE ASPARTATE; AMFETAMINE SULFATE; DEXAMFETAMINE SACCHARATE; DEXAMFETAMINE SULFATE	P/C/A	2019-01-01 (-519) / Ongoing	15 (mg) / QD / ORAL	No
US2051018	BIRTH CONTROL	MIRENA IUD / LEVONORGESTREL	P/C/A	2017-01-01 (-1254) / Ongoing	1 (OTHER: APPLIANCE) / No OTHER: 1 EVERY 5 YEARS / OTHER: INTRAUTERINE	

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051018	SUPPLEMENT	FISH OIL WITH VITAMIN D / FISH OIL; VITAMIN D NOS	P/C/A	2020-02 / Ongoing	1 (TABLET) / QD / ORAL	No
	DEPRESSION & ANXIETY	ZOLOFT / SERTRALINE HYDROCHLORIDE	P/C/A	2020-06-07 (-1) / Ongoing	50 (mg) / QD / ORAL	No
	HEADACHE	IBUPROFEN / IBUPROFEN	C	2020-07-08 (31) / 2020-07-08 (31)	200 (mg) / ONCE / ORAL	Yes
US2051027	SEASONAL ALLERGIES	FLONASE / FLUTICASONE PROPIONATE	P/C/A	2015-01-01 (-1985) / Ongoing	1 (OTHER: SPRAY) / PRN / NASAL	No
	BIRTH CONTROL	MIRENA / LEVONORGESTREL	P/C/A	2020-02-20 (-109) / Ongoing	1 (OTHER: DEVICE) / OTHER: EVERY 5 YEARS / OTHER: INTRAUTERINE	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051027	LEFT DELTOID AREA PAIN	IBUPROFEN/ IBUPROFEN	C	2020-06-08 (1) / 2020-06-08 (1)	400 (mg) / ONCE / ORAL	Yes
	INJECTION SITE PAIN, HEADACHE, JOINT ACHES, MUSCLE ACHES	IBUPROFEN/ IBUPROFEN	C	2020-07-07 (30) / 2020-07-09 (32)	200 (mg) / OTHER: EVERY 4 HOURS / ORAL	Yes
	INJECTION SITE PAIN, HEADACHE, JOINT ACHES, MUSCLE ACHES	TYLENOL/ PARACETAMOL	C	2020-07-07 (30) / 2020-07-09 (32)	500 (mg) / OTHER: EVERY 4 HOURS / ORAL	Yes
US2051031	OCCASIONAL HEADACHES	EXCEDRIN (ACETAMINOPHEN, ASPIRIN, CAFFEINE) / ACETYLSALICYLIC ACID; CAFFEINE; PARACETAMOL	P/C/A	2020-05-18 (-15) / Ongoing	2 (TABLET) / PRN / ORAL	No
	OCCASIONAL HEADACHES	TYLENOL/ PARACETAMOL	P/C/A	2020-05-26 (-7) / Ongoing	500 (mg) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051031	HEADACHE	EXCEDRIN (ACETAMINOPHEN, ASPIRIN, CAFFEINE) / ACETYLSALICYLIC ACID;CAFFEINE;PARACETAMOL	C	2020-06-09 (8) / 2020-06-09 (8)	2 (TABLET) / ONCE / ORAL	No
	VASECTOMY	CEPHALEXIN / CEFALEXIN	C	2020-06-12 (11) / 2020-06-14 (13)	500 (mg) / TID / ORAL	No
	HEADACHE	EXCEDRIN MIGRAINE / ACETYLSALICYLIC ACID;CAFFEINE;PARACETAMOL	C	2020-07-03 (32) / 2020-07-03 (32)	2 (TABLET) / QD / ORAL	Yes
US2051032	SUPPLEMENT	FISH OIL / FISH OIL	P/C/A	2016-01-01 (-1614) / Ongoing	400 (mg) / QD / ORAL	No
	SUPPLEMENT	MULTIVITAMIN / VITAMINS NOS	P/C/A	2016-01-01 (-1614) / Ongoing	1 (OTHER: GUMMY) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051032	BIRTH CONTROL	MIRENA/ LEVONORGESTREL	P/C/A	2019-04-01 (-428) / 2020-08	20 (ug) / QD/ OTHER: IMPLANT INTRAUTERINE	No
	DEPRESSION	PROZAC/ FLUOXETINE HYDROCHLORIDE	P/C/A	2019-04-01 (-428) / 2020-08	20 (mg) / QD/ ORAL	No
	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-06-06 (5) / 2020-06-06 (5)	1000 (mg) / ONCE/ ORAL	Yes
	RUNNY NOSE	DAYQUIL/ DEXTROMETHORPHAN HYDROBROMIDE;GUAIFENESIN; PARACETAMOL;PSEUDOEPHEDRI NE HYDROCHLORIDE	C	2020-06-26 (25) / 2020-07-02 (31)	1 (TABLET) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051033	DEPRESSION	BUPROPION/ BUPROPION	P/C/A	2000-01-01 (-7460) / Ongoing	300 (mg) / QD / ORAL	No
	ANXIETY	PROZAC/ FLUOXETINE HYDROCHLORIDE	P/C/A	2000-01-01 (-7460) / Ongoing	60 (mg) / QD / ORAL	No
	DIETARY SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2015-01-01 (-1981) / Ongoing	1 (TABLET) / QD / ORAL	No
	ANXIETY	KLONOPIN/ CLONAZEPAM	P/C/A	2019-07 / Ongoing	0.25 (mg) / PRN / ORAL	No
	PROPHYLAXIS HUMAN PAPILLOMAVIRUS	HUMAN PAPILLOMAVIRUS VACCINE #2 / HPV VACCINE	P	2020-05-07 (-28) / 2020-05-07 (-28)	1 (OTHER: INJECTION) / ONCE / INTRAMUSCULAR	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051033	HEADACHE, MUSCLE ACHES, JOINT ACHES, FEVER	TYLENOL/ PARACETAMOL	C	2020-07-08 (35) / 2020-07-12 (39)	1000 (mg) / TID / ORAL	Yes
US2051034	COLD AND COUGH DUE TO UPPER RESPIRATORY INFECTION	ALKA SELTZER PLUS COLD AND COUGH MAX (ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, PHEYLEPHRINE HYDROCHLORIDE) / CHLORPHENAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PARACETAMOL; PHENYLEPHRINE HYDROCHLORIDE	C	2020-06-09 (7) / 2020-06-15 (13)	2 (CAPSULE) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051038	BIRTH CONTROL	ESTARYLLA/ ETHINYLESTRADIOL;NORGESTI MATE	P/C/A	2016-02-01 (-1584) / Ongoing	1 (TABLET) / QD / ORAL	No
	HYPERHYDROSIS	GLYCOPYROLATE / GLYCOPYRRONIUM	P/C/A	2017-01-01 (-1249) / Ongoing	1 (mg) / QD / ORAL	No
US2051040	HEALTH MAINTENANCE	FISH OIL / FISH OIL	P/C/A	2010-01-01 (-3808) / Ongoing	1 (CAPSULE) / QD / ORAL	No
	HEALTH MAINTENANCE	IRON SUPPLEMENT / IRON	P/C/A	2010-01-01 (-3808) / Ongoing	65 (mg) / OTHER: 3 TIMES A WEEK / ORAL	No
	HEALTH MAINTENANCE	MULTIVITAMIN / VITAMINS NOS	P/C/A	2010-01-01 (-3808) / Ongoing	1 (TABLET) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051040	HEALTH MAINTENANCE	ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2019-08-01 (-309) / Ongoing	81 (mg) / QD/ ORAL	No
	SPRAINED ANKLE LEFT	IBUPROFEN/ IBUPROFEN	P/C	2020-06-01 (-4) / 2020-06-10 (6)	400 (mg) / OTHER: EVERY 4-6 HOURS/ ORAL	No
	CONTACT DERMATITIS (THIGHS, TRUNK, FOREARMS AND ANKLES)	CETIRIZINE-10/ CETIRIZINE	C	2020-06-21 (17) / 2020-06-25 (21)	1 (OTHER: APPLICATION) / PRN/ TOPICAL	No
US2051042	ECZEMA ELBOW	HYDROCORTIZONE CREAM/ HYDROCORTISONE	P/C/A	2019-12/ Ongoing	1 (OTHER: APPLICATION) / QD/ TOPICAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051042	HEADACHE	ASPIRIN/ ACETYLSALICYLIC ACID	P	2020-05-15 (-18) / 2020-05-15 (-18)	500 (mg) / QD/ ORAL	No
	TOOTHACHE	ASPIRIN/ ACETYLSALICYLIC ACID	C	2020-06-04 (3) / 2020-06-23 (22)	500 (mg) / EVERY WEEK/ ORAL	No
	ROOT CANAL	ASPIRIN/ ACETYLSALICYLIC ACID	C	2020-06-25 (24) / 2020-07-02 (31)	500 (mg) / PRN/ ORAL	No
	ROOT CANAL FOR TOOTHACHE	MEDROL DOSE PAK/ METHYLPREDNISOLONE	C	2020-07-01 (30) / 2020-07-01 (30)	24 (mg) / QD/ ORAL	No
	ROOT CANAL FOR TOOTHACHE	MEDROL DOSE PAK/ METHYLPREDNISOLONE	C	2020-07-02 (31) / 2020-07-02 (31)	20 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051042	ROOT CANAL TOOTH INFECTION	PENICILLIN/ PENICILLIN NOS	C	2020-07-02 (31) / 2020-07-15 (44)	500 (mg) / QID/ ORAL	No
	ROOT CANAL FOR TOOTHACHE	MEDROL DOSE PAK/ METHYLPREDNISOLONE	C	2020-07-03 (32) / 2020-07-03 (32)	16 (mg) / QD/ ORAL	No
	ROOT CANAL FOR TOOTHACHE	MEDROL DOSE PAK/ METHYLPREDNISOLONE	C	2020-07-04 (33) / 2020-07-04 (33)	12 (mg) / QD/ ORAL	No
	ROOT CANAL FOR TOOTHACHE	MEDROL DOSE PAK/ METHYLPREDNISOLONE	C	2020-07-05 (34) / 2020-07-05 (34)	8 (mg) / QD/ ORAL	No
	ROOT CANAL FOR TOOTHACHE	MEDROL DOSE PAK/ METHYLPREDNISOLONE	C	2020-07-06 (35) / 2020-07-06 (35)	4 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051042	TOOTHACHE	IBUPROFEN/ IBUPROFEN	C/A	2020-07-16 (45) / Ongoing	200 (mg) / QD/ ORAL	No
US2051048	HEALTH MAINTENANCE	HAIR SKIN NAILS SUPPLEMENT/ BIOTIN	P/C/A	2018/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEALTH MAINTENANCE	IRON/ IRON	P/C/A	2018/ Ongoing	65 (mg) / QD/ ORAL	No
	HEALTH MAINTENANCE	VITAMIN B12/ VITAMIN B12 NOS	P/C/A	2018/ Ongoing	1 (TABLET) / QD/ ORAL	No
US2061001	COMMON COLD	PHENYLEPHRINE/ PHENYLEPHRINE	C	2020-07-18 (45) / 2020-07-23 (50)	5 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061001	COMMON COLD	DEXTROMETHORPHAN/ DEXTROMETHORPHAN	C	2020-07-24 (51) / 2020-07-31 (58)	20 (mg) / QD/ ORAL	No
	COMMON COLD	GUAIFENESIN/ GUAIFENESIN	C	2020-07-24 (51) / 2020-07-31 (58)	200 (mg) / BID/ ORAL	No
US2061006	GASTROESOPHAGEAL REFLUX DISEASE	PEPCID AC/ FAMOTIDINE	P/C/A	2020-01-15 (-140) / Ongoing	40 (mg) / PRN/ ORAL	No
	PAIN AT INJECTION SITE	IBUPROFEN (ADVIL) / IBUPROFEN	C	2020-06-04 (2) / 2020-06-04 (2)	400 (mg) / ONCE/ ORAL	Yes
	TENDERNESS UNDERARM	IBUPROFEN/ IBUPROFEN	C	2020-07-01 (29) / 2020-07-02 (30)	400 (mg) / PRN/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.
WHODrug version: WHODrug-Global-B3 March 2020
[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061009	GASTROESOPHAGEAL REFLUX DISEASE	NEXIUM/ ESOMEPRAZOLE MAGNESIUM	P/C/A	2019-08/ Ongoing	20 (mg) / PRN/ ORAL	No
	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-07-08 (36) / 2020-07-08 (36)	400 (mg) / ONCE/ ORAL	Yes
	HEADACHE	ZZZQUIL (DIPHENHYDRAMINE HYDROCHLORIDE)) / DIPHENHYDRAMINE HYDROCHLORIDE	C	2020-07-08 (36) / 2020-07-08 (36)	5 (mL) / ONCE/ ORAL	Yes
US2061019	HEADACHES, RECURRENT	ADVIL/ IBUPROFEN	P/C/A	2000-01/ Ongoing	200 (mg) / PRN/ ORAL	No
	DEPRESSION	VIIBRYD/ VILAZODONE HYDROCHLORIDE	P/C	2020-04-01 (-63) / 2020-06-10 (8)	40 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061019	GASTROESOPHAGEAL REFLUX DISEASE	OMEPRAZOLE (PRILOSEC) / OMEPRAZOLE	P/C/A	2020-04-01 (-63) / Ongoing	20 (mg) / PRN / ORAL	No
	DEPRESSION	WELLBUTRIN / BUPROPION HYDROCHLORIDE	C	2020-06-11 (9) / 2020-07-01 (29)	150 (mg) / QD / ORAL	No
	GASTROESOPHAGEAL REFLUX DISEASE	ORAFATE / SUCRALFATE	C/A	2020-06-11 (9) / Ongoing	10 (mL) / QD / ORAL	No
	OBESITY	TOPIRAMATE (TOPAMAX) / TOPIRAMATE	C/A	2020-07-06 (34) / Ongoing	25 (mg) / QD / ORAL	No
	HEADACHE	ADVIL / IBUPROFEN	C	2020-07-07 (35) / 2020-07-07 (35)	200 (mg) / PRN / ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061026	SEIZURES	VIMPAT/ LACOSAMIDE	P/C/A	2000-01-15 (-7447) / Ongoing	100 (mg) / BID / ORAL	No
	NUTRITIONAL SUPPLEMENT	CALCIUM/MAGNESIUM/ZINC/ CALCIUM;MAGNESIUM;ZINC	P/C/A	2016-06/ Ongoing	1 (CAPSULE) / QD / ORAL	No
	NUTRITIONAL SUPPLEMENT	FISH OIL/ FISH OIL	P/C/A	2019-06/ Ongoing	360 (mg) / QD / ORAL	No
	NUTRITIONAL SUPPLEMENT	KYOLIC/ ALLIUM SATIVUM	P/C/A	2019-06/ Ongoing	1 (CAPSULE) / QD / ORAL	No
	NUTRITIONAL SUPPLEMENT	MEN'S MULTIVITAMIN/ VITAMINS NOS	P/C/A	2019-06/ Ongoing	1 (OTHER: GUMMY) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061026	SEIZURES	KEPPRA XR (LEVETIRACETAM) / LEVETIRACETAM	P/C/A	2019-09/ Ongoing	500 (mg) / BID/ ORAL	No
US2071001	CONTRACEPTION	LEVONORGESTREL / LEVONORGESTREL	P/C/A	2016-09/ Ongoing	20 (ug) / QD/ OTHER: INTRAUTERINE	No
	HEADACHE	ACETAMINOPHEN / PARACETAMOL	C	2020-05-31 (3) / 2020-05-31 (3)	325 (mg) / PRN/ ORAL	Yes
	HEADACHE	ACETAMINOPHEN / PARACETAMOL	C	2020-07-02 (35) / 2020-07-05 (38)	500 (mg) / PRN/ ORAL	Yes
	PAIN AT INJECTION SITE	ACETAMINOPHEN / PARACETAMOL	C	2020-07-02 (35) / 2020-07-05 (38)	500 (mg) / PRN/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071003	HYPOTHYROIDISM	SYNTHROID/ LEVOTHYROXINE SODIUM	P/C/A	2010/ Ongoing	150 (ug) / QD/ ORAL	No
	ANXIETY	XANAX/ ALPRAZOLAM	P/C/A	2010/ Ongoing	0.5 (mg) / QD/ ORAL	No
	EDEMA BILATERAL LEGS	MAXZIDE/ HYDROCHLOROTHIAZIDE; TRIAM TERENE	P/C/A	2015/ Ongoing	(mg) / QD/ ORAL	No
	ATTENTION DEFICIT HYPERACTIVITY DISORDER	ADDERALL/ AMFETAMINE ASPARTATE; AMFETAMINE SULFATE; DEXAMFETAMINE SACCHARATE; DEXAMFETAMINE SULFATE	P/C/A	2017/ Ongoing	30 (mg) / BID/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071003	CHRONIC CONSTIPATION	LINZESS/ LINACLOTIDE	P/C/A	2017/ Ongoing	290 (ug) / QD/ ORAL	No
	PAIN AT INJECTION SITE	TYLENOL/ PARACETAMOL	C	2020-06-02 (2) / 2020-06-02 (2)	500 (mg) / ONCE/ ORAL	Yes
	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-07-01 (31) / 2020-07-01 (31)	500 (mg) / ONCE/ ORAL	Yes
US2071004	GENERALIZED ANXIETY	CONCERTA/ METHYLPHENIDATE HYDROCHLORIDE	P/C/A	2019-03/ Ongoing	27 (mg) / QD/ ORAL	No
	PAIN AT INJECTION SITE	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-09 (36) / 2020-07-09 (36)	500 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071004	HEADACHE	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-13 (40) / 2020-07-15 (42)	500 (mg) / PRN/ ORAL	Yes
US2071030	CONTRACEPTION	LILETTA/ LEVONORGESTREL	P/C/A	2019-05/ Ongoing	52 (mg) / QD/ VAGINAL	No
	PAIN AT INJECTION SITE	ACETAMINOPHEN/ PARACETAMOL	C	2020-06-13 (11) / 2020-06-18 (16)	325 (mg) / PRN/ ORAL	No
	PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-06-13 (11) / 2020-06-18 (16)	400 (mg) / PRN/ ORAL	No
	PAIN AT INJECTION SITE AND FEVER	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-07 (35) / 2020-07-08 (36)	325 (mg) / PRN/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071030	PAIN AT INJECTION SITE AND FEVER	IBUPROFEN/ IBUPROFEN	C	2020-07-07 (35) / 2020-07-08 (36)	400 (mg) / PRN/ ORAL	Yes
US2071067	CONTRACEPTION	MIRENA/ LEVONORGESTREL	P/C/A	2018/ Ongoing	20 (ug) / QD/ OTHER: INTRAUTERINE	No
	PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-06-08 (4) / 2020-06-08 (4)	400 (mg) / ONCE/ ORAL	Yes
	FEVER	IBUPROFEN/ IBUPROFEN	C	2020-07-09 (35) / 2020-07-09 (35)	400 (mg) / PRN/ ORAL	Yes
	HEADACHES	IBUPROFEN/ IBUPROFEN	C	2020-07-09 (35) / 2020-07-11 (37)	400 (mg) / PRN/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071067	GENERALIZED MUSCLE ACHES	IBUPROFEN/ IBUPROFEN	C	2020-07-09 (35) / 2020-07-11 (37)	400 (mg) / PRN/ ORAL	Yes
US2071081	PAIN AT INJECTION SITE	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-08 (31) / 2020-07-08 (31)	500 (mg) / PRN/ ORAL	Yes
US2081036	MIGRAINES	IMITREX/ SUMATRIPTAN	P/C/A	2000/ Ongoing	50 (mg) / PRN/ ORAL	No
	ALLERGIC RHINITIS	FLONASE/ FLUTICASONE PROPIONATE	P/C/A	2020-02/ Ongoing	50 (ug) / QD/ NASAL	No
	ALLERGIC RHINITIS	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2020-02/ Ongoing	25 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081036	DAY 2 TO TREAT HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-06-05 (2) / 2020-06-05 (2)	600 (mg) / PRN / ORAL	Yes
	DAY 2 JOINT ACHES	IBUPROFEN/ IBUPROFEN	C	2020-07-10 (37) / 2020-07-10 (37)	600 (mg) / ONCE / ORAL	Yes
US2081039	ATTENTION DEFICIT DISORDER	ADDERALL EXTENDED RELEASE / AMFETAMINE ASPARTATE; AMFETAMINE SULFATE; DEXAMFETAMINE SACCHARATE; DEXAMFETAMINE SULFATE	P/C/A	2017-05 / Ongoing	20 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081039	ATTENTION DEFICIT DISORDER	ADDERALL INSTANT RELEASE/ AMFETAMINE ASPARTATE;AMFETAMINE SULFATE;DEXAMFETAMINE SACCHARATE;DEXAMFETAMINE SULFATE	P/C/A	2017-05/ Ongoing	20 (mg) / QD/ ORAL	No
	BIRTH CONTROL	KYLEENA [LEVONORGESTREL] / LEVONORGESTREL	P/C/A	2018-08/ Ongoing	19.5 (mg) / OTHER: EVERY 5 YEARS/ OTHER: INTRAUTERINE	No
	SUPPLEMENT	MELATONIN/ MELATONIN	P/C/A	2020-03/ Ongoing	3 (mg) / PRN/ ORAL	No
	HEADACHE	ADVIL [IBUPROFEN] / IBUPROFEN	C	2020-06-08 (1) / 2020-06-10 (3)	200 (mg) / QD/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081039	PAIN AT INJECTION SITE	ADVIL/ IBUPROFEN	C	2020-07-09 (32) / 2020-07-09 (32)	400 (mg) / ONCE / ORAL	Yes
US2081052	DEPRESSION	WELLBUTRIN/ BUPROPION HYDROCHLORIDE	P/C/A	2015/ Ongoing	300 (mg) / QD / ORAL	No
	SEASONAL ALLERGIES	SINGULAIR/ MONTELUKAST SODIUM	P/C/A	2019/ Ongoing	10 (mg) / PRN / ORAL	No
US2081059	FEVER	IBUPROFEN/ IBUPROFEN	C	2020-07-14 (37) / 2020-07-14 (37)	400 (mg) / ONCE / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011039	SEASONAL ALLERGIES, UNSPECIFIED	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2010/ Ongoing	10 (mg) / PRN/ ORAL	No
	SEASONAL ALLERGIES	ADVIL COLD & SINUS (IBUPROFEN, PSEUDOEPHEDRINE HCL) / IBUPROFEN;PSEUDOEPHEDRINE HYDROCHLORIDE	C	2020-06-27 (27) / 2020-06-27 (27)	(mg) / ONCE/ ORAL	No
	MUSCLE ACHES/HEADACHE (SOLICITED SYMPTOMS)	TYLENOL/ PARACETAMOL	C	2020-06-30 (30) / 2020-06-30 (30)	500 (mg) / BID/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011046	BIRTH CONTROL	JUNEL-FE (NORETHINDRONE ACETATE 1MG, ETHINYL ESTRADIOL 20UG) / ETHINYLESTRADIOL; FERROUS FUMARATE; NORETHISTERONE ACETATE	P/C/A	2016-01-01 (-1614) / Ongoing	(OTHER: MG/UG) / QD / ORAL	No
	GENERAL ANXIETY	FLUOXETINE / FLUOXETINE	P/C/A	2017-07-01 (-1067) / Ongoing	20 (mg) / QD / ORAL	No
	BIRTH CONTROL	SKYLA IUD / LEVONORGESTREL	P/C/A	2018-12 / Ongoing	1 (OTHER: DEVICE) / OTHER: EVERY 3 YEARS / OTHER: INTRAUTERINE	No
	GENERAL ANXIETY	LAMOTRIGINE / LAMOTRIGINE	P/C/A	2019-05-01 (-398) / Ongoing	200 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011065	TENSION/SINUS HEADACHES	IBUPROFEN/ IBUPROFEN	P/C/A	1990/ Ongoing	400 (mg) / PRN/ ORAL	No
	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-06-03 (2) / 2020-06-05 (4)	1000 (mg) / QD/ ORAL	Yes
	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-07-01 (30) / 2020-07-05 (34)	1000 (mg) / BID/ ORAL	Yes
US2011080	BIRTH CONTROL	JUNEL-FE (NORETHINDRONE ACETATE, ETHINYL ESTRADIOL) / ETHINYLESTRADIOL; FERROUS FUMARATE; NORETHISTERONE ACETATE	P/C/A	2018-02-01 (-853) / Ongoing	(OTHER: MG / UG) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011080	ACID REFLUX	PANTOPRAZOLE/ PANTOPRAZOLE	P/C/A	2019-04-01 (-429) / Ongoing	40 (mg) / QD/ ORAL	No
	HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-06-09 (7) / 2020-06-09 (7)	800 (mg) / ONCE/ ORAL	Yes
	INJECTION SITE PAIN	IBUPROFEN/ IBUPROFEN	C	2020-07-02 (30) / 2020-07-04 (32)	800 (mg) / QD/ ORAL	Yes
US2011085	BIRTH CONTROL	MURINA/ LEVONORGESTREL	P/C/A	2015/ Ongoing	(OTHER: IUD) / OTHER: CONTINUOUS DOSING/ VAGINAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011089	HEADACHES	IBUPROFEN/ IBUPROFEN	P/C/A	2006/ Ongoing	400 (mg) / PRN/ ORAL	No
	CONTRACEPTION	BLISOVI (NORETHINDRONE ACETATE, ETHINYL ESTRADIOL) / ETHINYLESTRADIOL; NORETHIS TERONE ACETATE	P/C/A	2018/ Ongoing	(OTHER: MG (MG / UG)) / No QD/ ORAL	No
	SEASONAL ALLERGIES	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2019/ Ongoing	10 (mg) / PRN/ ORAL	No
	HEADACHE (AE #1)	IBUPROFEN/ IBUPROFEN	C	2020-06-27 (23) / 2020-06-30 (26)	400 (mg) / QD/ ORAL	No
	HEADACHE (AE #1)	ACETAMINOPHEN/ PARACETAMOL	C/A	2020-06-28 (24) / Ongoing	1000 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011089	PAIN AT INJECTION SITE / HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-07-11 (37) / 2020-07-12 (38)	400 (mg) / QD/ ORAL	Yes
US2021063	ANXIETY	CLONAZEPAM/ CLONAZEPAM	P/C/A	2009/ Ongoing	1 (mg) / QD/ ORAL	No
	BIRTH CONTROL	CRYSSELLE BIRTH CONTROL PILLS NORGESTREL AND ETHINYL ESTRADIOL/ ETHINYLESTRADIOL;NORGESTR EL	P/C/A	2009/ Ongoing	(mg) / QD/ ORAL	No
	ANXIETY	SERTRALINE/ SERTRALINE	P/C/A	2012/ Ongoing	50 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021063	BODY ACHES ALL OVER	NAPROXEN/ NAPROXEN	C	2020-07-08 (35) / 2020-07-08 (35)	500 (mg) / ONCE / ORAL	Yes
	FEVER	NAPROXEN/ NAPROXEN	C	2020-07-08 (35) / 2020-07-09 (36)	500 (mg) / QD / ORAL	Yes
	MUSCLE ACHES ALL OVER BODY	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-11 (38) / 2020-07-11 (38)	325 (mg) / ONCE / ORAL	Yes
US2021068	ACQUIRED HYPOGONADISM	TESTOSTERONE CYPIONATE/ TESTOSTERONE CIPIONATE	P/C/A	2020-02-10 (-113) / Ongoing	200 (mg) / OTHER: EVERY 2 WEEKS / INTRAMUSCULAR	No
US2021074	ACNE FACE	DOXYCYCLIN/ DOXYCYCLINE	P/C/A	2019 / Ongoing	100 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021074	BIRTH CONTROL	JUNEL/ ETHINYLESTRADIOL;NORETHIS TERONE ACETATE	P/C/A	2020-02/ Ongoing	(ug) / QD/ ORAL	No
	ACNE FACE	SPIRONOLACTONE/ SPIRONOLACTONE	P/C/A	2020-02/ Ongoing	50 (mg) / QD/ ORAL	No
	PAIN AT INJECTION SITE	ACETAMINOPHEN/ PARACETAMOL	C	2020-06-03 (2) / 2020-06-04 (3)	500 (mg) / QD/ ORAL	Yes
	FATIGUE	NAPROXEN/ NAPROXEN	C	2020-07-08 (37) / 2020-07-09 (38)	500 (mg) / QD/ ORAL	Yes
US2021080	HERPES SIMPLEX 2	ACYCLOVIR/ ACICLOVIR	P/C/A	2014/ Ongoing	250 (mg) / BID/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021080	SEASONAL ALLERGIES	IBUPROFEN/ IBUPROFEN	P/C/A	2020-05/ Ongoing	400 (mg) / QD/ ORAL	No
	HEADACHE	IBUPROFEN/ IBUPROFEN	C/A	2020-07-08 (34) / Ongoing	400 (mg) / QD/ ORAL	Yes
US2021093	BIRTH CONTROL	LO-LOESTRIN/ ETHINYLESTRADIOL; FERROUS FUMARATE; NORETHISTERONE ACETATE	P/C/A	2019/ Ongoing	(OTHER: MG/MCG) / QD/ ORAL	No
	FATIGUE	ADVIL/ IBUPROFEN	C	2020-07-07 (35) / 2020-07-08 (36)	200 (mg) / QD/ ORAL	Yes
	MUSCLE ACHES ALL OVER	TYLENOL/ PARACETAMOL	C	2020-07-07 (35) / 2020-07-08 (36)	500 (mg) / QD/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021099	HERPES LABIALIS	VALCYCLOVIV/ VALACICLOVIR	P/C/A	1996/ Ongoing	2 (g) / BID/ ORAL	No
US2021101	PAIN AT THE INJECTION SITE	TYLENOL/ PARACETAMOL	C	2020-06-08 (1) / 2020-06-08 (1)	500 (mg) / ONCE/ ORAL	Yes
	PAIN AT INJECTION SITE	TYLENOL/ PARACETAMOL	C	2020-06-20 (13) / 2020-06-20 (13)	500 (mg) / ONCE/ ORAL	Yes
	MUSCLE ACHES ALL OVER	TYLENOL/ PARACETAMOL	C	2020-07-09 (32) / 2020-07-10 (33)	500 (mg) / TID/ ORAL	Yes
	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-07-14 (37) / 2020-07-14 (37)	500 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021121	PAIN AT INJECTION SITE	TYLENOL/ PARACETAMOL	C	2020-07-01 (29) / 2020-07-02 (30)	500 (mg) / QD/ ORAL	Yes
US2021145	BIRTH CONTROL	TRI SPRINTec/ ETHINYLESTRADIOL;NORGESTI MATE	P/C/A	2004/ Ongoing	(mg) / QD/ ORAL	No
	GASTROESOPHAGEAL REFLUX DISEASE	OMEPRazole/ OMEPRazole	P/C/A	2013/ Ongoing	40 (mg) / QD/ ORAL	No
	SEVERE MENSTRUAL CRAMPS	NAPROXEN SODIUM/ NAPROXEN SODIUM	P/C/A	2019/ Ongoing	550 (mg) / PRN/ ORAL	No
	ELEVATED TEMPERATURE	IBUPROFEN/ IBUPROFEN	C	2020-07-11 (38) / 2020-07-11 (38)	200 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021151	ATTENTION DEFICIT DISORDER	VYVANSE/ LISDEXAMFETAMINE MESILATE	P/C/A	2004/ Ongoing	70 (mg) / QD/ ORAL	No
	HORMONE REPLACEMENT / HYSTERECTOMY	ESTRADIOL/ ESTRADIOL	P/C/A	2015/ Ongoing	2 (mg) / QD/ ORAL	No
	ANXIETY	LEXAPRO/ ESCITALOPRAM OXALATE	P/C/A	2018/ Ongoing	20 (mg) / QD/ ORAL	No
	FEVER	TYLENOL/ PARACETAMOL	C	2020-07-10 (33) / 2020-07-10 (33)	1000 (mg) / QD/ ORAL	Yes
US2021154	ATTENTION DEFICIT HYPERACTIVITY DISORDER	METHYLPHENIDATE/ METHYLPHENIDATE	P/C/A	2009/ Ongoing	54 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021154	SEASONAL ALLERGIES	CETIRIZINE HYDROCHLORIDE/ CETIRIZINE HYDROCHLORIDE	P/C/A	2010 / Ongoing	10 (mg) / PRN / ORAL	No
	HEADACHE	IBUPROFEN / IBUPROFEN	C	2020-06-06 (2) / 2020-06-07 (3)	400 (mg) / QD / ORAL	Yes
	BUG BITE BOTH ARMS	DEXAMETHASONE / DEXAMETHASONE	C	2020-06-24 (20) / 2020-06-24 (20)	6 (mg) / ONCE / INTRAMUSCULAR	No
	BUG BITE BOTH ARMS	PREDNISONE / PREDNISONE	C	2020-06-24 (20) / 2020-06-28 (24)	10 (mg) / BID / ORAL	No
	BUG BITE BOTH ARMS	TRIAMCINOLONE ACETONIDE CREAM / TRIAMCINOLONE ACETONIDE	C	2020-06-24 (20) / 2020-06-28 (24)	1 (OTHER: APPLICATION) / BID / TOPICAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021154	HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-07-08 (34) / 2020-07-13 (39)	400 (mg) / TID/ ORAL	Yes
US2021164	BIRTH CONTROL	LOW-OGESTREL/ ETHINYLESTRADIOL;NORGESTR EL	P/C/A	2016-09-09 (-1368) / Ongoing	(mg) / QD/ ORAL	No
	UNDERARM TENDERNESS	ALEVE/ NAPROXEN SODIUM	C	2020-06-09 (2) / 2020-06-16 (9)	200 (mg) / QD/ ORAL	Yes
	WORSENING OF ACNE AROUND MOUTH	DOXYCYCLINE/ DOXYCYCLINE	C	2020-06-10 (3) / 2020-06-28 (21)	100 (mg) / QD/ ORAL	No
	WORSENING OF ACNE AROUND MOUTH	SPIRONOLACTONE/ SPIRONOLACTONE	C/A	2020-06-10 (3) / Ongoing	50 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021164	HEADACHE	ADVIL/ IBUPROFEN	C	2020-07-08 (31) / 2020-07-14 (37)	200 (mg) / QD/ ORAL	Yes
US2021180	FEVER	ACTEAMINOPHEN/ PARACETAMOL	C	2020-07-09 (32) / 2020-07-09 (32)	500 (mg) / BID/ ORAL	Yes
	FEVER	IBUPROFEN/ IBUPROFEN	C	2020-07-09 (32) / 2020-07-09 (32)	400 (mg) / BID/ ORAL	Yes
	BRUISING RIGHT POSTERIOR HAMSTRING	IBUPROFEN/ IBUPROFEN	C	2020-07-14 (37) / 2020-07-14 (37)	400 (mg) / ONCE/ ORAL	No
	BACK STRAIN	IBUPROFEN/ IBUPROFEN	C	2020-07-30 (53) / 2020-08-01 (55)	800 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021182	BIRTH CONTROL	ETONOGESTREL/ETHINYL ESTRADIOL/ ETHINYLESTRADIOL;ETONOGES TREL	P/C/A	2018/ Ongoing	(mg) / OTHER: EVERY 21 DAYS/ VAGINAL	No
	PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-08 (31) / 2020-07-09 (32)	400 (mg) / QD/ ORAL	Yes
US2031012	BIRTH CONTROL	SPRINTEC/ ETHINYLESTRADIOL;NORGESTI MATE	P/C/A	2015/ Ongoing	1 (TABLET) / QD/ ORAL	No
US2031013	SEASONAL ALLERGIES	LORATADINE/ LORATADINE	P/C/A	2010/ Ongoing	10 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031013	CONTRACEPTION	ESTARYLLA/ ETHINYLESTRADIOL;NORGESTI MATE	P/C/A	2013/ Ongoing	(mg) / QD/ ORAL	No
	INJECTION SITE PAIN	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-01 (30) / 2020-07-05 (34)	1000 (mg) / PRN/ ORAL	Yes
	INJECTION SITE PAIN	IBUPROFEN/ IBUPROFEN	C	2020-07-01 (30) / 2020-07-05 (34)	400 (mg) / PRN/ ORAL	Yes
US2031019	NUTRITIONAL SUPPLEMENT	CHROMIUM PICOLINATE/ CHROMIUM PICOLINATE	P/C/A	2019/ Ongoing	0.8 (mg) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	MULTI VITAMIN/ VITAMINS NOS	P/C/A	2019/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031019	NUTRITIONAL SUPPLEMENT	PROBIOTIC/ PROBIOTICS NOS	P/C/A	2019/ Ongoing	1 (TABLET) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	VITAMIN D3/ COLECALCIFEROL	P/C/A	2019/ Ongoing	0.025 (mg) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	FISH OIL/ FISH OIL	P/C/A	2020-01/ Ongoing	1000 (mg) / QD/ ORAL	No
US2031026	DEPRESSION	LEXAPRO/ ESCITALOPRAM OXALATE	P/C/A	2017/ Ongoing	10 (mg) / QD/ ORAL	No
	INJECTION SITE PAIN	ACETAMINOPHEN/ PARACETAMOL	C	2020-05-30 (2) / 2020-05-31 (3)	1000 (mg) / PRN/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031035	POLYSISTE OVARIAN SYNDROME	PROMETRIUM/ PROGESTERONE	P/C/A	2018/ Ongoing	200 (mg) / PRN/ ORAL	No
	MUSCLE ACHES/ JOINT PAIN	IBUPROFEN/ IBUPROFEN	C	2020-06-30 (30) / 2020-07-03 (33)	400 (mg) / PRN/ ORAL	Yes
	MUSCLE ACHES/ JOINT PAIN	TYLONOL/ PARACETAMOL	C	2020-06-30 (30) / 2020-07-03 (33)	1000 (mg) / PRN/ ORAL	Yes
	HEADACHE	IBUPROFEN/ IBUPROFEN	C/A	2020-07-27 (57) / Ongoing	400 (mg) / PRN/ ORAL	No
US2031037	INJECTION SITE PAIN	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-01 (30) / 2020-07-04 (33)	1000 (mg) / PRN/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031047	FEVER	ACETAMINOPHEN/ PARACETAMOL	C	2020-06-30 (30) / 2020-07-01 (31)	650 (mg) / PRN/ ORAL	Yes
US2031050	MYALGIA, FEVER, ARTHRALGIA	IBUPROFEN/ IBUPROFEN	C	2020-07-02 (30) / 2020-07-04 (32)	400 (mg) / PRN/ ORAL	Yes
US2031060	INJECTION SITE PAIN	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-03 (30) / 2020-07-05 (32)	1000 (mg) / PRN/ ORAL	Yes
US2031062	ANXIETY	LEXAPRO/ ESCITALOPRAM OXALATE	P/C/A	2018/ Ongoing	10 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031062	CONTRACEPTION	LOLOESTRIN FE/ ETHINYLESTRADIOL; FERROUS FUMARATE; NORETHISTERONE ACETATE	P/C/A	2018/ Ongoing	1 (TABLET) / QD/ ORAL	No
US2031073	PAIN AT INJECTION SITE	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-03 (32) / 2020-07-03 (32)	1000 (mg) / QD/ ORAL	Yes
US2031079	CONTRACEPTION	PARAGARD/ INTRAUTERINE CONTRACEPTIVE DEVICE	P/C/A	2019/ Ongoing	(OTHER: NA) / OTHER: CONTINUOUS/ VAGINAL	No
	CHRONIC BACK PAIN	OXYCODONE/ACETAMINOPHEN/ OXYCODONE HYDROCHLORIDE; PARACETAMOL	P/C/A	2020-02/ Ongoing	(mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031079	INJECTION SITE PAIN	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-03 (30) / 2020-07-03 (30)	1000 (mg) / PRN/ ORAL	Yes
	ADVERSE EVENT: WORSENING OF DEPRESSION	BUSPIRONE/ BUSPIRONE	A	2020-07-31 (58) / Ongoing	15 (mg) / BID/ ORAL	No
	ADVERSE EVENT: WORSENING OF DEPRESSION	VIIIBRYD/ VILAZODONE HYDROCHLORIDE	A	2020-07-31 (58) / Ongoing	10 (mg) / QD/ ORAL	No
US2031084	INJECTION SITE PAIN	TYLENOL/ PARACETAMOL	C	2020-06-11 (2) / 2020-06-11 (2)	350 (mg) / PRN/ ORAL	Yes
US2041008	MEDICAL HISTORY - SEASONAL ALLERGIES	CLARITIN/ LORATADINE	P/C/A	2018/ Ongoing	10 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041008	MEDICAL HISTORY - SEASONAL ALLERGIES	FLONASE/ FLUTICASONE PROPIONATE	P/C/A	2018/ Ongoing	1 (OTHER: SPRAY) / QD/ NASAL	No
	SOLICITED SYMPTOMS-PAIN AT INJECTION SITE	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-02 (32) / 2020-07-03 (33)	500 (mg) / PRN/ ORAL	Yes
US2041010	MEDICAL HISOTRY - ANXIETY	BUPROPRION SR/ BUPROPION	P/C/A	2002-10/ Ongoing	200 (mg) / BID/ ORAL	No
	PROPHYLAXIS	FIBERWELL GUMMIES/ FIBRE, DIETARY	P/C/A	2017-11/ Ongoing	5 (mg) / QD/ ORAL	No
	MEDICAL HISTORY - ATTENTION DEFICIT DISORDER	CONCERTA ER/ METHYLPHENIDATE HYDROCHLORIDE	P/C/A	2019-05/ Ongoing	27 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041010	SOLICITED EVENT-HEADACHE AND GENERALIZED BODY ACHES	TYLENOL/ PARACETAMOL	C	2020-06-29 (32) / 2020-06-30 (33)	500 (mg) / QD/ ORAL	Yes
US2041024	MEDICAL HISTORY - SEASONAL ALLERGIES	NASACORT/ TRIAMCINOLONE ACETONIDE	P/C/A	2015/ Ongoing	220 (ug) / PRN/ NASAL	No
	CARDIAC PROPHYLAXIS	ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2019/ Ongoing	81 (mg) / PRN/ ORAL	No
	SOLICITED SYMPTOMS-JOINT AND BODY ACHES, PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-02 (30) / 2020-07-02 (30)	600 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041024	SOLICITED SYMPTOMS-FEVER, JOINT AND BODY ACHES, FATIGUE, HEADACHE, CHILLS	ASPIRIN/ ACETYLSALICYLIC ACID	C	2020-07-02 (30) / 2020-07-04 (32)	325 (mg) / QD/ ORAL	Yes
US2041026	OTHER - NUTRITIONAL SUPPLEMENT	VITAMIN D AND C/ ASCORBIC ACID;VITAMIN D NOS	P/C/A	2019/ Ongoing	1 (TABLET) / QD/ ORAL	No
US2041041	ANXIETY	ALPRAZOLAM/ ALPRAZOLAM	P/C/A	2020-03-13 (-80) / Ongoing	0.5 (mg) / BID/ ORAL	No
US2041046	BACK PAIN	IBUPROFEN/ IBUPROFEN	P/C/A	2015/ Ongoing	800 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041046	DEPRESSION	CITOLOPRAM/ CITALOPRAM	P/C/A	2016/ Ongoing	20 (mg) / QD/ ORAL	No
US2041048	ANXIETY	BUSIPRONE/ BUSPIRONE	P/C/A	2018-12/ Ongoing	7.5 (mg) / QD/ ORAL	No
	ANXIETY AND DEPRESSION	FETZIMA/ LEVOMILNACIPRAN HYDROCHLORIDE	P/C/A	2018-12/ Ongoing	80 (mg) / QD/ ORAL	No
	CONTRACEPTION	ESTARYLLA/ ETHINYLESTRADIOL;NORGESTI MATE	P/C/A	2020-01/ Ongoing	(mg) / QD/ ORAL	No
	SOLICITED EVENT-MUSCLE AND JOINT ACHES, FATIGUE, HEADACHE	IBURPOFEN/ IBUPROFEN	C	2020-07-02 (31) / 2020-07-02 (31)	800 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041048	SOLICITED EVENT-JOINT AND MUSCLE ACHES, HEADACHE, FATIGUE	IBUPROFEN/ IBUPROFEN	C	2020-07-02 (31) / 2020-07-03 (32)	400 (mg) / PRN/ ORAL	Yes
US2041060	SOLICITED SYMPTOM-UNDER ARM SWELLING/ PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-06-02 (1) / 2020-06-03 (2)	400 (mg) / PRN/ ORAL	Yes
	SOLICITED SYMPTOM-UNDER ARM SWELLING/ PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-01 (30) / 2020-07-02 (31)	400 (mg) / PRN/ ORAL	Yes
US2041061	GENERAL OSTEOARTHRITIS	GABAPENTIN/ GABAPENTIN	P/C/A	2019/ Ongoing	300 (mg) / TID/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041061	GENERAL HEALTH	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2019/ Ongoing	1 (TABLET) / QD/ ORAL	No
	URINARY TRACT INFECTION	METRONIDAZOLE/ METRONIDAZOLE	C	2020-07-06 (35) / 2020-07-16 (45)	500 (mg) / BID/ ORAL	No
US2041073	CHRONIC LOW BACK PAIN	HYDROCODONE ACTAMINOPHEN/ HYDROCODONE; PARACETAMOL	P/C/A	2014/ Ongoing	(mg) / PRN/ ORAL	No
	PREMENSTRAUL DYSPHORIC DISORDER	SERTRALINE/ SERTRALINE	P/C/A	2015/ Ongoing	150 (mg) / QD/ ORAL	No
	RESTLESS LEG SYNDROME	GABAPENTIN/ GABAPENTIN	P/C/A	2016/ Ongoing	500 (mg) / BID/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041079	INSOMNIA	TRAZODONE/ TRAZODONE	P/C/A	2012/ Ongoing	100 (mg) / QD/ ORAL	No
	CONTRACEPTIVE	MIRENA/ LEVONORGESTREL	P/C/A	2017-04/ Ongoing	1 (OTHER: DEVICE) / OTHER: EVERY 5 YEARS / OTHER: INTRAUTERINE	No
	SOLICITED SYMPTOMS-MUSCLE ACHES AND FATIGUE	IBUPROFEN/ IBUPROFEN	C	2020-07-08 (36) / 2020-07-09 (37)	220 (mg) / OTHER: Q4HOURS / ORAL	Yes
US2041080	CONTRACEPTION	LEVONORGESTREL/ LEVONORGESTREL	P/C/A	2017/ Ongoing	52 (mg) / OTHER: Q5YEARS / OTHER: INTRAUTERINE	No
	MUSCLES ACHES-SOLICITED EVENT	IBUPROFEN/ IBUPROFEN	C	2020-07-02 (30) / 2020-07-03 (31)	400 (mg) / PRN / ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041084	ACNE (FACE)	SPIVONLACTONE/ SPIRONOLACTONE	P/C/A	1998/ Ongoing	25 (mg) / QD/ ORAL	No
	FIBROMYALGIA	NALTREXONE/ NALTREXONE	P/C/A	2016/ Ongoing	50 (mg) / QD/ ORAL	No
	FAMILIAL HYPERCHOLESTEROLEMIA	EZETIMIBE/ EZETIMIBE	C/A	2020-06-11 (8) / Ongoing	10 (mg) / QD/ ORAL	No
	SOLICITED SYMPTOM/ PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-03 (30) / 2020-07-04 (31)	200 (mg) / QD/ ORAL	Yes
US2051001	FEVER	TYLENOL/ PARACETAMOL	C	2020-07-02 (29) / 2020-07-03 (30)	500 (mg) / QD/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051002	HEALTH SUPPLEMENT	ELEMENTAL IRON (FERROUS GLUCONATE) / FERROUS GLUCONATE	P/C/A	2015/ Ongoing	29 (mg) / QD/ ORAL	No
	HEALTH SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2015/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEALTH SUPPLEMENT	VITAMIN D 3/ COLECALCIFEROL	P/C/A	2015/ Ongoing	2000 (IU) / QD/ ORAL	No
	HEALTH SUPPLEMENT	PRENATAL + DHA + IRON/ MINERALS NOS; VITAMINS NOS	P/C/A	2020-05-31 (-2) / Ongoing	1 (TABLET) / QD/ ORAL	No
	CONSTIPATION	MAGNESIUM/ MAGNESIUM	P	2020-06-01 (-1) / 2020-06-01 (-1)	120 (mg) / ONCE/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051002	MUSCLE ACHES LEFT ARM AND GENERALIZED CHILLS	IBUPROFEN/ IBUPROFEN	C	2020-07-03 (32) / 2020-07-03 (32)	400 (mg) / ONCE / ORAL	Yes
US2051003	INSOMNIA	MELATONIN/ MELATONIN	P/C/A	2019/ Ongoing	20 (mg) / EVERY WEEK / ORAL	No
	HEADACHE	TYLENOL/ PARACETAMOL	P	2020-05-23 (-6) / 2020-05-23 (-6)	975 (mg) / ONCE / ORAL	No
	PAIN AT THE INJECTION SITE LEFT ARM	TYLENOL/ PARACETAMOL	C	2020-05-29 (1) / 2020-05-29 (1)	500 (mg) / ONCE / ORAL	Yes
US2051012	SEASONAL ALLERGIES	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P	2020-05-30 (-3) / 2020-05-31 (-2)	10 (mg) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051012	HEADACHE	ALEVE/ NAPROXEN SODIUM	C	2020-06-03 (2) / 2020-06-03 (2)	440 (mg) / ONCE / ORAL	Yes
	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-06-03 (2) / 2020-06-03 (2)	1000 (mg) / ONCE / ORAL	Yes
	HEADACHE	ALEVE/ NAPROXEN SODIUM	C	2020-07-02 (31) / 2020-07-02 (31)	440 (mg) / ONCE / ORAL	Yes
	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-07-02 (31) / 2020-07-02 (31)	1000 (mg) / ONCE / ORAL	Yes
US2051013	ANXIETY	SERTRALINE/ SERTRALINE	P	2014-03 / 2017-04	100 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051013	ANXIETY	PROZAC/ FLUOXETINE HYDROCHLORIDE	P/C/A	2020-05-21 (-13) / Ongoing	20 (mg) / QD/ ORAL	No
	PAIN TENDERNESS/SWELLING AT THE INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-06-03 (1) / 2020-06-05 (3)	600 (mg) / QD/ ORAL	Yes
	PAIN AT INJECTION SITE/ TENDERNESS AND SWELLING AT INJECTION SITE / HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-07-01 (29) / 2020-07-03 (31)	200 (mg) / PRN/ ORAL	Yes
US2051017	HEALTH MAINTENANCE	FIBER/ FIBRE, DIETARY	P/C/A	2018-01/ Ongoing	1250 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051017	HEALTH MAINTENANCE	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2018-01/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEALTH MAINTENANCE	VITAMIN C/ ASCORBIC ACID	P/C/A	2018-01/ Ongoing	1000 (mg) / QD/ ORAL	No
	ONYCHOMYCOSIS (TOENAILS)	TERBINAFINE/ TERBINAFINE	P/C/A	2019-03/ Ongoing	250 (mg) / OTHER: ONCE DAILY FOR 7 DAYS EVERY OTHER MONTH/ ORAL	No
	HEALTH MAINTENANCE	GLUCOSAMINE / CHONDROITIN/ CHONDROITIN;GLUCOSAMINE	P/C/A	2019-10/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEALTH MAINTENANCE	VITAMIN B COMPLEX/ VITAMIN B COMPLEX	P/C/A	2019-10/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051017	INJECTION SITE PAIN AND FEVER/HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-07-07 (33) / 2020-07-12 (38)	600 (mg) / PRN/ ORAL	Yes
US2051019	MIGRAINES	IBUPROFEN/ IBUPROFEN	P/C/A	2010/ Ongoing	600 (mg) / PRN/ ORAL	No
	CONSTIPATION	MIRALAX/ MACROGOL 3350	P/C/A	2010/ Ongoing	17 (g) / PRN/ ORAL	No
	HEALTH MAINTENANCE	PRENATAL MULTIVITAMIN/ MINERALS NOS;VITAMINS NOS	P/C/A	2017/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEALTH MAINTENANCE	VITAMIN D/ VITAMIN D NOS	P/C/A	2019/ Ongoing	5000 (IU) / EVERY WEEK/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051019	BILATERAL ANKLE AND KNEE PAIN	IBUPROFEN/ IBUPROFEN	P/C/A	2019-07/ Ongoing	600 (mg) / PRN/ ORAL	No
	HEADACHE/FEVER	IBUPROFEN/ IBUPROFEN	C	2020-06-12 (4) / 2020-06-12 (4)	200 (mg) / ONCE/ ORAL	Yes
	FEVER PAIN AT INJECTION SITE AND HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-07-07 (29) / 2020-07-09 (31)	600 (mg) / QD/ ORAL	Yes
US2051020	BIRTH CONTROL	MIERNA/ LEVONORGESTREL	P/C/A	2010/ Ongoing	52 (mg) / OTHER: EVERY 5 YRS/ OTHER: IUD	No
US2051024	MIGRAINES	MOTRIN/ IBUPROFEN	P/C/A	1987-01-01 (-12206) / Ongoing	600 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051024	INSOMNIA	TEMAZEPAM/ TEMAZEPAM	P/C/A	2016-10-01 (-1340) / Ongoing	7.5 (mg) / QD / ORAL	No
	BIRTH CONTROL	NORETHINDRONE / NORETHISTERONE	P/C/A	2017 / Ongoing	1 (TABLET) / QD / ORAL	No
	HEADACHE	IBUPROFEN / IBUPROFEN	C	2020-07-08 (37) / 2020-07-08 (37)	800 (mg) / PRN / ORAL	Yes
US2051025	HEALTH MAINTENANCE	PRENATAL MULTIVITAMIN / MINERALS NOS; VITAMINS NOS	P/C/A	2015 / Ongoing	1 (TABLET) / PRN / ORAL	No
	BIRTH CONTROL	ESTROGEN / PROGESTERON / PROGESTOGENS AND ESTROGENS IN COMBINATION	P/C/A	2016 / Ongoing	1 (TABLET) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051025	HEALTH MAINTENANCE	FISH OIL/ FISH OIL	P/C/A	2017/ Ongoing	1 (CAPSULE) / QOD/ ORAL	No
	CONSTIPATION (IRRITABLE BOWEL SYNDROME)	PRUNELAX/ PRUNUS SPP.; SENNA SPP. LEAF	P/C/A	2020-02/ Ongoing	2 (TABLET) / QD/ ORAL	No
US2051026	HEALTH MAINTENANCE	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2000-01-01 (-7458) / Ongoing	1 (TABLET) / QD/ ORAL	No
	HYPERCHOLESTEROLEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	2017-02/ Ongoing	10 (mg) / QD/ ORAL	No
	PAIN AT INJECTION SITE, HEADACHE, FATIGUE, MUSCLE ACHES, CHILLS	TYLENOL/ PARACETAMOL	C	2020-07-01 (30) / 2020-07-02 (31)	1000 (mg) / PRN/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051026	PAIN AT INJECTION SITE, HEADACHE, FATIGUE, MUSCLE ACHES, CHILLS	IBUPROFEN/ IBUPROFEN	C	2020-07-02 (31) / 2020-07-02 (31)	500 (mg) / PRN / ORAL	Yes
US2051028	HEALTH MAINTENANCE	FISH OIL/ FISH OIL	P/C/A	2017 / Ongoing	1 (TABLET) / QD / ORAL	No
	HEALTH MAINTENANCE	VITAMIN C / ASCORBIC ACID	P/C/A	2017 / Ongoing	1 (TABLET) / QD / ORAL	No
	HEALTH MAINTENANCE	VITAMIN B12 / VITAMIN B12 NOS	P/C/A	2019 / Ongoing	1 (TABLET) / QD / ORAL	No
	RIGHT HAND INJURY PAIN	IBUPROFEN / IBUPROFEN	P/C/A	2020-05-22 (-13) / Ongoing	400 (mg) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051030	SEASONAL ALLERGIES	ALLERGRA (FEXOFENADINE) / FEXOFENADINE HYDROCHLORIDE	P/C/A	2012-01-01 (-3076) / Ongoing	180 (mg) / QD / ORAL	No
	SEASONAL ALLERGIES	ZYRTEC / CETIRIZINE HYDROCHLORIDE	P/C/A	2012-01-01 (-3076) / Ongoing	10 (mg) / QD / ORAL	No
	BIRTH CONTROL	MICROGESTIN / ETHINYLESTRADIOL; NORETHIS TERONE ACETATE	P/C/A	2014-01-01 (-2345) / Ongoing	1 (TABLET) / QD / ORAL	No
	HEALTH MAINTENANCE	PROBIOTIC / PROBIOTICS NOS	P/C/A	2016-01-01 (-1615) / Ongoing	1 (TABLET) / QD / ORAL	No
	HEALTH MAINTENANCE	B COMPLEX / VITAMIN B COMPLEX	P/C/A	2018-01-01 (-884) / Ongoing	1 (TABLET) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051030	SEASONAL ALLERGIES	NASACORT/ TRIAMCINOLONE ACETONIDE	P/C/A	2018-01-01 (-884) / Ongoing	1 (OTHER: SPRAY) / QD/ NASAL	No
	HEALTH MAINTENANCE	VITAMIN D/ VITAMIN D NOS	P/C/A	2020-05-21 (-13) / Ongoing	2000 (IU) / QD/ ORAL	No
	PAIN AT INJECTION SITE	ADVIL/ IBUPROFEN	C	2020-07-07 (35) / 2020-07-07 (35)	600 (mg) / OTHER: EVERY 6 HOURS / ORAL	Yes
US2051045	OCCASIONAL HEADACHE	TYLENOL/ PARACETAMOL	P/C/A	2015-01-01 (-1987) / Ongoing	500 (mg) / PRN / ORAL	No
	VACCINE REACTION PAIN AT INJECTION SITE/FEVER	TYLENOL/ PARACETAMOL	C	2020-07-09 (30) / 2020-07-09 (30)	1500 (mg) / ONCE / ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061008	GASTROESOPHAGEAL REFLUX DISEASE	PRILOSEC OTC/ OMEPRAZOLE	P/C	2020-05-14 (-20) / 2020-06-11 (9)	20 (mg) / QD/ ORAL	No
	DEPRESSION	LEXAPRO/ ESCITALOPRAM OXALATE	P/C/A	2020-05-14 (-20) / Ongoing	10 (mg) / QD/ ORAL	No
	GASTROESOPHAGEAL REFLUX DISEASE	PANTOPRAZOLE/ PANTOPRAZOLE	C/A	2020-06-12 (10) / Ongoing	40 (mg) / QD/ ORAL	No
	JOINT ACHES, GENERALIZED	ASPIRIN/ ACETYLSALICYLIC ACID	C	2020-07-07 (35) / 2020-07-08 (36)	325 (mg) / PRN/ ORAL	Yes
	GENERALIZED JOINT ACHES	ALEVE/ NAPROXEN SODIUM	C	2020-07-20 (48) / 2020-07-29 (57)	220 (mg) / PRN/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061010	PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-09 (37) / 2020-07-09 (37)	400 (mg) / ONCE / ORAL	Yes
US2061020	GASTROESOPHAGEAL REFLUX DISEASE	PRILOSEC/ OMEPRazole	P/C/A	2020-05-01 (-38) / Ongoing	40 (mg) / PRN / ORAL	No
US2061023	BIRTH CONTROL	NORGESTIMATE/ETHINYL ESTRADIOL/ ETHINYLESTRADIOL;NORGESTI MATE	P/C/A	2018-01 / Ongoing	1 (TABLET) / QD / ORAL	No
US2061025	SEASONAL ALLERGIES	LORATADINE/ LORATADINE	P/C/A	1998 / Ongoing	10 (mg) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061025	PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-02 (30) / 2020-07-03 (31)	400 (mg) / PRN / ORAL	Yes
US2061027	NUTRITIONAL SUPPLEMENT	CALCIUM/ CALCIUM	P/C/A	2000 / Ongoing	1 (TABLET) / QD / ORAL	No
	NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2000 / Ongoing	1 (TABLET) / QD / ORAL	No
	NUTRITIONAL SUPPLEMENT	VITAMIN C / ASCORBIC ACID	P/C/A	2000 / Ongoing	1 (TABLET) / QD / ORAL	No
	BIRTH CONTROL	SPRINTEC / ETHINYLESTRADIOL;NORGESTI MATE	P/C/A	2009 / Ongoing	1 (TABLET) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061027	NUTRITIONAL SUPPLEMENT	IRON/ IRON	P/C/A	2015/ Ongoing	1 (TABLET) / QD/ ORAL	No
	TENNIS ELBOW RIGHT	IBUPROFEN/ IBUPROFEN	P/C/A	2019-06-20 (-351) / Ongoing	400 (mg) / PRN/ ORAL	No
	PAIN AT INJECTION SITE	ADVIL/ IBUPROFEN	C	2020-07-09 (35) / 2020-07-09 (35)	400 (mg) / PRN/ ORAL	Yes
US2071002	HEADACHE	IBUOROFEN/ IBUPROFEN	C	2020-06-02 (2) / 2020-06-03 (3)	400 (mg) / PRN/ ORAL	Yes
	FEVER	TYLENOL/ PARACETAMOL	C	2020-07-01 (31) / 2020-07-10 (40)	500 (mg) / PRN/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071002	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-07-01 (31) / 2020-07-13 (43)	500 (mg) / PRN/ ORAL	Yes
US2071036	PAIN AT INJECTION SITE	TYLENOL/ PARACETAMOL	C	2020-07-14 (37) / 2020-07-15 (38)	500 (mg) / PRN/ ORAL	Yes
US2071038	TREATMENT OF FEVER	TYLENOL/ PARACETAMOL	C	2020-07-14 (41) / 2020-07-15 (42)	500 (mg) / PRN/ ORAL	Yes
US2071039	INSOMNIA	SEROQUEL/ QUETIAPINE FUMARATE	P/C/A	2016/ Ongoing	100 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071039	TOTAL HYSTERECTOMY	ESTRADIOL/ ESTRADIOL	P/C/A	2018/ Ongoing	1 (mg) / QD/ ORAL	No
	HYPOTHYROIDISM	SYNTHROID/ LEVOTHYROXINE SODIUM	P/C/A	2018/ Ongoing	75 (ug) / QD/ ORAL	No
	DIETARY SUPPLEMENT	OMEGA 3/ OMEGA-3 NOS	C/A	2020-06-20 (16) / Ongoing	250 (mg) / QD/ ORAL	No
	DIETARY SUPPLEMENT	PRENATAL VITAMINS/ MINERALS NOS;VITAMINS NOS	C/A	2020-06-20 (16) / Ongoing	1 (TABLET) / QD/ ORAL	No
	FEVER (SOLICITED SYMPTOM)	IBUPROFEN/ IBUPROFEN	C	2020-07-14 (40) / 2020-07-15 (41)	800 (mg) / PRN/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071051	MENORRHAGIE	MIRENA/ LEVONORGESTREL	P/C/A	2018-02/ Ongoing	52 (mg) / OTHER: REPLACED EVERY 5 YEARS./ OTHER: INTRA-UTERINE	No
	ATTENTION DEFICIT HYPERACTIVITY DISORDER	ADDERALL XR/ AMFETAMINE ASPARTATE;AMFETAMINE SULFATE;DEXAMFETAMINE SACCHARATE;DEXAMFETAMINE SULFATE	P/C/A	2020-04/ Ongoing	30 (mg) / QD/ ORAL	No
	PAIN AT INJECTION SITE	TYLENOL/ PARACETAMOL	C	2020-06-06 (2) / 2020-06-06 (2)	325 (mg) / ONCE/ ORAL	Yes
	SWELLING AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-08 (34) / 2020-07-08 (34)	400 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071069	FEVER	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-14 (37) / 2020-07-14 (37)	325 (mg) / PRN/ ORAL	Yes
US2071073	CONTRACEPTION	LORYNA/ DROSPIRENONE;ETHINYLESTRA DIOL	P/C/A	2020-02/ Ongoing	1 (TABLET) / QD/ ORAL	No
US2081023	SUPPLEMENT	GINSENG/ GINSENG NOS	P/C/A	2000/ Ongoing	400 (mg) / QD/ ORAL	No
	HEADACHE	ASPIRIN/ ACETYLSALICYLIC ACID	C	2020-07-08 (36) / 2020-07-08 (36)	650 (mg) / BID/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081025	SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2018/ Ongoing	1 (TABLET) / QD/ ORAL	No
	SUPPLEMENT	SAM-E[S-ADENOSYLMETHIONINE] / ADEMETIONINE	P/C/A	2018/ Ongoing	1 (TABLET) / QD/ ORAL	No
	SUPPLEMENT	ASHWAGANDHA/ UNSPECIFIED HERBAL AND TRADITIONAL MEDICINE	P/C/A	2019/ Ongoing	500 (mg) / QD/ ORAL	No
	ANXIETY	ZOLOFT/ SERTRALINE HYDROCHLORIDE	P/C	2020-05-29 (-5) / 2020-06-05 (3)	12.5 (mg) / QD/ ORAL	No
	ANXIETY	ZOLOFT/ SERTRALINE HYDROCHLORIDE	C	2020-06-06 (4) / 2020-06-15 (13)	25 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081025	ANXIETY	ZOLOFT/ SERTRALINE HYDROCHLORIDE	C	2020-06-16 (14) / 2020-07-06 (34)	50 (mg) / QD/ ORAL	No
	ANXIETY	ZOLOFT/ SERTRALINE HYDROCHLORIDE	C/A	2020-07-07 (35) / Ongoing	100 (mg) / QD/ ORAL	No
	HEADACHE, FEVER, CHILLS, JOINT ACHE/MUSCLE ACHE (ELBOWS AND SHOULDERS) [EDIARY]	DAYQUIL [ACETAMINOPHEN 325MG, DEXTROMETHORPHAN HBR 10MG, PHENYLEPHRINE HCL 5MG] / DEXTROMETHORPHAN HYDROBROMIDE; PARACETAMOL; PHENYLEPHRINE HYDROCHLORIDE	C	2020-07-08 (36) / 2020-07-09 (37)	1 (CAPSULE) / BID/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081025	HEADACHE, FEVER, CHILLS, JOINT ACHES/MUSCLE ACHE (ELBOWS AND SHOULDERS) [EDIARY]	NYQUIL [ACETAMINOPHEN 325MG, DOXYLAMINE SUCCINATE 6.25MG, DEXTROMETHORPHAN HBR 15MG] / DEXTROMETHORPHAN HYDROBROMIDE; DOXYLAMINE SUCCINATE; PARACETAMOL	C	2020-07-08 (36) / 2020-07-09 (37)	1 (CAPSULE) / QD / ORAL	Yes
	EPISCLERITIS (LEFT EYE)	PREDNISONE ACETATE / PREDNISONE ACETATE	C	2020-07-23 (51) / 2020-08-02 (61)	4 (OTHER: DROPS) / QD / INTRAOCULAR	No
	EPISCLERITIS OF LEFT EYE	PREDNISONE ACETATE / PREDNISONE ACETATE	C/A	2020-08-02 (61) / 2020-08-12 (71)	3 (OTHER: DROPS) / QD / INTRAOCULAR	No
US2081028	GASTROESOPHAGEAL REFLUX DISEASE	OMEPRazole / OMEPRazole	P/C/A	2018 / Ongoing	20 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081028	DYSLIPIDEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	2019/ Ongoing	20 (mg) / QD/ ORAL	No
US2081045	ROSACEA [FACE]	FINACEA/ AZELAIC ACID	P/C/A	2015/ Ongoing	1 (OTHER: LAYER) / QD/ TOPICAL	No
	FEVER/CHILLS [EDIARY]	TYLENOL [ACETAMINOPHEN] / PARACETAMOL	C	2020-07-08 (35) / 2020-07-09 (36)	500 (mg) / QID/ ORAL	No
	FEVER/CHILLS [EDIARY]	TYLENOL [ACETAMINOPHEN] / PARACETAMOL	C	2020-07-13 (40) / 2020-07-13 (40)	500 (mg) / QID/ ORAL	No
US2081051	PTSD	CARBAMAZEPINE/ CARBAMAZEPINE	P/C/A	1994/ Ongoing	400 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081051	ANXIETY	ZOLOFT/ SERTRALINE HYDROCHLORIDE	P/C/A	1995/ Ongoing	50 (mg) / QD/ ORAL	No
	NECK PAIN	FLEXERIL/ CEFIXIME	P/C/A	2010/ Ongoing	5 (mg) / PRN/ ORAL	No
	DYSLIPIDEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	2019/ Ongoing	5 (mg) / PRN/ ORAL	No
US2081062	HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-07-10 (33) / 2020-07-10 (33)	600 (mg) / ONCE/ ORAL	Yes
US2081063	DEPRESSION	LEXAPRO/ ESCITALOPRAM OXALATE	C/A	2020-07-20 (43) / 2020-08-19 (73)	10 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081064	SUPPLEMENT	FISH OIL/ FISH OIL	P/C/A	2010/ Ongoing	250 (mg) / QD/ ORAL	No
	GOUT [HEELS]	ALLOPURINOL/ ALLOPURINOL	P/C/A	2017/ Ongoing	100 (mg) / QD/ ORAL	No
	PAIN PREVENTATIVE	IBUPROFEN/ IBUPROFEN	C	2020-06-13 (6) / 2020-06-13 (6)	250 (mg) / ONCE/ ORAL	No
	ACUTE GASTROENTERITIS	IBUPROFEN/ IBUPROFEN	C	2020-07-10 (33) / 2020-07-10 (33)	400 (mg) / ONCE/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011007	GENERAL MYALGIAS	BAYER ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2000/ Ongoing	325 (mg) / QD/ ORAL	No
	HEADACHES	BAYER ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2000/ Ongoing	325 (mg) / QD/ ORAL	No
	SEASONAL ALLERGIES	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2017/ Ongoing	10 (mg) / QD/ ORAL	No
	HIGH CHOLESTEROL	ATORVASTATIN/ ATORVASTATIN	P/C/A	2018/ Ongoing	20 (mg) / QD/ ORAL	No
US2011023	IBS-C	LINZESS/ LINACLOTIDE	P/C/A	2019-12/ Ongoing	145 (ug) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011023	HEARTBURN	PANTOPRAZOLE/ PANTOPRAZOLE	P/C/A	2019-12/ Ongoing	40 (mg) / QD/ ORAL	No
	NAUSEA	ONDANSETRON/ ONDANSETRON	P/C/A	2020-02/ Ongoing	4 (mg) / PRN/ ORAL	No
US2011109	HYPOTHYROIDISM	LEVOTHYROXINE/ LEVOTHYROXINE	P/C/A	2010/ Ongoing	62.5 (ug) / QD/ ORAL	No
	OSTEOPOROSIS	ALENDRONATE/ ALENDRONATE SODIUM	P/C/A	2017/ Ongoing	70 (mg) / EVERY WEEK/ ORAL	No
US2011114	MIGRAINES	SUMATRIPTAN/ SUMATRIPTAN	P/C/A	1998/ Ongoing	50 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011114	HYPOTHYROIDISM	LEVOTHYROXINE/ LEVOTHYROXINE	P/C/A	2001/ Ongoing	100 (ug) / QD/ ORAL	No
US2011116	HEADACHES	IBUPROFEN/ IBUPROFEN	P/C/A	2010/ Ongoing	250 (mg) / PRN/ ORAL	No
	HEARTBURN	MAALOX/ ALGELDRADE;MAGNESIUM HYDROXIDE	P/C/A	2010/ Ongoing	20 (mL) / PRN/ ORAL	No
US2011120	SEASONAL ALLERGIES	CLARITIN/ LORATADINE	P/C/A	2000/ Ongoing	10 (mg) / PRN/ ORAL	No
	HEADACHES, ALLERGY-RELATED	IBUPROFEN/ IBUPROFEN	P/C/A	2000/ Ongoing	400 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011120	OSTEOPENIA	CALCIUM/ CALCIUM	P/C/A	2018/ Ongoing	1200 (mg) / QD/ ORAL	No
US2011124	SEASONAL ALLERGIES	LORATIDINE/ LORATADINE	P/C/A	2000/ Ongoing	10 (mg) / PRN/ ORAL	No
	SEASONAL ALLERGIES	OXYMETAZOLINE/ OXYMETAZOLINE	P/C/A	2000/ Ongoing	1 (OTHER: SPRAY) / PRN/ NASAL	No
	DIFFICULTY SLEEPING	DIPHENHYDRAMINE/ DIPHENHYDRAMINE	P/C/A	2010/ Ongoing	25 (mg) / PRN/ ORAL	No
	MIGRAINES	SUMATRIPTAN/ SUMATRIPTAN	P/C/A	2019/ Ongoing	50 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011124	MIGRAINE (REPORTED AS HEADACHE IN DIARY)	ADVIL/ IBUPROFEN	C	2020-06-26 (1) / 2020-06-27 (2)	200 (mg) / PRN/ ORAL	Yes
	MIGRAINE (REPORTED AS HEADACHE IN DIARY)	SUMATRIPTAN/ SUMATRIPTAN	C	2020-06-29 (4) / 2020-06-29 (4)	50 (mg) / ONCE/ ORAL	Yes
US2011126	GLAUCOMA, BILATERAL, UNKNOWN TYPE	LATANOPROST/ LATANOPROST	P/C/A	2006/ Ongoing	2 (OTHER: DROPS) / QD/ INTRAOCULAR	No
	ANXIETY	SERTRALINE/ SERTRALINE	P/C/A	2012/ Ongoing	50 (mg) / QD/ ORAL	No
	LT KNEE PAIN	IBUPROFEN/ IBUPROFEN	P/C/A	2018/ Ongoing	200 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011126	OSTEOPOROSIS	VITAMIN D3/ COLECALCIFEROL	P/C/A	2018/ Ongoing	50 (ug) / QD/ ORAL	No
	OSTEOPOROSIS	CALCIUM/ CALCIUM	P/C/A	2019/ Ongoing	1260 (mg) / BID/ ORAL	No
	OSTEOPOROSIS	PROLIA/ DENOSUMAB	P/C/A	2019-03-12 (-472) / Ongoing	60 (mg) / OTHER: EVERY SIX MONTHS/ INTRAMUSCULAR	No
US2011131	RATTLE, LEFT EAR	GABAPENTIN/ GABAPENTIN	P/C/A	2019-03-01 (-483) / Ongoing	300 (mg) / TID/ ORAL	No
	SEASONAL ALLERGIES	FLUTICASONE/ FLUTICASONE	P/C/A	2019-05-01 (-422) / Ongoing	150 (ug) / BID/ NASAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011131	SEASONAL ALLERGIES	XYZAL/ LEVOCETIRIZINE DIHYDROCHLORIDE	P/C/A	2019-05-01 (-422) / Ongoing	10 (mg) / QD / ORAL	No
	NECK/SHOULDER PAIN	NAPROXEN/ NAPROXEN	C	2020-07-26 (31) / 2020-07-26 (31)	500 (mg) / ONCE / ORAL	No
US2011142	ADHD	RITALIN/ METHYLPHENIDATE HYDROCHLORIDE	P/C/A	2010-05 / Ongoing	10 (mg) / PRN / ORAL	No
	HYPERCHOLESTEROLEMIA	LIPITOR/ ATORVASTATIN	P/C/A	2018-05 / Ongoing	20 (mg) / QD / ORAL	No
	MUSCLE ACHES (ALL OVER BODY)	IBUPROFEN/ IBUPROFEN	C	2020-07-29 (31) / 2020-08-03 (36)	400 (mg) / PRN / ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011145	MIGRAINES	IMITREX/ SUMATRIPTAN	P/C/A	2000/ Ongoing	50 (mg) / PRN/ ORAL	No
	MIGRAINE (REPORTED AS HEADACHE IN DIARY-DAY 3)	IMITREX/ SUMATRIPTAN	C	2020-06-28 (3) / 2020-06-28 (3)	50 (mg) / ONCE/ ORAL	No
US2011152	PULLED MUSCLE, RIGHT BACK MUSCLE	IBUPROFEN/ IBUPROFEN	P	2020-06-28 (-1) / 2020-06-28 (-1)	200 (mg) / PRN/ ORAL	No
US2011155	MIGRAINES	EXCEDRINE (ACETAMINOPHEN, ASPIRIN, CAFFEINE) / ACETYLSALICYLIC ACID; CAFFEINE; PARACETAMOL	P/C/A	1992/ Ongoing	(mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection. WHODrug version: WHODrug-Global-B3 March 2020
[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011155	OSTEOPENIA	IBANDRONATE/ IBANDRONATE SODIUM	P/C/A	2004/ Ongoing	150 (mg) / QM/ INTRAMUSCULAR	No
	SEASONAL ALLERGIES	NASONEX/ MOMETASONE FUROATE	P/C/A	2010/ Ongoing	2 (OTHER: SPRAYS EACH NOSTRIL) / PRN/ NASAL	No
	HORMONE REPLACEMENT/POSTMENO PAUSAL	ESTRADIOL/NORETHINDRONE ACETATE/ ESTRADIOL;NORETHISTERONE ACETATE	P/C/A	2011/ Ongoing	(mg) / QD/ ORAL	No
	HERPES SIMPLEX I	VALACYCLOVIR/ VALACICLOVIR	P/C/A	2012/ Ongoing	1 (g) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011155	HEADACHE	EXCEDRINE (ACETAMINOPHEN, ASPIRIN, CAFFEINE) / ACETYLSALICYLIC ACID; CAFFEINE; PARACETAMOL	C	2020-07-02 (3) / 2020-07-02 (3)	(mg) / ONCE / ORAL	Yes
US2011156	TENSION HEADACHES	ACETAMINOPHEN / PARACETAMOL	P/C/A	2010 / Ongoing	500 (mg) / PRN / ORAL	No
	HYPERCHOLESTEROLEMIA	ROSUVASTATIN / ROSUVASTATIN	P/C/A	2010 / Ongoing	10 (mg) / QD / ORAL	No
	MUSCLE TENSION, GENERAL	BACLOFEN / BACLOFEN	P/C/A	2017 / Ongoing	10 (mg) / PRN / ORAL	No
	GERD	OMEPRAZOLE / OMEPRAZOLE	P/C/A	2019 / Ongoing	40 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011156	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-07-01 (2) / 2020-07-02 (3)	500 (mg) / QD/ ORAL	Yes
US2011157	DEPRESSION	ZOLOFT/ SERTRALINE HYDROCHLORIDE	P/C/A	2005/ Ongoing	50 (mg) / QD/ ORAL	No
	MENOPAUSE/HORMONE REPLACEMENT THERAPY	ESTRADIOL/ ESTRADIOL	P/C/A	2010/ Ongoing	0.5 (mg) / QD/ ORAL	No
	MENOPAUSE/HORMONE REPLACEMENT THERAPY	PROVERA/ MEDROXYPROGESTERONE ACETATE	P/C/A	2010/ Ongoing	10 (mg) / QD/ ORAL	No
	CARDIAC PROPHYLAXIS	ASPIRIN/ ACETYLSALICYLIC ACID	P/C	2019/ 2020-07-16 (17)	81 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011157	GENERAL MYALGIAS	IBUPROFEN/ IBUPROFEN	P/C/A	2019/ Ongoing	1000 (mg) / PRN/ ORAL	No
	GENERAL MYALGIAS	TYLENOL/ PARACETAMOL	P/C/A	2019/ Ongoing	500 (mg) / PRN/ ORAL	No
US2021015	HYPERCHOLESTEROLEMIA	SIMVASTATIN/ SIMVASTATIN	P/C/A	2014/ Ongoing	40 (mg) / QD/ ORAL	No
	OVERACTIVE BLADDER	OXYBUTYNIN/ OXYBUTYNIN	P/C/A	2015/ Ongoing	5 (mg) / BID/ ORAL	No
	DEPRESSION	MIRTAZAPINE/ MIRTAZAPINE	P/C/A	2019/ Ongoing	15 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021021	HYPERCHOLESTEROLEMIA	LOVASTATIN/ LOVASTATIN	P/C/A	2008/ Ongoing	10 (mg) / QD/ ORAL	No
	CARDIAC PROPHYLAXIS	ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2016/ Ongoing	81 (mg) / QD/ ORAL	No
US2021043	HYPERLIPIDEMIA	SIMVASTATIN/ SIMVASTATIN	P/C/A	2014/ Ongoing	40 (mg) / QD/ ORAL	No
	POISON IVY ALLERGIC CONTACT DERMATITIS	BENADRYL/ DIPHENHYDRAMINE HYDROCHLORIDE	C	2020-06-14 (14) / 2020-06-14 (14)	1 (OTHER: SPRAY) / QD/ TOPICAL	No
	POISON IVY ALLERGIC CONTACT DERMATITIS	TECNU ANTI-ITCH SPRAY/ CALENDULA OFFICINALIS;GRINDELIA ROBUSTA;PLANTAGO MAJOR	C	2020-06-14 (14) / 2020-06-14 (14)	1 (OTHER: SPRAY) / QD/ TOPICAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021043	ANAPHYLAXIS TO WASP	BENADRYL/ DIPHENHYDRAMINE HYDROCHLORIDE	C	2020-06-17 (17) / 2020-06-23 (23)	25 (mg) / QD/ ORAL	No
	ANAPHYLAXIS TO WASP	MEDROL/ METHYLPREDNISOLONE	C	2020-06-17 (17) / 2020-06-23 (23)	4 (mg) / QD/ ORAL	No
US2021130	HYPERLIPIDEMIA	PRAVASTATIN/ PRAVASTATIN	P/C/A	2002/ Ongoing	40 (mg) / QD/ ORAL	No
	OSTEOPENIA	VITAMIN D/ VITAMIN D NOS	P/C/A	2015/ Ongoing	2000 (IU) / QD/ ORAL	No
	LEFT UPPER ARM ABRASION	CORITSONE-10/ HYDROCORTISONE	C/A	2020/ 2020	2 (OTHER: APPLICATION) / PRN/ TOPICAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021130	RASH ON RIGHT WRIST	CORITSONE-10/ HYDROCORTISONE	C/A	2020-08-25 (61) / 2020-08-27 (63)	1 (OTHER: APPLICATION) / PRN/ TOPICAL	No
US2021185	RIGHT SHOULDER PAIN	IBUPROFEN/ IBUPROFEN	C/A	2020-06-26 (1) / Ongoing	200 (mg) / PRN/ ORAL	No
	HEADACHE	EXCEDRIN (ASPIRIN, ACETAMINOPHEN & CAFFEINE) / ACETYLSALICYLIC ACID;CAFFEINE;PARACETAMOL	C	2020-08-04 (40) / 2020-08-04 (40)	(mg) / ONCE/ ORAL	Yes
US2021189	OSTEOPOROSIS	ALENDRONATE/ ALENDRONATE SODIUM	P/C/A	2020-01/ Ongoing	70 (mg) / EVERY WEEK/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021196	POST MENOPAUSAL	PRASTERANE/ PRASTERONE	P/C/A	2017/ Ongoing	6.5 (mg) / QD/ VAGINAL	No
US2021198	MIGRAINES	TROKENDI XR/ TOPIRAMATE	P/C/A	2012/ Ongoing	100 (mg) / QD/ ORAL	No
US2021206	SEASONAL ALLERGIES	LORATADINE/ LORATADINE	P/C/A	2010/ Ongoing	10 (mg) / PRN/ ORAL	No
	HYPERCHOLESTEROLEMIA	CRESTOR/ ROSUVASTATIN CALCIUM	P/C/A	2016/ Ongoing	10 (mg) / QD/ ORAL	No
	HYPERCHOLESTEROLOMIA	CRESTOR/ ROSUVASTATIN CALCIUM	P/C/A	2016/ Ongoing	10 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021206	BILATERAL GLAUCOMA	LATANOPROST OPTHALMIC/ LATANOPROST	P/C/A	2019/ Ongoing	1 (OTHER: DROP) / QD/ INTRAOCULAR	No
	SEASONAL ALLERGIES	LORATADINE/ LORATADINE	P/C/A	2019-10/ Ongoing	10 (mg) / PRN/ ORAL	No
	BILATERAL GLAUCOMA	TRAVATAN 2/ TRAVOPROST	P/C/A	2019-10/ Ongoing	1 (OTHER: DROP) / QD/ TOPICAL	No
	HEADACHE	ADVIL/ IBUPROFEN	C	2020-07-04 (3) / 2020-07-04 (3)	200 (mg) / ONCE/ ORAL	Yes
	RIGHT HIP BURSITIS	SENSORCIAN/ BUPIVACAINE HYDROCHLORIDE	C	2020-07-16 (15) / 2020-07-16 (15)	0.5 (mg) / ONCE/ INTRAMUSCULAR	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021206	RIGHT HIP BURSITIS	TRIAMCINOLONE/ TRIAMCINOLONE	C	2020-07-16 (15) / 2020-07-16 (15)	40 (mg) / ONCE / INTRAMUSCULAR	No
	BONE SPUR RIGHT TOE	IBUPROFEN/ IBUPROFEN	C/A	2020-07-30 (29) / Ongoing	800 (mg) / PRN / ORAL	No
US2021207	GASTROESOPHAGEAL REFLUX DISEASE	ESOMEPRAZOLE/ ESOMEPRAZOLE	P/C/A	2015 / Ongoing	20 (mg) / QD / ORAL	No
	GASTROESOPHAGEAL REFLEX DISEASE	ESOMEPRAZOLE/ ESOMEPRAZOLE	P/C/A	2015 / Ongoing	20 (mg) / QD / ORAL	No
US2021219	HEADACHES	SUMATRIPTANL/ SUMATRIPTAN	P/C/A	2012 / Ongoing	(mg) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021219	MIGRAINES	TREXIMET/ NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE	P/C/A	2015/ Ongoing	(mg) / QD/ ORAL	No
	DRY EYES BILATERAL	XIIDRA/ LIFITEGRAST	P/C/A	2017/ Ongoing	1 (OTHER: DROP) / BID/ INTRAOCULAR	No
	DRY EYES	XIIDRA 5%/ LIFITEGRAST	P/C/A	2017/ Ongoing	1 (OTHER: DROP) / BID/ TOPICAL	No
US2021222	HYPERLIPIDEMIA	ROSUVASTATIN/ ROSUVASTATIN	P/C/A	2020-05-11 (-52) / Ongoing	10 (mg) / QD/ ORAL	No
	HYERLIPIDEMIA	ROSUVASTATIN/ ROSUVASTATIN	P/C/A	2020-05-11 (-52) / Ongoing	10 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021222	SEASONAL ALLERGIES	ADVIL SINUS (CHLOROPHENIRAMINE MALEATE, ANTIHISTAMINE IBUPROFEN, PHENYLEPHRINE HCl) / CHLORPHENAMINE MALEATE; IBUPROFEN; PHENYLE PHRINE HYDROCHLORIDE	C	2020-07-07 (6) / 2020-07-07 (6)	(mg) / ONCE / ORAL	No
	FIRE ANT BITES EXTREMITIES	HYDROCORTISONE CREAM/ HYDROCORTISONE	C	2020-08-22 (52) / 2020-08-22 (52)	1 (OTHER: APPLICATION) / QD / TOPICAL	No
US2031085	HYPOESTROGENISM	PREMARIN/ ESTROGENS CONJUGATED	P/C/A	1998 / Ongoing	0.45 (mg) / QOD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031085	INJECTION SITE PAIN	ACETAMINOPHEN/ PARACETAMOL	C	2020-06-28 (3) / 2020-07-02 (7)	1000 (mg) / PRN/ ORAL	Yes
	FEVER/GENERALIZED PAIN	ACETAMINOPHEN/ PARACETAMOL	C	2020-08-03 (39) / 2020-08-03 (39)	1000 (mg) / PRN/ ORAL	Yes
US2031089	HYPERLIPIDEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	2015/ Ongoing	20 (mg) / QD/ ORAL	No
	GASTROESOPHAGEAL REFLUX DISEASE	OMEPRAZOLE/ OMEPRAZOLE	P/C/A	2015/ Ongoing	20 (mg) / QD/ ORAL	No
	BENIGN PROSTATIC HYPERPLASIA	TAMSOLUSIN/ TAMSULOSIN	P/C/A	2015/ Ongoing	0.4 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031089	CHRONIC BACK PAIN	TRAMADOL/ TRAMADOL	P/C/A	2015/ Ongoing	50 (mg) / PRN/ ORAL	No
US2031092	GOT FLASHES	ESTRADIAL/ ESTRADIOL	P/C/A	2005/ Ongoing	0.5 (mg) / QD/ ORAL	No
	HOT FLASHES	MEDROXYPROGESTERONE/ MEDROXYPROGESTERONE	P/C/A	2005/ Ongoing	5 (mg) / QD/ ORAL	No
	OPEN- ANGLE LEFT EYE GLAUCOMA	LUMIGAN .01%/ BIMATOPROST	P/C/A	2019-09/ Ongoing	1 (OTHER: DROP) / QD/ OTHER: OCULAR	No
	OPEN - ANGLE LEFT EYE GLAUCOMA	DORZOLAMIDE 2%/ DORZOLAMIDE	P/C/A	2019-12/ Ongoing	1 (OTHER: DROP) / BID/ OTHER: OCULAR	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031095	POST MENOPAUSAL	DUAVEE/ BAZEDOXIFENE;ESTROGENS CONJUGATED	P/C	2015/ 2020-08-06 (39)	(mg) / QD/ ORAL	No
	HORMONE REPLACEMENT THERAPY- POSTMENOPAUSAL	ESTRADIOL/ ESTRADIOL	C/A	2020-08-06 (39) / Ongoing	1 (mg) / QD/ ORAL	No
	HORMONE REPLACEMENT THERAPY- POSTMENOPAUSAL	MEDROXY PR/ MEDROXYPROGESTERONE ACETATE	C/A	2020-08-06 (39) / Ongoing	2.5 (mg) / QD/ ORAL	No
US2031098	HYERLIPIDEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	2017/ Ongoing	20 (mg) / QD/ ORAL	No
US2031103	SINUS CONGESTION	ACETAMINOPHEN/ PARACETAMOL	C/A	2020-07-27 (29) / Ongoing	1000 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031103	SINUS CONGESTION	PSEUDOEPHEDRINE/ PSEUDOEPHEDRINE	C/A	2020-07-27 (29) / Ongoing	330 (mg) / PRN / ORAL	No
US2031125	SEASONAL ALLERGIES	ALLERGY RELIEF / LORATADINE	P/C/A	1999 / Ongoing	25 (mg) / QD / ORAL	No
	HYPERCHOLESTEROLEMIA	ATORVASTATIN / ATORVASTATIN	P/C/A	1999 / Ongoing	20 (mg) / QD / ORAL	No
	RESTLESS LEG SYNDROME	PRAMIPEXOLE / PRAMIPEXOLE	P/C/A	2000 / Ongoing	1 (mg) / QD / ORAL	No
	ACID REFLUX	OMEPRAZOLE / OMEPRAZOLE	P/C/A	2017 / Ongoing	20 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041102	NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2017/ Ongoing	1 (TABLET) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	VITAMIN C/ ASCORBIC ACID	P/C/A	2017/ Ongoing	1 (TABLET) / QD/ ORAL	No
US2041121	CHRONIC SINUSITIS	SINGULAIR/ MONTELUKAST SODIUM	P/C/A	2019/ Ongoing	10 (mg) / PRN/ ORAL	No
US2041132	POST MENOPAUSAL	ESTROGEN/ ESTRADIOL	P/C/A	2018/ Ongoing	0.5 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041142	DEPRESSION	PAROXITINE HCL/ PAROXETINE HYDROCHLORIDE	P/C/A	2015/ Ongoing	10 (mg) / QD/ ORAL	No
	HISTORY OF PULMONARY EMBOLISM	APIXIBAN/ APIXABAN	P/C/A	2018/ Ongoing	5 (mg) / QD/ ORAL	No
US2041146	ANXIETY	CITALOPRAM HYDROBROMIDE/ CITALOPRAM HYDROBROMIDE	P/C/A	1998/ Ongoing	40 (mg) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2000/ Ongoing	1 (TABLET) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	CALCIUM + VITAMIN D/ CALCIUM;VITAMIN D NOS	P/C/A	2015/ Ongoing	600 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041146	NUTRITIONAL SUPPLEMENT	IRON/ IRON	P/C/A	2015/ Ongoing	65 (mg) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	VITAMIN B12/ VITAMIN B12 NOS	P/C/A	2015/ Ongoing	1 (TABLET) / QD/ ORAL	No
	CELLULITIS-RIGHT FOREARM	CEPHALEXIN/ CEFALEXIN	C	2020-07-06 (5) / 2020-07-10 (9)	500 (mg) / BID/ ORAL	No
US2041151	SEASONAL ALLERGIES	CETIRIZINE/ CETIRIZINE	P/C/A	1992/ Ongoing	10 (mg) / PRN/ ORAL	No
	GENERAL ACHES AND PAINS	IBUPROFEN/ IBUPROFEN	P/C/A	2000/ Ongoing	200 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041151	SLEEP AID/ INTERMITTENT INSOMNIA	MELATONIN/ MELATONIN	P/C/A	2000/ Ongoing	5 (mg) / PRN/ ORAL	No
	GASTROESOPHAGEAL REFLUX DISEASE	FAMOTIDINE/ FAMOTIDINE	P/C/A	2020-03/ Ongoing	10 (mg) / PRN/ ORAL	No
US2041166	DEPRESSION	FLUOXETINE/ FLUOXETINE	P/C/A	2010/ Ongoing	30 (mg) / QD/ ORAL	No
US2051055	GASTROESOPHAGEAL REFLUX DISEASE	OMEPRAZOLE/ OMEPRAZOLE	P/C/A	2014-03-01 (-2309) / Ongoing	20 (mg) / PRN/ ORAL	No
	LUMBAR BACK PAIN	DICLOFENAC SODIUM/ DICLOFENAC SODIUM	P/C/A	2017-01-01 (-1272) / Ongoing	50 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051055	SEASONAL ALLERGIES	LORATADINE/ LORATADINE	P/C/A	2020-03-01 (-117) / Ongoing	10 (mg) / PRN / ORAL	No
	SEASONAL ALLERGIES	CHLORPHENIRAMINE MALEATE / CHLORPHENAMINE MALEATE	C/A	2020-08-14 (50) / Ongoing	4 (mg) / PRN / ORAL	No
US2051072	GENERALIZED BODY ACHES	ACETAMINOPHEN / PARACETAMOL	C	2020-07-18 (13) / 2020-07-18 (13)	500 (mg) / ONCE / ORAL	No
	GENERALIZED BODY ACHES	HYDROCODONE / HYDROCODONE	C	2020-07-18 (13) / 2020-07-18 (13)	5 (mg) / ONCE / ORAL	No
	GENERALIZED BODY ACHES	IBUPROFEN / IBUPROFEN	C	2020-08-02 (28) / 2020-08-02 (28)	400 (mg) / ONCE / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051072	HEADACHES/GENERALIZE D BODY ACHES	ALEVE (NAPROXEN SODIUM) / NAPROXEN SODIUM	C/A	2020-08-17 (43) / 2020-09-06 (63)	660 (mg) / PRN/ ORAL	No
US2051073	HEALTH MAINTENANCE	GLUCOSAMINE CHONDROTIN/ CHONDROITIN;GLUCOSAMINE	P/C/A	2009-01-01 (-4204) / Ongoing	1 (TABLET) / QD/ ORAL	No
US2051086	OSTEOARTHRITIS BILATERAL KNEES	ALEVE/ NAPROXEN SODIUM	P/C/A	2013-01-01 (-2743) / Ongoing	440 (mg) / PRN/ ORAL	No
	RAGWEED ALLERGY	ALLEGRA/ FEXOFENADINE HYDROCHLORIDE	C/A	2020-08-18 (44) / Ongoing	60 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051087	SUPPLEMENT	CALCIUM WITH VITAMIN D/ CALCIUM;VITAMIN D NOS	P/C/A	2004-01-01 (-6031) / Ongoing	(OTHER: MG/IU) / BID / ORAL	No
	SUPPLEMENT	FISH OIL / FISH OIL	P/C/A	2004-01-01 (-6031) / Ongoing	400 (IU) / QD / ORAL	No
	SUPPLEMENT	GLUCOSAMINE / GLUCOSAMINE	P/C/A	2004-01-01 (-6031) / Ongoing	1500 (mg) / BID / ORAL	No
	INFLUENZA PROPHYLAXIS	INFLUENZA VACCINE / INFLUENZA VACCINE	P	2008-11-04 (-4262) / 2014-10-15 (-2091)	1 (OTHER: INJECTION) / OTHER: YEARLY / INTRAMUSCULAR	No
US2051089	INSOMNIA	MELATONIN / MELATONIN	P	2020-06-24 (-8) / 2020-06-24 (-8)	5 (mg) / ONCE / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051089	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-07-08 (7) / 2020-07-08 (7)	650 (mg) / ONCE / ORAL	Yes
	SEASONAL ALLERGIES	NYQUIL COLD AND FLU ACEAMINOPHEN 325MG DOXYLAMINE SUCCINATE 6.25MG DEXTROMETHORPHEN 15MG / DEXTROMETHORPHAN HYDROBROMIDE; DOXYLAMINE SUCCINATE; PARACETAMOL	C	2020-08-24 (54) / 2020-08-24 (54)	1 (CAPSULE) / ONCE / ORAL	No
US2051098	GENERAL BODY ACHES	ALEVE/ NAPROXEN SODIUM	P/C/A	1975 / Ongoing	200 (mg) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection. WHODrug version: WHODrug-Global-B3 March 2020
[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051112	SEASONAL ALLERGIES	BENADRYL/ DIPHENHYDRAMINE HYDROCHLORIDE	P/C/A	2016/ Ongoing	25 (mg) / PRN/ ORAL	No
	ABDOMINAL TENDERNESS	DUCOLAX/ BISACODYL	C	2020-08-26 (52) / 2020-08-26 (52)	1 (TABLET) / ONCE/ ORAL	No
US2061035	DEPRESSION	ELAVIL (AMITRIPTYLINE) / AMITRIPTYLINE HYDROCHLORIDE	P/C/A	2019-06/ Ongoing	10 (mg) / QD/ ORAL	No
US2061043	SEASONAL ALLERGIES	PSEUDOEPHEDRINE / PSEUDOEPHEDRINE	C/A	2020-08-19 (52) / Ongoing	30 (mg) / TID/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061046	OSTEOARTHRITIS BILATERAL HANDS	ALEVE/ NAPROXEN SODIUM	P/C/A	2008/ Ongoing	220 (mg) / PRN/ ORAL	No
US2061051	ANXIETY	ZOLOFT/ SERTRALINE HYDROCHLORIDE	P/C/A	1990/ Ongoing	50 (mg) / QD/ ORAL	No
	MIGRAINES	ADVIL/ IBUPROFEN	P/C/A	2019/ Ongoing	800 (mg) / PRN/ ORAL	No
US2061055	NUTRITIONAL SUPPLEMENT	CENTRUM SILVER MULTIVITAMIN/ VITAMINS NOS	P/C/A	2000-01/ Ongoing	1 (TABLET) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	OMEGA 3/ OMEGA-3 NOS	P/C/A	2000-01-01 (-7486) / Ongoing	690 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061055	NUTRITIONAL SUPPLEMENT	VITAMIN C/ ASCORBIC ACID	P/C/A	2000-01-01 (-7486) / Ongoing	500 (mg) / QD/ ORAL	No
	CARDIAC PROPHYLAXIS	ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2015-01/ Ongoing	80 (mg) / QD/ ORAL	No
US2071005	ATTENTION DEFICIT HYPERACTIVITY DISORDER	ADDERALL/ AMFETAMINE ASPARTATE; AMFETAMINE SULFATE; DEXAMFETAMINE SACCHARATE; DEXAMFETAMINE SULFATE	P/C/A	2020-02/ Ongoing	45 (mg) / QD/ ORAL	No
US2071084	ANXIETY	CITALOPRAM/ CITALOPRAM	P/C/A	2001/ Ongoing	20 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071085	ACID REFLUX	ESOMEPRAZOLE/ ESOMEPRAZOLE	P/C/A	2005/ Ongoing	40 (mg) / QD/ ORAL	No
	CHRONIC CONSTIPATION	DOCUSATE/ DOCUSATE	P/C/A	2009/ Ongoing	100 (mg) / QD/ ORAL	No
	OSTEOPOROSIS	CALCIUM/ CALCIUM	P/C/A	2011/ Ongoing	500 (mg) / QD/ ORAL	No
	OVERACTIVE BLADDER	TOLTERODINE TART/ TOLTERODINE L-TARTRATE	P/C/A	2016/ Ongoing	4 (mg) / QD/ ORAL	No
	CARDIAC PROPHYLAXIS	ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2018/ Ongoing	81 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071086	GOUT RIGHT BIG TOE	CELEBREX/ CELECOXIB	P/C	2018/ 2020-08-16 (52)	400 (mg) / QD/ ORAL	No
	GOUT IN THE RIGHT LARGE TOE	ALLOPURINOL/ ALLOPURINOL	P/C/A	2018/ Ongoing	300 (mg) / QD/ ORAL	No
	GOUT RIGHT BIG TOE	MELOXICAM/ MELOXICAM	C/A	2020-08-19 (55) / Ongoing	7.5 (mg) / QD/ ORAL	No
US2071092	OSTEOPOROSIS	CALCIUM/ CALCIUM	P/C/A	2015/ Ongoing	500 (mg) / QD/ ORAL	No
	OSTEOPOROSIS	VITAMIN D/ VITAMIN D NOS	P/C/A	2015/ Ongoing	(ug) / EVERY WEEK/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071094	HYPOTHYROIDISM	SYNTHROID/ LEVOTHYROXINE SODIUM	P/C/A	1980/ Ongoing	125 (ug) / QD/ ORAL	No
	PAIN AT INJECTION SITE	TYLENOL/ PARACETAMOL	C	2020-07-07 (2) / 2020-07-08 (3)	325 (mg) / PRN/ ORAL	Yes
US2071098	HYPERLIPIDEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	2010/ Ongoing	20 (mg) / QD/ ORAL	No
	HYPOTHYROIDISM	SYNTHROID/ LEVOTHYROXINE SODIUM	P/C/A	2015/ Ongoing	75 (ug) / QD/ ORAL	No
US2071100	CARDIAC PROPHYLAXIS	ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2007-01-01 (-4935) / Ongoing	81 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071100	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-07-10 (5) / 2020-07-10 (5)	500 (mg) / ONCE / ORAL	Yes
	HYPERLIPIDEMIA	ATORVASTATIN/ ATORVASTATIN	C/A	2020-08-24 (50) / Ongoing	20 (mg) / QD / ORAL	No
US2071102	ANXIETY/DEPRESSION	CYMBALTA/ DULOXETINE HYDROCHLORIDE	P/C/A	2010 / Ongoing	60 (mg) / QD / ORAL	No
	HORMONE SUPPLEMENT POST HYSTERECTOMY	ESTADIOL/ ESTRADIOL	P/C/A	2016 / Ongoing	1 (mg) / QD / ORAL	No
	RESTLESS LEG SYNDROME	REQUIP/ ROPINIROLE HYDROCHLORIDE	P/C/A	2018 / Ongoing	1.5 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071102	INSOMNIA	TRAZADONE/ TRAZODONE	P/C/A	2018/ Ongoing	100 (mg) / QD/ ORAL	No
	ANEMIA	FERROUS SULFATE/ FERROUS SULFATE	P/C/A	2020-06-12 (-17) / Ongoing	65 (mg) / QD/ ORAL	No
	SEASONAL ALLERGIC RHINITIS	ALLEGRA D 24 HOUR/ FEXOFENADINE HYDROCHLORIDE;PSEUDOEPHED RINE HYDROCHLORIDE	C/A	2020-08/ Ongoing	(mg) / PRN/ ORAL	No
	SEASONAL ALLERGIC RHINITIS	CLARITIN D 24 HOUR/ LORATADINE;PSEUDOEPHEDRIN E SULFATE	C/A	2020-08/ Ongoing	(mg) / PRN/ ORAL	No
US2071103	MILD DEPRESSION	PRISTIQ/ DESVENLAFAXINE SUCCINATE	P/C/A	2014/ Ongoing	150 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071103	BILATERAL EDEMA LEGS	ALDACTONE/ SPIRONOLACTONE	P/C/A	2018/ Ongoing	25 (mg) / QD/ ORAL	No
	BILATERAL EDEMA LEGS	DIAZIDE/ HYDRALAZINE HYDROCHLORIDE	P/C/A	2018/ Ongoing	37.5 (mg) / QD/ ORAL	No
US2071105	NECK SHOULDER PAIN	ADVIL/ IBUPROFEN	P/C/A	2020-06-29 (-7) / Ongoing	600 (mg) / PRN/ ORAL	No
	LOW TESTOSTERONE	TESTOPEL/ TESTOSTERONE	P/C/A	2020-06-29 (-7) / Ongoing	75 (mg) / OTHER: EVERY 3 MONTHS/ OTHER: SUBDERMAL	No
	NECK AND SHOULDER PAIN	TYLENOL/ PARACETAMOL	P/C/A	2020-06-29 (-7) / Ongoing	1000 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081004	MENOPAUSE	ETHINYL ESTRADIOL/ ETHINYLESTRADIOL	P/C/A	2010/ Ongoing	5 (ug) / QD/ ORAL	No
	MENOPAUSE	NORETHINDRONE ACETATE/ NORETHISTERONE ACETATE	P/C/A	2010/ Ongoing	1 (mg) / QD/ ORAL	No
	SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2015/ Ongoing	1 (TABLET) / QD/ ORAL	No
	SUPPLEMENT	VITAMIN D/ VITAMIN D NOS	P/C/A	2015/ Ongoing	400 (IU) / QD/ ORAL	No
	ANXIETY	PAXIL [PAROXETINE] / PAROXETINE HYDROCHLORIDE	P/C/A	2017/ Ongoing	10 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081004	SEASONAL ALLERGIES	ALLEGRA [FEXOFENADINE] / FEXOFENADINE HYDROCHLORIDE	P/C/A	2019 / Ongoing	180 (mg) / QD / ORAL	No
	INSOMNIA	LUNESTA [ESZOPICLONE] / ESZOPICLONE	P/C/A	2019 / Ongoing	2 (mg) / PRN / ORAL	No
	ADHD	ADDERALL [AMPHETAMINE] / AMFETAMINE ASPARTATE; AMFETAMINE SULFATE; DEXAMFETAMINE SACCHARATE; DEXAMFETAMINE SULFATE	P/C/A	2019-03-01 (-455) / Ongoing	20 (mg) / BID / ORAL	No
US2081005	SUPPLEMENT	MULTIVITAMIN / VITAMINS NOS	P/C/A	2020-03 / Ongoing	1 (TABLET) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081005	ANGIOEDEMA (LIP)	ACYCLOVIR/ ACICLOVIR	C	2020-06-09 (9) / 2020-06-13 (13)	750 (mg) / OTHER: 2 TO 3 TABS DAILY FOR 5 DAYS/ ORAL	No
	ANGIEDEMA (LIPS)	BENADRYL/ DIPHENHYDRAMINE HYDROCHLORIDE	C	2020-06-09 (9) / 2020-07-25 (55)	25 (mg) / PRN/ ORAL	No
	ANGIOEDEMA (LIP)	VALCYCLOVIR HCL/ VALACICLOVIR HYDROCHLORIDE	C	2020-06-16 (16) / 2020-06-18 (18)	2 (g) / BID/ ORAL	No
	ANGIOEDEMA (LIP)	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	C	2020-06-25 (25) / 2020-07-25 (55)	2 (TABLET) / QD/ ORAL	No
	ANGIOEDEMA (LIP)	CLARITIN/ LORATADINE	C	2020-07-10 (40) / 2020-07-25 (55)	(TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081005	ANGIOEDEMA (LIPS)	ALLEGRA/ FEXOFENADINE HYDROCHLORIDE	C/A	2020-07-26 (56) / Ongoing	180 (mg) / QD/ ORAL	No
	ANGIOEDEMA (LIPS)	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	C/A	2020-07-26 (56) / Ongoing	10 (mg) / QD/ ORAL	No
US2081007	SUPPLEMENT	CALCIUM/ CALCIUM	P/C/A	2010/ Ongoing	1200 (mg) / QD/ ORAL	No
	SUPPLEMENT	FISH OIL/ FISH OIL	P/C/A	2010/ Ongoing	1200 (mg) / QD/ ORAL	No
	SUPPLEMENT	GARLIC/ UNSPECIFIED HERBAL AND TRADITIONAL MEDICINE	P/C/A	2010/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081007	SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2010/ Ongoing	1 (TABLET) / QD/ ORAL	No
	ALLERGIC RHINITIS	ZYRTEC [CETIRIZINE] / CETIRIZINE HYDROCHLORIDE	P/C/A	2010/ Ongoing	10 (mg) / PRN/ ORAL	No
	ALLERGIC RHINITIS	ALLERGY SHOTS/ ALLERGENS NOS	P/C/A	2017/ Ongoing	0.5 (mL) / OTHER: THREE TIMES A WEEK/ INTRAMUSCULAR	No
	ALLERGIC RHINITIS	DYMISTA [AZECLASTINE 137 UG, FLUTICASONE 50 UG] / AZECLASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE	P/C/A	2017/ Ongoing	1 (OTHER: SPRAY) / QD/ NASAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081007	SUPPLEMENT	ESTER C [VITAMIN C, VITAMIN C-1000] / ASCORBIC ACID	C/A	2020 / Ongoing	1 (TABLET) / QD / ORAL	No
US2081015	ATTENTION DEFICIT HYPERACTIVITY DISORDER	ADDERALL [AMPHETAMINE] / AMFETAMINE ASPARTATE; AMFETAMINE SULFATE; DEXAMFETAMINE SACCHARATE; DEXAMFETAMINE SULFATE	P/C/A	2018 / Ongoing	10 (mg) / QD / ORAL	No
US2081017	SUPPLEMENT	CALCIUM / CALCIUM	P/C/A	1990 / Ongoing	2 (TABLET) / QD / ORAL	No
	SUPPLEMENT	MULTIVITAMIN / VITAMINS NOS	P/C/A	1990 / Ongoing	1 (TABLET) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081017	SUPPLEMENT	PROBIOTIC/ PROBIOTICS NOS	P/C/A	1990/ Ongoing	1 (TABLET) / QD/ ORAL	No
	SUPPLEMENT	MELATONIN/ MELATONIN	P/C/A	2019/ Ongoing	3 (mg) / OTHER: NIGHTLY/ ORAL	No
	DRY EYE (BILATERAL)	XIIDRA 5% [LIFITEGRAST] / LIFITEGRAST	P/C/A	2019/ Ongoing	1 (OTHER: DROP) / PRN/ INTRAOCULAR	No
	DAY 2 PREVENTATIVE FOR PAIN	ASPIRIN/ ACETYLSALICYLIC ACID	C	2020-06-03 (2) / 2020-06-03 (2)	500 (mg) / ONCE/ ORAL	No
	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-07-07 (36) / 2020-07-07 (36)	500 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081017	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-07-09 (38) / 2020-07-10 (39)	500 (mg) / PRN / ORAL	Yes
US2081029	SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2015/ Ongoing	2 (TABLET) / QD / ORAL	No
US2081030	DYSLIPIDEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	2019/ Ongoing	10 (mg) / QD / ORAL	No
	SUPPLEMENT	FEOSOL/ FERROUS SULFATE	P/C	2020-05-18 (-15) / 2020-06-08 (7)	325 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081065	MAJOR DEPRESSIVE DISORDER	CITALOPRAM HYDROBOMIDE/ CITALOPRAM HYDROBROMIDE	P/C/A	2015/ Ongoing	20 (mg) / QD/ ORAL	No
US2081066	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-08-02 (38) / 2020-08-02 (38)	650 (mg) / ONCE/ ORAL	No
US2081073	MIGRAINES	IMITREX/ SUMATRIPTAN	P/C/A	1990/ Ongoing	100 (mg) / PRN/ ORAL	No
	HERPES LABIALIS	VALCYCLOVIR/ VALACICLOVIR	P/C/A	1990/ Ongoing	500 (mg) / PRN/ ORAL	No
	MENOPAUSE	ESTRIADOL/ ESTRADIOL	P/C/A	1999/ Ongoing	1 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081073	MENOPAUSE	PROGESTERONE/ PROGESTERONE	P/C/A	1999/ Ongoing	5 (mg) / OTHER: 12 DAYS PER MONTH/ ORAL	No
	VITAMIN D DEFICIENCY	VITAMIN D/ VITAMIN D NOS	P/C/A	2012/ Ongoing	2000 (IU) / QD/ ORAL	No
	SUPPLEMENT	BIOTIN/ BIOTIN	P/C/A	2015/ Ongoing	5000 (ug) / QD/ ORAL	No
	SEASONAL ALLERGIES	ZYRTEC-D (5MG/120MG) / CETIRIZINE HYDROCHLORIDE; PSEUDOEPHED RINE HYDROCHLORIDE	P/C/A	2015/ Ongoing	1 (TABLET) / BID/ ORAL	No
	ACID REFLUX	OMEPRazole/ OMEPRazole	C	2020-07-30 (35) / 2020-08-13 (49)	20 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081077	DYSLIPIDEMIA	ATORVASTATIN CALCIUM/ ATORVASTATIN CALCIUM	P/C/A	2016/ Ongoing	40 (mg) / QD/ ORAL	No
	PROPHYLAXIS FOR CONSTIPATION	LAXATIVE [BISACODYL] / BISACODYL	P/C/A	2017/ Ongoing	8.6 (mg) / QD/ ORAL	No
	PROPHYLAXIS FOR CONSTIPATION	STOOL SOFTENER [DOCUSATE SODIUM] / DOCUSATE SODIUM	P/C/A	2017/ Ongoing	100 (mg) / QD/ ORAL	No
	HERPES LABIALIS	VALCYCLOVIR / VALACICLOVIR	P/C/A	2017/ Ongoing	1 (g) / PRN/ ORAL	No
	INSOMNIA	TRAZODONE / TRAZODONE	P/C/A	2017-12-11 (-932) / Ongoing	50 (mg) / OTHER: QHS PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081077	DEPRESSION	BUPROPION HCI/ BUPROPION HYDROCHLORIDE	P/C	2018-09-04 (-665) / 2020-08-29 (61)	150 (mg) / QD/ ORAL	No
	CARDIO PREVENTATIVE	BABY ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2020-06-15 (-15) / Ongoing	81 (mg) / QD/ ORAL	No
	DEPRESSION	BUSPIRONE/ BUSPIRONE	C/A	2020-08-29 (61) / Ongoing	5 (mg) / QD/ ORAL	No
	DEPRESSION	ESCITALOPRAM (LEXAPRO) / ESCITALOPRAM OXALATE	C/A	2020-08-29 (61) / Ongoing	5 (mg) / QD/ ORAL	No
US2081080	SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2010 / Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081080	ERECTILE DYSFUNCTION	VARDENAFIL HCL/ VARDENAFIL HYDROCHLORIDE	P/C/A	2010/ Ongoing	20 (mg) / PRN/ ORAL	No
	CHRONIC KNEE PAIN (LEFT)	CELECOXIB/ CELECOXIB	P/C/A	2014/ Ongoing	50 (mg) / QD/ ORAL	No
	SUPPLEMENT	GLUCOSAMINE CHONDROITIN (500MG/ 400MG) / CHONDROITIN;GLUCOSAMINE	P/C/A	2015/ Ongoing	(mg) / QD/ ORAL	No
	SUPPLEMENT	TUMERIC/ CURCUMA LONGA	P/C/A	2015/ Ongoing	500 (mg) / QD/ ORAL	No
	VERTIGO	MECLIZINE HCL/ MECLOZINE HYDROCHLORIDE	P/C/A	2018/ Ongoing	25 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081097	SUPPLEMENT	CENTRUM SILVER/ VITAMINS NOS	P/C/A	1990/ Ongoing	1 (TABLET) / QD/ ORAL	No
	SEASONAL ALLERGIES	FLUTICASONE/ FLUTICASONE	P/C/A	2015/ Ongoing	50 (ug) / PRN/ NASAL	No
	SUPPLEMENT	CALCIUM/ CALCIUM	P/C/A	2017/ Ongoing	600 (mg) / QD/ ORAL	No
	SUPPLEMENT	VITAMIN D3/ COLECALCIFEROL	P/C/A	2017/ Ongoing	400 (IU) / QD/ ORAL	No
	SUPPLEMENT	FISH OIL/ FISH OIL	P/C/A	2018/ Ongoing	950 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081097	ACNE OF FACE	TRETINOIN CREAM .05%/ TRETINOIN	P/C/A	2018/ Ongoing	1 (OTHER: APPLICATION) / QOD/ TOPICAL	No
	CARDIOPREVENTATIVE	ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2019/ Ongoing	81 (mg) / QD/ ORAL	No
	DYSLIPIDEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	2019-11/ Ongoing	20 (mg) / QD/ ORAL	No
US2081103	SUPPLEMENT	CALCIUM/ CALCIUM	P/C/A	2010/ Ongoing	238 (mg) / QD/ ORAL	No
	SUPPLEMENT	MAGNESIUM/ MAGNESIUM	P/C/A	2010/ Ongoing	143 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081104	SUPPLEMENT	SLOWMAG/ MAGNESIUM CHLORIDE	P/C/A	2010/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEADACHE [EDIARY]	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-07 (6) / 2020-08-20 (50)	500 (mg) / PRN/ ORAL	Yes
US2081113	SUPPLEMENT	FISH OIL/ FISH OIL	P/C/A	2015/ Ongoing	1000 (mg) / QD/ ORAL	No
	SUPPLEMENT	MEDIUM-CHAIN TRIGLYCERIDES OIL/ MEDIUM-CHAIN TRIGLYCERIDES	P/C/A	2019/ Ongoing	2 (OTHER: TBSP) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081113	SUPPLEMENT	TUMERIC/ CURCUMA LONGA	P/C/A	2019/ Ongoing	15 (mL) / OTHER: 2 TO 3 TIMES WEEKLY/ ORAL	No
	ERECTILE DYSFUNCTION	CIALIS/ TADALAFIL	P/C/A	2020-06-29 (-9) / Ongoing	20 (mg) / PRN/ ORAL	No
	PAIN (VEIN SURGERY)	IBUPROPHEN/ IBUPROFEN	C	2020-08-17 (41) / 2020-08-17 (41)	250 (mg) / PRN/ ORAL	No
US2081119	ALLERGIC RHINITIS	LORATADINE/ LORATADINE	P/C/A	2000/ Ongoing	10 (mg) / QD/ ORAL	No
	OSTEOPENIA	VITAMIN D/ VITAMIN D NOS	P/C/A	2012/ Ongoing	1000 (IU) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081119	VITAMIN B12 DEFICIENCY	VITAMIN B12/ VITAMIN B12 NOS	P/C/A	2015/ Ongoing	500 (ug) / QD/ ORAL	No
US2081125	CARDIOPREVENTATIVE	BABY ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2010/ Ongoing	81 (mg) / QD/ ORAL	No
	SUPPLEMENT	KRILL OIL/ KRILL OIL	P/C/A	2010/ Ongoing	300 (mg) / QD/ ORAL	No
	INSOMNIA	KLONOPIN/ CLONAZEPAM	P/C/A	2016/ Ongoing	0.5 (mg) / PRN/ ORAL	No
	SUPPLEMENT	ZINC/ ZINC	P/C/A	2020-01/ Ongoing	150 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081125	COMMON COLD	TYLENOL/ PARACETAMOL	C	2020-08-05 (35) / 2020-08-08 (38)	325 (mg) / QD/ ORAL	No
	COMMON COLD	CVS HEALTH NASAL DECONGESTANT NON-DROWSY PHENYLEPHRINE HYDROCHLORIDE TABLETS (PHENYLEPHRINE HCL (10 MG)) / PHENYLEPHRINE HYDROCHLORIDE	C	2020-08-06 (36) / 2020-08-08 (38)	10 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011012	ANXIETY	EFFEXOR/ VENLAFAXINE HYDROCHLORIDE	P/C/A	1995/ Ongoing	75 (mg) / QD/ ORAL	No
US2011014	ROSACEA ON BILATERAL CHEEKS	METRONIDAZOLE (0.75%) / METRONIDAZOLE	P/C/A	1994/ Ongoing	1 (OTHER: APPLICATION) / QD/ TOPICAL	No
	POST-MENOPAUSAL	ESTRADIOL/ ESTRADIOL	P/C/A	2001/ Ongoing	0.0375 (mg) / QD/ TRANSDERMAL	No
	MIGRAINES	IMITREX/ SUMATRIPTAN	P/C/A	2004/ Ongoing	50 (mg) / PRN/ ORAL	No
	IRRITABLE BOWEL SYNDROME	AMITIZA/ LUBIPROSTONE	P/C/A	2009/ Ongoing	24 (ug) / BID/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011014	HYPERTHYROIDISM	LEVOTHYROXINE/ LEVOTHYROXINE	P/C/A	2014/ Ongoing	50 (ug) / QD/ ORAL	No
	SEASONAL ALLERGIES	LORATIDINE/ LORATADINE	P/C/A	2018/ Ongoing	10 (mg) / PRN/ ORAL	No
	HEADACHE	IMITREX/ SUMATRIPTAN	C	2020-06-03 (3) / 2020-06-04 (4)	50 (mg) / QD/ ORAL	Yes
	HEADACHE	IMITREX/ SUMATRIPTAN	C	2020-06-06 (6) / 2020-06-06 (6)	50 (mg) / QD/ ORAL	Yes
	INJECTION SITE PAIN	IBUPROFEN/ IBUPROFEN	C	2020-06-30 (30) / 2020-06-30 (30)	600 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011014	HEADACHE	IMITREX/ SUMATRIPTAN	C	2020-06-30 (30) / 2020-06-30 (30)	50 (mg) / QD/ ORAL	No
	HEADACHE	IMITREX/ SUMATRIPTAN	C	2020-07-02 (32) / 2020-07-03 (33)	50 (mg) / QD/ ORAL	No
US2011040	OVERACTIVE BLADDER	OXYBUTYNIN/ OXYBUTYNIN	P/C/A	2020-03-26 (-67) / Ongoing	15 (mg) / QD/ ORAL	No
	SHINGLES	VALOCYCLOVIR/ VALACICLOVIR	P	2020-04-30 (-32) / 2020-05-06 (-26)	1 (g) / TID/ ORAL	No
US2011117	HYPOTHYROIDISM	LEVOTHYROXINE/ LEVOTHYROXINE	P/C/A	2020-04-09 (-78) / Ongoing	50 (ug) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011125	HERPES SIMPLEX	ACYCLOVIR/ ACICLOVIR	P/C/A	2000/ Ongoing	1000 (mg) / PRN/ ORAL	No
	SEASONAL ALLERGIES, CEDAR	CLARITIN/ LORATADINE	P/C/A	2017/ Ongoing	10 (mg) / PRN/ ORAL	No
	SEASONAL ALLERGIES	FLUTICASONE/ FLUTICASONE	P/C/A	2017/ Ongoing	2 (OTHER: SPRAYS) / PRN/ NASAL	No
	HYPERCHOLESTEROLEMIA	CRESTOR/ ROSUVASTATIN CALCIUM	P/C/A	2019/ Ongoing	10 (mg) / QD/ ORAL	No
US2011127	SEASONAL ALLERGIES	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2006/ Ongoing	10 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011127	IRRITABLE BOWEL SYNDROME	IMODIUM/ LOPERAMIDE HYDROCHLORIDE	P/C/A	2007/ Ongoing	2 (TABLET) / PRN/ ORAL	No
	INGUINAL HERNIA PAIN, UNKNOWN LOCATION	IBUPROFEN/ IBUPROFEN	P/C/A	2008/ Ongoing	400 (mg) / PRN/ ORAL	No
US2011137	OVERACTIVE BLADDER	MYRBETRIQ/ MIRABEGRON	P/C/A	2017/ Ongoing	50 (mg) / QD/ ORAL	No
	HEADACHE	ALEVE/ NAPROXEN SODIUM	C	2020-07-02 (7) / 2020-07-02 (7)	220 (mg) / ONCE/ ORAL	Yes
	HEADACHE	ALEVE/ NAPROXEN SODIUM	C/A	2020-07-23 (28) / Ongoing	220 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011137	HEADACHE	ALEVE/ NAPROXEN SODIUM	C	2020-07-25 (30) / 2020-07-25 (30)	220 (mg) / QD/ ORAL	Yes
	HEADACHE	ALEVE/ NAPROXEN SODIUM	C	2020-07-29 (34) / 2020-07-29 (34)	220 (mg) / ONCE/ ORAL	Yes
US2011138	LEFT KNEE PAIN	NAPROXEN/ NAPROXEN	P/C/A	2020-05/ Ongoing	500 (mg) / PRN/ ORAL	No
US2011153	RIGHT KNEE PAIN	NAPROXEN/ NAPROXEN	C	2020-08-23 (56) / 2020-08-23 (56)	400 (mg) / ONCE/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021004	HERPES SIMPLEX	VALACYCLOVIR/ VALACICLOVIR	P/C/A	2000/ Ongoing	500 (mg) / PRN/ ORAL	No
	PAIN AT INJECTION SITE	ACETAMINOPHEN/ PARACETAMOL	C	2020-06-27 (30) / 2020-06-27 (30)	400 (mg) / QD/ ORAL	Yes
US2021012	SEASONAL ALLERGIES	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2015/ Ongoing	10 (mg) / PRN/ ORAL	No
	CHRONIC LEFT FOOT PAIN	GABAPENTIN/ GABAPENTIN	P/C/A	2019-05/ Ongoing	300 (mg) / TID/ ORAL	No
	HEADACHE	ASPIRIN/ ACETYLSALICYLIC ACID	C	2020-06-30 (30) / 2020-06-30 (30)	325 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021018	OSTEOPENIA	RAYLOXIFENE/ RALOXIFENE	P/C/A	2000/ Ongoing	60 (mg) / QD/ ORAL	No
	OVERACTIVE BLADDER	OXYBUTININ/ OXYBUTYNIN	P/C/A	2010/ Ongoing	15 (mg) / QD/ ORAL	No
	BACK PAIN	ALEVE/ NAPROXEN SODIUM	P/C/A	2019/ Ongoing	220 (mg) / PRN/ ORAL	No
	URINARY TRACT INFECTION	NITRUFURANTION/ NITROFURANTOIN	C	2020-07-01 (34) / 2020-07-07 (40)	100 (mg) / BID/ ORAL	No
	BACK PAIN	DICOLFENAC SODIUM/ DICLOFENAC SODIUM	C/A	2020-08-06 (70) / 2020-08-14 (78)	75 (mg) / BID/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021018	BACK PAIN	CYCLOBENZAPRINE/ CYCLOBENZAPRINE	C/A	2020-08-07 (71) / 2020-08-14 (78)	5 (mg) / PRN/ ORAL	No
	BACK PAIN	PREDNISONE/ PREDNISONE	C/A	2020-08-07 (71) / 2020-08-15 (79)	10 (mg) / QD/ ORAL	No
US2021019	SUPPLEMENT	ASPIRIN/ ACETYLSALICYLIC ACID	P	2020-03/ 2020-05-26 (-3)	81 (mg) / PRN/ ORAL	No
	KIDNEY STONE BILATERAL	OXYCODONE ACETAMINOHEN/ OXYCODONE; PARACETAMOL	C	2020-06-24 (27) / 2020-07-08 (41)	(mg) / PRN/ ORAL	No
	KIDNEY STONES BILATERAL	OXYCODONE ACETAMINOPHEN/ OXYCODONE; PARACETAMOL	C	2020-06-26 (29) / 2020-07-08 (41)	(mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021019	NEPHROLITHIASIS RIGHT	IBUPROFEN/ IBUPROFEN	C	2020-06-27 (30) / 2020-07-06 (39)	400 (mg) / TID / ORAL	No
US2021020	HEADACHE DAIRY DAY	NAPROXEN/ NAPROXEN	C	2020-06-08 (8) / 2020-06-08 (8)	220 (mg) / ONCE / ORAL	Yes
US2021045	HORMONE REPLACEMENT THERAPY	ESTRADIOL/ ESTRADIOL	P/C/A	2015 / Ongoing	1 (mg) / QD / ORAL	No
	HORMONE REPLACEMENT THERAPY	PROGESTERONE/ PROGESTERONE	P/C/A	2015 / Ongoing	200 (mg) / QD / ORAL	No
	GENERALIZED BODY ACHES	ACETAMINOPHEN/ PARACETAMOL	C	2020-06-30 (30) / 2020-06-30 (30)	500 (mg) / QD / ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021045	GENERALIZED BODY ACHES	IBUPROFEN/ IBUPROFEN	C	2020-06-30 (30) / 2020-06-30 (30)	600 (mg) / QD/ ORAL	Yes
	TOOTHACHE	AMOXICILLIN/ AMOXICILLIN	C	2020-07-03 (33) / 2020-07-07 (37)	500 (mg) / TID/ ORAL	No
US2021133	DEPRESSION	ESCITALOPRAM/ ESCITALOPRAM	P/C/A	2012/ Ongoing	10 (mg) / QD/ ORAL	No
	HYPERLIPIDEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	2016/ Ongoing	20 (mg) / QD/ ORAL	No
	RIGHT SHOULDER PAIN	CELECOXIB/ CELECOXIB	P/C/A	2016/ Ongoing	200 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021133	HYPERLIPIDEMIA	FENOFIBRATE/ FENOFIBRATE	P/C/A	2016/ Ongoing	160 (mg) / QD/ ORAL	No
	GASTROESOPHAGEAL REFLUX DISEASE	OMEPRAZOLE/ OMEPRAZOLE	P/C/A	2016/ Ongoing	20 (mg) / QD/ ORAL	No
US2021190	WEIGHT LOSS	PHENTERMINE/ PHENTERMINE	P/C/A	2012/ Ongoing	15 (mg) / QD/ ORAL	No
	PREVENTIVE FOR SHINGLES	VALACYCLOVIR/ VALACICLOVIR	P/C/A	2014/ Ongoing	500 (mg) / QD/ ORAL	No
	INSOMNIA	ZOLPIDEM/ ZOLPIDEM	P/C/A	2014/ Ongoing	5 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021205	SUPPLEMENT	IRON/ IRON	P/C/A	1970 / Ongoing	65 (mg) / QD / ORAL	No
	SUPPLEMENT	VITAMIN B12 / VITAMIN B12 NOS	P/C/A	2010 / Ongoing	1000 (ug) / QD / ORAL	No
	GENERALIZED PRURITIS	BENADRYL / DIPHENHYDRAMINE HYDROCHLORIDE	C/A	2020-06-30 (5) / Ongoing	25 (mg) / PRN / ORAL	No
	GENERALIZED PRUITIS	CLARITIN / LORATADINE	C	2020-07-09 (14) / 2020-07-16 (21)	10 (mg) / QD / ORAL	No
	PAIN AT INJECTION SITE	ACETAMINOPHEN / PARACETAMOL	C	2020-08-01 (37) / 2020-08-02 (38)	500 (mg) / QD / ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021216	SUPPLEMENT	VITAMIN C/ ASCORBIC ACID	P/C/A	2005/ Ongoing	1000 (mg) / QD/ ORAL	No
	SUPPLEMENT	VITAMIN D3/ COLECALCIFEROL	P/C/A	2005/ Ongoing	1000 (IU) / QD/ ORAL	No
	FEVER/PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-08-04 (34) / 2020-08-05 (35)	200 (mg) / PRN/ ORAL	Yes
US2021217	DRY EYES BILATERAL	CYCLOSPORINE/ CICLOSPORIN	P/C/A	2005/ Ongoing	1 (OTHER: DROP) / BID/ OTHER: OPHTHALMIC	No
	POST MENOPAUSAL	ESTRADOL/ ESTRADIOL	P/C/A	2015/ Ongoing	1 (OTHER: APPLICATION) / QD/ VAGINAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021217	POST MENOPAUSAL	PROGESTERONE/ PROGESTERONE	P/C/A	2015/ Ongoing	40 (mL) / QD/ VAGINAL	No
	HYPERCHOLESTEROLEMIA	ROSUVASTATIN/ ROSUVASTATIN	P/C/A	2019-08/ Ongoing	10 (mg) / QD/ ORAL	No
	HEADACHE	NAPROXEN/ NAPROXEN	C	2020-07-29 (31) / 2020-07-29 (31)	500 (mg) / QD/ ORAL	Yes
	MUSCLE ACHES ALL OVER	NAPROXEN/ NAPROXEN	C	2020-07-29 (31) / 2020-07-29 (31)	500 (mg) / QD/ ORAL	Yes
US2021226	POST MENOPAUSAL	ESTRADIOL/ ESTRADIOL	P/C/A	1998/ Ongoing	1 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021226	MIGRAINE PREVENTION	PROPRANOLOL/ PROPRANOLOL	P/C/A	2005/ Ongoing	60 (mg) / QD/ ORAL	No
	HYPERCHOLESTEROLEMIA	LOVASTATIN/ LOVASTATIN	P/C/A	2010/ Ongoing	40 (mg) / QD/ ORAL	No
	GASTROESOPHAGEAL REFLUX DISEASE	PANTOPRAZOLE/ PANTOPRAZOLE	P/C/A	2015/ Ongoing	40 (mg) / QD/ ORAL	No
	INSOMNIA	AMITRIPTYLINE/ AMITRIPTYLINE	P/C/A	2018/ Ongoing	25 (mg) / QD/ ORAL	No
	ROSACEA FACIAL	DOXYCLINE/ DOXYCYCLINE	P/C/A	2020-01/ Ongoing	300 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021226	ANXIETY	ECITALOPRAM/ ESCITALOPRAM	P/C/A	2020-03/ Ongoing	5 (mg) / QD/ ORAL	No
US2031086	OSTEOPOROSIS	PROLIA/ DENOSUMAB	P/C/A	2018/ Ongoing	60 (mg) / OTHER: EVERY 6 MONTHS/ SUBCUTANEOUS	No
US2031096	INJECTION SITE PAIN	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-28 (33) / 2020-07-30 (35)	1000 (mg) / PRN/ ORAL	Yes
US2031097	HYOERCHOLESTEROLEMIA	SIMVASTATIN/ SIMVASTATIN	P/C/A	2015/ Ongoing	20 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031097	OPEN- ANGLE BILATERAL GLAUCOMA	COMBIGAN/ BRIMONIDINE TARTRATE;TIMOLOL MALEATE	P/C/A	2016/ Ongoing	1 (OTHER: DROP) / BID/ INTRAOCULAR	No
	GENERALIZED OSTEOARTHRITIS	MELOXICAM/ MELOXICAM	P/C/A	2018/ Ongoing	7.5 (mg) / QD/ ORAL	No
US2031104	SEASONAL ALLERGIES	CLARATIN D PSEUDOEPHEDRINE SULFATE LORATADINE/ LORATADINE;PSEUDOEPHEDRIN E SULFATE	P/C/A	2015/ Ongoing	(mg) / PRN/ ORAL	No
	SEASONAL ALLERGIES	BEPOTASINE/ BEPOTASTINE	C/A	2020-07-01 (6) / Ongoing	1 (OTHER: DROP) / BID/ OTHER: EYE DROPS	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031106	DEPRESSION	WELLBUTRIN XL/ BUPROPION HYDROCHLORIDE	P/C/A	2019/ Ongoing	150 (mg) / QD/ ORAL	No
US2031107	HOT FLASHES	ESTRALNORETH/ ESTRADIOL;NORETHISTERONE ACETATE	P/C/A	2010/ Ongoing	(mg) / QD/ ORAL	No
	DEPRESSION	ESCITALOPRAM/ ESCITALOPRAM	P/C/A	2012/ Ongoing	10 (mg) / QD/ ORAL	No
	INSOMNIA	ZOLPIDEM/ ZOLPIDEM	P/C/A	2012/ Ongoing	10 (mg) / QD/ ORAL	No
US2031108	HYPERCHOLESTEROLEMIA	SIMVASTATIN/ SIMVASTATIN	P/C/A	2019-06/ Ongoing	10 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031109	HYPERC HOLESTEROLEMIA	SIMVASTATIN/ SIMVASTATIN	P/C/A	2015/ Ongoing	40 (mg) / QD/ ORAL	No
US2031114	BACK PAIN	NAPROXEN/ NAPROXEN	P	2020-06-30 (-1) / 2020-06-30 (-1)	220 (mg) / ONCE/ ORAL	No
US2031121	SEASONAL ALLERGIES	CLARITIN/ LORATADINE	P/C/A	2015/ Ongoing	10 (mg) / QD/ ORAL	No
US2031128	OSTEOPENIA	PROLIA/ DENOSUMAB	P/C/A	2014/ Ongoing	0.5 (mL) / OTHER: EVERY 6 MONTHS/ INTRAMUSCULAR	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031128	BILATERAL MACULAR DEGENERATION	BEOVU/ BROLUCIZUMAB DBLL	P/C/A	2018/ Ongoing	6 (mg) / OTHER: EVERY 8 WEEKS/ OTHER: INNER OCCULAR INJECTION	No
US2041094	NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	1990/ Ongoing	1 (TABLET) / QD/ ORAL	No
	SEASONAL ALLERGIES	ALLERGA/ FEXOFENADINE HYDROCHLORIDE	P/C/A	2010/ Ongoing	1 (TABLET) / QD/ ORAL	No
	CHRONIC DRY EYES	DE 3 DRY EYE OMEGA BENEFITS/ COLECALCIFEROL;DOCOSAHEXA ENOIC ACID;EICOSAPENTAENOIC ACID	P/C/A	2017/ Ongoing	3 (OTHER: SOFT GELS) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041100	NUTRITIONAL SUPPLEMENT	HERBAL VITAMINS/ VITAMINS NOS	P/C/A	2017/ Ongoing	1 (TABLET) / QD/ ORAL	No
	POST MENOPAUSAL SYMPTOMS	PROGESTERONE/ PROGESTERONE	P/C/A	2020-03-01 (-120) / Ongoing	40 (mg) / QD/ TOPICAL	No
	SOLICITED SYMPTOMS-INJECTION SITE PAIN/SWELLING AND FEVER	IBUPROFEN/ IBUPROFEN	C	2020-07-28 (30) / 2020-07-29 (31)	600 (mg) / PRN/ ORAL	Yes
US2041103	HYPERCHOLESTEROLEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	1998/ Ongoing	20 (mg) / QD/ ORAL	No
	BILATERAL GLAUCOMA	LATANOPROST/ LATANOPROST	P/C/A	2005/ Ongoing	1 (ug) / QD/ INTRAOCULAR	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041103	INSOMNIA	ZOLPIDEM/ ZOLPIDEM	P/C/A	2015-11/ Ongoing	10 (mg) / PRN/ ORAL	No
US2041104	NUTRITIONAL SUPPLEMENT	PERSERVISION/ ASCORBIC ACID;BETACAROTENE;CUPRIC OXIDE;TOCOPHERYL ACETATE;ZINC OXIDE	P/C/A	2018/ Ongoing	25 (mg) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	VITAMIN D3/ COLECALCIFEROL	P/C/A	2018/ Ongoing	25 (ug) / QD/ ORAL	No
	CHIARI MALFORMATION	OXCARBAZAPINE/ OXCARBAZEPINE	P	2018-10/ 2020-06-20 (-6)	300 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041104	CHIARIMAL FORMATION	TOPIRAMATE/ TOPIRAMATE	P/C/A	2020-06-20 (-6) / Ongoing	50 (mg) / QD/ ORAL	No
	INSOMNIA	AMITRIPTYLIN/ AMITRIPTYLINE HYDROCHLORIDE	C/A	2020-07-08 (13) / Ongoing	25 (mg) / PRN/ ORAL	No
	INSOMNIA	AMITRIPTYLINE/ AMITRIPTYLINE	C/A	2020-07-08 (13) / Ongoing	25 (mg) / PRN/ ORAL	No
US2041106	BILATERAL EYE GLAUCOMA	DOROLAMIDE/ DORZOLAMIDE	P/C/A	2010/ Ongoing	1 (OTHER: DROP) / TID/ INTRAOCULAR	No
	BILATERAL EYE GLAUCOMA	LATANOPROST/ LATANOPROST	P/C/A	2010/ Ongoing	1 (OTHER: DROP) / TID/ INTRAOCULAR	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041106	HYPERCHOLESTEROLEMIA	SIMVASTATIN/ SIMVASTATIN	P/C/A	2010/ Ongoing	20 (mg) / QD/ ORAL	No
US2041109	CARDIAC PROPHYLAXIS	ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2013/ Ongoing	80 (mg) / QD/ ORAL	No
	HYPERCHOLESTEROLEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	2016/ Ongoing	20 (mg) / QD/ ORAL	No
	SEASONAL ALLERGIES	MONTELUKAST/ MONTELUKAST	P/C/A	2016/ Ongoing	10 (mg) / QD/ ORAL	No
	SEASONAL ALLERGIES	ALLEGRA/ FEXOFENADINE HYDROCHLORIDE	C/A	2020/ Ongoing	180 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041109	SOLICITED SYMPTOMS-BODY ACHES	TYLENOL/ PARACETAMOL	C	2020-07-28 (33) / 2020-07-28 (33)	700 (mg) / ONCE / ORAL	Yes
US2041111	CARDIAC PROPHYLAXIS	ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2010 / Ongoing	81 (mg) / QD / ORAL	No
	HYPERCHOLESTEROLEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	2010 / Ongoing	10 (mg) / QD / ORAL	No
	GENERALIZED JOINT PAIN	GLUCOSARINE/ GLUCOSAMINE	P/C/A	2015 / Ongoing	1500 (mg) / QD / ORAL	No
	GENERALIZED JOINT PAIN	ALEVE/ NAPROXEN SODIUM	P/C/A	2019 / Ongoing	220 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041113	HEADACHES	NOTRIPTYLINE/ NORTRIPTYLINE	P/C/A	2020-06-11 (-19) / Ongoing	10 (mg) / QD/ ORAL	No
	SOLICITED EVENT-PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-01 (2) / 2020-07-02 (3)	200 (mg) / QD/ ORAL	Yes
	SOLICITED SYMPTOMS-BODY AND JOINT ACHES	IBUPROFEN/ IBUPROFEN	C	2020-07-29 (30) / 2020-07-30 (31)	400 (mg) / OTHER: Q6HOURS/ ORAL	Yes
US2041118	INSOMNIA	MELATONIN/ MELATONIN	P/C	2018/ 2020-07-12 (14)	10 (mg) / PRN/ ORAL	No
	NUTRITIONAL SUPPLEMENT	PROBIOTIC/ PROBIOTICS NOS	P/C/A	2019/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041118	INSOMNIA	TYLENOL PM/ DIPHENHYDRAMINE HYDROCHLORIDE; PARACETAMOL	C/A	2020/ Ongoing	(mg) / PRN / ORAL	No
US2041119	BOWEL HEALTH	METAMUCIL/ PLANTAGO OVATA	P/C/A	2010/ Ongoing	2 (OTHER: TSP) / QD / ORAL	No
	NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2010/ Ongoing	1 (TABLET) / QD / ORAL	No
	CARDIAC PROPHYLAXIS	ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2015/ Ongoing	81 (mg) / QD / ORAL	No
	PROPHYLAXIS	ATORVASTATIN/ ATORVASTATIN	P/C/A	2015/ Ongoing	5 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041119	ENLARGED PROSTATE	TAMSULOSIN/ TAMSULOSIN	P/C/A	2019/ Ongoing	0.4 (mg) / QD/ ORAL	No
	CHRONIC LOWER BACK PAIN	EPIDURAL/ ANESTHETICS, LOCAL	C/A	2020-08/ Ongoing	1 (OTHER: INJECTION) /No PRN/ INTRAMUSCULAR	
US2041127	PROSTATIC HYPERPLASIA	TAMSULOSIN/ TAMSULOSIN	P/C/A	2015/ Ongoing	0.4 (mg) / BID/ ORAL	No
	ERECTILE DYSFUCTION	TADALAFIL/ TADALAFIL	P/C/A	2018/ Ongoing	5 (mg) / BID/ ORAL	No
US2041130	ANXIETY	CLONAZEPAM/ CLONAZEPAM	P/C/A	2019/ Ongoing	5 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041130	RIGHT SCIATIC NERVE DAMAGE	GABAPENTIN/ GABAPENTIN	P/C/A	2019/ Ongoing	300 (mg) / QD/ ORAL	No
US2041139	NUTRITIONAL SUPPLEMENT	CENTRUM MULTIVITAMIN/ VITAMINS NOS	P/C/A	2000/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HYPERCHOLESTEROLEMIA	SIMVASTATIN/ SIMVASTATIN	P/C/A	2000/ Ongoing	20 (mg) / QD/ ORAL	No
	ANXIETY	ESCITALOPRAM/ ESCITALOPRAM	P/C/A	2020-05-22 (-38) / Ongoing	10 (mg) / QD/ ORAL	No
US2041145	SEASONAL ALLERGIES	CLARITIN/ LORATADINE	P/C/A	1965/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041145	SEASONAL ALLERGIES	FLONASE/ FLUTICASONE PROPIONATE	P/C/A	1985/ Ongoing	1 (OTHER: SPRAY) / QD/ OTHER: INTRANASAL	No
	ANXIETY	PAROXETINE HCL/ PAROXETINE HYDROCHLORIDE	P/C/A	1995/ Ongoing	20 (mg) / QD/ ORAL	No
	CYSTIC ACNE	MINOCYCLINE HCL/ MINOCYCLINE HYDROCHLORIDE	P/C/A	2000/ Ongoing	50 (mg) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	FISH OIL/ FISH OIL	P/C/A	2015/ Ongoing	1200 (mg) / QD/ ORAL	No
	HOT FLASHES	GABAPENTIN/ GABAPENTIN	P/C/A	2015/ Ongoing	100 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041145	NUTRITIONAL SUPPLEMENT	CHONDROITIN/ CHONDROITIN	P/C/A	2018/ Ongoing	1200 (mg) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	GLUCOSAMINE/ GLUCOSAMINE	P/C/A	2018/ Ongoing	1500 (mg) / QD/ ORAL	No
US2041155	HYPERCHOLESTEROLEMIA	LOVASTATIN/ LOVASTATIN	P/C/A	1980/ Ongoing	50 (mg) / QD/ ORAL	No
	SOLICITED SYMPTOMS-HEADACHES	IBUPROFEN/ IBUPROFEN	C	2020-07-06 (1) / 2020-07-10 (5)	220 (mg) / PRN/ ORAL	Yes
	SOLICITED SYMPTOMS-HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-08-03 (29) / 2020-08-09 (35)	200 (mg) / PRN/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051057	GENERALIZED MUSCLE ACHES DUE TO OVERDOING EXERCISE	ALEVE (NAPROXEN) / NAPROXEN SODIUM	P/C/A	2019-01-01 (-542) / Ongoing	220 (mg) / PRN / ORAL	No
	HEALTH MAINTENANCE	MULTIVITAMIN / VITAMINS NOS	P/C/A	2020-03-01 (-117) / Ongoing	1 (TABLET) / QD / ORAL	No
	HEADACHE, FATIGUE, MUSCLE ACHES ALL OVER BODY, JOINT ACHES IN SEVERAL JOINTS	ADVIL (IBUPROFEN) / IBUPROFEN	C	2020-06-28 (3) / 2020-06-28 (3)	200 (mg) / ONCE / ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051057	PAIN AT INJECTION SITE, HEADACHE, FATIGUE, MUSCLE ACHES ALL OVER BODY, JOINT ACHES IN SEVERAL JOINTS, CHILLS	ADVIL (IBUPROFEN) / IBUPROFEN	C	2020-07-26 (31) / 2020-07-26 (31)	400 (mg) / QD / ORAL	Yes
	PAIN AT INJECTION SITE, MUSCLE ACHES ALL OVER BODY, FATIGUE	ALEVE / NAPROXEN SODIUM	C	2020-07-31 (36) / 2020-08-04 (40)	440 (mg) / QD / ORAL	Yes
US2051059	OSTEOARTHRITIS PAIN LEFT HIP AND RIGHT KNEE	ACETAMINOPHEN / PARACETAMOL	P/C/A	1993-01-01 (-10038) / Ongoing	500 (mg) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051059	OSTEOARTHRITIS PAIN AND LOWER BACK PAIN	IBUPROFEN/ IBUPROFEN	P/C/A	1993-01-01 (-10038) / Ongoing	400 (mg) / PRN / ORAL	No
	SEASONAL ALLERGIES	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2001-01-01 (-7116) / Ongoing	10 (mg) / PRN / ORAL	No
	SEASONAL ALLERGIES	SINGULAIR/ MONTELUKAST SODIUM	P/C/A	2010-01-01 (-3829) / Ongoing	10 (mg) / PRN / ORAL	No
	HOT FLASHES	EFFEXOR/ VENLAFAXINE HYDROCHLORIDE	P/C/A	2015-01-01 (-2003) / Ongoing	150 (mg) / QD / ORAL	No
	ADULT ACNE FACE	ADAPALENE 0.3% / ADAPALENE	P/C/A	2018-01-01 (-907) / Ongoing	1 (OTHER: APPLICATION) / PRN / TOPICAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051059	PAIN AT THE INJECTION SITE & HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-07-28 (33) / 2020-08-01 (37)	400 (mg) / BID / ORAL	Yes
	PAIN AT THE INJECTION SITE & HEADACHE	TYLENOL/ PARACETAMOL	C	2020-07-28 (33) / 2020-08-01 (37)	500 (mg) / BID / ORAL	Yes
US2051060	DEPRESSION	ESCITALOPRAM/ ESCITALOPRAM	P	2002-01-01 (-6751) / 2020-06-01 (-25)	5 (mg) / QOD / ORAL	No
	HORMONE REPLACEMENT	ESTRADIOL/ ESTRADIOL	P/C/A	2010-01-01 (-3829) / Ongoing	1 (mg) / QD / ORAL	No
	SUPPLEMENT	PROBIOTIC/ PROBIOTICS NOS	P/C/A	2015-01-01 (-2003) / Ongoing	250 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051060	SUPPLEMENT	VITAMIN D3/ COLECALCIFEROL	P/C/A	2015-01-01 (-2003) / Ongoing	10000 (IU) / QD / ORAL	No
	SUPPLEMENT	CALCIUM MAGNESIUM/ CALCIUM;MAGNESIUM	P/C/A	2018-01-01 (-907) / Ongoing	1 (TABLET) / QD / ORAL	No
	GASTROESOPHAGEAL REFLUX DISEASE	PANTOPRAZOLE/ PANTOPRAZOLE	P/C/A	2018-01-01 (-907) / Ongoing	40 (mg) / QD / ORAL	No
	SUPPLEMENT	VITAMIN B12/ VITAMIN B12 NOS	P/C/A	2018-01-01 (-907) / Ongoing	3000 (ug) / QD / ORAL	No
	SUPPLEMENT	FLAX SEED OIL/ LINUM USITATISSIMUM SEED OIL	P/C/A	2019-01-01 (-542) / Ongoing	1000 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051060	DEPRESSION	ESCITALOPRAM/ ESCITALOPRAM	P/C/A	2020-06-01 (-25) / Ongoing	5 (mg) / OTHER: 3 TIMES A WEEK / ORAL	No
US2051066	HEALTH MAINTENANCE	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2000-01-01 (-7485) / Ongoing	1 (TABLET) / QD / ORAL	No
	HEALTH MAINTENANCE	FISH OIL/ FISH OIL	P/C/A	2010-01-01 (-3832) / Ongoing	1000 (mg) / QD / ORAL	No
	HEALTH MAINTENANCE	OCUVITE (LUTEIN & ZEAXANTHIN) / ASCORBIC ACID; SELENIUM; VITAMIN E NOS; XANTOXYL; ZEAXANTHIN; Z INC	P/C/A	2019-01-01 (-545) / Ongoing	1 (TABLET) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051066	DRUSEN BILATERAL EYES	TIMOLOL MALEATE/ TIMOLOL MALEATE	P/C/A	2020-02/ Ongoing	1 (OTHER: DROP) / QD/ OTHER: OPHTHALMIC	No
US2051068	HEALTH MAINTENANCE	VITAMIN C/ ASCORBIC ACID	P/C/A	2015/ Ongoing	1800 (ug) / QD/ ORAL	No
	HEALTH MAINTENANCE	FISH OIL/ FISH OIL	P/C/A	2015-09/ Ongoing	1500 (mg) / QD/ ORAL	No
	HEALTH MAINTENANCE	VITAMIN D3/ COLECALCIFEROL	P/C/A	2017/ Ongoing	375 (ug) / QD/ ORAL	No
	HEALTH MAINTENANCE	VITAMIN E/ VITAMIN E NOS	P/C/A	2017/ Ongoing	400 (IU) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051068	HEALTH MAINTENANCE	TUMERIC/ CURCUMA LONGA	P/C/A	2018/ Ongoing	500 (mg) / QD/ ORAL	No
	HEALTH MAINTENANCE	VITAMIN B12/ VITAMIN B12 NOS	P/C/A	2018/ Ongoing	2500 (ug) / QD/ ORAL	No
	HEALTH MAINTENANCE	VITAMIN B6/ PYRIDOXINE HYDROCHLORIDE	P/C/A	2018/ Ongoing	100 (mg) / QD/ ORAL	No
	HEALTH MAINTENANCE	VITAMIN B3/ NICOTINAMIDE	P/C/A	2019/ Ongoing	3 (TABLET) / QD/ ORAL	No
	HEALTH MAINTENANCE	VITAMIN D/ VITAMIN D NOS	P/C/A	2019/ Ongoing	400 (IU) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051068	HEALTH MAINTENANCE	VITAMIN K/ VITAMIN K NOS	P/C/A	2019/ Ongoing	1 (TABLET) / QD/ ORAL	No
US2051071	HYPERTENSION	VALASARTAN/ VALSARTAN	P/C/A	2015/ Ongoing	320 (mg) / QD/ ORAL	No
	TENDONITIS LEFT FOOT	MELOXICAM/ MELOXICAM	C/A	2020-07-26 (28) / Ongoing	7.5 (mg) / PRN/ ORAL	No
	PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-28 (30) / 2020-08-01 (34)	400 (mg) / QD/ ORAL	Yes
	INFLUENZA FLU SHOT PROHYLZXIS	QUADRAIVALENT INFLUENZA/ INFLUENZA VACCINE INACT SPLIT 4V	C	2020-08-21 (54) / 2020-08-21 (54)	1 (OTHER: LIQUID INJECTION) / ONCE/ INTRAMUSCULAR	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051071	SHINGLES VACCINE PROPHYLAXIS	SHINGRIX/ VARICELLA ZOSTER VACCINE RGE (CHO)	C	2020-08-21 (54) / 2020-08-21 (54)	1 (OTHER: LIQUID INJECTION) / ONCE/ INTRAMUSCULAR	No
US2051078	INSOMNIA	AMBIEN/ ZOLPIDEM TARTRATE	P/C/A	2019-01-01 (-546) / Ongoing	5 (mg) / QD/ ORAL	No
US2051081	ANXIETY	PROZAC/ FLUOXETINE HYDROCHLORIDE	P/C/A	1992 / Ongoing	5 (mg) / PRN/ ORAL	No
	SEASONAL ALLERGIES	XYZAL (LEVACETIRIZINE) / LEVOCETIRIZINE DIHYDROCHLORIDE	P/C/A	2016 / Ongoing	2.5 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051081	HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-07-28 (30) / 2020-07-28 (30)	200 (mg) / PRN / ORAL	Yes
US2051092	HEALTH MAINTENANCE	CALCIUM/ CALCIUM	P/C/A	2008 / Ongoing	1 (TABLET) / QD / ORAL	No
	HEALTH MAINTENANCE	FLAXSEED OIL / LINUM USITATISSIMUM OIL	P/C/A	2015 / Ongoing	1 (CAPSULE) / QD / ORAL	No
	SEASONAL ALLERGIES	XYZAL / LEVOCETIRIZINE DIHYDROCHLORIDE	P/C/A	2015 / Ongoing	5 (mg) / QD / ORAL	No
	HEART HEALTH	BABY ASPIRIN / ACETYLSALICYLIC ACID	P/C/A	2020-04 / Ongoing	81 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051093	MIGRAINES	IMITREX/ SUMATRIPTAN	P/C/A	2000-01-01 (-7492) / Ongoing	25 (mg) / PRN / ORAL	No
	GENERAL ACHES AND PAINS	TYLENOL/ PARACETAMOL	P/C/A	2010-01-01 (-3839) / Ongoing	325 (mg) / PRN / ORAL	No
	DEPRESSION / ANXIETY	CITALOPRAM/ CITALOPRAM	P/C/A	2015-01-01 (-2013) / Ongoing	40 (mg) / QD / ORAL	No
	HEALTH MAINTENANCE	COQ10/ UBIDECARENONE	P/C/A	2015-01-01 (-2013) / Ongoing	200 (mg) / QD / ORAL	No
	HEALTH MAINTENANCE	MULTI VITAMIN/ VITAMINS NOS	P/C/A	2015-01-01 (-2013) / Ongoing	1 (TABLET) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051093	HEALTH MAINTENANCE	VITAMIN D/ VITAMIN D NOS	P/C/A	2015-01-01 (-2013) / Ongoing	250 (OTHER: MICROGRAMS) / QD/ ORAL	No
	MIGRAINES	ALEVE/ NAPROXEN SODIUM	P/C/A	2018-01-01 (-917) / Ongoing	220 (mg) / PRN/ ORAL	No
	HEALTH MAINTENANCE	CALCIUM + VIT D/ CALCIUM;VITAMIN D NOS	P/C/A	2019-01-01 (-552) / Ongoing	1 (TABLET) / QD/ ORAL	No
	HEALTH MAINTENANCE	GLUCOSAMINE AND CHONDROITIN/ CHONDROITIN;GLUCOSAMINE	P/C/A	2020-01-01 (-187) / Ongoing	1 (TABLET) / QD/ ORAL	No
	HEALTH MAINTENANCE	PROBIOTIC/ PROBIOTICS NOS	P/C/A	2020-01-01 (-187) / Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051093	HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-07-07 (2) / 2020-07-09 (4)	400 (mg) / QOD/ ORAL	Yes
US2051094	HEALTH MAINTENANCE	CO-ENZYME Q10/ UBIDECARENONE	P/C/A	2013/ Ongoing	200 (mg) / QD/ ORAL	No
	HEALTH MAINTENANCE	VITAMIN D3/ COLECALCIFEROL	P/C/A	2013/ Ongoing	2000 (IU) / QD/ ORAL	No
US2051095	BACK PAIN	IBUPROFEN/ IBUPROFEN	P/C/A	2018/ Ongoing	800 (mg) / OTHER: 2X WEEKLY/ ORAL	No
	HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-07-31 (30) / 2020-07-31 (30)	800 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051095	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-07-31 (30) / 2020-07-31 (30)	1000 (mg) / ONCE / ORAL	Yes
US2051096	PROPHYLAXIS FOR GENERAL ACHES AND PAINS	ALEVE/ NAPROXEN SODIUM	P/C/A	2009-01-10 (-4195) / Ongoing	200 (mg) / PRN / ORAL	No
	SUPPLEMENT	MAGNESIUM/ MAGNESIUM	P/C/A	2019-01 / Ongoing	400 (mg) / PRN / ORAL	No
	SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2019-07-01 (-371) / Ongoing	1 (TABLET) / QD / ORAL	No
	SUPPLEMENT	BORAGE OIL/ BORAGO OFFICINALIS OIL	P/C/A	2020-01 / Ongoing	1300 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051099	CARDIAC PROPHYLAXIS	ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2008/ Ongoing	81 (mg) / QD/ ORAL	No
	BENIGN PROSTATIC HYERPLASIA	TAMSULOSIN/ TAMSULOSIN	P/C/A	2013/ Ongoing	0.4 (mg) / QD/ ORAL	No
	SEASONAL ALLERGIES	ALLEGRA/ FEXOFENADINE HYDROCHLORIDE	P/C/A	2015-06/ Ongoing	60 (mg) / PRN/ ORAL	No
	GASTROESOPHAGEAL REFLUX DISEASE	OMEPRAZOLE/ OMEPRAZOLE	P/C/A	2016/ Ongoing	40 (mg) / QD/ ORAL	No
	HEADACHE	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-06 (1) / 2020-07-07 (2)	325 (mg) / PRN/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051099	SLEEP AID FOR OCCASIONAL INSOMNIA	MELATONIN/ MELATONIN	C/A	2020-07-29 (24) / Ongoing	10 (mg) / QD/ ORAL	No
	HEADACHE	ACETAMINOPHEN/ PARACETAMOL	C	2020-08-04 (30) / 2020-08-04 (30)	650 (mg) / ONCE/ ORAL	Yes
US2051100	HEALTH MAINTENANCE	OMEGA 3 FATTY ACID/ OMEGA-3 FATTY ACIDS	P/C/A	2010/ Ongoing	1 (CAPSULE) / QD/ ORAL	No
	HEALTH MAINTENANCE	TUMERIC/ CURCUMA LONGA	P/C/A	2010/ Ongoing	2 (TABLET) / QD/ ORAL	No
	HEALTH MAINTENANCE	VITAMIN B12/ VITAMIN B12 NOS	P/C/A	2015/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051100	HEALTH MAINTENANCE	VITAMIN D3/ COLECALCIFEROL	P/C/A	2015/ Ongoing	1 (CAPSULE) / QD/ ORAL	No
	HEALTH MAINTENANCE	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2017/ Ongoing	1 (TABLET) / QD/ ORAL	No
	RESTLESS LEG SYNDROME	ROPINIROLE/ ROPINIROLE	P/C/A	2019-01-01 (-548) / Ongoing	0.25 (mg) / PRN/ ORAL	No
	HEADACHE	EXTRA STRENGTH TYLENOL/ PARACETAMOL	C	2020-08-05 (35) / 2020-08-05 (35)	1000 (mg) / ONCE/ ORAL	Yes
US2051103	HEALTH MAINTENANCE	FLAX - SEED OIL/ LINUM USITATISSIMUM SEED OIL	P/C/A	2014/ Ongoing	1 (CAPSULE) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051103	SHOULDER PAIN - BILATERAL	IBUPROFEN/ IBUPROFEN	P/C/A	2016/ Ongoing	400 (mg) / PRN/ ORAL	No
	SHOULDER PAIN BILATERAL	NAPROXEN/ NAPROXEN	P/C/A	2016/ Ongoing	440 (mg) / PRN/ ORAL	No
	CHRONIC MIGRAINES	ZOMIG/ ZOLMITRIPTAN	P/C/A	2016/ Ongoing	5 (mg) / PRN/ NASAL	No
	INSOMNIA	TRAZADONE/ TRAZODONE	P/C/A	2017/ Ongoing	100 (mg) / QD/ ORAL	No
	BUG BITE NECK	BENEDRYL/ DIPHENHYDRAMINE HYDROCHLORIDE	P	2020-07-01 (-1) / 2020-07-01 (-1)	50 (mg) / ONCE/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051103	BUG BITE ON NECK	HYDROCORTISONE CREAM 2.5%/ HYDROCORTISONE	C	2020-07-03 (2) / 2020-07-08 (7)	1 (OTHER: APPLICATION) / PRN/ TOPICAL	No
	HEADACHE	NAPROXEN/ NAPROXEN	C	2020-07-08 (7) / 2020-07-08 (7)	440 (mg) / ONCE/ ORAL	Yes
	MIGRAINE	IMITREX/ SUMATRIPTAN	C	2020-07-10 (9) / 2020-07-10 (9)	6 (mg) / ONCE/ SUBCUTANEOUS	No
	CONTACT DERMATITIS BILATERAL ARMS AND BACK	BENADRYL/ DIPHENHYDRAMINE HYDROCHLORIDE	C	2020-07-14 (13) / 2020-07-14 (13)	50 (mg) / ONCE/ ORAL	No
	HEADACHE, MUSCLE ACHES, JOINT ACHES	NAPROXEN/ NAPROXEN	C	2020-07-31 (30) / 2020-07-31 (30)	440 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051103	INSOMNIA	BENEDRYL/ DIPHENHYDRAMINE HYDROCHLORIDE	C	2020-08-04 (34) / 2020-08-04 (34)	50 (mg) / ONCE / ORAL	No
	MIGRAINE	ZOMIG (ZOLMITRIPTAN) NASAL SPRAY / ZOLMITRIPTAN	C	2020-08-04 (34) / 2020-08-04 (34)	5 (mg) / ONCE / NASAL	No
US2051105	GENERAL ACHES AND PAINS	IBUPROFEN / IBUPROFEN	P/C/A	2000-01-01 (-7488) / Ongoing	200 (mg) / PRN / ORAL	No
	INSOMNIA	SIMPLY SLEEP / DIPHENHYDRAMINE HYDROCHLORIDE	P/C/A	2017-01-01 (-1278) / Ongoing	25 (mg) / QD / ORAL	No
	SUPPLEMENT	VITAMIN D / VITAMIN D NOS	P/C/A	2018-01-01 (-913) / Ongoing	2000 (IU) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051105	VACCINE REACTIONS (INJECTION SITE PAIN, FATIGUE, MUSCLE ACHES, JOINT ACHES, NAUSEA) MUSCLE ACHES	IBUPROFEN/ IBUPROFEN	C	2020-07-03 (2) / 2020-07-03 (2)	200 (mg) / ONCE / ORAL	Yes
		IBUPROFEN/ IBUPROFEN	C	2020-08-01 (31) / 2020-08-01 (31)	200 (mg) / ONCE / ORAL	Yes
US2051107	GENERAL ACHES AND PAINS	NAPROXEN/ NAPROXEN	P/C/A	2000 / Ongoing	220 (mg) / QD / ORAL	No
	KERATOCONJUNCTIVITIS SICCA BILATERAL	THERATEARS / CARMELLOSE SODIUM	P/C/A	2015 / Ongoing	2 (OTHER: GTT) / PRN / TOPICAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.
WHODrug version: WHODrug-Global-B3 March 2020
[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051107	HEALTH MAINTENANCE	FLAX SEED OIL/ LINUM USITATISSIMUM SEED OIL	P/C/A	2018/ Ongoing	1 (CAPSULE) / QD/ ORAL	No
US2051109	SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	1993-01-01 (-10048) / Ongoing	1 (TABLET) / QD/ ORAL	No
	SEASONAL ALLERGIES	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2008/ Ongoing	10 (mg) / PRN/ ORAL	No
	DEGENERATIVE DISC	MOBIC/ MELOXICAM	P/C/A	2010-10-01 (-3566) / Ongoing	15 (mg) / PRN/ ORAL	No
	HEART HEALTH	ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2015-01-01 (-2013) / Ongoing	81 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061037	NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2020-04-01 (-86) / Ongoing	1 (TABLET) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	VITAMIN C/ ASCORBIC ACID	P/C/A	2020-04-01 (-86) / Ongoing	500 (mg) / QD/ ORAL	No
	NOSE PAIN	IBUPROFEN/ IBUPROFEN	C	2020-06-26 (1) / 2020-06-26 (1)	400 (mg) / ONCE/ ORAL	No
	PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-29 (34) / 2020-07-29 (34)	600 (mg) / PRN/ ORAL	Yes
US2061053	ANXIETY	ABILIFY/ ARIPIPIRAZOLE	P/C/A	2000-01/ Ongoing	5 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061053	INSOMNIA	AMBIEN/ ZOLPIDEM TARTRATE	P/C/A	2000-01/ Ongoing	10 (mg) / QD/ ORAL	No
	DEPRESSION	ESCITALOPRAM/ ESCITALOPRAM	P/C/A	2000-01/ Ongoing	40 (mg) / QD/ ORAL	No
	LOWER BACK PAIN	ALEVE/ NAPROXEN SODIUM	P/C/A	2010-01/ Ongoing	220 (mg) / PRN/ ORAL	No
US2061057	NUTRITIONAL SUPPLEMENT	CALCIUM PLUS VITAMIN D (500MG/500IU) / CALCIUM;VITAMIN D NOS	P/C/A	2020-03-27 (-96) / Ongoing	1 (TABLET) / PRN/ ORAL	No
US2061064	OSTEOARTHRITIS, GENERALIZED	ACETAMINOPHEN/ PARACETAMOL	P/C/A	2015/ Ongoing	500 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061064	OSTEOARTHRITIS - GENERALIZED	CELEBREX/ CELECOXIB	P/C/A	2015/ Ongoing	200 (mg) / BID/ ORAL	No
	NUTRITIONAL SUPPLEMENT	CRANBERRY VITAMIN/ VACCINIUM MACROCARPON	P/C/A	2017/ Ongoing	1 (TABLET) / QD/ ORAL	No
	GASTROESOPHAGEAL REFLUX DISEASE	OMEPRazole/ OMEPRazole	P/C/A	2017/ Ongoing	40 (mg) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	VITAMIN C/ ASCORBIC ACID	P/C/A	2017/ Ongoing	500 (mg) / QD/ ORAL	No
	OSTEOPOROSIS	BONIVA/ IBANDRONATE SODIUM	P/C/A	2020-01-01 (-181) / Ongoing	150 (mg) / QM/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061064	DEPRESSION	CELEXA/ CITALOPRAM HYDROBROMIDE	P/C/A	2020-02-01 (-150) / Ongoing	100 (mg) / QD / ORAL	No
US2061068	MIGRAINES, RECURRENT	MAXALT/ RIZATRIPTAN BENZOATE	P/C/A	2010-01 / Ongoing	10 (mg) / PRN / ORAL	No
	MIGRAINES, RECURRENT	TYLENOL/ PARACETAMOL	P/C/A	2010-01 / Ongoing	325 (mg) / PRN / ORAL	No
US2071007	SEASONAL ALLERGIES	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2010 / Ongoing	10 (mg) / QD / ORAL	No
	PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-08 (37) / 2020-07-10 (39)	400 (mg) / PRN / ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071024	HYPOTHYROIDISM	LEVOTHYROXINE/ LEVOTHYROXINE	P/C/A	2010/ Ongoing	112 (ug) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	CALCIUM/ CALCIUM	P/C/A	2015/ Ongoing	1200 (mg) / QD/ ORAL	No
US2071025	VITAMIN D DEFICINENCY	VITAMIN D/ VITAMIN D NOS	P/C/A	2019-08/ Ongoing	5000 (IU) / QD/ ORAL	No
	HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-07-09 (37) / 2020-07-09 (37)	600 (mg) / ONCE/ ORAL	Yes
US2071083	CARDIAC PROPHYLAXIS	ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2001-04-01 (-7026) / Ongoing	81 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071083	OSTEOARTHRITIS BILATERAL HANDS	CALCIUM + D/ CALCIUM;VITAMIN D NOS	P/C/A	2001-04-01 (-7026) / Ongoing	(OTHER: MG/IU) / QD/ ORAL	No
	HIGH CHOLESTEROL	GEMFIBROZIL/ GEMFIBROZIL	P/C/A	2019-03-07 (-477) / Ongoing	600 (mg) / QD/ ORAL	No
	HYPOTHYROIDISM	LEVOTHYROXINE/ LEVOTHYROXINE	P/C/A	2019-05-15 (-408) / Ongoing	125 (ug) / QD/ ORAL	No
	HIGH CHOLESTEROL	LOVASTATIN/ LOVASTATIN	P/C/A	2019-08-15 (-316) / Ongoing	20 (mg) / QD/ ORAL	No
US2071101	GASTROESOPHAGEAL REFLUX DISEASE	OMEPRAZOLE/ OMEPRAZOLE	P/C/A	2015/ Ongoing	20 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071101	MILD DEPRESSION	ESCITALOPRAM/ ESCITALOPRAM	P/C/A	2018-03-01 (-851) / Ongoing	10 (mg) / QD/ ORAL	No
US2071106	COVID 19 SYMPTOMS	IBUPROFEN/ IBUPROFEN	C	2020-07-13 (8) / 2020-07-15 (10)	800 (mg) / PRN/ ORAL	No
US2081003	SLEEP (INSOMNIA)	AMBIEN [ZOLPIDEM] / ZOLPIDEM TARTRATE	P/C/A	2015 / Ongoing	10 (mg) / QD/ ORAL	No
	OSTEOPOROSIS	CALCIUM / CALCIUM	P/C/A	2015 / Ongoing	600 (mg) / QD/ ORAL	No
	MIGRAINE	IMITREX [SUMATRIPTAN] / SUMATRIPTAN	P/C/A	2015 / Ongoing	100 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081003	DEGENERATIVE DISC DISEASE	NEUROTINE [GABAPENTIN] / GABAPENTIN	P/C/A	2015 / Ongoing	900 (mg) / QD / ORAL	No
	OSTEOPOROSIS	PROLIA [DENOSUMAB] / DENOSUMAB	P/C/A	2015 / Ongoing	60 (mg) / OTHER: EVERY 6 MONTHS / SUBCUTANEOUS	No
	SUPPLEMENT	VITAMIN D / VITAMIN D NOS	P/C/A	2015 / Ongoing	5000 (IU) / QD / ORAL	No
	DEGENERATIVE DISC DISEASE	TRAMODOL / TRAMADOL	P/C/A	2016 / Ongoing	50 (mg) / PRN / ORAL	No
	MIGRAINE	VITAMIN B-12 / VITAMIN B12 NOS	P/C/A	2018 / Ongoing	25 (mg) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081003	SUPPLEMENT	ESTER C [VITAMIN C, VITAMIN C-1000] / ASCORBIC ACID	P/C/A	2019 / Ongoing	120 (mg) / QD / ORAL	No
	SUPPLEMENT	HYLARONIC ACID / HYALURONIC ACID	P/C/A	2019 / Ongoing	200 (mg) / QD / ORAL	No
	SUPPLEMENT	VITAMIN C / ASCORBIC ACID	C/A	2020 / Ongoing	100 (mg) / QD / ORAL	No
	SUPPLEMENT	ZINC / ZINC	P/C/A	2020-02 / Ongoing	30 (mg) / QOD / ORAL	No
	MIGRAINE	TOPRAMAX [TOPIRAMATE] / TOPIRAMATE	P/C/A	2020-05-20 (-9) / Ongoing	30 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081003	PAIN AT INJECTION SITE	ALEVE [NAPROXEN SODIUM] / NAPROXEN SODIUM	C	2020-05-30 (2) / 2020-05-30 (2)	440 (mg) / ONCE / ORAL	Yes
	MIGRAINES	AJOVY [FREMANEZUMAB] / FREMANEZUMAB	C/A	2020-06-13 (16) / Ongoing	225 (ug) / EVERY WEEK / SUBCUTANEOUS	No
US2081009	ALLERGIC RHINITIS	ZYRTEC [CETIRIZINE] / CETIRIZINE HYDROCHLORIDE	P/C/A	1990 / Ongoing	10 (mg) / QD / ORAL	No
	SUPPLEMENT	MULTIVITAMIN / VITAMINS NOS	P/C/A	2000 / Ongoing	1 (TABLET) / QD / ORAL	No
	SUPPLEMENT	CALCIUM / CALCIUM	P/C/A	2015 / Ongoing	300 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081009	SUPPLEMENT	VITAMIN D/ VITAMIN D NOS	P/C/A	2015/ Ongoing	100 (IU) / QD/ ORAL	No
	ALLERGIC RHINITIS	BENADRYL ALLERGY [DIPHENHYDRAMINE] / DIPHENHYDRAMINE HYDROCHLORIDE	P/C/A	2019/ Ongoing	25 (mg) / PRN/ ORAL	No
	SUPPLEMENT	BIOTIN/ BIOTIN	P/C/A	2019/ Ongoing	1 (TABLET) / QD/ ORAL	No
	SUPPLEMENT	VITAMIN B/ VITAMIN B NOS	C/A	2020/ Ongoing	500 (mg) / QD/ ORAL	No
US2081020	SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	1990/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081020	DYSLIPIDEMIA	SIMVASTATIN/ SIMVASTATIN	P/C/A	2015/ Ongoing	10 (mg) / QD/ ORAL	No
	SUPPLEMENT	UNISOM [DOXYLAMINE SUCCINATE] / DOXYLAMINE SUCCINATE	P/C/A	2018/ Ongoing	0.5 (TABLET) / QD/ ORAL	No
	SUPPLEMENT	VITAMIN C / ASCORBIC ACID	P/C/A	2020-03/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEADACHE	TYLENOL EXTRA STRENGTH / PARACETAMOL	C	2020-06-30 (29) / 2020-06-30 (29)	500 (mg) / ONCE / ORAL	Yes
US2081070	SEASONAL ALLERGIES	CETIRIZINE / CETIRIZINE	P/C/A	2000 / Ongoing	10 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081070	SUPPLEMENT	FISH OIL/ FISH OIL	P/C/A	2005/ Ongoing	435 (mg) / QD/ ORAL	No
	SUPPLEMENT	LACTASE/ TILACTASE	P/C/A	2015/ Ongoing	3000 (IU) / PRN/ ORAL	No
	GASTROESOPHAGEAL REFLUX DISEASE	TUMS [CALCIUM CARBONATE] / CALCIUM CARBONATE	P/C/A	2015/ Ongoing	1000 (mg) / PRN/ ORAL	No
US2081071	SUPPLEMENT	FISH OIL/ FISH OIL	P/C/A	2019/ Ongoing	1000 (mg) / QD/ ORAL	No
	VITAMIN D DEFICIENCY	VTAMIN D / VITAMIN D NOS	P/C/A	2019-12 / Ongoing	2000 (IU) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081071	SUPPLEMENT	MILK THISTLE/ SILYBUM MARIANUM	P/C/A	2020-01/ Ongoing	250 (mg) / QD/ ORAL	No
	SORE THROAT WITH MUCUS	ADVIL/ IBUPROFEN	C	2020-08-03 (35) / 2020-08-04 (36)	400 (mg) / QD/ ORAL	No
US2081085	SUPPLEMENT	VITAMIN D/ VITAMIN D NOS	P/C/A	2008/ Ongoing	5000 (IU) / QD/ ORAL	No
	MIGRAINE	BUTALBITAL-ACETAMINOPHEN-CA FFEINE (FIORICET, ESGIC) / BUTALBITAL;CAFFEINE;PARAC ETAMOL	P/C/A	2017/ Ongoing	(mg) / PRN/ ORAL	No
	HYPOTHYROIDISM	DHEA [DEHYDROEPIANDROSTERONE] / PRASTERONE	P/C/A	2017/ Ongoing	(mg) / QD/ TOPICAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081085	HYPOTHYROIDISM	SYNTHROID [LEVOTHYROXINE SODIUM] / LEVOTHYROXINE SODIUM	P/C/A	2017 / Ongoing	75 (ug) / QD / ORAL	No
	SUPPLEMENT	BIOTIN / BIOTIN	P/C/A	2020-03 / Ongoing	1000 (ug) / QD / ORAL	No
	SUPPLEMENT	FISH OIL / FISH OIL	P/C/A	2020-03 / Ongoing	1200 (mg) / QD / ORAL	No
US2081092	SUPPLEMENT	B COMPLEX / VITAMIN B COMPLEX	P/C/A	2010 / Ongoing	1 (TABLET) / QD / ORAL	No
	SUPPLEMENT	FISH OIL / FISH OIL	P/C/A	2010 / Ongoing	1200 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081092	SUPPLEMENT	VITAMIN C/ ASCORBIC ACID	P/C/A	2010/ Ongoing	500 (mg) / QD/ ORAL	No
	SUPPLEMENT	GLUCOSAMINE/CHONDROITIN/ CHONDROITIN;GLUCOSAMINE	P/C/A	2015/ Ongoing	(mg) / BID/ ORAL	No
	SUPPLEMENT	MELATONIN/ MELATONIN	P/C/A	2015/ Ongoing	1 (TABLET) / PRN/ ORAL	No
	SUPPLEMENT	N-ACETYL CYSTEINE/ ACETYLCYSTEINE	P/C/A	2015/ Ongoing	500 (mg) / QD/ ORAL	No
	SUPPLEMENT	QUERCETIN WITH BROMELAIN [QUERCETIN 800 MG, BROMELAIN 165 MG] / BROMELAINS;QUERCETIN	P/C/A	2015/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081092	SUPPLEMENT	S-ADENOSYL METHIONINE/ ADEMETIONINE	P/C/A	2015/ Ongoing	400 (mg) / QD/ ORAL	No
	SUPPLEMENT	TUMERIC/ CURCUMA LONGA	P/C/A	2015/ Ongoing	1000 (mg) / QD/ ORAL	No
	SUPPLEMENT	UBIQUINOL/ UBIQUINOL	P/C/A	2015/ Ongoing	100 (mg) / QOD/ ORAL	No
	SUPPLEMENT	VITAMIN D3/ COLECALCIFEROL	P/C/A	2015/ Ongoing	1000 (IU) / BID/ ORAL	No
	SUPPLEMENT	MORINGA LEAF/ MORINGA OLEIFERA LEAF	P/C/A	2018/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081092	SUPPLEMENT	OLIVE LEAF EXTRACT/ OLEA EUROPAEA LEAF	P/C/A	2018/ Ongoing	215 (mg) / QD/ ORAL	No
	SUPPLEMENT	RED YEAST RICE/ MONASCUS PURPUREUS	P/C/A	2018/ Ongoing	1200 (mg) / QD/ ORAL	No
	LICHEN PLANUS [SCALP]	CLOBETESOL 0.05%/ CLOBETASOL	P/C/A	2019/ Ongoing	1 (OTHER: APPLICATION) / OTHER: TWICE PER WEEK/ TOPICAL	No
	TO PREVENT SHOULDER PAN DUE TO PICKLE BALL (UNRELATED TO STUDY)	IBUPROFEN/ IBUPROFEN	C	2020-07-02 (1) / 2020-07-02 (1)	600 (mg) / ONCE/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081092	TO PREVENT/TREAT SHOULD PAIN DUE TO PICKLE BALL (UNRELATED TO STUDY)	IBUPROFEN/ IBUPROFEN	C	2020-07-07 (6) / 2020-07-07 (6)	600 (mg) / ONCE / ORAL	No
	PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-08-01 (31) / 2020-08-01 (31)	600 (mg) / QD / ORAL	Yes
US2081100	SUPPLEMENT	NATURE'S BOUNTY HAIR, SKIN, AND NAILS GUMMIES / ASCORBIC ACID;BIOTIN;DL-ALPHA TOCOPHERYL ACETATE	P/C/A	2000-01 / Ongoing	3000 (ug) / QD / ORAL	No
	DEPRESSION	BUPROPION HCL / BUPROPION HYDROCHLORIDE	P/C/A	2018 / Ongoing	150 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081100	SEASONAL ALLERGIES	FLUTICASONE PROPIONATE/ FLUTICASONE PROPIONATE	P/C/A	2018/ Ongoing	50 (ug) / QD/ OTHER: INTRANASAL	No
	GASTROESOPHAGEAL REFLUX DISEASE	OMEPRAZOLE/ OMEPRAZOLE	P/C/A	2018/ Ongoing	20 (mg) / QD/ ORAL	No
	HEADACHE	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-03 (2) / 2020-07-03 (2)	225 (mg) / ONCE/ ORAL	Yes
	HEADACHE	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-07 (6) / 2020-07-07 (6)	225 (mg) / ONCE/ ORAL	Yes
US2081110	SEASONAL ALLERGIES	FLONASE/ FLUTICASONE PROPIONATE	P/C/A	2020-02/ Ongoing	100 (ug) / QD/ NASAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081110	GLAUCOMA (BILATERAL)	XELPROS 125 MCG/ LATANOPROST	P/C/A	2020-04/ Ongoing	1 (OTHER: DROPLET PERNO AFFECTED EYE) / QD/	No
	SUPPLEMENT	MAGNESIUM/ MAGNESIUM	P/C/A	2020-06-22 (-11) / Ongoing	OTHER: OPHTHALMIC 1 (OTHER: TSP) / QD/	No
	SUPPLEMENT	NEOCELL [COLLAGEN] / COLLAGEN	P/C/A	2020-06-22 (-11) / Ongoing	ORAL 6.6 (g) / QD/	No
US2081112	MIGRAINES	IMITREX [SUMATRIPTAN] / SUMATRIPTAN	P/C/A	2015/ Ongoing	ORAL 50 (mg) / PRN/	No
	INSOMNIA	MELATONIN / MELATONIN	P/C/A	2018/ Ongoing	ORAL 5 (mg) / PRN/	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081112	TO TREAT PAIN AT INJECTION SITE	MOTRIN [IBUPROFEN] / IBUPROFEN	C	2020-07-04 (2) / 2020-07-04 (2)	600 (mg) / BID / ORAL	Yes
	PAIN AT INJECTION SITE	MOTRIN / IBUPROFEN	C	2020-08-11 (40) / 2020-08-12 (41)	600 (mg) / QD / ORAL	Yes
US2081118	SUPPLEMENT	MULTIVITAMIN / VITAMINS NOS	P/C/A	2015 / Ongoing	1 (TABLET) / QD / ORAL	No
	SUPPLEMENT	MAGNESIUM / MAGNESIUM	P/C/A	2018 / Ongoing	500 (mg) / QD / ORAL	No
	INSOMNIA	MELATONIN / MELATONIN	P/C/A	2018 / Ongoing	20 (mg) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081118	SUPPLEMENT	VITAMIN B12/ VITAMIN B12 NOS	P/C/A	2018/ Ongoing	1000 (ug) / QD/ ORAL	No
	SUPPLEMENT	ACIDOPHILUS/ LACTOBACILLUS ACIDOPHILUS	P/C/A	2019/ Ongoing	1 (CAPSULE) / QD/ ORAL	No
	HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-07-06 (6) / 2020-07-06 (6)	400 (mg) / ONCE/ ORAL	Yes
	OVERACTIVE BLADDER	OXYBUTININ/ OXYBUTYNIN	C	2020-07-10 (10) / 2020-07-28 (28)	5 (mg) / QD/ ORAL	No
	OVERACTIVE BLADDER	OXYBUTININ/ OXYBUTYNIN	C/A	2020-07-30 (30) / Ongoing	10 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081123	DEPRESSION/OSTEOARTH RITIS (LOWER BACK)	DULOXETINE HCL/ DULOXETINE HYDROCHLORIDE	P/C/A	2015/ Ongoing	60 (mg) / QD/ ORAL	No
	SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2015/ Ongoing	1 (TABLET) / QD/ ORAL	No
	ATTENTION DEFICIT HYPERACTIVITY DISORDER	METHYLPHENIDATE/ METHYLPHENIDATE	P/C/A	2020-03/ Ongoing	25.9 (mg) / BID/ ORAL	No
	PAIN- SAE OF BILATERAL ATYPICAL INFECTION	IBUPROFEN/ IBUPROFEN	C/A	2020-07-25 (26) / 2020-08-01 (33)	400 (mg) / OTHER: EVERY 6 HOURS/ ORAL	No
	PAIN- ASSOCIATED WITH SAE OF PNEUMONIA	ACETAMINOPHEN/ PARACETAMOL	C/A	2020-07-25 (26) / Ongoing	1000 (mg) / OTHER: EVERY 6 HOURS/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081123	PNEUMONIA	SODIUM CHLORIDE 0.9% (BOLUS) / SODIUM CHLORIDE	A	2020-08-01 (33) / 2020-08-01 (33)	2.448 (mL) / QD / INTRAVENOUS BOLUS	No
	PNEUMONIA	SODIUM CHLORIDE 0.9% INFUSION / SODIUM CHLORIDE	A	2020-08-01 (33) / 2020-08-01 (33)	75 (mL) / OTHER: EVERY 12 HOURS / INTRAVENOUS	No
	PROPHYLACTIC FOR DEEP VEIN THROMBOSIS	ENOXAPARIN / ENOXAPARIN	A	2020-08-01 (33) / 2020-08-04 (36)	40 (mg) / QD / SUBCUTANEOUS	No
	DIARRHEA R/T PNEUMONIA	LOEPRAMIDE / LOPERAMIDE	A	2020-08-01 (33) / 2020-08-04 (36)	2 (mg) / QD / ORAL	No
	PNEUMONIA	AZITHROMYCIN IN 0.99% SODIUM CHLORIDE / AZITHROMYCIN	A	2020-08-01 (33) / 2020-08-05 (37)	500 (mg) / QD / INTRAVENOUS	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081123	PNEUMONIA	CEFTRIAXONE IN DEXTROSE/ CEFTRIAXONE	A	2020-08-01 (33) / 2020-08-05 (37)	1 (g) / QD/ INTRAVENOUS	No
	TENSION HEADACHES R/T PNEUMONIA	BUTALBITAL[50MG]-ACETOMINOP HEN[325MG]-CAFFIENE[40MG] / BUTALBITAL;CAFFEINE;PARAC ETAMOL	A	2020-08-04 (36) / 2020-08-05 (37)	1 (TABLET) / OTHER: EVERY 4 HOURS / ORAL	No
	PNEUMONIA	TESSALON PERLES (BENZONATATE) / BENZONATATE	A	2020-08-05 (37) / 2020-08-10 (42)	100 (mg) / TID / ORAL	No
	PNEUMONIA	GUAIFENESIN / GUAIFENESIN	A	2020-08-05 (37) / 2020-09-04 (67)	600 (mg) / BID / ORAL	No
	SEPSIS R/T PNEUMONIA	LEVOFLOXACIN / LEVOFLOXACIN	A	2020-08-06 (38) / 2020-08-08 (40)	500 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011009	HORMONE REPLACEMENT THERAPY (MENOPAUSE)	ESTRADIOL/ ESTRADIOL	P/C/A	2015/ Ongoing	0.25 (mg) / QD/ ORAL	No
	HEARTBURN	OMEPRazole/ OMEPRazole	P/C/A	2015/ Ongoing	40 (mg) / PRN/ ORAL	No
	HEADACHE	ACETAMINOPHEN/ PARACETAMOL	C	2020-06-30 (30) / 2020-06-30 (30)	500 (mg) / ONCE/ ORAL	No
US2011028	GOUT, RIGHT GREAT TOE	INDOMETHACIN/ INDOMETACIN	C	2020-06-09 (9) / 2020-06-11 (11)	50 (mg) / TID/ ORAL	No
	GOUT, RIGHT GREAT TOE	INDOMETHACIN/ INDOMETACIN	C	2020-06-11 (11) / 2020-06-16 (16)	50 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011028	MUSCLE ACHES (ALL OVER BODY/SOLICITED SYMPTOM)	ALEVE/ NAPROXEN SODIUM	C	2020-06-30 (30) / 2020-06-30 (30)	220 (mg) / ONCE / ORAL	Yes
US2011113	HEADACHE, PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-31 (30) / 2020-07-31 (30)	800 (mg) / ONCE / ORAL	Yes
US2011121	MIGRAINES	EXCEDRIN MIGRAINE (ACETAMINOPHEN/ASPIRIN/CAFF EINE) / ACETYLSALICYLIC ACID;CAFFEINE;PARACETAMOL	P/C/A	1986 / Ongoing	(mg) / PRN / ORAL	No
	SEASONAL ALLERGIES	CLARITIN/ LORATADINE	P/C/A	2016 / Ongoing	10 (mg) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011121	MUSCLE ACHES ALL OVER BODY	IBUPROFEN/ IBUPROFEN	C	2020-07-31 (30) / 2020-07-31 (30)	200 (mg) / QD/ ORAL	Yes
	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-08-12 (42) / 2020-08-12 (42)	500 (mg) / ONCE/ ORAL	No
	HERPES I	VALACYCLOVIR/ VALACICLOVIR	C/A	2020-08-23 (53) / Ongoing	500 (mg) / PRN/ ORAL	No
US2011122	INJECTION SITE PAIN	TYLENOL/ PARACETAMOL	C	2020-06-27 (2) / 2020-06-27 (2)	500 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011128	MIGRAINES	AJOVY/ FREMANEZUMAB	P/C/A	2019-08-10 (-325) / Ongoing	675 (mg) / OTHER: ONCE EVERY 3 MONTHS/ SUBCUTANEOUS	No
	HEADACHE	SUMATRIPTAN/ SUMATRIPTAN	C	2020-07-31 (32) / 2020-07-31 (32)	50 (mg) / ONCE/ ORAL	Yes
US2011139	HIGH CHOLSTEROL	ROSUVASTATIN/ ROSUVASTATIN	P/C/A	2016/ Ongoing	20 (mg) / QD/ ORAL	No
	CARDIAC PROPHYLAXIS	ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2018/ Ongoing	81 (mg) / QD/ ORAL	No
	DIABETES PROPHYLAXIS	METFORMIN/ METFORMIN	P/C/A	2018-11/ Ongoing	1000 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011149	HEADACHE	ALEVE/ NAPROXEN SODIUM	C	2020-07-28 (30) / 2020-07-28 (30)	440 (mg) / PRN/ ORAL	Yes
	FEVER/HEADACHE	MUCINEX/ GUAIFENESIN	C	2020-07-28 (30) / 2020-07-28 (30)	2 (TABLET) / PRN/ ORAL	Yes
US2011159	HYPERCHOLESTEROLEMIA	LIPITOR/ ATORVASTATIN	P/C/A	1985/ Ongoing	40 (mg) / QD/ ORAL	No
	POSTMENOPAUSAL / HORMONE REPLACEMENT THERAPY	TESTOSTERONE/ TESTOSTERONE	P/C/A	2017/ Ongoing	0.5 (mL) / OTHER: Q3M/ INTRAMUSCULAR	No
	POSTMENOPAUSAL / HORMONE REPLACEMENT THERAPY	PROGESTERONE/ PROGESTERONE	P/C/A	2018/ Ongoing	100 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2011159	DEPRESSION	TRINTELLIX/ VORTIOXETINE HYDROBROMIDE	P/C/A	2019/ Ongoing	10 (mg) / QD/ ORAL	No
	INJECTION SITE PAIN	TYLENOL/ PARACETAMOL	C	2020-07-30 (29) / 2020-08-01 (31)	500 (mg) / PRN/ ORAL	Yes
US2011162	BACK ITCH	BENADRYL (1%) / DIPHENHYDRAMINE HYDROCHLORIDE	C	2020-07-13 (8) / 2020-07-22 (17)	1 (OTHER: APPLICATION) / PRN/ TOPICAL	No
US2021003	NECK PAIN	IBUPROFEN/ IBUPROFEN	P/C/A	2013/ Ongoing	200 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021003	LOW TESTOSTERONE	TESTOSTERONE/ TESTOSTERONE	P/C/A	2016/ Ongoing	160 (mg) / EVERY WEEK/ INTRAMUSCULAR	No
	SEASONAL ALLERGIES	FLUTICASONE/ FLUTICASONE	P/C/A	2018/ Ongoing	50 (ug) / QD/ NASAL	No
	ERECTILE DYSFUNCTION	CIALIS/ TADALAFIL	P/C/A	2019/ Ongoing	10 (mg) / PRN/ ORAL	No
	SEASONAL ALLERGIES	FEXOFENADINE/ FEXOFENADINE	C	2020-06-11 (14) / 2020-06-11 (14)	60 (mg) / ONCE/ ORAL	No
US2021007	MENOPAUSE	ESTRADIOL/ ESTRADIOL	P/C/A	2001-11-30 (-6758) / Ongoing	1 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021007	OSTEOARTHRITIS GENERALIZED	MELOOXICAM/ MELOXICAM	P/C/A	2019-01/ Ongoing	15 (mg) / PRN/ ORAL	No
	OSTEOARTHRITIS GENERALIZED	CELECOXIB/ CELECOXIB	P/C/A	2019-05/ Ongoing	200 (mg) / PRN/ ORAL	No
	HEADACHE	ACETAMINOPHEN/ASPIRIN/CAFFE INE/ ACETYLSALICYLIC ACID;CAFFEINE;PARACETAMOL	C	2020-06-02 (2) / 2020-06-02 (2)	(mg) / ONCE/ ORAL	Yes
	HEADACHE	ACETAMINOPHEN/ PARACETAMOL	C	2020-06-29 (29) / 2020-07-01 (31)	400 (mg) / QD/ ORAL	No
US2021031	HYPERLIPIDEMIA	SIMVASTATIN/ SIMVASTATIN	P/C/A	1976/ Ongoing	20 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021031	ANXIETY	BUSPAR/ BUSPIRONE HYDROCHLORIDE	P/C/A	1985/ Ongoing	15 (mg) / QD/ ORAL	No
	DEPRESSION	SERTRALINE/ SERTRALINE	P/C/A	1985/ Ongoing	50 (mg) / QD/ ORAL	No
	LOW TESTOSTERONE	TESTOSTERONE/ TESTOSTERONE	P/C/A	2015/ Ongoing	20.25 (mg) / QD/ TOPICAL	No
US2021114	HYPERLIPIDEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	2020-02/ Ongoing	5 (mg) / QD/ ORAL	No
	FEVER	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-30 (35) / 2020-07-30 (35)	500 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021115	ANXIETY	DULOXETINE/ DULOXETINE	P/C/A	2005/ Ongoing	30 (mg) / QD/ ORAL	No
	HEADACHE	ADVIL/ IBUPROFEN	C	2020-06-27 (2) / 2020-06-27 (2)	200 (mg) / QD/ ORAL	Yes
	HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-08-01 (37) / 2020-08-02 (38)	800 (mg) / PRN/ ORAL	Yes
US2021186	VAGINAL DRYNESS	OSPEMIFENE/ OSPEMIFENE	P/C/A	2016/ Ongoing	60 (mg) / QD/ ORAL	No
	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-06-26 (1) / 2020-07-01 (6)	500 (mg) / PRN/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021186	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-08-01 (37) / 2020-08-01 (37)	500 (mg) / ONCE / ORAL	Yes
US2021208	HYPERCHOLESTEROLEMIA	ROSUVASTATIN/ ROSUVASTATIN	P/C/A	2014 / Ongoing	10 (mg) / QD / ORAL	No
	HYPERCHOLESTEROLEMIA	ROSUVASTATIN/ ROSUVASTATIN	P/C/A	2014 / Ongoing	10 (mg) / QD / ORAL	No
	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-07-30 (30) / 2020-07-30 (30)	500 (mg) / ONCE / ORAL	Yes
	SINUS DRAINAGE	DIPHENHYDRAMINE/ DIPHENHYDRAMINE	C	2020-08-04 (35) / 2020-08-07 (38)	25 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021208	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-08-06 (37) / 2020-08-06 (37)	500 (mg) / ONCE / ORAL	Yes
US2021211	GASTROESOPHEGEAL REFLUX DISEASE	PANTOPRAZOLE/ PANTOPRAZOLE	P/C/A	2004 / Ongoing	20 (mg) / QD / ORAL	No
	BILATERAL KNEE PAIN	MELOXICAM/ MELOXICAM	P/C/A	2008 / Ongoing	7.5 (mg) / QD / ORAL	No
	HYPERLIPIDEMIA	CRESTOR/ ROSUVASTATIN CALCIUM	P/C/A	2010 / Ongoing	10 (mg) / QD / ORAL	No
	HYPERCHOLESTEROLEMIA	CRESTOR/ ROSUVASTATIN CALCIUM	P/C/A	2010 / Ongoing	5 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021211	OSTEOARTHRITIS BILATERAL KNEES	MELOXICAM/ MELOXICAM	P/C/A	2010/ Ongoing	7.5 (mg) / QD/ ORAL	No
	GERD	PANTOPRAZOLE/ PANTOPRAZOLE	P/C/A	2010/ Ongoing	20 (mg) / QD/ ORAL	No
	DRY EYES BILATERAL	RESTASIS/ CICLOSPORIN	P/C/A	2012/ Ongoing	1 (OTHER: DROP) / QD/ INTRAOCULAR	No
	INFECTION OF TOOTH FROM FILLING	PENICILLIN/ PENICILLIN NOS	C	2020-07-21 (20) / 2020-08-06 (36)	500 (mg) / QID/ ORAL	No
US2021214	HERPES SIMPLEX I	GENITAL VALACICLOVIR/ VALACICLOVIR	P/C/A	2010/ Ongoing	1 (g) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021214	RE-INJURED RIGHT HIP	NAPROXEN/ NAPROXEN	C/A	2020-07-14 (19) / Ongoing	200 (mg) / PRN/ ORAL	No
US2021215	PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-06-29 (1) / 2020-06-29 (1)	600 (mg) / QD/ ORAL	Yes
	PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-08-04 (37) / 2020-08-04 (37)	600 (mg) / QD/ ORAL	Yes
US2021218	SEASONAL ALLERGIES	SUDAFED/ PSEUDOEPHEDRINE HYDROCHLORIDE	P/C/A	2018/ Ongoing	120 (mg) / PRN/ ORAL	No
	SEASONAL ALLERGIES	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2018/ Ongoing	5 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021218	SEASONAL ALLERGIES	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2018/ Ongoing	10 (mg) / QD/ ORAL	No
	LEFT ARM SORENESS AT THE INJECTION SITE	ADVIL/ IBUPROFEN	C	2020-07-01 (2) / 2020-07-01 (2)	400 (mg) / BID/ ORAL	Yes
	WORSENING OF SEASONAL ALLERGIES	MUCINEX-D/ GUAIFENESIN; PSEUDOEPHEDRI NE HYDROCHLORIDE	C/A	2020-07-05 (6) / Ongoing	(mg) / PRN/ ORAL	No
	FEVER & BODY ACHES	TYLENOL/ PARACETAMOL	C	2020-08-01 (33) / 2020-08-01 (33)	500 (mg) / ONCE/ ORAL	Yes
	PAIN AT INJECTION SITE	TYLENOL/ PARACETAMOL	C	2020-08-02 (34) / 2020-08-02 (34)	500 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021230	GASTROESOPHAGEAL REFLUX DISEASE	PANTOPRAZOLE/ PANTOPRAZOLE	P/C/A	2018/ Ongoing	40 (mg) / QD/ ORAL	No
US2021232	SEASONAL ALLERGIES	LORATADINE/ LORATADINE	P/C/A	2010/ Ongoing	10 (mg) / PRN/ ORAL	No
	SEASONAL ALLEGIES	DIPHENYDRAMINE/ DIPHENHYDRAMINE	P/C/A	2015/ Ongoing	25 (mg) / PRN/ ORAL	No
	FEVER	IBUPROFEN/ IBUPROFEN	C	2020-08-07 (33) / 2020-08-07 (33)	800 (mg) / QD/ ORAL	No
US2021234	GASTROESOPHAGEAL REFLUX DISEASE	ESOMEPRAZOLE/ ESOMEPRAZOLE	P/C/A	2012/ Ongoing	20 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2021234	SEASONAL ALLERGIES	CETIRIZINE/ CETIRIZINE	P/C/A	2015/ Ongoing	5 (mg) / PRN/ ORAL	No
	POST MENOPAUSAL	ESTRADIOL/ ESTRADIOL	P/C/A	2016/ Ongoing	0.0375 (mg) / QD/ VAGINAL	No
	HYPERCHOLESTEROLEMIA	ROSUVASTATIN/ ROSUVASTATIN	P/C/A	2018/ Ongoing	10 (mg) / QD/ ORAL	No
	WORSENING OF NECK PAIN	EXCEDRIN (ASPIRIN, ACETAMINOPHEN & CAFFEINE) / ACETYLSALICYLIC ACID; CAFFEINE; PARACETAMOL	C	2020-08-12 (37) / 2020-08-28 (53)	(mg) / QD/ ORAL	No
	WORSENING OF NECK PAIN	OXYCODONE/ OXYCODONE	C	2020-08-16 (41) / 2020-08-28 (53)	5 (mg) / OTHER: HALF DAILY/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031091	MIGRAINES	IBUPROFEN/ IBUPROFEN	P/C/A	1973/ Ongoing	400 (mg) / OTHER: BID PRN/ ORAL	No
US2031093	HYPERCHOLESTEROLEMIA	ROSUVASTATIN/ ROSUVASTATIN	P/C/A	2019-10/ Ongoing	5 (mg) / QD/ ORAL	No
US2031101	HOT FLASHES	ESTRADIOL/ ESTRADIOL	P/C/A	2017/ Ongoing	1 (mg) / QD/ ORAL	No
	HOT FLASHES	MEDROXYPROGEST/ MEDROXYPROGESTERONE ACETATE	P/C/A	2017/ Ongoing	5 (mg) / QD/ ORAL	No
	ACID REFLUX	PANTOPRAZOLE/ PANTOPRAZOLE	P/C/A	2017/ Ongoing	40 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2031112	GENERALIZED MYALGIA, GENERALIZED ARTHRALGIA, HEADACHE	ACETAMINOPHEN/ PARACETAMOL	C	2020-07-27 (32) / 2020-07-29 (34)	1000 (mg) / PRN / ORAL	Yes
US2031122	HYPERCHOLESTEROLEMIA	CRESTOR/ ROSUVASTATIN CALCIUM	P/C/A	2019/ Ongoing	10 (mg) / QD / ORAL	No
US2041108	HYPERCHOLESTEROLEMIA	ATORVISTATIN/ ATORVASTATIN	P/C/A	2015/ Ongoing	40 (mg) / QD / ORAL	No
	OVER ACTIVE BLADDER	OXYBUTININ/ OXYBUTYNIN	P/C/A	2019/ Ongoing	10 (mg) / QD / ORAL	No
	SOLICITED SYMPTOMS-LOW GRADE FEVER	TYLENOL/ PARACETAMOL	C	2020-07-28 (33) / 2020-07-28 (33)	650 (mg) / BID / ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041112	URINARY RETENTION	TAMSULOSIN/ TAMSULOSIN	P/C/A	2018/ Ongoing	0.4 (mg) / QD/ ORAL	No
US2041117	POST MENOPAUSAL OSTEOPOROSIS	RALOXIFENE/ RALOXIFENE	P/C/A	1990/ Ongoing	60 (mg) / QD/ ORAL	No
US2041120	SOLICITED SYMPTOMS-FATIGUE, MUSCLE ACHES, JOINT ACHES	ASPIRIN/ ACETYLSALICYLIC ACID	C	2020-07-06 (7) / 2020-07-06 (7)	325 (mg) / ONCE/ ORAL	Yes
US2041122	OVER ACTIVE BLADDER	OXYBUTYNIN/ OXYBUTYNIN	P/C/A	2000/ Ongoing	5 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041122	SOLICITED SYMPTOMS-CIRCUMFEREN TIAL REDNESS	HYDROCORTISONE 1% CREAM/ HYDROCORTISONE	C	2020-07-08 (10) / 2020-07-19 (21)	1 (OTHER: APPLICATION) / PRN/ TOPICAL	Yes
	INSOMNIA	TRAZADONE/ TRAZODONE	C/A	2020-08-02 (35) / Ongoing	50 (mg) / QD/ ORAL	No
US2041123	SOLICITED SYMPTOMS-FATIGUE, MUSCLE ACHES	NAPROXEN/ NAPROXEN	C	2020-07-25 (30) / 2020-07-25 (30)	200 (mg) / BID/ ORAL	Yes
US2041125	CHRONIC CONSTIPATION	DOCUSATE SODIUM/ DOCUSATE SODIUM	P/C/A	2008/ Ongoing	100 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041125	CHRONIC CONSTIPATION	FIBER CAPSULES/ FIBRE, DIETARY	P/C/A	2008/ Ongoing	100 (mg) / QD/ ORAL	No
US2041126	HEADACHES	ADVIL/ IBUPROFEN	P/C/A	2000/ Ongoing	200 (mg) / PRN/ ORAL	No
	ANXIETY	SERTRALINE/ SERTRALINE	P/C/A	2010/ Ongoing	50 (mg) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	VITAMIN C/ ASCORBIC ACID	P/C/A	2020-04/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEADACHES SOLICITED SYMPTOM	ADVIL/ IBUPROFEN	C	2020-07-02 (7) / 2020-07-05 (10)	220 (mg) / BID/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041126	SOLICITED SYMPTOMS-PAIN AT INJECTION SITE AND HEADACHE	ADVIL/ IBUPROFEN	C	2020-07-29 (34) / 2020-08-02 (38)	200 (mg) / PRN/ ORAL	Yes
US2041131	SOLICITED SYMPTOMS-BODY ACHES	EXCEDRIN (ACETAMINOPHEN/ASPIRIN/CAFF EINE) / ACETYLSALICYLIC ACID;CAFFEINE;PARACETAMOL	C	2020-08-11 (44) / 2020-08-11 (44)	(mg) / PRN/ ORAL	Yes
US2041138	SEASONAL ALLERIGES	ALKA-SELTZER PLUS SINUS/ ACETYLSALICYLIC ACID;ASPARTAME;PHENYLALAN INE;PHENYLPROPANOLAMINE BITARTRATE	P/C/A	1970/ Ongoing	1 (TABLET) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2041149	NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2013/ Ongoing	1 (TABLET) / QD/ ORAL	No
	DEPRESSION	BUPROPION/ BUPROPION	P/C/A	2018/ Ongoing	150 (mg) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	VITAMIN D/ VITAMIN D NOS	C/A	2020-07-15 (10) / Ongoing	25 (ug) / QD/ ORAL	No
US2051054	PAIN AT INJECTION SITE, FATIGUE, MUSCLE ACES ALL OVER BODY	ASPIRIN/ ACETYLSALICYLIC ACID	C	2020-07-25 (30) / 2020-07-25 (30)	650 (mg) / ONCE/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051064	HEALTH MAINTENANCE	MULTIVITAMIN/ VITAMINS NOS	P/C/A	1990/ Ongoing	1 (TABLET) / QD/ ORAL	No
	ADULT ACNE- FACE AND SCALP	SPIRONOLACTONE/ SPIRONOLACTONE	P/C/A	2013/ Ongoing	50 (mg) / BID/ ORAL	No
	INSOMNIA	TRAZADONE/ TRAZODONE	P/C/A	2020-03-02 (-121) / Ongoing	50 (mg) / QD/ ORAL	No
	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-07-30 (30) / 2020-07-30 (30)	500 (mg) / QD/ ORAL	Yes
US2051069	HEALTH MAINTENANCE	FISH OIL/ FISH OIL	P/C/A	2010-01-01 (-3829) / Ongoing	1000 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051069	HEALTH MAINTENANCE	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2010-01-01 (-3829) / Ongoing	1 (TABLET) / QD / ORAL	No
	HEALTH MAINTENANCE	PROBIOTIC DIGESTIVE ENZYMES / ENZYMES NOS; PROBIOTICS NOS	P/C/A	2019-01-01 (-542) / Ongoing	1 (TABLET) / QD / ORAL	No
	HEADACHE	IBUPROFEN / IBUPROFEN	C	2020-07-29 (34) / 2020-07-29 (34)	400 (mg) / BID / ORAL	Yes
	STOMACH VIRUS	IBUPROFEN / IBUPROFEN	C	2020-08-19 (55) / 2020-08-19 (55)	400 (mg) / ONCE / ORAL	No
US2051070	HEARTBURN	TUMS / CALCIUM CARBONATE	P/C/A	1980 / Ongoing	2 (TABLET) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051070	OSTEOARTHRITIS RIGHT KNEE	IBUPROFEN/ IBUPROFEN	P/C/A	2017/ Ongoing	600 (mg) / PRN/ ORAL	No
US2051074	HEADACHE	TYLENOL/ PARACETAMOL	P/C/A	1981-01-01 (-14425) / Ongoing	650 (mg) / PRN/ ORAL	No
	GASTROESOPHAGEAL REFLUX DISEASE	NEXIUM/ ESOMEPRAZOLE MAGNESIUM	P/C/A	2010-01-01 (-3833) / Ongoing	40 (mg) / PRN/ ORAL	No
	ANXIETY	EFFEXOR/ VENLAFAXINE HYDROCHLORIDE	P/C/A	2017-01-01 (-1276) / Ongoing	75 (mg) / QD/ ORAL	No
	SEASONAL ALLERGIES	BENADRYL/ DIPHENHYDRAMINE HYDROCHLORIDE	P/C/A	2018-01-01 (-911) / Ongoing	50 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051074	MUSCLE ACHES AND JOINT ACHES (GENERALIZED)	TYLENOL/ PARACETAMOL	C	2020-07-29 (30) / 2020-07-29 (30)	500 (mg) / QD/ ORAL	Yes
US2051075	GENERAL ACHES AND PAIN	TYLENOL/ PARACETAMOL	P/C/A	2000/ Ongoing	500 (mg) / PRN/ ORAL	No
	DEPRESSION	ZOLOFT/ SERTRALINE HYDROCHLORIDE	P/C	2005/ 2020-08-06 (38)	100 (mg) / QD/ ORAL	No
	SEASONAL ALLERGIES	SINGULAIR/ MONTELUKAST SODIUM	P/C/A	2005/ Ongoing	10 (mg) / QD/ ORAL	No
	INSOMNIA	MELATONIN/ MELATONIN	P/C/A	2016/ Ongoing	10 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051075	KNEE PAIN OSTEOARTHRITIS BILATERAL	VOLTAREN (DICLOFENAC SODIUM GEL) 4 GRAMS/ DICLOFENAC	C/A	2020/ Ongoing	1 (OTHER: APPLICATION) / PRN/ TOPICAL	No
	DEPRESSION	ZOLOFT/ SERTRALINE HYDROCHLORIDE	C/A	2020-08-07 (39) / Ongoing	150 (mg) / QD/ ORAL	No
US2051077	HEALTH MAINTENANCE	MULTIVITAMIN/ VITAMINS NOS	P/C/A	1978/ Ongoing	1 (TABLET) / QD/ ORAL	No
US2051084	DRY EYE PAIN LEFT	PREDNISOLONE ACETATE OPHTHALMIC/ PREDNISOLONE ACETATE	P/C/A	2020-04/ Ongoing	1 (OTHER: DROP) / QD/ INTRAOCULAR	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051084	DRY EYE PAIN - LEFT	IBUPROFEN/ IBUPROFEN	P/C/A	2020-06-19 (-12) / Ongoing	200 (mg) / PRN / ORAL	No
	GASTROESOPHAGEAL REFLUX DISEASE	PRILOSEC/ OMEPRazole	C	2020-07-10 (10) / 2020-07-12 (12)	20 (mg) / QD / ORAL	No
	DYSGUESIA	FLONASE/ FLUTICASONE PROPIONATE	C	2020-07-24 (24) / 2020-07-27 (27)	50 (ug) / QD / NASAL	No
	SHINGLES PROPHYLAXIS	SHINGRIX/ VARICELLA ZOSTER VACCINE RGE (CHO)	C	2020-08-10 (41) / 2020-08-10 (41)	0.5 (mL) / ONCE / INTRAMUSCULAR	No
US2051085	HEALTH MAINTENANCE	FISH OIL/ FISH OIL	P/C/A	2006-01-01 (-5296) / Ongoing	2400 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051085	HEALTH MAINTENANCE	OSTEO-BIFLEX/ CHONDROITIN SULFATE SODIUM; GLUCOSAMINE HYDROCHLORIDE	P/C/A	2006-01-01 (-5296) / Ongoing	2 (TABLET) / QD / ORAL	No
	DRY EYE BILATERAL	RESTASIS/ CICLOSPORIN	P/C/A	2008-01-01 (-4566) / Ongoing	1 (OTHER: DROP IN EACH EYE) / QD / OTHER: OPHTHALMIC	No
	HEALTH MAINTENANCE	BIOTIN/ BIOTIN	P/C/A	2014-09-01 (-2131) / Ongoing	1 (TABLET) / QD / ORAL	No
	OSTEOARTHRITIS KNEE BILATERAL	EXTRA- STRENGTH TYLENOL/ PARACETAMOL	P/C/A	2014-09-01 (-2131) / Ongoing	1000 (mg) / PRN / ORAL	No
	HEALTH MAINTENANCE	CALCIUM/ CALCIUM	P/C/A	2015-06-01 (-1858) / Ongoing	1200 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051085	DRY EYE BILATERAL	PRESERVISION/ ASCORBIC ACID;BETACAROTENE;CUPRIC OXIDE;TOCOPHERYL ACETATE;ZINC OXIDE	P/C/A	2020-01-01 (-183) / Ongoing	2 (TABLET) / QD/ ORAL	No
	HEADACHE	EXTRA STRENGTH TYLENOL/ PARACETAMOL	C	2020-07-31 (30) / 2020-07-31 (30)	1000 (mg) / ONCE/ ORAL	Yes
US2051088	HEALTH MAINTENANCE	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2018/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEALTH MAINTENANCE	VITAMIN C/ ASCORBIC ACID	P/C/A	2018/ Ongoing	1 (CAPSULE) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051088	HEALTH MAINTENANCE	VITAMIN D3/ COLECALCIFEROL	P/C/A	2018/ Ongoing	1 (CAPSULE) / QD/ ORAL	No
	GASTROESOPHAGEAL REFLUX DISEASE	OMEPRazole/ OMEPRazole	P/C/A	2019/ Ongoing	20 (mg) / QD/ ORAL	No
	FEVER	IBUPROFEN/ IBUPROFEN	C	2020-07-01 (2) / 2020-07-02 (3)	400 (mg) / QD/ ORAL	Yes
	MUSCLE ACHES ALL OVER BODY	ALEVE/ NAPROXEN SODIUM	C	2020-07-28 (29) / 2020-07-28 (29)	220 (mg) / ONCE/ ORAL	Yes
	BACK PAIN	ALEVE/ NAPROXEN SODIUM	C	2020-08-01 (33) / 2020-08-01 (33)	220 (mg) / ONCE/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051097	HEALTH MAINTENANCE	SUPER B COMPLEX/ VITAMIN B COMPLEX	P/C/A	1994-01-01 (-9683) / Ongoing	1 (TABLET) / QD / ORAL	No
	HEALTH MAINTENANCE	CALCUIM/ CALCIUM	P/C/A	1998-01-01 (-8222) / Ongoing	600 (mg) / QD / ORAL	No
	OSTEOARTHRITIS BILATERAL KNEES	CELEBREX/ CELECOXIB	P/C/A	2007-01-01 (-4935) / Ongoing	200 (mg) / QD / ORAL	No
	HEALTH MAINTENANCE	D3/ COLECALCIFEROL	P/C/A	2010-01-01 (-3839) / Ongoing	2000 (IU) / QD / ORAL	No
	HEALTH MAINTENANCE	GLUIOSAMINE CHONDROTIN/ CHONDROITIN; GLUCOSAMINE	P/C/A	2010-01-01 (-3839) / Ongoing	1 (TABLET) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051097	INSOMNIA	AMBIEN/ ZOLPIDEM TARTRATE	P/C/A	2012-01-01 (-3109) / Ongoing	10 (mg) / QD / ORAL	No
	HEALTH MAINTENANCE	FISH OIL/ FISH OIL	P/C/A	2012-01-01 (-3109) / Ongoing	1 (TABLET) / BID / ORAL	No
	SCIATICA BACK PAIN LEFT	GABAPENTIN/ GABAPENTIN	P/C/A	2015-01-01 (-2013) / Ongoing	100 (mg) / BID / ORAL	No
	PAIN LEFT CALF	FLEXIRIL/ CYCLOBENZAPRINE HYDROCHLORIDE	P/C	2020-06-26 (-10) / 2020-07-16 (11)	5 (mg) / PRN / ORAL	No
US2051101	HEADACHES	IBUPROFEN/ IBUPROFEN	P/C/A	2020-06-28 (-8) / Ongoing	400 (mg) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051101	HEADACHE, MYALGIA, ARTHRALGIA	IBUPROFEN/ IBUPROFEN	C	2020-08-11 (37) / 2020-08-12 (38)	400 (mg) / OTHER: EVERY 4 HOURS / ORAL	Yes
	HYPERTENSION	LISINOPRIL/ LISINOPRIL	C	2020-08-14 (40) / 2020-08-26 (52)	20 (mg) / QD / ORAL	No
US2051102	OSTEOARTHRITIS OF KNEE - BILATERAL	ALEVE/ NAPROXEN SODIUM	P/C/A	2014-01-01 (-2378) / Ongoing	440 (mg) / PRN / ORAL	No
	TOE NAIL FUNGUS BILATERAL FEET	JUBLIA/ EFINACONAZOLE	P/C/A	2019-06-01 (-401) / Ongoing	4 (mL) / QD / TOPICAL	No
US2051104	SEASONAL ALLERGIC RHINITIS	CLARITAN/ LORATADINE	P/C/A	2010 / Ongoing	10 (mg) / PRN / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051104	SEASONAL ALLERGIC RHINITIS	SINEX (OXYMETAZOLINE HCL) / OXYMETAZOLINE HYDROCHLORIDE	P/C/A	2010/ Ongoing	1 (OTHER: SPRAY) / PRN/ NASAL	No
	GOUT LEFT FOOT	AILOPURINOL / ALLOPURINOL	P/C/A	2014/ Ongoing	300 (mg) / QD/ ORAL	No
	INSOMNIA	AMBIEN / ZOLPIDEM TARTRATE	P/C/A	2014/ Ongoing	10 (mg) / PRN/ ORAL	No
	GOUT LEFT FOOT	COLCHICINE / COLCHICINE	P/C/A	2014/ Ongoing	0.6 (mg) / PRN/ ORAL	No
	OSTEOARTHRITIS RIGHT KNEE LEFT HAND	MOTRIN / IBUPROFEN	P/C/A	2015/ Ongoing	400 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051104	SEASONAL ALLERGIC RHINITIS	ZYRTEC/ CETIRIZINE HYDROCHLORIDE	P/C/A	2015/ Ongoing	5 (mg) / PRN/ ORAL	No
	OSTEOARTHRITIS RIGHT KNEE LEFT HAND	MOBIC/ MELOXICAM	P/C/A	2017/ Ongoing	30 (mg) / PRN/ ORAL	No
	LEFT FOOT PAIN	HYDROCODONE/ACETAMINOPHEN/ HYDROCODONE BITARTRATE;PARACETAMOL	P/C/A	2019/ Ongoing	(mg) / PRN/ ORAL	No
	HEADACHE, INJECTION SITE PAIN, MUSCLE PAIN ALL OVER BODY, JOINT PAIN IN SEVERAL JOINTS	IBUPROFEN/ IBUPROFEN	C	2020-07-08 (2) / 2020-07-11 (5)	400 (mg) / OTHER: EVERY 6 HOURS/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051106	HEALTH MAINTENANCE	B COMPLEX/ VITAMIN B COMPLEX	P/C/A	2017/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEALTH MAINTENANCE	MULTI VITAMIN/ VITAMINS NOS	P/C/A	2017/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEALTH MAINTENANCE	OMEGA 3/ OMEGA-3 NOS	P/C/A	2017/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEALTH MAINTENANCE	VITAMIN D3/ COLECALCIFEROL	P/C/A	2017/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEALTH MAINTENANCE	VITAMIN E/ VITAMIN E NOS	P/C/A	2017/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051106	HEADACHE & MUSCLE ACHES, FEVER	TYLENOL/ PARACETAMOL	C	2020-08-05 (31) / 2020-08-06 (32)	500 (mg) / QD/ ORAL	Yes
US2051108	HEALTH MAINTENANCE	VITAMIN C/ ASCORBIC ACID	P/C/A	2018/ Ongoing	500 (mg) / QD/ ORAL	No
	HEALTH MAINTENANCE	ZINC ECHINACEA/ ECHINACEA SPP.; ZINC	P/C/A	2018/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEALTH MAINTENANCE	DIGESTIVE ENZYME/ ALPHA-AMYLASE SWINE PANCREAS; CELLULASE; LIPASE ; PROTEASE NOS	P/C/A	2020-02/ Ongoing	1 (TABLET) / QD/ ORAL	No
	CONTACT DERMATITIS RIGHT FOREARM & RIGHT THIGH	DIPHENHYDRAMINE/ DIPHENHYDRAMINE	C	2020-07-21 (16) / 2020-07-23 (18)	50 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051108	CONTACT DERMATITIS RIGHT FOREARM & RIGHT THIGH	TOPICAL STEROID 1% HYDROCORTISONE/ HYDROCORTISONE	C	2020-07-21 (16) / 2020-07-23 (18)	1 (OTHER: APPLICATION) / BID/ TOPICAL	No
US2051111	ANXIETY	PROZAC/ FLUOXETINE HYDROCHLORIDE	P/C/A	1990/ Ongoing	20 (mg) / QD/ ORAL	No
	HEALTH MAINTENANCE	MULTI VITAMIN/ VITAMINS NOS	P/C/A	2000/ Ongoing	2 (TABLET) / QD/ ORAL	No
	DOG BITE - RIGHT HAND	AMOXICILLIN 500MG / CLAVULANATE 125MG/ AMOXICILLIN;CLAVULANATE POTASSIUM	P	2020-01/ 2020-07-05 (-1)	1 (TABLET) / BID/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2051111	DOG BITE RIGHT HAND	AZITHROMYCIN/ AZITHROMYCIN	C/A	2020-07-06 (1) / Ongoing	500 (mg) / QD/ ORAL	No
	DOG BITE RIGHT HAND	MOXIFLOXACIN/ MOXIFLOXACIN	C/A	2020-07-06 (1) / Ongoing	400 (mg) / QD/ ORAL	No
US2061036	POSTMENOPAUSAL	LOESTRIN (1.5/30) / ETHINYLESTRADIOL; NORETHIS TERONE ACETATE	P/C/A	2015-01/ Ongoing	1 (TABLET) / QD/ ORAL	No
	DEPRESSION	PRISTIQ / DESVENLAFAXINE SUCCINATE	P/C/A	2018-01/ Ongoing	50 (mg) / QD/ ORAL	No
	TOENAIL INFECTION, RIGHT GREAT TOE	KEFLEX / CEFALEXIN	P	2020-06-07 (-19) / 2020-06-16 (-10)	500 (mg) / TID/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2061036	PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-27 (32) / 2020-07-27 (32)	400 (mg) / PRN/ ORAL	Yes
US2061045	NTUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2015/ Ongoing	1 (TABLET) / QD/ ORAL	No
	PAINFUL INTERCOURSE	PREMARIN - CONJUGATED ESTROGEN/ ESTROGENS CONJUGATED	P/C/A	2017/ Ongoing	1 (OTHER: APPLICATION) / OTHER: 3 TIMES PER WEEK/ TOPICAL	No
US2061063	NUTRITIONAL SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2010-01/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071006	PAIN AT INJECTION SITE	TYLENOL/ PARACETAMOL	C	2020-07-02 (31) / 2020-07-02 (31)	500 (mg) / ONCE / ORAL	Yes
US2071013	BILATERAL GLAUCOMA	LATANOPROST/ LATANOPROST	P/C/A	2014 / Ongoing	0.005 (OTHER: DROP) / QD / OTHER: GTT	No
	BILATERAL GLAUCOMA	BRIMONIDINE TARTRATE / BRIMONIDINE TARTRATE	P/C/A	2017-06-01 (-1097) / Ongoing	0.2 (OTHER: DROP) / QD / OTHER: GTT	No
	OSTEOPOROSIS PREVENTION	ALENDRONATE SODIUM / ALENDRONATE SODIUM	P/C/A	2019-03 / Ongoing	70 (mg) / EVERY WEEK / ORAL	No
	NUTRITIONAL SUPPLEMENT	CALCIUM CITRATE / CALCIUM CITRATE	P/C/A	2019-09 / Ongoing	600 (mg) / BID / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071037	ATTENTION DEFICIT DISORDER	ADDERALL/ AMFETAMINE ASPARTATE; AMFETAMINE SULFATE; DEXAMFETAMINE SACCHARATE; DEXAMFETAMINE SULFATE	P/C/A	2013/ Ongoing	10 (mg) / BID/ ORAL	No
	DEPRESSION	QUETIAPINE/ QUETIAPINE	P/C/A	2016/ Ongoing	50 (mg) / QD/ ORAL	No
	DEPRESSION	SERTRALINE/ SERTRALINE	P/C/A	2016/ Ongoing	25 (mg) / QD/ ORAL	No
	ENLARGED PROSTATE	TERAZOSIN/ TERAZOSIN	P/C/A	2016/ Ongoing	1 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071037	INSOMNIA	TRAZADONE/ TRAZODONE	P/C/A	2016/ Ongoing	50 (mg) / QD/ ORAL	No
US2071082	ENLARGED PROSTATE	ALFUZOZIN/ ALFUZOSIN	P/C/A	2010/ Ongoing	10 (mg) / QD/ ORAL	No
	ENLARGED PROSTATE	FINASTERIDE/ FINASTERIDE	P/C/A	2010/ Ongoing	5 (mg) / QD/ ORAL	No
	IRON DEFICIENCY	IRON SUPPLEMENT/ IRON	P/C/A	2010/ Ongoing	65 (mg) / QD/ ORAL	No
	INSOMNIA	TRAZADONE/ TRAZODONE	P/C/A	2015/ Ongoing	50 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071082	ATTENTION DEFICIT DISORDER	BUPROPION/ BUPROPION	P/C/A	2018/ Ongoing	150 (mg) / QD/ ORAL	No
	ERYTHEMA AND TENDERNESS, LEFT, FIRST MTP JOINT	IBUPROFEN/ IBUPROFEN	C/A	2020-08-21 (57) / Ongoing	500 (mg) / PRN/ ORAL	No
	ERYTHEMA AND TENDERNESS, LEFT, FIRST MTP JOINT	NAPROXEN/ NAPROXEN	C/A	2020-08-21 (57) / Ongoing	500 (mg) / PRN/ ORAL	No
	ERYTHEMA AND TENDERNESS, LEFT, FIRST MTP JOINT	TORADOL/ KETOROLAC TROMETHAMINE	A	2020-08-26 (62) / 2020-08-26 (62)	60 (mg) / ONCE/ INTRAMUSCULAR	No
US2071087	HYPERLIPIDEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	2013-09-01 (-2490) / Ongoing	20 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071087	RIGHT ANKLE PAIN	TRAMADOL/ TRAMADOL	P/C/A	2016-02/ Ongoing	50 (mg) / PRN/ ORAL	No
	HEADACHES	TOPIRAMATE/ TOPIRAMATE	P/C/A	2018-02/ Ongoing	50 (mg) / QD/ ORAL	No
	BONE HEALTH	VITAMIN D/ VITAMIN D NOS	P/C/A	2018-03/ Ongoing	1.25 (ug) / OTHER: EVERY 10 DAYS/ ORAL	No
	NUEROPATHY	GABAPENTINE/ GABAPENTIN	P/C/A	2018-07-13 (-714) / Ongoing	600 (mg) / TID/ ORAL	No
	HYPOTHYROIDISM	LEVOTHYROXINE/ LEVOTHYROXINE	P/C/A	2018-07-13 (-714) / Ongoing	75 (ug) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071087	OSTEOPOROSIS	RALOXIFENE/ RALOXIFENE	P/C/A	2019-07/ Ongoing	60 (mg) / QD/ ORAL	No
US2071089	HYPERLIPIDEMIA	ATORVASTATIN/ ATORVASTATIN	P/C/A	2010/ Ongoing	40 (mg) / QD/ ORAL	No
	NUTRITIONAL SUPPLEMENT	VITAMIN D/ VITAMIN D NOS	P/C/A	2013/ Ongoing	25 (ug) / QD/ ORAL	No
US2071093	LEFT EYE GLAUCOMA	LANTANOPROST/ LATANOPROST	P/C/A	2017/ Ongoing	1 (OTHER: DROP) / QD/ OTHER: TOPICAL EYE DROP	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2071093	OSTEOPOROSIS	PROLIA/ DENOSUMAB	P/C/A	2019-05/ Ongoing	60 (mg) / OTHER: EVERY 6 MONTHS/ SUBCUTANEOUS	No
US2071095	CARDIAC PROPHYLAXIS	BABY ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2019-06/ Ongoing	81 (mg) / QD/ ORAL	No
US2071096	TREATMENT OF FEVER	ACETAMINOPHEN/ PARACETAMOL	C	2020-08-06 (36) / 2020-08-07 (37)	500 (mg) / PRN/ ORAL	Yes
US2081001	CARDIO PREVENTATIVE	BABY ASPIRIN/ ACETYLSALICYLIC ACID	P/C/A	2015/ Ongoing	81 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081001	SUPPLEMENT	FIBER CAPSULES/ FIBRE, DIETARY	P/C/A	2015/ Ongoing	1 (CAPSULE) / QD/ ORAL	No
	SUPPLEMENT	MULTI-VITAMIN/ VITAMINS NOS	P/C/A	2015/ Ongoing	1 (TABLET) / QD/ ORAL	No
	SUPPLEMENT	PROBIOTIC/ PROBIOTICS NOS	P/C/A	2015/ Ongoing	1 (TABLET) / QD/ ORAL	No
	TO TREAT FEVER	MOTRIN/ IBUPROFEN	C	2020-06-25 (28) / 2020-06-25 (28)	800 (mg) / ONCE/ ORAL	No
US2081002	DYSLIPIDEMIA	ZOCOR [SIMVASTATIN] / SIMVASTATIN	P/C/A	2008/ Ongoing	20 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081002	SUPPLEMENT	VITAMIN B COMPLEX/ VITAMIN B COMPLEX	P/C/A	2010/ Ongoing	1 (TABLET) / QD/ ORAL	No
	SUPPLEMENT	VITAMIN D3/ COLECALCIFEROL	P/C/A	2010/ Ongoing	1 (TABLET) / QD/ ORAL	No
US2081014	HYPOTHYROIDISM	LEVOTHYROXIN/ LEVOTHYROXINE SODIUM	P/C/A	2000/ Ongoing	75 (ug) / QD/ ORAL	No
	SUPPLEMENT	VITAMIN D/ VITAMIN D NOS	P/C/A	2010/ Ongoing	2000 (IU) / QD/ ORAL	No
	DYSLIPIDEMIA	PRAVASTATIN/ PRAVASTATIN	P/C/A	2015/ Ongoing	40 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081014	DEPRESSION	ESCITOLOPRAM/ ESCITALOPRAM	P/C/A	2017/ Ongoing	5 (mg) / QD/ ORAL	No
	SUPPLEMENT	FIBER/ FIBRE, DIETARY	P/C/A	2017/ Ongoing	6 (TABLET) / QD/ ORAL	No
	INSOMNIA	TRAZADONE/ TRAZODONE	P/C/A	2019/ Ongoing	50 (mg) / PRN/ ORAL	No
	SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	C/A	2020/ Ongoing	1 (TABLET) / QD/ ORAL	No
US2081016	SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2000/ Ongoing	1 (TABLET) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081016	SUPPLEMENT	CHONDROITIN/ CHONDROITIN	P/C/A	2015/ Ongoing	1200 (mg) / QD/ ORAL	No
	SUPPLEMENT	GLUCOSAMINE/ GLUCOSAMINE	P/C/A	2015/ Ongoing	1500 (mg) / QD/ ORAL	No
	SUPPLEMENT	TUMERIC/ CURCUMA LONGA	P/C/A	2015/ Ongoing	500 (mg) / QD/ ORAL	No
	SEASONAL ALLERGIES	AZELASTINE/ AZELASTINE	P/C/A	2017-03-24 (-1165) / Ongoing	137 (ug) / BID/ NASAL	No
	SEASONAL ALLERGIES	FLONASE/ FLUTICASONE PROPIONATE	P/C/A	2017-03-24 (-1165) / Ongoing	50 (ug) / QD/ NASAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081016	MENOPAUSE	ESTRADIOL/ ESTRADIOL	P/C/A	2018/ Ongoing	0.5 (mg) / QD/ ORAL	No
	MENOPAUSE	PROGESTERONE/ PROGESTERONE	P/C/A	2018/ Ongoing	100 (mg) / QD/ ORAL	No
	FEVER/ HEADACHE	ADVIL/ IBUPROFEN	C	2020-06-30 (30) / 2020-06-30 (30)	400 (mg) / ONCE/ ORAL	Yes
	SINUS INFECTION	PREDNISONE/ PREDNISONE	C	2020-07-14 (44) / 2020-07-19 (49)	20 (mg) / OTHER: 3 TABS DAILY FOR FIRST THREE DAYS. 2 TABS DAILY FOR FOLLOWING 3 DAYS. TOTAL OF 6 DAYS/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081016	SINUS INFECTION	CEFUROXIME AXETIL/ CEFUROXIME AXETIL	C	2020-07-14 (44) / 2020-07-23 (53)	250 (mg) / BID / ORAL	No
US2081019	SUPPLEMENT	FISH OIL/ FISH OIL	P/C/A	2010 / Ongoing	500 (mg) / QD / ORAL	No
	SUPPLEMENT	VITAMIN C / ASCORBIC ACID	P/C/A	2010 / Ongoing	1 (TABLET) / QD / ORAL	No
	DEPRESSION	ZOLOFT / SERTRALINE HYDROCHLORIDE	P/C/A	2018 / Ongoing	50 (mg) / QD / ORAL	No
	BOWEL REGULATION [CONSTIPAT ION]	TRULANCE / PLECANATIDE	P/C/A	2020-01 / Ongoing	3 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081035	ATTENTION-DEFICIT HYPERACTIVITY DISORDER	VYVANSE/ LISDEXAMFETAMINE MESILATE	P/C/A	2010/ Ongoing	30 (mg) / PRN/ ORAL	No
US2081069	INSOMNIA	TRAZODONE/ TRAZODONE	P/C/A	2015/ Ongoing	100 (mg) / QD/ ORAL	No
	HERPES LABIALIS [FEVER BLISTERS]	VALACYCLOVIR/ VALACICLOVIR	P/C/A	2020-02-04 (-143) / Ongoing	1 (g) / PRN/ ORAL	No
	HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-06-26 (1) / 2020-06-26 (1)	400 (mg) / ONCE/ ORAL	Yes
	SINUS HEADACHE R/T SEASONAL ALLERGIES	SUDAFED [PSEUDOEPHEDRINE] / PSEUDOEPHEDRINE HYDROCHLORIDE	C	2020-07-08 (13) / 2020-07-10 (15)	30 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081069	SINUS HEADACHE R/T SEASONAL ALLERGIES	TYLENOL [ACETAMINOPHEN] / PARACETAMOL	C	2020-07-08 (13) / 2020-07-10 (15)	1000 (mg) / QD / ORAL	No
	SUPPLEMENT	STOOL SOFTENER (DOCUSATE SODIUM) / DOCUSATE SODIUM	C	2020-07-13 (18) / 2020-07-13 (18)	100 (mg) / PRN / ORAL	No
	SUPPLEMENT (BOWEL REGULARITY)	FLEET SUPOSITORY / GLYCEROL	C	2020-07-15 (20) / 2020-07-15 (20)	1 (TABLET) / PRN / RECTAL	No
	SEASONAL ALLERGIES	SUDAFED / PSEUDOEPHEDRINE HYDROCHLORIDE	C	2020-07-22 (27) / 2020-07-22 (27)	120 (mg) / PRN / ORAL	No
	HEADACHE AND LOW GRADE FEVER	ACETAMINOPHEN / PARACETAMOL	C	2020-07-25 (30) / 2020-07-25 (30)	1000 (mg) / BID / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081069	SINUS HEADACHE (ACROSS FOREHEAD)	SUDAFED/ PSEUDOEPHEDRINE HYDROCHLORIDE	C	2020-07-26 (31) / 2020-07-26 (31)	120 (mg) / ONCE / ORAL	No
	SINUS HEADACHE (ACROSS FOREHEAD)	TYLENOL/ PARACETAMOL	C	2020-07-26 (31) / 2020-07-26 (31)	1000 (mg) / ONCE / ORAL	No
US2081072	HEADACHE	ASPIRIN/ ACETYLSALICYLIC ACID	C	2020-07-25 (30) / 2020-07-25 (30)	650 (mg) / BID / ORAL	Yes
US2081075	SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	1990 / Ongoing	1 (TABLET) / QD / ORAL	No
	SUPPLEMENT	HYALURONIC ACID / HYALURONIC ACID	P/C/A	2010 / Ongoing	100 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081075	SEASONAL ALLERGIES	ALLERGY SHOTS/ ALLERGENS NOS	P/C/A	2015/ Ongoing	0.5 (mL) / QM/ INTRAMUSCULAR	No
US2081076	INSOMNIA	AMBIEN/ ZOLPIDEM TARTRATE	P/C/A	2010/ Ongoing	5 (mg) / PRN/ ORAL	No
	ANXIETY	LORAZEPAM/ LORAZEPAM	P/C/A	2010/ Ongoing	0.5 (mg) / QD/ ORAL	No
	DEPRESSION	MIRTAZAPINE/ MIRTAZAPINE	P/C/A	2010/ Ongoing	15 (mg) / QD/ ORAL	No
	DEPRESSION	SERTRALINE HCL/ SERTRALINE HYDROCHLORIDE	P/C/A	2010/ Ongoing	100 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081076	ALL OVER BODY ACHES AND LOW GRADE FEVER	ADVIL-IBUPROFEN (3 TABS) / IBUPROFEN	C	2020-08-06 (37) / 2020-08-07 (38)	200 (mg) / BID / ORAL	Yes
US2081081	PAIN PREVENTATIVE [GENERALIZED JOINT/MUSCLE PAIN] GASTROPARESIS	ALEVE / NAPROXEN SODIUM	P/C/A	2009 / Ongoing	200 (mg) / PRN / ORAL	No
		BUSPIRONE / BUSPIRONE	P/C/A	2020-02 / Ongoing	10 (mg) / TID / ORAL	No
	IBS	IBGARD / MENTHA X PIPERITA OIL	P/C/A	2020-05 / Ongoing	90 (mg) / BID / ORAL	No
US2081088	SUPPLEMENT	MULTIVITAMIN / VITAMINS NOS	P/C/A	2010 / Ongoing	1 (TABLET) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081088	SUPPLEMENT	VITAMIN C/ ASCORBIC ACID	P/C/A	2010/ Ongoing	1000 (mg) / QD/ ORAL	No
	SUPPLEMENT	FISH OIL/ FISH OIL	P/C/A	2015/ Ongoing	1000 (mg) / QD/ ORAL	No
	HYPERLIPIDEMIA	SIMVISTATIN/ SIMVASTATIN	P/C/A	2015/ Ongoing	20 (mg) / QD/ ORAL	No
	GERD [GASTROESOPHAGEAL REFLUX DISEASE]	PROTONIX (PANTOPRAZOLE) / PANTOPRAZOLE SODIUM SESQUIHYDRATE	P/C/A	2019/ Ongoing	40 (mg) / QD/ ORAL	No
	LOW GRADE FEVER	ALEVE/ NAPROXEN SODIUM	C	2020-08-03 (33) / 2020-08-04 (34)	220 (mg) / QD/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081091	MIGRAINES	ADVIL (MIGRAINE) / IBUPROFEN	P/C/A	2000 / Ongoing	400 (mg) / PRN / ORAL	No
	DEPRESSION	CITALOPRAM / CITALOPRAM	P/C/A	2009 / Ongoing	40 (mg) / QD / ORAL	No
	ATTENTION-DEFICIT HYPERACTIVITY DISORDER	DEXTROAMP-AMPHETAMIN / AMFETAMINE; DEXAMFETAMINE	P/C/A	2009 / Ongoing	10 (mg) / PRN / ORAL	No
	HYPOTHYROIDISM	LEVOTHYROXINE / LEVOTHYROXINE	P/C/A	2009 / Ongoing	125 (ug) / QD / ORAL	No
	SEASONAL ALLERGIES	LORATADINE / LORATADINE	P/C/A	2010 / Ongoing	10 (mg) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081091	HEADACHE	ASPIRIN/ ACETYLSALICYLIC ACID	C	2020-07-05 (3) / 2020-07-05 (3)	650 (mg) / ONCE / ORAL	Yes
	GRADE 3 FATIGUE, BODY ACHES, AND JOINT PAIN	ADVIL/ IBUPROFEN	C	2020-08-04 (33) / 2020-08-04 (33)	400 (mg) / ONCE / ORAL	Yes
	GRADE 3 FATIGUE, BODY ACHES, AND JOINT PAIN	BAYER ASPIRIN/ ACETYLSALICYLIC ACID	C	2020-08-04 (33) / 2020-08-04 (33)	650 (mg) / ONCE / ORAL	Yes
	GRADE 3 FATIGUE, BODY ACHES, AND JOINT PAIN	TYLENOL/ PARACETAMOL	C	2020-08-04 (33) / 2020-08-04 (33)	450 (mg) / ONCE / ORAL	Yes
	GRADE 3 FATIGUE, BODY ACHES, AND JOINT PAIN	HYDROCODONE-ACETAMINOPHEN/ HYDROCODONE; PARACETAMOL	C	2020-08-05 (34) / 2020-08-05 (34)	(mg) / ONCE / ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081093	HYPOTHYROIDISM	LEVOTHYROXINE/ LEVOTHYROXINE	P/C/A	2010/ Ongoing	112 (ug) / QD/ ORAL	No
	OSTEOARTHRITIS IN RIGHT KNEE	SYNISC/ HYLAN G-F 20	P/C/A	2017-01/ Ongoing	32 (mg) / OTHER: EVERY 9 MONTHS TO A YEAR/ INTRAMUSCULAR	No
	SUPPLEMENT	CALCIUM CITRATE/ CALCIUM CITRATE	P/C/A	2019/ Ongoing	400 (mg) / QD/ ORAL	No
	SUPPLEMENT	VITAMIN D3/ COLECALCIFEROL	P/C/A	2019/ Ongoing	12.5 (ug) / QD/ ORAL	No
	ROTATOR CUFF STIFFNESS	ALEVE/ NAPROXEN SODIUM	P/C/A	2020-01/ Ongoing	200 (mg) / BID/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081093	SHOULDER PAIN FROM PLAYING PICKLE BALL. (NOT RELATED TO STUDY)	ALEVE/ NAPROXEN SODIUM	C	2020-07-03 (2) / 2020-07-03 (2)	220 (mg) / ONCE / ORAL	No
	SHOULDER PAIN FROM PLAYING PICKLE BALL. (NOT RELATED T STUDY)	ALEVE/ NAPROXEN SODIUM	C	2020-07-08 (7) / 2020-07-08 (7)	220 (mg) / ONCE / ORAL	No
US2081099	HYPOTHYROIDISM	SYNTHROID/ LEVOTHYROXINE SODIUM	P/C/A	2010 / Ongoing	75 (ug) / QD / ORAL	No
	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-07-30 (35) / 2020-07-30 (35)	500 (mg) / QD / ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081099	HEADACHE	TYLENOL/ PARACETAMOL	C	2020-08-01 (37) / 2020-08-01 (37)	500 (mg) / QD/ ORAL	Yes
	HEADACHE/JOINT PAIN (FROM EDIARY)	ACETOMINOPHEN/ PARACETAMOL	C	2020-08-06 (42) / 2020-08-11 (47)	400 (mg) / PRN/ ORAL	Yes
US2081108	INSOMNIA	DIPHENHYDRAMINE [BENADRYL] / DIPHENHYDRAMINE HYDROCHLORIDE	P/C/A	2015/ Ongoing	25 (mg) / PRN/ ORAL	No
US2081116	SUPPLEMENT	FISH OIL/ FISH OIL	P/C/A	2015/ Ongoing	1000 (mg) / QD/ ORAL	No
	ERECTILE DYSFUNCTION	SILDENAFIL/ SILDENAFIL	P/C/A	2018/ Ongoing	100 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081116	LOW GRADE FEVER AND CHILLS	ASPIRIN/ ACETYLSALICYLIC ACID	C	2020-07-30 (32) / 2020-07-30 (32)	1000 (mg) / TID/ ORAL	No
US2081117	SUPPLEMENT	CALCIUM/ CALCIUM	P/C/A	2000/ Ongoing	600 (mg) / QD/ ORAL	No
	GENITAL HERPES	VALACYCLOVIR/ VALACICLOVIR	P/C/A	2006/ Ongoing	1 (g) / PRN/ ORAL	No
	ALLERGIC RHINITIS	CETIRIZINE/ CETIRIZINE	P/C/A	2010/ Ongoing	10 (mg) / QD/ ORAL	No
	SUPPLEMENT	BIOTIN/ BIOTIN	P/C/A	2018/ Ongoing	5000 (ug) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081117	SUPPLEMENT	VITAMIN D/ VITAMIN D NOS	P/C/A	2019/ Ongoing	100 (ug) / QD/ ORAL	No
	SUPPLEMENT	CRANBERRY WITH VITAMIN C/ ASCORBIC ACID;VACCINIUM MACROCARPON	P/C/A	2020-01/ Ongoing	1 (TABLET) / QD/ ORAL	No
	HEADACHE AND SORENESS AROUND INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-08-12 (38) / 2020-08-12 (38)	500 (mg) / PRN/ ORAL	Yes
US2081120	SUPPLEMENT	PROBIOTIC/ PROBIOTICS NOS	P/C/A	2017/ Ongoing	1 (TABLET) / QD/ ORAL	No
	ERECTILE DYSFUNCTION	SILDENAFIL/ SILDENAFIL	P/C/A	2017/ Ongoing	20 (mg) / PRN/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081121	SUPPLEMENT	MULTIVITAMIN/ VITAMINS NOS	P/C/A	2015/ Ongoing	1 (TABLET) / QD/ ORAL	No
	MENOPAUSE	ESTRADIOL [SKIN PATCH] / ESTRADIOL	P/C/A	2016/ Ongoing	0.0375 (mg) / QD/ TRANSDERMAL	No
	MENOPAUSE	PROGESTERONE / PROGESTERONE	P/C/A	2016/ Ongoing	200 (mg) / QD/ ORAL	No
	OSTEOARTHRITIS OF BACK	TYLENOL / PARACETAMOL	P/C/A	2019/ Ongoing	325 (mg) / PRN / ORAL	No
	SUPPLEMENT	PROBIOTIC / PROBIOTICS NOS	P/C/A	2020-05 / Ongoing	1 (TABLET) / QD / ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081121	PAIN R/T STIFF NECK	IBUPROFEN/ IBUPROFEN	C	2020-07-09 (4) / 2020-07-12 (7)	400 (mg) / BID/ ORAL	No
	STIFF NECK AND HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-07-13 (8) / 2020-07-13 (8)	600 (mg) / BID/ ORAL	Yes
	STIFF NECK AND HEADACHE	IBUPROFEN/ IBUPROFEN	C	2020-07-14 (9) / 2020-07-14 (9)	600 (mg) / ONCE/ ORAL	Yes
	PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-08-11 (37) / 2020-08-11 (37)	600 (mg) / QD/ ORAL	No
	HYPERTENSION	LISINOPRIL/ LISINOPRIL	C/A	2020-08-24 (50) / Ongoing	2.5 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081129	HYPOTHYROIDISM	ARMOUR THYROID/ THYROID	P/C/A	2008/ Ongoing	120 (mg) / QD/ ORAL	No
	HYPOTHYROIDISM	LIOTHYRONINE/ LIOTHYRONINE	P/C/A	2008/ Ongoing	5 (ug) / QD/ ORAL	No
	ANXIETY	LORAZEPAM/ LORAZEPAM	P/C/A	2010/ Ongoing	5 (mg) / BID/ ORAL	No
	HORMONES (PARTIAL HYSTERECTOMY)	PROGESTERONE/ PROGESTERONE	P/C	2016/ 2020-07-20 (19)	100 (mg) / QD/ ORAL	No
	HORMONE THERAPY	HORMONE PELLETS (ESTROGEN AND TESTOSTERONE) / ESTROGEN NOS;TESTOSTERONE	P/C/A	2016/ Ongoing	2 (OTHER: PELLETS) / OTHER: EVERY 3 MONTHS/ SUBCUTANEOUS	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081129	DEPRESSION AND ANXIETY	DESVENALAFAXINE ER/ DESVENLAFAXINE	P/C/A	2017/ Ongoing	50 (mg) / QD/ ORAL	No
	INSOMNIA	ESZOPICLONE/ ESZOPICLONE	P/C/A	2017/ Ongoing	3 (mg) / PRN/ ORAL	No
	ALLERGIC RHINITIS	CEFTIRIZINE/ CETIRIZINE	P/C/A	2020-04/ Ongoing	10 (mg) / QD/ ORAL	No
	PAIN AT INJECTION SITE	IBUPROFEN/ IBUPROFEN	C	2020-07-03 (2) / 2020-07-03 (2)	600 (mg) / ONCE/ ORAL	Yes
	HORMONES (PARTIAL HYSTERECTOMY)	PROGESTERONE/ PROGESTERONE	C/A	2020-07-21 (20) / Ongoing	200 (mg) / QD/ ORAL	No

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.4
Prior and Concomitant Medications
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Indication	Medication Term/ Preferred Name	Flag [1]	Start Date (Day) / Stop Date (Day)	Dose (Unit) / Frequency / Route	Medication Taken for Solicited Adverse Reaction
US2081129	FEVER, INJECTION SITE PAIN, BODY ACHES (ALL OVER BODY ACHES)	IBUPROFEN/ IBUPROFEN	C	2020-08-03 (33) / 2020-08-09 (39)	600 (mg) / QD/ ORAL	Yes
	FEVER, INJECTION SITE PAIN, BODY ACHES (ALL OVER BODY ACHES)	TYLENOL/ PARACETAMOL	C	2020-08-03 (33) / 2020-08-09 (39)	1000 (mg) / QD/ ORAL	Yes

Day is defined as study day from first injection date. Prior medication is defined as medication received before first vaccination. Concomitant medication is defined as medication continued or newly received at or after the first vaccination through 28 days after the last vaccination. Post medication is defined as medication received 28 days after the last injection.

WHODrug version: WHODrug-Global-B3 March 2020

[1] A: Post, C: Concomitant, P: Prior.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020404.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.5
Concomitant Procedures
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Procedure	Indication	If Indication is Other, Specify	Procedure Date (Day)
US2011060	ROOT CANAL, LEFT LOWER SECOND MOLAR	MEDICAL HISTORY		2020-07-23 (52)
US2021073	REPAIR OF ROOT CANAL	ADVERSE EVENT		2020-07-20 (49)
US2041019	LEFT HAND LACERATION REPAIR	ADVERSE EVENT		2020-07-06 (35)
US2081038	2 STITCHES (CUT ON LEFT FOREARM)	ADVERSE EVENT		2020-07-08 (31)

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020405.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.5
Concomitant Procedures
Safety Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Procedure	Indication	If Indication is Other, Specify	Procedure Date (Day)
US2051031	VASECTOMY	MEDICAL HISTORY		2020-06-12 (11)
US2051042	ROOT CANAL	ADVERSE EVENT		2020-06-24 (23)

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020405.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

ModernaTX, Inc.
mRNA-1273-P201

Page 3 of 6

Primary Analysis (Extraction Date: 06NOV2020)

Listing 16.2.4.5
Concomitant Procedures
Safety Set

Cohort 1 (Age ≥ 18 and age < 55); Vaccination Group: mRNA-1273 100 μg

Subject ID	Procedure	Indication	If Indication is Other, Specify	Procedure Date (Day)
------------	-----------	------------	---------------------------------	----------------------

There are no observations for this section.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020405.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.5
Concomitant Procedures
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Procedure	Indication	If Indication is Other, Specify	Procedure Date (Day)
US2021196	2 POLYPS REMOVAL FROM COLON (BENIGN)	ADVERSE EVENT		2020-07-15 (14)
US2021206	BONE SPUR REMOVAL RIGHT TOE	ADVERSE EVENT		2020-07-30 (29)
US2081113	COLONOSCOPY (ROUTINE)	OTHER	ROUTINE	2020-07-27 (20)
	VEIN SURGERY	OTHER	PLANNED MEDICAL VISIT (VARICOSE VEIN TREATMENT)	2020-08-17 (41)
	VEIN SURGERY	OTHER	PLANNED MEDICAL PROCEDURE (VARICOSE VEIN TREATMENT)	2020-08-25 (49)

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020405.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

Listing 16.2.4.5
Concomitant Procedures
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Procedure	Indication	If Indication is Other, Specify	Procedure Date (Day)
US2021019	NEPHRECTOMY	ADVERSE EVENT		2020-07-09 (42)
US2031097	TOOTH EXTRACTION	ADVERSE EVENT		2020-08-19 (51)
US2081123	X-RAY	DIAGNOSTIC		2020-07-29 (30)
	SARS-COV-2 NASAL SWAB	ADVERSE EVENT		2020-08-01 (33)
	X-RAY CHEST	ADVERSE EVENT		2020-08-01 (33)
	CREATINE KINASE:LOW VALUE OF 41	ADVERSE EVENT		2020-08-17 (49)
	EPSTEIN BARR VIRUS ANTIBODY PANEL (HIGH VALUES)	ADVERSE EVENT		2020-08-17 (49)
	UREA NITROGEN TEST: HIGH VALUE: 29	ADVERSE EVENT		2020-08-17 (49)
	CHEST XRAY FOLLOW UP	ADVERSE EVENT		2020-08-20 (52)
	ALKALINE PHOSPHATASE TEST: VALUE OF 160: HIGH	ADVERSE EVENT		2020-08-24 (56)
	CBC: RED BLOOD CELLS LOW, HEMOGLOBIN LOW, HEMATOCRIT LOW, PLATELET LOW	ADVERSE EVENT		2020-08-24 (56)
	CREATININE TEST: LOW: VALUE OF 0.68	ADVERSE EVENT		2020-08-24 (56)
	GAMMA-GLUTAMYL TRANSFERASE TEST: HIGH. VALUE OF 155.	ADVERSE EVENT		2020-08-24 (56)
	LIVER FUNCTION TEST- ABNORMAL	ADVERSE EVENT		2020-08-24 (56)

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020405.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020

ModernaTX, Inc.
mRNA-1273-P201

Page 6 of 6

Primary Analysis (Extraction Date: 06NOV2020)

Listing 16.2.4.5
Concomitant Procedures
Safety Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Procedure	Indication	If Indication is Other, Specify	Procedure Date (Day)
US2051084	ENDOSCOPY WITH BIOPSY.	MEDICAL HISTORY		2020-06-09 (-22)

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020405.sas 19NOV2020 01:28 Database Lock Date: 05NOV2020